<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-0"><publication-reference><document-id><country>US</country><doc-number>20230000913</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="left"/><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>                               SEQUENCE LISTING</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;160&#x3e; NUMBER OF SEQ ID NOS: 122</entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 1</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 112</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 1</entry></row><row><entry> </entry></row><row><entry>Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 2</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 112</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 2</entry></row><row><entry> </entry></row><row><entry>Arg Val Lys Phe Ser Arg Ser Ala Glu Pro Pro Ala Tyr Gln Gln Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 3</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 220</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      CD28 sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 3</entry></row><row><entry> </entry></row><row><entry>Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 4</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 107</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      co-stimulatory signalling region&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 4</entry></row><row><entry> </entry></row><row><entry>Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser</entry></row><row><entry>            100                 105</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 5</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 10</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 5</entry></row><row><entry> </entry></row><row><entry>Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 6</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 111</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 6</entry></row><row><entry> </entry></row><row><entry>Ile Glu Val Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Leu Asp Asn</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 7</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 702</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 7</entry></row><row><entry> </entry></row><row><entry>Met Gly Pro Gly Val Leu Leu Leu Leu Leu Val Ala Thr Ala Trp His</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gly Gln Gly Gly Val Val Ser His Phe Asn Asp Cys Pro Leu Ser His</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asp Gly Tyr Cys Leu His Asp Gly Val Cys Met Tyr Ile Glu Ala Leu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asp Lys Tyr Ala Cys Asn Cys Val Val Gly Tyr Ile Gly Glu Arg Cys</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Gln Tyr Arg Asp Leu Lys Trp Trp Glu Leu Arg Ala Ala Ala Pro Thr</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Thr Leu Tyr Cys Asn His Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Arg Arg Lys Arg Ser Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met Ala Leu Pro Val Thr</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His Ala Glu Val Gln Leu</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr Trp Met Asn Trp</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Leu Lys Ser Asn Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Phe</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr Ser Pro Gly Glu</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His Leu Phe Thr Gly</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val Pro Ala Arg Phe</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile Thr Gly Ala</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Gln Thr Glu Asp Glu Ala Ile Tyr Phe Cys Ala Leu Trp Tyr Ser Asn</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ser Glu</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Ala Ala Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val</entry></row><row><entry>            580                 585                 590</entry></row><row><entry> </entry></row><row><entry>Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn</entry></row><row><entry>        595                 600                 605</entry></row><row><entry> </entry></row><row><entry>Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val</entry></row><row><entry>    610                 615                 620</entry></row><row><entry> </entry></row><row><entry>Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg</entry></row><row><entry>625                 630                 635                 640</entry></row><row><entry> </entry></row><row><entry>Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys</entry></row><row><entry>                645                 650                 655</entry></row><row><entry> </entry></row><row><entry>Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg</entry></row><row><entry>            660                 665                 670</entry></row><row><entry> </entry></row><row><entry>Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys</entry></row><row><entry>        675                 680                 685</entry></row><row><entry> </entry></row><row><entry>Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg</entry></row><row><entry>    690                 695                 700</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 8</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 8</entry></row><row><entry> </entry></row><row><entry>Gly Phe Thr Phe Ser Asn Tyr</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 9</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 9</entry></row><row><entry> </entry></row><row><entry>Arg Leu Lys Ser Asn Asn Tyr Ala</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 10</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 10</entry></row><row><entry> </entry></row><row><entry>Gly Asn Ser Phe Ala Tyr</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 11</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 11</entry></row><row><entry> </entry></row><row><entry>Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 12</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 7</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 12</entry></row><row><entry> </entry></row><row><entry>Gly Thr Asn Asn Arg Ala Pro</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 13</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 13</entry></row><row><entry> </entry></row><row><entry>Ala Leu Trp Tyr Ser Asn His Trp Val</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 14</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 117</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 14</entry></row><row><entry> </entry></row><row><entry>Glu Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Glu Ile Arg Leu Lys Ser Asn Asn Tyr Ala Thr His Tyr Ala Glu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Tyr Cys Thr Phe Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Val Thr Val Ser Ser</entry></row><row><entry>        115</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 15</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 112</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 15</entry></row><row><entry> </entry></row><row><entry>Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr Ser Pro Gly Glu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His Leu Phe Thr Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val Pro Ala Arg Phe</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile Thr Gly Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Thr Glu Asp Glu Ala Ile Tyr Phe Cys Ala Leu Trp Tyr Ser Asn</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ser Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 16</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 244</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 16</entry></row><row><entry> </entry></row><row><entry>Glu Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Glu Ile Arg Leu Lys Ser Asn Asn Tyr Ala Thr His Tyr Ala Glu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Tyr Cys Thr Phe Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Gly Gly Ser Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ser Pro Gly Glu Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Leu Phe Thr Gly Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Pro Ala Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ile Thr Gly Ala Gln Thr Glu Asp Glu Ala Ile Tyr Phe Cys Ala Leu</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Trp Tyr Ser Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Leu Gly Ser Glu</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 17</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 732</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 17</entry></row><row><entry> </entry></row><row><entry>gaggtgcagc tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc     60</entry></row><row><entry> </entry></row><row><entry>tcctgtgttg cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct    120</entry></row><row><entry> </entry></row><row><entry>ccagagaagg ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca    180</entry></row><row><entry> </entry></row><row><entry>cattatgcgg agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt    240</entry></row><row><entry> </entry></row><row><entry>gtctacctgc aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt    300</entry></row><row><entry> </entry></row><row><entry>ggtaactcct ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc    360</entry></row><row><entry> </entry></row><row><entry>ggttcaggcg gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct    420</entry></row><row><entry> </entry></row><row><entry>gcactcacca catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct    480</entry></row><row><entry> </entry></row><row><entry>gttacaacta gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt    540</entry></row><row><entry> </entry></row><row><entry>ctaataggtg gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg    600</entry></row><row><entry> </entry></row><row><entry>attggagaca aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat    660</entry></row><row><entry> </entry></row><row><entry>ttctgtgctc tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc    720</entry></row><row><entry> </entry></row><row><entry>ctaggatcag ag                                                        732</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 18</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 55</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 18</entry></row><row><entry> </entry></row><row><entry>Val Val Ser His Phe Asn Asp Cys Pro Leu Ser His Asp Gly Tyr Cys</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Leu His Asp Gly Val Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Cys Asn Cys Val Val Gly Tyr Ile Gly Glu Arg Cys Gln Tyr Arg Asp</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Lys Trp Trp Glu Leu Arg</entry></row><row><entry>    50                  55</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 19</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 165</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 19</entry></row><row><entry> </entry></row><row><entry>gtggtgagcc acttcaacga ctgccctctg agccacgacg gctactgcct gcacgacggc     60</entry></row><row><entry> </entry></row><row><entry>gtgtgcatgt acatcgaggc cctggacaag tacgcctgca actgcgtggt gggctacatc    120</entry></row><row><entry> </entry></row><row><entry>ggcgagagat gccagtacag agacctgaag tggtgggagc tgaga                    165</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 20</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 247</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 20</entry></row><row><entry> </entry></row><row><entry>Met Gln Pro Ile Leu Leu Leu Leu Ala Phe Leu Leu Leu Pro Arg Ala</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Asp Ala Gly Glu Ile Ile Gly Gly His Glu Ala Lys Pro His Ser Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Pro Tyr Met Ala Tyr Leu Met Ile Trp Asp Gln Lys Ser Leu Lys Arg</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Cys Gly Gly Phe Leu Ile Arg Asp Asp Phe Val Leu Thr Ala Ala His</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Cys Trp Gly Ser Ser Ile Asn Val Thr Leu Gly Ala His Asn Ile Lys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Glu Gln Glu Pro Thr Gln Gln Phe Ile Pro Val Lys Arg Pro Ile Pro</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>His Pro Ala Tyr Asn Pro Lys Asn Phe Ser Asn Asp Ile Met Leu Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gln Leu Glu Arg Lys Ala Lys Arg Thr Arg Ala Val Gln Pro Leu Arg</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Leu Pro Ser Asn Lys Ala Gln Val Lys Pro Gly Gln Thr Cys Ser Val</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ala Gly Trp Gly Gln Thr Ala Pro Leu Gly Lys His Ser His Thr Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gln Glu Val Lys Met Thr Val Gln Glu Asp Arg Lys Cys Glu Ser Asp</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Leu Arg His Tyr Tyr Asp Ser Thr Ile Glu Leu Cys Val Gly Asp Pro</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Glu Ile Lys Lys Thr Ser Phe Lys Gly Asp Ser Gly Gly Pro Leu Val</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Cys Asn Lys Val Ala Gln Gly Ile Val Ser Tyr Gly Arg Asn Asn Gly</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Met Pro Pro Arg Ala Cys Thr Lys Val Ser Ser Phe Val His Trp Ile</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Lys Lys Thr Met Lys Arg Tyr</entry></row><row><entry>                245</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 21</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 277</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 21</entry></row><row><entry> </entry></row><row><entry>Met Glu Asn Thr Glu Asn Ser Val Asp Ser Lys Ser Ile Lys Asn Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Pro Lys Ile Ile His Gly Ser Glu Ser Met Asp Ser Gly Ile Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Asp Asn Ser Tyr Lys Met Asp Tyr Pro Glu Met Gly Leu Cys Ile</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ile Ile Asn Asn Lys Asn Phe His Lys Ser Thr Gly Met Thr Ser Arg</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Gly Thr Asp Val Asp Ala Ala Asn Leu Arg Glu Thr Phe Arg Asn</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Leu Lys Tyr Glu Val Arg Asn Lys Asn Asp Leu Thr Arg Glu Glu Ile</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Val Glu Leu Met Arg Asp Val Ser Lys Glu Asp His Ser Lys Arg Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ser Phe Val Cys Val Leu Leu Ser His Gly Glu Glu Gly Ile Ile Phe</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Thr Asn Gly Pro Val Asp Leu Lys Lys Ile Thr Asn Phe Phe Arg</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly Asp Arg Cys Arg Ser Leu Thr Gly Lys Pro Lys Leu Phe Ile Ile</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gln Ala Cys Arg Gly Thr Glu Leu Asp Cys Gly Ile Glu Thr Asp Ser</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Gly Val Asp Asp Asp Met Ala Cys His Lys Ile Pro Val Glu Ala Asp</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Phe Leu Tyr Ala Tyr Ser Thr Ala Pro Gly Tyr Tyr Ser Trp Arg Asn</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ser Lys Asp Gly Ser Trp Phe Ile Gln Ser Leu Cys Ala Met Leu Lys</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Gln Tyr Ala Asp Lys Leu Glu Phe Met His Ile Leu Thr Arg Val Asn</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Arg Lys Val Ala Thr Glu Phe Glu Ser Phe Ser Phe Asp Ala Thr Phe</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>His Ala Lys Lys Gln Ile Pro Cys Ile Val Ser Met Leu Thr Lys Glu</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Leu Tyr Phe Tyr His</entry></row><row><entry>        275</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 22</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 479</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 22</entry></row><row><entry> </entry></row><row><entry>Met Asp Phe Ser Arg Asn Leu Tyr Asp Ile Gly Glu Gln Leu Asp Ser</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Glu Asp Leu Ala Ser Leu Lys Phe Leu Ser Leu Asp Tyr Ile Pro Gln</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Lys Gln Glu Pro Ile Lys Asp Ala Leu Met Leu Phe Gln Arg Leu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gln Glu Lys Arg Met Leu Glu Glu Ser Asn Leu Ser Phe Leu Lys Glu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Leu Leu Phe Arg Ile Asn Arg Leu Asp Leu Leu Ile Thr Tyr Leu Asn</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Arg Lys Glu Glu Met Glu Arg Glu Leu Gln Thr Pro Gly Arg Ala</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Gln Ile Ser Ala Tyr Arg Val Met Leu Tyr Gln Ile Ser Glu Glu Val</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ser Arg Ser Glu Leu Arg Ser Phe Lys Phe Leu Leu Gln Glu Glu Ile</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ser Lys Cys Lys Leu Asp Asp Asp Met Asn Leu Leu Asp Ile Phe Ile</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Glu Met Glu Lys Arg Val Ile Leu Gly Glu Gly Lys Leu Asp Ile Leu</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Lys Arg Val Cys Ala Gln Ile Asn Lys Ser Leu Leu Lys Ile Ile Asn</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Asp Tyr Glu Glu Phe Ser Lys Glu Arg Ser Ser Ser Leu Glu Gly Ser</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Pro Asp Glu Phe Ser Asn Gly Glu Glu Leu Cys Gly Val Met Thr Ile</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ser Asp Ser Pro Arg Glu Gln Asp Ser Glu Ser Gln Thr Leu Asp Lys</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Val Tyr Gln Met Lys Ser Lys Pro Arg Gly Tyr Cys Leu Ile Ile Asn</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Asn His Asn Phe Ala Lys Ala Arg Glu Lys Val Pro Lys Leu His Ser</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Ile Arg Asp Arg Asn Gly Thr His Leu Asp Ala Gly Ala Leu Thr Thr</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Thr Phe Glu Glu Leu His Phe Glu Ile Lys Pro His Asp Asp Cys Thr</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Val Glu Gln Ile Tyr Glu Ile Leu Lys Ile Tyr Gln Leu Met Asp His</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Ser Asn Met Asp Cys Phe Ile Cys Cys Ile Leu Ser His Gly Asp Lys</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Gly Ile Ile Tyr Gly Thr Asp Gly Gln Glu Ala Pro Ile Tyr Glu Leu</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Thr Ser Gln Phe Thr Gly Leu Lys Cys Pro Ser Leu Ala Gly Lys Pro</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Lys Val Phe Phe Ile Gln Ala Cys Gln Gly Asp Asn Tyr Gln Lys Gly</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Ile Pro Val Glu Thr Asp Ser Glu Glu Gln Pro Tyr Leu Glu Met Asp</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Leu Ser Ser Pro Gln Thr Arg Tyr Ile Pro Asp Glu Ala Asp Phe Leu</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Leu Gly Met Ala Thr Val Asn Asn Cys Val Ser Tyr Arg Asn Pro Ala</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Glu Gly Thr Trp Tyr Ile Gln Ser Leu Cys Gln Ser Leu Arg Glu Arg</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Cys Pro Arg Gly Asp Asp Ile Leu Thr Ile Leu Thr Glu Val Asn Tyr</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Glu Val Ser Asn Lys Asp Asp Lys Lys Asn Met Gly Lys Gln Met Pro</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Gln Pro Thr Phe Thr Leu Arg Lys Lys Leu Val Phe Pro Ser Asp</entry></row><row><entry>465                 470                 475</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 23</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 582</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 23</entry></row><row><entry> </entry></row><row><entry>Met Ser Pro Ala Pro Arg Pro Pro Arg Cys Leu Leu Leu Pro Leu Leu</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Thr Leu Gly Thr Ala Leu Ala Ser Leu Gly Ser Ala Gln Ser Ser Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Phe Ser Pro Glu Ala Trp Leu Gln Gln Tyr Gly Tyr Leu Pro Pro Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asp Leu Arg Thr His Thr Gln Arg Ser Pro Gln Ser Leu Ser Ala Ala</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Ala Ala Met Gln Lys Phe Tyr Gly Leu Gln Val Thr Gly Lys Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Asp Ala Asp Thr Met Lys Ala Met Arg Arg Pro Arg Cys Gly Val Pro</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Asp Lys Phe Gly Ala Glu Ile Lys Ala Asn Val Arg Arg Lys Arg Tyr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ala Ile Gln Gly Leu Lys Trp Gln His Asn Glu Ile Thr Phe Cys Ile</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gln Asn Tyr Thr Pro Lys Val Gly Glu Tyr Ala Thr Tyr Glu Ala Ile</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Arg Lys Ala Phe Arg Val Trp Glu Ser Ala Thr Pro Leu Arg Phe Arg</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Glu Val Pro Tyr Ala Tyr Ile Arg Glu Gly His Glu Lys Gln Ala Asp</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Ile Met Ile Phe Phe Ala Glu Gly Phe His Gly Asp Ser Thr Pro Phe</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Asp Gly Glu Gly Gly Phe Leu Ala His Ala Tyr Phe Pro Gly Pro Asn</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Ile Gly Gly Asp Thr His Phe Asp Ser Ala Glu Pro Trp Thr Val Arg</entry></row><row><entry>    210                 215                 220</entry></row><row><entry> </entry></row><row><entry>Asn Glu Asp Leu Asn Gly Asn Asp Ile Phe Leu Val Ala Val His Glu</entry></row><row><entry>225                 230                 235                 240</entry></row><row><entry> </entry></row><row><entry>Leu Gly His Ala Leu Gly Leu Glu His Ser Ser Asp Pro Ser Ala Ile</entry></row><row><entry>                245                 250                 255</entry></row><row><entry> </entry></row><row><entry>Met Ala Pro Phe Tyr Gln Trp Met Asp Thr Glu Asn Phe Val Leu Pro</entry></row><row><entry>            260                 265                 270</entry></row><row><entry> </entry></row><row><entry>Asp Asp Asp Arg Arg Gly Ile Gln Gln Leu Tyr Gly Gly Glu Ser Gly</entry></row><row><entry>        275                 280                 285</entry></row><row><entry> </entry></row><row><entry>Phe Pro Thr Lys Met Pro Pro Gln Pro Arg Thr Thr Ser Arg Pro Ser</entry></row><row><entry>    290                 295                 300</entry></row><row><entry> </entry></row><row><entry>Val Pro Asp Lys Pro Lys Asn Pro Thr Tyr Gly Pro Asn Ile Cys Asp</entry></row><row><entry>305                 310                 315                 320</entry></row><row><entry> </entry></row><row><entry>Gly Asn Phe Asp Thr Val Ala Met Leu Arg Gly Glu Met Phe Val Phe</entry></row><row><entry>                325                 330                 335</entry></row><row><entry> </entry></row><row><entry>Lys Glu Arg Trp Phe Trp Arg Val Arg Asn Asn Gln Val Met Asp Gly</entry></row><row><entry>            340                 345                 350</entry></row><row><entry> </entry></row><row><entry>Tyr Pro Met Pro Ile Gly Gln Phe Trp Arg Gly Leu Pro Ala Ser Ile</entry></row><row><entry>        355                 360                 365</entry></row><row><entry> </entry></row><row><entry>Asn Thr Ala Tyr Glu Arg Lys Asp Gly Lys Phe Val Phe Phe Lys Gly</entry></row><row><entry>    370                 375                 380</entry></row><row><entry> </entry></row><row><entry>Asp Lys His Trp Val Phe Asp Glu Ala Ser Leu Glu Pro Gly Tyr Pro</entry></row><row><entry>385                 390                 395                 400</entry></row><row><entry> </entry></row><row><entry>Lys His Ile Lys Glu Leu Gly Arg Gly Leu Pro Thr Asp Lys Ile Asp</entry></row><row><entry>                405                 410                 415</entry></row><row><entry> </entry></row><row><entry>Ala Ala Leu Phe Trp Met Pro Asn Gly Lys Thr Tyr Phe Phe Arg Gly</entry></row><row><entry>            420                 425                 430</entry></row><row><entry> </entry></row><row><entry>Asn Lys Tyr Tyr Arg Phe Asn Glu Glu Leu Arg Ala Val Asp Ser Glu</entry></row><row><entry>        435                 440                 445</entry></row><row><entry> </entry></row><row><entry>Tyr Pro Lys Asn Ile Lys Val Trp Glu Gly Ile Pro Glu Ser Pro Arg</entry></row><row><entry>    450                 455                 460</entry></row><row><entry> </entry></row><row><entry>Gly Ser Phe Met Gly Ser Asp Glu Val Phe Thr Tyr Phe Tyr Lys Gly</entry></row><row><entry>465                 470                 475                 480</entry></row><row><entry> </entry></row><row><entry>Asn Lys Tyr Trp Lys Phe Asn Asn Gln Lys Leu Lys Val Glu Pro Gly</entry></row><row><entry>                485                 490                 495</entry></row><row><entry> </entry></row><row><entry>Tyr Pro Lys Ser Ala Leu Arg Asp Trp Met Gly Cys Pro Ser Gly Gly</entry></row><row><entry>            500                 505                 510</entry></row><row><entry> </entry></row><row><entry>Arg Pro Asp Glu Gly Thr Glu Glu Glu Thr Glu Val Ile Ile Ile Glu</entry></row><row><entry>        515                 520                 525</entry></row><row><entry> </entry></row><row><entry>Val Asp Glu Glu Gly Gly Gly Ala Val Ser Ala Ala Ala Val Val Leu</entry></row><row><entry>    530                 535                 540</entry></row><row><entry> </entry></row><row><entry>Pro Val Leu Leu Leu Leu Leu Val Leu Ala Val Gly Leu Ala Val Phe</entry></row><row><entry>545                 550                 555                 560</entry></row><row><entry> </entry></row><row><entry>Phe Phe Arg Arg His Gly Thr Pro Arg Arg Leu Leu Tyr Cys Gln Arg</entry></row><row><entry>                565                 570                 575</entry></row><row><entry> </entry></row><row><entry>Ser Leu Leu Asp Lys Val</entry></row><row><entry>            580</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 24</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 157</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      Mature IL-18 sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 24</entry></row><row><entry> </entry></row><row><entry>Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile Arg Asn Leu Asn</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro Leu Phe Glu Asp</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg Thr Ile Phe Ile</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met Ala Val Thr Ile</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys Glu Asn Lys Ile</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile Lys Asp Thr Lys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly His Asp Asn Lys</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe Leu Ala Cys Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys Glu Asp Glu Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu Asp</entry></row><row><entry>145                 150                 155</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 25</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 36</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      Pro-peptide sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 25</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala Met</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Glu Ser Asp</entry></row><row><entry>        35</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 26</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      GzB cleavage site sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 26</entry></row><row><entry> </entry></row><row><entry>Ile Glu Pro Asp</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 27</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 193</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 27</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala Met</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ile Glu Pro Asp Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Arg Asn Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Leu Phe Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Thr Ile Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Ala Val Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Glu Asn Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Asp Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>His Asp Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Leu Ala Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Glu Asp Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Asp</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 28</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      Caspase-3 cleavage site sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 28</entry></row><row><entry> </entry></row><row><entry>Asp Glu Val Asp Ile</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 29</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 194</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 29</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala Met</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Asp Glu Val Asp Ile Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ile Arg Asn Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Pro Leu Phe Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Thr Ile Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Met Ala Val Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Cys Glu Asn Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ile Lys Asp Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly His Asp Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Phe Leu Ala Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Lys Glu Asp Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Glu Asp</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 30</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      Caspase-8 cleavage site sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 30</entry></row><row><entry> </entry></row><row><entry>Ile Glu Thr Asp Ile</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 31</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 194</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 31</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala Met</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ile Glu Thr Asp Ile Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ile Arg Asn Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Pro Leu Phe Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Arg Thr Ile Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Met Ala Val Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Cys Glu Asn Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ile Lys Asp Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly His Asp Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Phe Leu Ala Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Lys Glu Asp Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Glu Asp</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 32</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 21</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 32</entry></row><row><entry> </entry></row><row><entry>Gly Gly Gly Gly Ser Ile Pro Glu Ser Leu Arg Ala Gly Gly Gly Gly</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gly Ser Ala Ala Ala</entry></row><row><entry>            20</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 33</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 210</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 33</entry></row><row><entry> </entry></row><row><entry>Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala Met</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gly Gly Gly Gly Ser Ile Pro Glu Ser Leu Arg Ala Gly Gly Gly Gly</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Gly Ser Ala Ala Ala Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Ile Arg Asn Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Pro Leu Phe Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Arg Thr Ile Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Met Ala Val Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Cys Glu Asn Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ile Lys Asp Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Gly His Asp Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr</entry></row><row><entry>                165                 170                 175</entry></row><row><entry> </entry></row><row><entry>Phe Leu Ala Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys</entry></row><row><entry>            180                 185                 190</entry></row><row><entry> </entry></row><row><entry>Lys Glu Asp Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn</entry></row><row><entry>        195                 200                 205</entry></row><row><entry> </entry></row><row><entry>Glu Asp</entry></row><row><entry>    210</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 34</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic oligonucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 34</entry></row><row><entry> </entry></row><row><entry>gacgacgaga acctggagag cgactac                                         27</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 35</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 27</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic oligonucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 35</entry></row><row><entry> </entry></row><row><entry>gacgacgaga acatcgagcc cgactac                                         27</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 36</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 158</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 36</entry></row><row><entry> </entry></row><row><entry>Met Glu Lys Ala Leu Lys Ile Asp Thr Pro Gln Gln Gly Ser Ile Gln</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Asp Ile Asn His Arg Val Trp Val Leu Gln Asp Gln Thr Leu Ile Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Val Pro Arg Lys Asp Arg Met Ser Pro Val Thr Ile Ala Leu Ile Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Cys Arg His Val Glu Thr Leu Glu Lys Asp Arg Gly Asn Pro Ile Tyr</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Leu Gly Leu Asn Gly Leu Asn Leu Cys Leu Met Cys Ala Lys Val Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Asp Gln Pro Thr Leu Gln Leu Lys Glu Lys Asp Ile Met Asp Leu Tyr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Asn Gln Pro Glu Pro Val Lys Ser Phe Leu Phe Tyr His Ser Gln Ser</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Gly Arg Asn Ser Thr Phe Glu Ser Val Ala Phe Pro Gly Trp Phe Ile</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Ala Val Ser Ser Glu Gly Gly Cys Pro Leu Ile Leu Thr Gln Glu Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Gly Lys Ala Asn Thr Thr Asp Phe Gly Leu Thr Met Leu Phe</entry></row><row><entry>145                 150                 155</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 37</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 162</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 37</entry></row><row><entry> </entry></row><row><entry>Met Glu Lys Ala Leu Ile Glu Pro Asp Lys Ile Asp Thr Pro Gln Gln</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gly Ser Ile Gln Asp Ile Asn His Arg Val Trp Val Leu Gln Asp Gln</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Thr Leu Ile Ala Val Pro Arg Lys Asp Arg Met Ser Pro Val Thr Ile</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Leu Ile Ser Cys Arg His Val Glu Thr Leu Glu Lys Asp Arg Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Asn Pro Ile Tyr Leu Gly Leu Asn Gly Leu Asn Leu Cys Leu Met Cys</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Ala Lys Val Gly Asp Gln Pro Thr Leu Gln Leu Lys Glu Lys Asp Ile</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Met Asp Leu Tyr Asn Gln Pro Glu Pro Val Lys Ser Phe Leu Phe Tyr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>His Ser Gln Ser Gly Arg Asn Ser Thr Phe Glu Ser Val Ala Phe Pro</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Trp Phe Ile Ala Val Ser Ser Glu Gly Gly Cys Pro Leu Ile Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Thr Gln Glu Leu Gly Lys Ala Asn Thr Thr Asp Phe Gly Leu Thr Met</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Leu Phe</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 38</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 164</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 38</entry></row><row><entry> </entry></row><row><entry>Met Asn Pro Gln Arg Glu Ala Ala Pro Lys Ser Tyr Ala Ile Arg Asp</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ser Arg Gln Met Val Trp Val Leu Ser Gly Asn Ser Leu Ile Ala Ala</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Pro Leu Ser Arg Ser Ile Lys Pro Val Thr Leu His Leu Ile Ala Cys</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Arg Asp Thr Glu Phe Ser Asp Lys Glu Lys Gly Asn Met Val Tyr Leu</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Gly Ile Lys Gly Lys Asp Leu Cys Leu Phe Cys Ala Glu Ile Gln Gly</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Lys Pro Thr Leu Gln Leu Lys Leu Gln Gly Ser Gln Asp Asn Ile Gly</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Lys Asp Thr Cys Trp Lys Leu Val Gly Ile His Thr Cys Ile Asn Leu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Asp Val Arg Glu Ser Cys Phe Met Gly Thr Leu Asp Gln Trp Gly Ile</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Val Gly Arg Lys Lys Trp Lys Ser Ser Phe Gln His His His Leu</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Arg Lys Lys Asp Lys Asp Phe Ser Ser Met Arg Thr Asn Ile Gly Met</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Pro Gly Arg Met</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 39</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 168</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 39</entry></row><row><entry> </entry></row><row><entry>Met Asn Pro Gln Ile Glu Pro Asp Arg Glu Ala Ala Pro Lys Ser Tyr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ala Ile Arg Asp Ser Arg Gln Met Val Trp Val Leu Ser Gly Asn Ser</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Leu Ile Ala Ala Pro Leu Ser Arg Ser Ile Lys Pro Val Thr Leu His</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Leu Ile Ala Cys Arg Asp Thr Glu Phe Ser Asp Lys Glu Lys Gly Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Met Val Tyr Leu Gly Ile Lys Gly Lys Asp Leu Cys Leu Phe Cys Ala</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Glu Ile Gln Gly Lys Pro Thr Leu Gln Leu Lys Leu Gln Gly Ser Gln</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Asp Asn Ile Gly Lys Asp Thr Cys Trp Lys Leu Val Gly Ile His Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Cys Ile Asn Leu Asp Val Arg Glu Ser Cys Phe Met Gly Thr Leu Asp</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gln Trp Gly Ile Gly Val Gly Arg Lys Lys Trp Lys Ser Ser Phe Gln</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>His His His Leu Arg Lys Lys Asp Lys Asp Phe Ser Ser Met Arg Thr</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Asn Ile Gly Met Pro Gly Arg Met</entry></row><row><entry>                165</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 40</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 169</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Homo sapiens</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 40</entry></row><row><entry> </entry></row><row><entry>Met Arg Gly Thr Pro Gly Asp Ala Asp Gly Gly Gly Arg Ala Val Tyr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gln Ser Met Cys Lys Pro Ile Thr Gly Thr Ile Asn Asp Leu Asn Gln</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gln Val Trp Thr Leu Gln Gly Gln Asn Leu Val Ala Val Pro Arg Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asp Ser Val Thr Pro Val Thr Val Ala Val Ile Thr Cys Lys Tyr Pro</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Glu Ala Leu Glu Gln Gly Arg Gly Asp Pro Ile Tyr Leu Gly Ile Gln</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Asn Pro Glu Met Cys Leu Tyr Cys Glu Lys Val Gly Glu Gln Pro Thr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Leu Gln Leu Lys Glu Gln Lys Ile Met Asp Leu Tyr Gly Gln Pro Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Pro Val Lys Pro Phe Leu Phe Tyr Arg Ala Lys Thr Gly Arg Thr Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Thr Leu Glu Ser Val Ala Phe Pro Asp Trp Phe Ile Ala Ser Ser Lys</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Arg Asp Gln Pro Ile Ile Leu Thr Ser Glu Leu Gly Lys Ser Tyr Asn</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Thr Ala Phe Glu Leu Asn Ile Asn Asp</entry></row><row><entry>                165</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 41</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 169</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 41</entry></row><row><entry> </entry></row><row><entry>Met Arg Gly Thr Pro Gly Asp Ala Asp Gly Gly Gly Arg Ile Glu Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Asp Ser Met Cys Lys Pro Ile Thr Gly Thr Ile Asn Asp Leu Asn Gln</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Gln Val Trp Thr Leu Gln Gly Gln Asn Leu Val Ala Val Pro Arg Ser</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Asp Ser Val Thr Pro Val Thr Val Ala Val Ile Thr Cys Lys Tyr Pro</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Glu Ala Leu Glu Gln Gly Arg Gly Asp Pro Ile Tyr Leu Gly Ile Gln</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Asn Pro Glu Met Cys Leu Tyr Cys Glu Lys Val Gly Glu Gln Pro Thr</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Leu Gln Leu Lys Glu Gln Lys Ile Met Asp Leu Tyr Gly Gln Pro Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Pro Val Lys Pro Phe Leu Phe Tyr Arg Ala Lys Thr Gly Arg Thr Ser</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Thr Leu Glu Ser Val Ala Phe Pro Asp Trp Phe Ile Ala Ser Ser Lys</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Arg Asp Gln Pro Ile Ile Leu Thr Ser Glu Leu Gly Lys Ser Tyr Asn</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry>Thr Ala Phe Glu Leu Asn Ile Asn Asp</entry></row><row><entry>                165</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 42</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 153</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      mature IL-36-alpha sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 42</entry></row><row><entry> </entry></row><row><entry>Lys Ile Asp Thr Pro Gln Gln Gly Ser Ile Gln Asp Ile Asn His Arg</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Val Trp Val Leu Gln Asp Gln Thr Leu Ile Ala Val Pro Arg Lys Asp</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Arg Met Ser Pro Val Thr Ile Ala Leu Ile Ser Cys Arg His Val Glu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Thr Leu Glu Lys Asp Arg Gly Asn Pro Ile Tyr Leu Gly Leu Asn Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Leu Asn Leu Cys Leu Met Cys Ala Lys Val Gly Asp Gln Pro Thr Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Leu Lys Glu Lys Asp Ile Met Asp Leu Tyr Asn Gln Pro Glu Pro</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Val Lys Ser Phe Leu Phe Tyr His Ser Gln Ser Gly Arg Asn Ser Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Phe Glu Ser Val Ala Phe Pro Gly Trp Phe Ile Ala Val Ser Ser Glu</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Gly Gly Cys Pro Leu Ile Leu Thr Gln Glu Leu Gly Lys Ala Asn Thr</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Thr Asp Phe Gly Leu Thr Met Leu Phe</entry></row><row><entry>145                 150</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 43</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 160</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      mature IL-36-beta sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 43</entry></row><row><entry> </entry></row><row><entry>Arg Glu Ala Ala Pro Lys Ser Tyr Ala Ile Arg Asp Ser Arg Gln Met</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Val Trp Val Leu Ser Gly Asn Ser Leu Ile Ala Ala Pro Leu Ser Arg</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ser Ile Lys Pro Val Thr Leu His Leu Ile Ala Cys Arg Asp Thr Glu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Phe Ser Asp Lys Glu Lys Gly Asn Met Val Tyr Leu Gly Ile Lys Gly</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Lys Asp Leu Cys Leu Phe Cys Ala Glu Ile Gln Gly Lys Pro Thr Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Leu Lys Leu Gln Gly Ser Gln Asp Asn Ile Gly Lys Asp Thr Cys</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Trp Lys Leu Val Gly Ile His Thr Cys Ile Asn Leu Asp Val Arg Glu</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Ser Cys Phe Met Gly Thr Leu Asp Gln Trp Gly Ile Gly Val Gly Arg</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Lys Lys Trp Lys Ser Ser Phe Gln His His His Leu Arg Lys Lys Asp</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Lys Asp Phe Ser Ser Met Arg Thr Asn Ile Gly Met Pro Gly Arg Met</entry></row><row><entry>145                 150                 155                 160</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 44</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 152</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      mature IL-36-gamma sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 44</entry></row><row><entry> </entry></row><row><entry>Ser Met Cys Lys Pro Ile Thr Gly Thr Ile Asn Asp Leu Asn Gln Gln</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Val Trp Thr Leu Gln Gly Gln Asn Leu Val Ala Val Pro Arg Ser Asp</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry>Ser Val Thr Pro Val Thr Val Ala Val Ile Thr Cys Lys Tyr Pro Glu</entry></row><row><entry>        35                  40                  45</entry></row><row><entry> </entry></row><row><entry>Ala Leu Glu Gln Gly Arg Gly Asp Pro Ile Tyr Leu Gly Ile Gln Asn</entry></row><row><entry>    50                  55                  60</entry></row><row><entry> </entry></row><row><entry>Pro Glu Met Cys Leu Tyr Cys Glu Lys Val Gly Glu Gln Pro Thr Leu</entry></row><row><entry>65                  70                  75                  80</entry></row><row><entry> </entry></row><row><entry>Gln Leu Lys Glu Gln Lys Ile Met Asp Leu Tyr Gly Gln Pro Glu Pro</entry></row><row><entry>                85                  90                  95</entry></row><row><entry> </entry></row><row><entry>Val Lys Pro Phe Leu Phe Tyr Arg Ala Lys Thr Gly Arg Thr Ser Thr</entry></row><row><entry>            100                 105                 110</entry></row><row><entry> </entry></row><row><entry>Leu Glu Ser Val Ala Phe Pro Asp Trp Phe Ile Ala Ser Ser Lys Arg</entry></row><row><entry>        115                 120                 125</entry></row><row><entry> </entry></row><row><entry>Asp Gln Pro Ile Ile Leu Thr Ser Glu Leu Gly Lys Ser Tyr Asn Thr</entry></row><row><entry>    130                 135                 140</entry></row><row><entry> </entry></row><row><entry>Ala Phe Glu Leu Asn Ile Asn Asp</entry></row><row><entry>145                 150</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 45</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 5</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      cleaved pro-peptide from Pro-IL-36-alpha sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 45</entry></row><row><entry> </entry></row><row><entry>Met Glu Lys Ala Leu</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 46</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 46</entry></row><row><entry> </entry></row><row><entry>Met Glu Lys Ala Leu Ile Glu Pro Asp</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 47</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      cleaved pro-peptide from Pro-IL-36-beta sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 47</entry></row><row><entry> </entry></row><row><entry>Met Asn Pro Gln</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 48</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 48</entry></row><row><entry> </entry></row><row><entry>Met Asn Pro Gln Ile Glu Pro Asp</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 49</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Unknown</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Unknown:</entry></row><row><entry>      cleaved pro-peptide from Pro-IL-36-gamma sequence&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 49</entry></row><row><entry> </entry></row><row><entry>Met Arg Gly Thr Pro Gly Asp Ala Asp Gly Gly Gly Arg Ala Val Tyr</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Gln</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 50</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 17</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 50</entry></row><row><entry> </entry></row><row><entry>Met Arg Gly Thr Pro Gly Asp Ala Asp Gly Gly Gly Arg Ile Glu Pro</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Asp</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 51</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 51</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 52</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 52</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 53</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 53</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 54</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 54</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 55</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 55</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 56</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 56</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 57</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 57</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 58</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 58</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 59</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 59</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 60</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 60</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 61</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 61</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 62</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 62</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 63</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 63</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 64</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 64</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 65</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 65</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 66</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 66</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 67</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 67</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 68</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 68</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 69</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 69</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 70</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 70</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 71</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 71</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 72</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 72</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 73</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 73</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 74</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 74</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 75</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 75</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 76</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 76</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 77</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 77</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 78</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 78</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 79</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 79</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 80</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 80</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 81</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 81</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 82</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 82</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 83</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 83</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 84</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 84</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 85</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 85</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 86</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 86</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 87</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 87</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 88</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 88</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 89</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 89</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 90</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 90</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 91</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 91</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 92</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 92</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 93</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 93</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 94</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 94</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 95</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 95</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 96</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 96</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 97</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 97</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 98</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 98</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 99</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 99</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 100</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 100</entry></row><row><entry> </entry></row><row><entry>000</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 101</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 882</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 101</entry></row><row><entry> </entry></row><row><entry>cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat     60</entry></row><row><entry> </entry></row><row><entry>gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc    120</entry></row><row><entry> </entry></row><row><entry>cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc    180</entry></row><row><entry> </entry></row><row><entry>tacgacgccc ttcacatgca ggccctgccc cctcgccggc ggaaacggtc tggatctggg    240</entry></row><row><entry> </entry></row><row><entry>gaaggtcggg gatctttgct cacatgtgga gatgtcgaag agaatcctgg ccctatggcc    300</entry></row><row><entry> </entry></row><row><entry>gccgagcccg tggaggacaa ctgcatcaac ttcgtggcca tgaagttcat cgacaacacc    360</entry></row><row><entry> </entry></row><row><entry>ctgtacttca tcgccgagga cgacgagaac ctggagagcg actacttcgg caagctggag    420</entry></row><row><entry> </entry></row><row><entry>agcaagctga gcgtgatccg gaacctgaac gaccaggtgc tgttcatcga ccagggcaac    480</entry></row><row><entry> </entry></row><row><entry>cggcctctgt tcgaggacat gaccgacagc gactgccggg acaacgctcc ccggaccatc    540</entry></row><row><entry> </entry></row><row><entry>ttcatcatca gcatgtacaa ggacagccag ccccggggaa tggccgtgac catcagcgtg    600</entry></row><row><entry> </entry></row><row><entry>aagtgcgaga agatcagcac cctgagctgc gagaacaaga tcatcagctt caaggagatg    660</entry></row><row><entry> </entry></row><row><entry>aaccctcccg acaacatcaa ggacaccaag agcgacatca tcttcttcca gcggagcgtg    720</entry></row><row><entry> </entry></row><row><entry>cctggccacg acaacaagat gcagttcgag agcagcagct acgagggcta cttcctggcc    780</entry></row><row><entry> </entry></row><row><entry>tgcgagaagg agcgggacct gttcaagctg atcctgaaga aggaggacga gctgggcgac    840</entry></row><row><entry> </entry></row><row><entry>cggagcatca tgttcaccgt gcagaacgag gactaactcg ag                       882</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 102</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9115</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 102</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tctggatctg gggaaggtcg gggatctttg ctcacatgtg   2160</entry></row><row><entry> </entry></row><row><entry>gagatgtcga agagaatcct ggccctatgg ccgccgagcc cgtggaggac aactgcatca   2220</entry></row><row><entry> </entry></row><row><entry>acttcgtggc catgaagttc atcgacaaca ccctgtactt catcgccgag gacgacgaga   2280</entry></row><row><entry> </entry></row><row><entry>acctggagag cgactacttc ggcaagctgg agagcaagct gagcgtgatc cggaacctga   2340</entry></row><row><entry> </entry></row><row><entry>acgaccaggt gctgttcatc gaccagggca accggcctct gttcgaggac atgaccgaca   2400</entry></row><row><entry> </entry></row><row><entry>gcgactgccg ggacaacgct ccccggacca tcttcatcat cagcatgtac aaggacagcc   2460</entry></row><row><entry> </entry></row><row><entry>agccccgggg aatggccgtg accatcagcg tgaagtgcga gaagatcagc accctgagct   2520</entry></row><row><entry> </entry></row><row><entry>gcgagaacaa gatcatcagc ttcaaggaga tgaaccctcc cgacaacatc aaggacacca   2580</entry></row><row><entry> </entry></row><row><entry>agagcgacat catcttcttc cagcggagcg tgcctggcca cgacaacaag atgcagttcg   2640</entry></row><row><entry> </entry></row><row><entry>agagcagcag ctacgagggc tacttcctgg cctgcgagaa ggagcgggac ctgttcaagc   2700</entry></row><row><entry> </entry></row><row><entry>tgatcctgaa gaaggaggac gagctgggcg accggagcat catgttcacc gtgcagaacg   2760</entry></row><row><entry> </entry></row><row><entry>aggactaact cgagggatcc ggattagtcc aatttgttaa agacaggata tcagtggtcc   2820</entry></row><row><entry> </entry></row><row><entry>aggctctagt tttgactcaa caatatcacc agctgaagcc tatagagtac gagccataga   2880</entry></row><row><entry> </entry></row><row><entry>taaaataaaa gattttattt agtctccaga aaaagggggg aatgaaagac cccacctgta   2940</entry></row><row><entry> </entry></row><row><entry>ggtttggcaa gctagcttaa gtaacgccat tttgcaaggc atggaaaaat acataactga   3000</entry></row><row><entry> </entry></row><row><entry>gaatagagaa gttcagatca aggtcaggaa cagatggaac agctgaatat gggccaaaca   3060</entry></row><row><entry> </entry></row><row><entry>ggatatctgt ggtaagcagt tcctgccccg gctcagggcc aagaacagat ggaacagctg   3120</entry></row><row><entry> </entry></row><row><entry>aatatgggcc aaacaggata tctgtggtaa gcagttcctg ccccggctca gggccaagaa   3180</entry></row><row><entry> </entry></row><row><entry>cagatggtcc ccagatgcgg tccagccctc agcagtttct agagaaccat cagatgtttc   3240</entry></row><row><entry> </entry></row><row><entry>cagggtgccc caaggacctg aaatgaccct gtgccttatt tgaactaacc aatcagttcg   3300</entry></row><row><entry> </entry></row><row><entry>cttctcgctt ctgttcgcgc gcttctgctc cccgagctca ataaaagagc ccacaacccc   3360</entry></row><row><entry> </entry></row><row><entry>tcactcgggg cgccagtcct ccgattgact gagtcgcccg ggtacccgtg tatccaataa   3420</entry></row><row><entry> </entry></row><row><entry>accctcttgc agttgcatcc gacttgtggt ctcgctgttc cttgggaggg tctcctctga   3480</entry></row><row><entry> </entry></row><row><entry>gtgattgact acccgtcagc gggggtcttt cacacatgca gcatgtatca aaattaattt   3540</entry></row><row><entry> </entry></row><row><entry>ggtttttttt cttaagtatt tacattaaat ggccatagta cttaaagtta cattggcttc   3600</entry></row><row><entry> </entry></row><row><entry>cttgaaataa acatggagta ttcagaatgt gtcataaata tttctaattt taagatagta   3660</entry></row><row><entry> </entry></row><row><entry>tctccattgg ctttctactt tttcttttat ttttttttgt cctctgtctt ccatttgttg   3720</entry></row><row><entry> </entry></row><row><entry>ttgttgttgt ttgtttgttt gtttgttggt tggttggtta attttttttt aaagatccta   3780</entry></row><row><entry> </entry></row><row><entry>cactatagtt caagctagac tattagctac tctgtaaccc agggtgacct tgaagtcatg   3840</entry></row><row><entry> </entry></row><row><entry>ggtagcctgc tgttttagcc ttcccacatc taagattaca ggtatgagct atcatttttg   3900</entry></row><row><entry> </entry></row><row><entry>gtatattgat tgattgattg attgatgtgt gtgtgtgtga ttgtgtttgt gtgtgtgact   3960</entry></row><row><entry> </entry></row><row><entry>gtgaaaatgt gtgtatgggt gtgtgtgaat gtgtgtatgt atgtgtgtgt gtgagtgtgt   4020</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtgt gtgcatgtgt gtgtgtgtga ctgtgtctat gtgtatgact gtgtgtgtgt   4080</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgttgtg aaaaaatatt ctatggtagt   4140</entry></row><row><entry> </entry></row><row><entry>gagagccaac gctccggctc aggtgtcagg ttggtttttg agacagagtc tttcacttag   4200</entry></row><row><entry> </entry></row><row><entry>cttggaattc actggccgtc gttttacaac gtcgtgactg ggaaaaccct ggcgttaccc   4260</entry></row><row><entry> </entry></row><row><entry>aacttaatcg ccttgcagca catccccctt tcgccagctg gcgtaatagc gaagaggccc   4320</entry></row><row><entry> </entry></row><row><entry>gcaccgatcg cccttcccaa cagttgcgca gcctgaatgg cgaatggcgc ctgatgcggt   4380</entry></row><row><entry> </entry></row><row><entry>attttctcct tacgcatctg tgcggtattt cacaccgcat atggtgcact ctcagtacaa   4440</entry></row><row><entry> </entry></row><row><entry>tctgctctga tgccgcatag ttaagccagc cccgacaccc gccaacaccc gctgacgcgc   4500</entry></row><row><entry> </entry></row><row><entry>cctgacgggc ttgtctgctc ccggcatccg cttacagaca agctgtgacc gtctccggga   4560</entry></row><row><entry> </entry></row><row><entry>gctgcatgtg tcagaggttt tcaccgtcat caccgaaacg cgcgatgacg aaagggcctc   4620</entry></row><row><entry> </entry></row><row><entry>gtgatacgcc tatttttata ggttaatgtc atgataataa tggtttctta gacgtcaggt   4680</entry></row><row><entry> </entry></row><row><entry>ggcacttttc ggggaaatgt gcgcggaacc cctatttgtt tatttttcta aatacattca   4740</entry></row><row><entry> </entry></row><row><entry>aatatgtatc cgctcatgag acaataaccc tgataaatgc ttcaataata ttgaaaaagg   4800</entry></row><row><entry> </entry></row><row><entry>aagagtatga gtattcaaca tttccgtgtc gcccttattc ccttttttgc ggcattttgc   4860</entry></row><row><entry> </entry></row><row><entry>cttcctgttt ttgctcaccc agaaacgctg gtgaaagtaa aagatgctga agatcagttg   4920</entry></row><row><entry> </entry></row><row><entry>ggtgcacgag tgggttacat cgaactggat ctcaacagcg gtaagatcct tgagagtttt   4980</entry></row><row><entry> </entry></row><row><entry>cgccccgaag aacgttttcc aatgatgagc acttttaaag ttctgctatg tggcgcggta   5040</entry></row><row><entry> </entry></row><row><entry>ttatcccgta ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat   5100</entry></row><row><entry> </entry></row><row><entry>gacttggttg agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga   5160</entry></row><row><entry> </entry></row><row><entry>gaattatgca gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca   5220</entry></row><row><entry> </entry></row><row><entry>acgatcggag gaccgaagga gctaaccgct tttttgcaca acatggggga tcatgtaact   5280</entry></row><row><entry> </entry></row><row><entry>cgccttgatc gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc   5340</entry></row><row><entry> </entry></row><row><entry>acgatgcctg tagcaatggc aacaacgttg cgcaaactat taactggcga actacttact   5400</entry></row><row><entry> </entry></row><row><entry>ctagcttccc ggcaacaatt aatagactgg atggaggcgg ataaagttgc aggaccactt   5460</entry></row><row><entry> </entry></row><row><entry>ctgcgctcgg cccttccggc tggctggttt attgctgata aatctggagc cggtgagcgt   5520</entry></row><row><entry> </entry></row><row><entry>gggtctcgcg gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagtt   5580</entry></row><row><entry> </entry></row><row><entry>atctacacga cggggagtca ggcaactatg gatgaacgaa atagacagat cgctgagata   5640</entry></row><row><entry> </entry></row><row><entry>ggtgcctcac tgattaagca ttggtaactg tcagaccaag tttactcata tatactttag   5700</entry></row><row><entry> </entry></row><row><entry>attgatttaa aacttcattt ttaatttaaa aggatctagg tgaagatcct ttttgataat   5760</entry></row><row><entry> </entry></row><row><entry>ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga ccccgtagaa   5820</entry></row><row><entry> </entry></row><row><entry>aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca   5880</entry></row><row><entry> </entry></row><row><entry>aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt   5940</entry></row><row><entry> </entry></row><row><entry>ccgaaggtaa ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg   6000</entry></row><row><entry> </entry></row><row><entry>tagttaggcc accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc   6060</entry></row><row><entry> </entry></row><row><entry>ctgttaccag tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga   6120</entry></row><row><entry> </entry></row><row><entry>cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc   6180</entry></row><row><entry> </entry></row><row><entry>agcttggagc gaacgaccta caccgaactg agatacctac agcgtgagca ttgagaaagc   6240</entry></row><row><entry> </entry></row><row><entry>gccacgcttc ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca   6300</entry></row><row><entry> </entry></row><row><entry>ggagagcgca cgagggagct tccaggggga aacgcctggt atctttatag tcctgtcggg   6360</entry></row><row><entry> </entry></row><row><entry>tttcgccacc tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta   6420</entry></row><row><entry> </entry></row><row><entry>tggaaaaacg ccagcaacgc ggccttttta cggttcctgg ccttttgctg gccttttgct   6480</entry></row><row><entry> </entry></row><row><entry>cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag   6540</entry></row><row><entry> </entry></row><row><entry>tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa   6600</entry></row><row><entry> </entry></row><row><entry>gcggaagagc gcccaatacg caaaccgcct ctccccgcgc gttggccgat tcattaatgc   6660</entry></row><row><entry> </entry></row><row><entry>agctggcacg acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg   6720</entry></row><row><entry> </entry></row><row><entry>agttagctca ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatgttg   6780</entry></row><row><entry> </entry></row><row><entry>tgtggaattg tgagcggata acaatttcac acaggaaaca gctatgacca tgattacgcc   6840</entry></row><row><entry> </entry></row><row><entry>aagctttgct cttaggagtt tcctaataca tcccaaactc aaatatataa agcatttgac   6900</entry></row><row><entry> </entry></row><row><entry>ttgttctatg ccctaggggg cggggggaag ctaagccagc tttttttaac atttaaaatg   6960</entry></row><row><entry> </entry></row><row><entry>ttaattccat tttaaatgca cagatgtttt tatttcataa gggtttcaat gtgcatgaat   7020</entry></row><row><entry> </entry></row><row><entry>gctgcaatat tcctgttacc aaagctagta taaataaaaa tagataaacg tggaaattac   7080</entry></row><row><entry> </entry></row><row><entry>ttagagtttc tgtcattaac gtttccttcc tcagttgaca acataaatgc gctgctgagc   7140</entry></row><row><entry> </entry></row><row><entry>aagccagttt gcatctgtca ggatcaattt cccattatgc cagtcatatt aattactagt   7200</entry></row><row><entry> </entry></row><row><entry>caattagttg atttttattt ttgacatata catgtgaatg aaagacccca cctgtaggtt   7260</entry></row><row><entry> </entry></row><row><entry>tggcaagcta gcttaagtaa cgccattttg caaggcatgg aaaaatacat aactgagaat   7320</entry></row><row><entry> </entry></row><row><entry>agaaaagttc agatcaaggt caggaacaga tggaacagct gaatatgggc caaacaggat   7380</entry></row><row><entry> </entry></row><row><entry>atctgtggta agcagttcct gccccggctc agggccaaga acagatggaa cagctgaata   7440</entry></row><row><entry> </entry></row><row><entry>tgggccaaac aggatatctg tggtaagcag ttcctgcccc ggctcagggc caagaacaga   7500</entry></row><row><entry> </entry></row><row><entry>tggtccccag atgcggtcca gccctcagca gtttctagag aaccatcaga tgtttccagg   7560</entry></row><row><entry> </entry></row><row><entry>gtgccccaag gacctgaaat gaccctgtgc cttatttgaa ctaaccaatc agttcgcttc   7620</entry></row><row><entry> </entry></row><row><entry>tcgcttctgt tcgcgcgctt atgctccccg agctcaataa aagagcccac aacccctcac   7680</entry></row><row><entry> </entry></row><row><entry>tcggggcgcc agtcctccga ttgactgagt cgcccgggta cccgtgtatc caataaaccc   7740</entry></row><row><entry> </entry></row><row><entry>tcttgcagtt gcatccgact tgtggtctcg ctgttccttg ggagggtctc ctctgagtga   7800</entry></row><row><entry> </entry></row><row><entry>ttgactaccc gtcagcgggg gtctttcatt tgggggctcg tccgggatcg ggagacccct   7860</entry></row><row><entry> </entry></row><row><entry>gcccagggac caccgaccca ccaccgggag gtaagctggc cagcaactta tctgtgtctg   7920</entry></row><row><entry> </entry></row><row><entry>tccgattgtc tagtgtctat gactgatttt atgcgcctgc gtcggtacta gttagctaac   7980</entry></row><row><entry> </entry></row><row><entry>tagctctgta tctggcggac ccgtggtgga actgacgagt tcggaacacc cggccgcaac   8040</entry></row><row><entry> </entry></row><row><entry>cctgggagac gtcccaggga cttcgggggc cgtttttgtg gcccgacctg agtcctaaaa   8100</entry></row><row><entry> </entry></row><row><entry>tcccgatcgt ttaggactct ttggtgcacc ccccttagag gagggatatg tggttctggt   8160</entry></row><row><entry> </entry></row><row><entry>aggagacgag aacctaaaac agttcccgcc tccgtctgaa tttttgcttt cggtttggga   8220</entry></row><row><entry> </entry></row><row><entry>ccgaagccgc gccgcgcgtc ttgtctgctg cagcatcgtt ctgtgttgtc tctgtctgac   8280</entry></row><row><entry> </entry></row><row><entry>tgtgtttctg tatttgtctg aaaatatggg cccgggctag actgttacca ctcccttaag   8340</entry></row><row><entry> </entry></row><row><entry>tttgacctta ggtcactgga aagatgtcga gcggatcgct cacaaccagt cggtagatgt   8400</entry></row><row><entry> </entry></row><row><entry>caagaagaga cgttgggtta ccttctgctc tgcagaatgg ccaaccttta acgtcggatg   8460</entry></row><row><entry> </entry></row><row><entry>gccgcgagac ggcaccttta accgagacct catcacccag gttaagatca aggtcttttc   8520</entry></row><row><entry> </entry></row><row><entry>acctggcccg catggacacc cagaccaggt cccctacatc gtgacctggg aagccttggc   8580</entry></row><row><entry> </entry></row><row><entry>ttttgacccc cctccctggg tcaagccctt tgtacaccct aagcctccgc ctcctcttcc   8640</entry></row><row><entry> </entry></row><row><entry>tccatccgcc ccgtctctcc cccttgaacc tcctcgttcg accccgcctc gatcctccct   8700</entry></row><row><entry> </entry></row><row><entry>ttatccagcc ctcactcctt ctctaggcgc ccccatatgg ccatatgaga tcttatatgg   8760</entry></row><row><entry> </entry></row><row><entry>ggcacccccg ccccttgtaa acttccctga ccctgacatg acaagagtta ctaacagccc   8820</entry></row><row><entry> </entry></row><row><entry>ctctctccaa gctcacttac aggctctcta cttagtccag cacgaagtct ggagacctct   8880</entry></row><row><entry> </entry></row><row><entry>ggcggcagcc taccaagaac aactggaccg accggtggta cctcaccctt accgagtcgg   8940</entry></row><row><entry> </entry></row><row><entry>cgacacagtg tgggtccgcc gacaccagac taagaaccta gaacctcgct ggaaaggacc   9000</entry></row><row><entry> </entry></row><row><entry>ttacacagtc ctgctgacca cccccaccgc cctcaaagta gacggcatcg cagcttggat   9060</entry></row><row><entry> </entry></row><row><entry>acacgccgcc cacgtgaagg ctgccgaccc cgggggtgga ccatcctcta gactg        9115</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 103</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9114</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 103</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tctggatctg gggaaggtcg gggatctttg ctcacatgtg   2160</entry></row><row><entry> </entry></row><row><entry>gagatgtcga agagaatcct ggccctatgg ccgccgagcc cgtggaggac aactgcatca   2220</entry></row><row><entry> </entry></row><row><entry>acttcgtggc catgaagttc atcgacaaca ccctgtactt catcgccgag gacgacgaga   2280</entry></row><row><entry> </entry></row><row><entry>acatcgagcc cgactacttc ggcaagctgg agagcaagct gagcgtgatc cggaacctga   2340</entry></row><row><entry> </entry></row><row><entry>acgaccaggt gctgttcatc gaccagggca accggcctct gttcgaggac atgaccgaca   2400</entry></row><row><entry> </entry></row><row><entry>gcgactgccg ggacaacgct ccccggacca tcttcatcat cagcatgtac aaggacagcc   2460</entry></row><row><entry> </entry></row><row><entry>agccccgggg aatggccgtg accatcagcg tgaagtgcga gaagatcagc accctgagct   2520</entry></row><row><entry> </entry></row><row><entry>gcgagaacaa gatcatcagc ttcaaggaga tgaaccctcc cgacaacatc aaggacacca   2580</entry></row><row><entry> </entry></row><row><entry>agagcgacat catcttcttc cagcggagcg tgcctggcca cgacaacaag atgcagttcg   2640</entry></row><row><entry> </entry></row><row><entry>agagcagcag ctacgagggc tacttcctgg cctgcgagaa ggagcgggac ctgttcaagc   2700</entry></row><row><entry> </entry></row><row><entry>tgatcctgaa gaaggaggac gagctgggcg accggagcat catgttcacc gtgcagaacg   2760</entry></row><row><entry> </entry></row><row><entry>aggactaact cgaggatccg gattagtcca atttgttaaa gacaggatat cagtggtcca   2820</entry></row><row><entry> </entry></row><row><entry>ggctctagtt ttgactcaac aatatcacca gctgaagcct atagagtacg agccatagat   2880</entry></row><row><entry> </entry></row><row><entry>aaaataaaag attttattta gtctccagaa aaagggggga atgaaagacc ccacctgtag   2940</entry></row><row><entry> </entry></row><row><entry>gtttggcaag ctagcttaag taacgccatt ttgcaaggca tggaaaaata cataactgag   3000</entry></row><row><entry> </entry></row><row><entry>aatagagaag ttcagatcaa ggtcaggaac agatggaaca gctgaatatg ggccaaacag   3060</entry></row><row><entry> </entry></row><row><entry>gatatctgtg gtaagcagtt cctgccccgg ctcagggcca agaacagatg gaacagctga   3120</entry></row><row><entry> </entry></row><row><entry>atatgggcca aacaggatat ctgtggtaag cagttcctgc cccggctcag ggccaagaac   3180</entry></row><row><entry> </entry></row><row><entry>agatggtccc cagatgcggt ccagccctca gcagtttcta gagaaccatc agatgtttcc   3240</entry></row><row><entry> </entry></row><row><entry>agggtgcccc aaggacctga aatgaccctg tgccttattt gaactaacca atcagttcgc   3300</entry></row><row><entry> </entry></row><row><entry>ttctcgcttc tgttcgcgcg cttctgctcc ccgagctcaa taaaagagcc cacaacccct   3360</entry></row><row><entry> </entry></row><row><entry>cactcggggc gccagtcctc cgattgactg agtcgcccgg gtacccgtgt atccaataaa   3420</entry></row><row><entry> </entry></row><row><entry>ccctcttgca gttgcatccg acttgtggtc tcgctgttcc ttgggagggt ctcctctgag   3480</entry></row><row><entry> </entry></row><row><entry>tgattgacta cccgtcagcg ggggtctttc acacatgcag catgtatcaa aattaatttg   3540</entry></row><row><entry> </entry></row><row><entry>gttttttttc ttaagtattt acattaaatg gccatagtac ttaaagttac attggcttcc   3600</entry></row><row><entry> </entry></row><row><entry>ttgaaataaa catggagtat tcagaatgtg tcataaatat ttctaatttt aagatagtat   3660</entry></row><row><entry> </entry></row><row><entry>ctccattggc tttctacttt ttcttttatt tttttttgtc ctctgtcttc catttgttgt   3720</entry></row><row><entry> </entry></row><row><entry>tgttgttgtt tgtttgtttg tttgttggtt ggttggttaa ttttttttta aagatcctac   3780</entry></row><row><entry> </entry></row><row><entry>actatagttc aagctagact attagctact ctgtaaccca gggtgacctt gaagtcatgg   3840</entry></row><row><entry> </entry></row><row><entry>gtagcctgct gttttagcct tcccacatct aagattacag gtatgagcta tcatttttgg   3900</entry></row><row><entry> </entry></row><row><entry>tatattgatt gattgattga ttgatgtgtg tgtgtgtgat tgtgtttgtg tgtgtgactg   3960</entry></row><row><entry> </entry></row><row><entry>tgaaaatgtg tgtatgggtg tgtgtgaatg tgtgtatgta tgtgtgtgtg tgagtgtgtg   4020</entry></row><row><entry> </entry></row><row><entry>tgtgtgtgtg tgcatgtgtg tgtgtgtgac tgtgtctatg tgtatgactg tgtgtgtgtg   4080</entry></row><row><entry> </entry></row><row><entry>tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgttgtga aaaaatattc tatggtagtg   4140</entry></row><row><entry> </entry></row><row><entry>agagccaacg ctccggctca ggtgtcaggt tggtttttga gacagagtct ttcacttagc   4200</entry></row><row><entry> </entry></row><row><entry>ttggaattca ctggccgtcg ttttacaacg tcgtgactgg gaaaaccctg gcgttaccca   4260</entry></row><row><entry> </entry></row><row><entry>acttaatcgc cttgcagcac atcccccttt cgccagctgg cgtaatagcg aagaggcccg   4320</entry></row><row><entry> </entry></row><row><entry>caccgatcgc ccttcccaac agttgcgcag cctgaatggc gaatggcgcc tgatgcggta   4380</entry></row><row><entry> </entry></row><row><entry>ttttctcctt acgcatctgt gcggtatttc acaccgcata tggtgcactc tcagtacaat   4440</entry></row><row><entry> </entry></row><row><entry>ctgctctgat gccgcatagt taagccagcc ccgacacccg ccaacacccg ctgacgcgcc   4500</entry></row><row><entry> </entry></row><row><entry>ctgacgggct tgtctgctcc cggcatccgc ttacagacaa gctgtgaccg tctccgggag   4560</entry></row><row><entry> </entry></row><row><entry>ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc gcgatgacga aagggcctcg   4620</entry></row><row><entry> </entry></row><row><entry>tgatacgcct atttttatag gttaatgtca tgataataat ggtttcttag acgtcaggtg   4680</entry></row><row><entry> </entry></row><row><entry>gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt atttttctaa atacattcaa   4740</entry></row><row><entry> </entry></row><row><entry>atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga   4800</entry></row><row><entry> </entry></row><row><entry>agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg gcattttgcc   4860</entry></row><row><entry> </entry></row><row><entry>ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg   4920</entry></row><row><entry> </entry></row><row><entry>gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc   4980</entry></row><row><entry> </entry></row><row><entry>gccccgaaga acgttttcca atgatgagca cttttaaagt tctgctatgt ggcgcggtat   5040</entry></row><row><entry> </entry></row><row><entry>tatcccgtat tgacgccggg caagagcaac tcggtcgccg catacactat tctcagaatg   5100</entry></row><row><entry> </entry></row><row><entry>acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag   5160</entry></row><row><entry> </entry></row><row><entry>aattatgcag tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa   5220</entry></row><row><entry> </entry></row><row><entry>cgatcggagg accgaaggag ctaaccgctt ttttgcacaa catgggggat catgtaactc   5280</entry></row><row><entry> </entry></row><row><entry>gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca   5340</entry></row><row><entry> </entry></row><row><entry>cgatgcctgt agcaatggca acaacgttgc gcaaactatt aactggcgaa ctacttactc   5400</entry></row><row><entry> </entry></row><row><entry>tagcttcccg gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc   5460</entry></row><row><entry> </entry></row><row><entry>tgcgctcggc ccttccggct ggctggttta ttgctgataa atctggagcc ggtgagcgtg   5520</entry></row><row><entry> </entry></row><row><entry>ggtctcgcgg tatcattgca gcactggggc cagatggtaa gccctcccgt atcgtagtta   5580</entry></row><row><entry> </entry></row><row><entry>tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag   5640</entry></row><row><entry> </entry></row><row><entry>gtgcctcact gattaagcat tggtaactgt cagaccaagt ttactcatat atactttaga   5700</entry></row><row><entry> </entry></row><row><entry>ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc   5760</entry></row><row><entry> </entry></row><row><entry>tcatgaccaa aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa   5820</entry></row><row><entry> </entry></row><row><entry>agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa   5880</entry></row><row><entry> </entry></row><row><entry>aaaaaccacc gctaccagcg gtggtttgtt tgccggatca agagctacca actctttttc   5940</entry></row><row><entry> </entry></row><row><entry>cgaaggtaac tggcttcagc agagcgcaga taccaaatac tgtccttcta gtgtagccgt   6000</entry></row><row><entry> </entry></row><row><entry>agttaggcca ccacttcaag aactctgtag caccgcctac atacctcgct ctgctaatcc   6060</entry></row><row><entry> </entry></row><row><entry>tgttaccagt ggctgctgcc agtggcgata agtcgtgtct taccgggttg gactcaagac   6120</entry></row><row><entry> </entry></row><row><entry>gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc acacagccca   6180</entry></row><row><entry> </entry></row><row><entry>gcttggagcg aacgacctac accgaactga gatacctaca gcgtgagcat tgagaaagcg   6240</entry></row><row><entry> </entry></row><row><entry>ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg gtcggaacag   6300</entry></row><row><entry> </entry></row><row><entry>gagagcgcac gagggagctt ccagggggaa acgcctggta tctttatagt cctgtcgggt   6360</entry></row><row><entry> </entry></row><row><entry>ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg cggagcctat   6420</entry></row><row><entry> </entry></row><row><entry>ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg ccttttgctc   6480</entry></row><row><entry> </entry></row><row><entry>acatgttctt tcctgcgtta tcccctgatt ctgtggataa ccgtattacc gcctttgagt   6540</entry></row><row><entry> </entry></row><row><entry>gagctgatac cgctcgccgc agccgaacga ccgagcgcag cgagtcagtg agcgaggaag   6600</entry></row><row><entry> </entry></row><row><entry>cggaagagcg cccaatacgc aaaccgcctc tccccgcgcg ttggccgatt cattaatgca   6660</entry></row><row><entry> </entry></row><row><entry>gctggcacga caggtttccc gactggaaag cgggcagtga gcgcaacgca attaatgtga   6720</entry></row><row><entry> </entry></row><row><entry>gttagctcac tcattaggca ccccaggctt tacactttat gcttccggct cgtatgttgt   6780</entry></row><row><entry> </entry></row><row><entry>gtggaattgt gagcggataa caatttcaca caggaaacag ctatgaccat gattacgcca   6840</entry></row><row><entry> </entry></row><row><entry>agctttgctc ttaggagttt cctaatacat cccaaactca aatatataaa gcatttgact   6900</entry></row><row><entry> </entry></row><row><entry>tgttctatgc cctagggggc ggggggaagc taagccagct ttttttaaca tttaaaatgt   6960</entry></row><row><entry> </entry></row><row><entry>taattccatt ttaaatgcac agatgttttt atttcataag ggtttcaatg tgcatgaatg   7020</entry></row><row><entry> </entry></row><row><entry>ctgcaatatt cctgttacca aagctagtat aaataaaaat agataaacgt ggaaattact   7080</entry></row><row><entry> </entry></row><row><entry>tagagtttct gtcattaacg tttccttcct cagttgacaa cataaatgcg ctgctgagca   7140</entry></row><row><entry> </entry></row><row><entry>agccagtttg catctgtcag gatcaatttc ccattatgcc agtcatatta attactagtc   7200</entry></row><row><entry> </entry></row><row><entry>aattagttga tttttatttt tgacatatac atgtgaatga aagaccccac ctgtaggttt   7260</entry></row><row><entry> </entry></row><row><entry>ggcaagctag cttaagtaac gccattttgc aaggcatgga aaaatacata actgagaata   7320</entry></row><row><entry> </entry></row><row><entry>gaaaagttca gatcaaggtc aggaacagat ggaacagctg aatatgggcc aaacaggata   7380</entry></row><row><entry> </entry></row><row><entry>tctgtggtaa gcagttcctg ccccggctca gggccaagaa cagatggaac agctgaatat   7440</entry></row><row><entry> </entry></row><row><entry>gggccaaaca ggatatctgt ggtaagcagt tcctgccccg gctcagggcc aagaacagat   7500</entry></row><row><entry> </entry></row><row><entry>ggtccccaga tgcggtccag ccctcagcag tttctagaga accatcagat gtttccaggg   7560</entry></row><row><entry> </entry></row><row><entry>tgccccaagg acctgaaatg accctgtgcc ttatttgaac taaccaatca gttcgcttct   7620</entry></row><row><entry> </entry></row><row><entry>cgcttctgtt cgcgcgctta tgctccccga gctcaataaa agagcccaca acccctcact   7680</entry></row><row><entry> </entry></row><row><entry>cggggcgcca gtcctccgat tgactgagtc gcccgggtac ccgtgtatcc aataaaccct   7740</entry></row><row><entry> </entry></row><row><entry>cttgcagttg catccgactt gtggtctcgc tgttccttgg gagggtctcc tctgagtgat   7800</entry></row><row><entry> </entry></row><row><entry>tgactacccg tcagcggggg tctttcattt gggggctcgt ccgggatcgg gagacccctg   7860</entry></row><row><entry> </entry></row><row><entry>cccagggacc accgacccac caccgggagg taagctggcc agcaacttat ctgtgtctgt   7920</entry></row><row><entry> </entry></row><row><entry>ccgattgtct agtgtctatg actgatttta tgcgcctgcg tcggtactag ttagctaact   7980</entry></row><row><entry> </entry></row><row><entry>agctctgtat ctggcggacc cgtggtggaa ctgacgagtt cggaacaccc ggccgcaacc   8040</entry></row><row><entry> </entry></row><row><entry>ctgggagacg tcccagggac ttcgggggcc gtttttgtgg cccgacctga gtcctaaaat   8100</entry></row><row><entry> </entry></row><row><entry>cccgatcgtt taggactctt tggtgcaccc cccttagagg agggatatgt ggttctggta   8160</entry></row><row><entry> </entry></row><row><entry>ggagacgaga acctaaaaca gttcccgcct ccgtctgaat ttttgctttc ggtttgggac   8220</entry></row><row><entry> </entry></row><row><entry>cgaagccgcg ccgcgcgtct tgtctgctgc agcatcgttc tgtgttgtct ctgtctgact   8280</entry></row><row><entry> </entry></row><row><entry>gtgtttctgt atttgtctga aaatatgggc ccgggctaga ctgttaccac tcccttaagt   8340</entry></row><row><entry> </entry></row><row><entry>ttgaccttag gtcactggaa agatgtcgag cggatcgctc acaaccagtc ggtagatgtc   8400</entry></row><row><entry> </entry></row><row><entry>aagaagagac gttgggttac cttctgctct gcagaatggc caacctttaa cgtcggatgg   8460</entry></row><row><entry> </entry></row><row><entry>ccgcgagacg gcacctttaa ccgagacctc atcacccagg ttaagatcaa ggtcttttca   8520</entry></row><row><entry> </entry></row><row><entry>cctggcccgc atggacaccc agaccaggtc ccctacatcg tgacctggga agccttggct   8580</entry></row><row><entry> </entry></row><row><entry>tttgaccccc ctccctgggt caagcccttt gtacacccta agcctccgcc tcctcttcct   8640</entry></row><row><entry> </entry></row><row><entry>ccatccgccc cgtctctccc ccttgaacct cctcgttcga ccccgcctcg atcctccctt   8700</entry></row><row><entry> </entry></row><row><entry>tatccagccc tcactccttc tctaggcgcc cccatatggc catatgagat cttatatggg   8760</entry></row><row><entry> </entry></row><row><entry>gcacccccgc cccttgtaaa cttccctgac cctgacatga caagagttac taacagcccc   8820</entry></row><row><entry> </entry></row><row><entry>tctctccaag ctcacttaca ggctctctac ttagtccagc acgaagtctg gagacctctg   8880</entry></row><row><entry> </entry></row><row><entry>gcggcagcct accaagaaca actggaccga ccggtggtac ctcaccctta ccgagtcggc   8940</entry></row><row><entry> </entry></row><row><entry>gacacagtgt gggtccgccg acaccagact aagaacctag aacctcgctg gaaaggacct   9000</entry></row><row><entry> </entry></row><row><entry>tacacagtcc tgctgaccac ccccaccgcc ctcaaagtag acggcatcgc agcttggata   9060</entry></row><row><entry> </entry></row><row><entry>cacgccgccc acgtgaaggc tgccgacccc gggggtggac catcctctag actg         9114</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 104</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 849</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 104</entry></row><row><entry> </entry></row><row><entry>cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat     60</entry></row><row><entry> </entry></row><row><entry>gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc    120</entry></row><row><entry> </entry></row><row><entry>cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc    180</entry></row><row><entry> </entry></row><row><entry>tacgacgccc ttcacatgca ggccctgccc cctcgccggc ggaaacggtc tggatctggg    240</entry></row><row><entry> </entry></row><row><entry>gaaggtcggg gatctttgct cacatgtgga gatgtcgaag agaatcctgg ccctatgaac    300</entry></row><row><entry> </entry></row><row><entry>cggggagtgc ccttccggca cctgctgctg gtgctgcagc tggccctgct gcctgccgct    360</entry></row><row><entry> </entry></row><row><entry>acccagggct acttcggcaa gctggagagc aagctgagcg tgatccggaa cctgaacgac    420</entry></row><row><entry> </entry></row><row><entry>caggtgctgt tcatcgacca gggcaaccgg cctctgttcg aggacatgac cgacagcgac    480</entry></row><row><entry> </entry></row><row><entry>tgccgggaca acgctccccg gaccatcttc atcatcagca tgtacaagga cagccagccc    540</entry></row><row><entry> </entry></row><row><entry>cggggaatgg ccgtgaccat cagcgtgaag tgcgagaaga tcagcaccct gagctgcgag    600</entry></row><row><entry> </entry></row><row><entry>aacaagatca tcagcttcaa ggagatgaac cctcccgaca acatcaagga caccaagagc    660</entry></row><row><entry> </entry></row><row><entry>gacatcatct tcttccagcg gagcgtgcct ggccacgaca acaagatgca gttcgagagc    720</entry></row><row><entry> </entry></row><row><entry>agcagctacg agggctactt cctggcctgc gagaaggagc gggacctgtt caagctgatc    780</entry></row><row><entry> </entry></row><row><entry>ctgaagaagg aggacgagct gggcgaccgg agcatcatgt tcaccgtgca gaacgaggac    840</entry></row><row><entry> </entry></row><row><entry>taactcgag                                                            849</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 105</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9082</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 105</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tctggatctg gggaaggtcg gggatctttg ctcacatgtg   2160</entry></row><row><entry> </entry></row><row><entry>gagatgtcga agagaatcct ggccctatga accggggagt gcccttccgg cacctgctgc   2220</entry></row><row><entry> </entry></row><row><entry>tggtgctgca gctggccctg ctgcctgccg ctacccaggg ctacttcggc aagctggaga   2280</entry></row><row><entry> </entry></row><row><entry>gcaagctgag cgtgatccgg aacctgaacg accaggtgct gttcatcgac cagggcaacc   2340</entry></row><row><entry> </entry></row><row><entry>ggcctctgtt cgaggacatg accgacagcg actgccggga caacgctccc cggaccatct   2400</entry></row><row><entry> </entry></row><row><entry>tcatcatcag catgtacaag gacagccagc cccggggaat ggccgtgacc atcagcgtga   2460</entry></row><row><entry> </entry></row><row><entry>agtgcgagaa gatcagcacc ctgagctgcg agaacaagat catcagcttc aaggagatga   2520</entry></row><row><entry> </entry></row><row><entry>accctcccga caacatcaag gacaccaaga gcgacatcat cttcttccag cggagcgtgc   2580</entry></row><row><entry> </entry></row><row><entry>ctggccacga caacaagatg cagttcgaga gcagcagcta cgagggctac ttcctggcct   2640</entry></row><row><entry> </entry></row><row><entry>gcgagaagga gcgggacctg ttcaagctga tcctgaagaa ggaggacgag ctgggcgacc   2700</entry></row><row><entry> </entry></row><row><entry>ggagcatcat gttcaccgtg cagaacgagg actaactcga gggatccgga ttagtccaat   2760</entry></row><row><entry> </entry></row><row><entry>ttgttaaaga caggatatca gtggtccagg ctctagtttt gactcaacaa tatcaccagc   2820</entry></row><row><entry> </entry></row><row><entry>tgaagcctat agagtacgag ccatagataa aataaaagat tttatttagt ctccagaaaa   2880</entry></row><row><entry> </entry></row><row><entry>aggggggaat gaaagacccc acctgtaggt ttggcaagct agcttaagta acgccatttt   2940</entry></row><row><entry> </entry></row><row><entry>gcaaggcatg gaaaaataca taactgagaa tagagaagtt cagatcaagg tcaggaacag   3000</entry></row><row><entry> </entry></row><row><entry>atggaacagc tgaatatggg ccaaacagga tatctgtggt aagcagttcc tgccccggct   3060</entry></row><row><entry> </entry></row><row><entry>cagggccaag aacagatgga acagctgaat atgggccaaa caggatatct gtggtaagca   3120</entry></row><row><entry> </entry></row><row><entry>gttcctgccc cggctcaggg ccaagaacag atggtcccca gatgcggtcc agccctcagc   3180</entry></row><row><entry> </entry></row><row><entry>agtttctaga gaaccatcag atgtttccag ggtgccccaa ggacctgaaa tgaccctgtg   3240</entry></row><row><entry> </entry></row><row><entry>ccttatttga actaaccaat cagttcgctt ctcgcttctg ttcgcgcgct tctgctcccc   3300</entry></row><row><entry> </entry></row><row><entry>gagctcaata aaagagccca caacccctca ctcggggcgc cagtcctccg attgactgag   3360</entry></row><row><entry> </entry></row><row><entry>tcgcccgggt acccgtgtat ccaataaacc ctcttgcagt tgcatccgac ttgtggtctc   3420</entry></row><row><entry> </entry></row><row><entry>gctgttcctt gggagggtct cctctgagtg attgactacc cgtcagcggg ggtctttcac   3480</entry></row><row><entry> </entry></row><row><entry>acatgcagca tgtatcaaaa ttaatttggt tttttttctt aagtatttac attaaatggc   3540</entry></row><row><entry> </entry></row><row><entry>catagtactt aaagttacat tggcttcctt gaaataaaca tggagtattc agaatgtgtc   3600</entry></row><row><entry> </entry></row><row><entry>ataaatattt ctaattttaa gatagtatct ccattggctt tctacttttt cttttatttt   3660</entry></row><row><entry> </entry></row><row><entry>tttttgtcct ctgtcttcca tttgttgttg ttgttgtttg tttgtttgtt tgttggttgg   3720</entry></row><row><entry> </entry></row><row><entry>ttggttaatt tttttttaaa gatcctacac tatagttcaa gctagactat tagctactct   3780</entry></row><row><entry> </entry></row><row><entry>gtaacccagg gtgaccttga agtcatgggt agcctgctgt tttagccttc ccacatctaa   3840</entry></row><row><entry> </entry></row><row><entry>gattacaggt atgagctatc atttttggta tattgattga ttgattgatt gatgtgtgtg   3900</entry></row><row><entry> </entry></row><row><entry>tgtgtgattg tgtttgtgtg tgtgactgtg aaaatgtgtg tatgggtgtg tgtgaatgtg   3960</entry></row><row><entry> </entry></row><row><entry>tgtatgtatg tgtgtgtgtg agtgtgtgtg tgtgtgtgtg catgtgtgtg tgtgtgactg   4020</entry></row><row><entry> </entry></row><row><entry>tgtctatgtg tatgactgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg   4080</entry></row><row><entry> </entry></row><row><entry>tgttgtgaaa aaatattcta tggtagtgag agccaacgct ccggctcagg tgtcaggttg   4140</entry></row><row><entry> </entry></row><row><entry>gtttttgaga cagagtcttt cacttagctt ggaattcact ggccgtcgtt ttacaacgtc   4200</entry></row><row><entry> </entry></row><row><entry>gtgactggga aaaccctggc gttacccaac ttaatcgcct tgcagcacat ccccctttcg   4260</entry></row><row><entry> </entry></row><row><entry>ccagctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag ttgcgcagcc   4320</entry></row><row><entry> </entry></row><row><entry>tgaatggcga atggcgcctg atgcggtatt ttctccttac gcatctgtgc ggtatttcac   4380</entry></row><row><entry> </entry></row><row><entry>accgcatatg gtgcactctc agtacaatct gctctgatgc cgcatagtta agccagcccc   4440</entry></row><row><entry> </entry></row><row><entry>gacacccgcc aacacccgct gacgcgccct gacgggcttg tctgctcccg gcatccgctt   4500</entry></row><row><entry> </entry></row><row><entry>acagacaagc tgtgaccgtc tccgggagct gcatgtgtca gaggttttca ccgtcatcac   4560</entry></row><row><entry> </entry></row><row><entry>cgaaacgcgc gatgacgaaa gggcctcgtg atacgcctat ttttataggt taatgtcatg   4620</entry></row><row><entry> </entry></row><row><entry>ataataatgg tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaacccct   4680</entry></row><row><entry> </entry></row><row><entry>atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga   4740</entry></row><row><entry> </entry></row><row><entry>taaatgcttc aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc   4800</entry></row><row><entry> </entry></row><row><entry>cttattccct tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg   4860</entry></row><row><entry> </entry></row><row><entry>aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc   4920</entry></row><row><entry> </entry></row><row><entry>aacagcggta agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact   4980</entry></row><row><entry> </entry></row><row><entry>tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc   5040</entry></row><row><entry> </entry></row><row><entry>ggtcgccgca tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag   5100</entry></row><row><entry> </entry></row><row><entry>catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat   5160</entry></row><row><entry> </entry></row><row><entry>aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt   5220</entry></row><row><entry> </entry></row><row><entry>ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa   5280</entry></row><row><entry> </entry></row><row><entry>gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcgc   5340</entry></row><row><entry> </entry></row><row><entry>aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg   5400</entry></row><row><entry> </entry></row><row><entry>gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt   5460</entry></row><row><entry> </entry></row><row><entry>gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca   5520</entry></row><row><entry> </entry></row><row><entry>gatggtaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat   5580</entry></row><row><entry> </entry></row><row><entry>gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca   5640</entry></row><row><entry> </entry></row><row><entry>gaccaagttt actcatatat actttagatt gatttaaaac ttcattttta atttaaaagg   5700</entry></row><row><entry> </entry></row><row><entry>atctaggtga agatcctttt tgataatctc atgaccaaaa tcccttaacg tgagttttcg   5760</entry></row><row><entry> </entry></row><row><entry>ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tccttttttt   5820</entry></row><row><entry> </entry></row><row><entry>ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg   5880</entry></row><row><entry> </entry></row><row><entry>ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata   5940</entry></row><row><entry> </entry></row><row><entry>ccaaatactg tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca   6000</entry></row><row><entry> </entry></row><row><entry>ccgcctacat acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag   6060</entry></row><row><entry> </entry></row><row><entry>tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc   6120</entry></row><row><entry> </entry></row><row><entry>tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga   6180</entry></row><row><entry> </entry></row><row><entry>tacctacagc gtgagcattg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg   6240</entry></row><row><entry> </entry></row><row><entry>tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac   6300</entry></row><row><entry> </entry></row><row><entry>gcctggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg   6360</entry></row><row><entry> </entry></row><row><entry>tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg   6420</entry></row><row><entry> </entry></row><row><entry>ttcctggcct tttgctggcc ttttgctcac atgttctttc ctgcgttatc ccctgattct   6480</entry></row><row><entry> </entry></row><row><entry>gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgcag ccgaacgacc   6540</entry></row><row><entry> </entry></row><row><entry>gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc caatacgcaa accgcctctc   6600</entry></row><row><entry> </entry></row><row><entry>cccgcgcgtt ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg   6660</entry></row><row><entry> </entry></row><row><entry>ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta   6720</entry></row><row><entry> </entry></row><row><entry>cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca   6780</entry></row><row><entry> </entry></row><row><entry>ggaaacagct atgaccatga ttacgccaag ctttgctctt aggagtttcc taatacatcc   6840</entry></row><row><entry> </entry></row><row><entry>caaactcaaa tatataaagc atttgacttg ttctatgccc tagggggcgg ggggaagcta   6900</entry></row><row><entry> </entry></row><row><entry>agccagcttt ttttaacatt taaaatgtta attccatttt aaatgcacag atgtttttat   6960</entry></row><row><entry> </entry></row><row><entry>ttcataaggg tttcaatgtg catgaatgct gcaatattcc tgttaccaaa gctagtataa   7020</entry></row><row><entry> </entry></row><row><entry>ataaaaatag ataaacgtgg aaattactta gagtttctgt cattaacgtt tccttcctca   7080</entry></row><row><entry> </entry></row><row><entry>gttgacaaca taaatgcgct gctgagcaag ccagtttgca tctgtcagga tcaatttccc   7140</entry></row><row><entry> </entry></row><row><entry>attatgccag tcatattaat tactagtcaa ttagttgatt tttatttttg acatatacat   7200</entry></row><row><entry> </entry></row><row><entry>gtgaatgaaa gaccccacct gtaggtttgg caagctagct taagtaacgc cattttgcaa   7260</entry></row><row><entry> </entry></row><row><entry>ggcatggaaa aatacataac tgagaataga aaagttcaga tcaaggtcag gaacagatgg   7320</entry></row><row><entry> </entry></row><row><entry>aacagctgaa tatgggccaa acaggatatc tgtggtaagc agttcctgcc ccggctcagg   7380</entry></row><row><entry> </entry></row><row><entry>gccaagaaca gatggaacag ctgaatatgg gccaaacagg atatctgtgg taagcagttc   7440</entry></row><row><entry> </entry></row><row><entry>ctgccccggc tcagggccaa gaacagatgg tccccagatg cggtccagcc ctcagcagtt   7500</entry></row><row><entry> </entry></row><row><entry>tctagagaac catcagatgt ttccagggtg ccccaaggac ctgaaatgac cctgtgcctt   7560</entry></row><row><entry> </entry></row><row><entry>atttgaacta accaatcagt tcgcttctcg cttctgttcg cgcgcttatg ctccccgagc   7620</entry></row><row><entry> </entry></row><row><entry>tcaataaaag agcccacaac ccctcactcg gggcgccagt cctccgattg actgagtcgc   7680</entry></row><row><entry> </entry></row><row><entry>ccgggtaccc gtgtatccaa taaaccctct tgcagttgca tccgacttgt ggtctcgctg   7740</entry></row><row><entry> </entry></row><row><entry>ttccttggga gggtctcctc tgagtgattg actacccgtc agcgggggtc tttcatttgg   7800</entry></row><row><entry> </entry></row><row><entry>gggctcgtcc gggatcggga gacccctgcc cagggaccac cgacccacca ccgggaggta   7860</entry></row><row><entry> </entry></row><row><entry>agctggccag caacttatct gtgtctgtcc gattgtctag tgtctatgac tgattttatg   7920</entry></row><row><entry> </entry></row><row><entry>cgcctgcgtc ggtactagtt agctaactag ctctgtatct ggcggacccg tggtggaact   7980</entry></row><row><entry> </entry></row><row><entry>gacgagttcg gaacacccgg ccgcaaccct gggagacgtc ccagggactt cgggggccgt   8040</entry></row><row><entry> </entry></row><row><entry>ttttgtggcc cgacctgagt cctaaaatcc cgatcgttta ggactctttg gtgcaccccc   8100</entry></row><row><entry> </entry></row><row><entry>cttagaggag ggatatgtgg ttctggtagg agacgagaac ctaaaacagt tcccgcctcc   8160</entry></row><row><entry> </entry></row><row><entry>gtctgaattt ttgctttcgg tttgggaccg aagccgcgcc gcgcgtcttg tctgctgcag   8220</entry></row><row><entry> </entry></row><row><entry>catcgttctg tgttgtctct gtctgactgt gtttctgtat ttgtctgaaa atatgggccc   8280</entry></row><row><entry> </entry></row><row><entry>gggctagact gttaccactc ccttaagttt gaccttaggt cactggaaag atgtcgagcg   8340</entry></row><row><entry> </entry></row><row><entry>gatcgctcac aaccagtcgg tagatgtcaa gaagagacgt tgggttacct tctgctctgc   8400</entry></row><row><entry> </entry></row><row><entry>agaatggcca acctttaacg tcggatggcc gcgagacggc acctttaacc gagacctcat   8460</entry></row><row><entry> </entry></row><row><entry>cacccaggtt aagatcaagg tcttttcacc tggcccgcat ggacacccag accaggtccc   8520</entry></row><row><entry> </entry></row><row><entry>ctacatcgtg acctgggaag ccttggcttt tgacccccct ccctgggtca agccctttgt   8580</entry></row><row><entry> </entry></row><row><entry>acaccctaag cctccgcctc ctcttcctcc atccgccccg tctctccccc ttgaacctcc   8640</entry></row><row><entry> </entry></row><row><entry>tcgttcgacc ccgcctcgat cctcccttta tccagccctc actccttctc taggcgcccc   8700</entry></row><row><entry> </entry></row><row><entry>catatggcca tatgagatct tatatggggc acccccgccc cttgtaaact tccctgaccc   8760</entry></row><row><entry> </entry></row><row><entry>tgacatgaca agagttacta acagcccctc tctccaagct cacttacagg ctctctactt   8820</entry></row><row><entry> </entry></row><row><entry>agtccagcac gaagtctgga gacctctggc ggcagcctac caagaacaac tggaccgacc   8880</entry></row><row><entry> </entry></row><row><entry>ggtggtacct cacccttacc gagtcggcga cacagtgtgg gtccgccgac accagactaa   8940</entry></row><row><entry> </entry></row><row><entry>gaacctagaa cctcgctgga aaggacctta cacagtcctg ctgaccaccc ccaccgccct   9000</entry></row><row><entry> </entry></row><row><entry>caaagtagac ggcatcgcag cttggataca cgccgcccac gtgaaggctg ccgaccccgg   9060</entry></row><row><entry> </entry></row><row><entry>gggtggacca tcctctagac tg                                            9082</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 106</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 885</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 106</entry></row><row><entry> </entry></row><row><entry>cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat     60</entry></row><row><entry> </entry></row><row><entry>gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc    120</entry></row><row><entry> </entry></row><row><entry>cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc    180</entry></row><row><entry> </entry></row><row><entry>tacgacgccc ttcacatgca ggccctgccc cctcgccggc ggaaacggtc tggatctggg    240</entry></row><row><entry> </entry></row><row><entry>gaaggtcggg gatctttgct cacatgtgga gatgtcgaag agaatcctgg ccctatggcc    300</entry></row><row><entry> </entry></row><row><entry>gccgagcccg tggaggacaa ctgcatcaac ttcgtggcca tgaagttcat cgacaacacc    360</entry></row><row><entry> </entry></row><row><entry>ctgtacttca tcgccgagga cgacgagaac atcgagaccg acatctactt cggcaagctg    420</entry></row><row><entry> </entry></row><row><entry>gagagcaagc tgagcgtgat ccggaacctg aacgaccagg tgctgttcat cgaccagggc    480</entry></row><row><entry> </entry></row><row><entry>aaccggcctc tgttcgagga catgaccgac agcgactgcc gggacaacgc tccccggacc    540</entry></row><row><entry> </entry></row><row><entry>atcttcatca tcagcatgta caaggacagc cagccccggg gaatggccgt gaccatcagc    600</entry></row><row><entry> </entry></row><row><entry>gtgaagtgcg agaagatcag caccctgagc tgcgagaaca agatcatcag cttcaaggag    660</entry></row><row><entry> </entry></row><row><entry>atgaaccctc ccgacaacat caaggacacc aagagcgaca tcatcttctt ccagcggagc    720</entry></row><row><entry> </entry></row><row><entry>gtgcctggcc acgacaacaa gatgcagttc gagagcagca gctacgaggg ctacttcctg    780</entry></row><row><entry> </entry></row><row><entry>gcctgcgaga aggagcggga cctgttcaag ctgatcctga agaaggagga cgagctgggc    840</entry></row><row><entry> </entry></row><row><entry>gaccggagca tcatgttcac cgtgcagaac gaggactaac tcgag                    885</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 107</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9118</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 107</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tctggatctg gggaaggtcg gggatctttg ctcacatgtg   2160</entry></row><row><entry> </entry></row><row><entry>gagatgtcga agagaatcct ggccctatgg ccgccgagcc cgtggaggac aactgcatca   2220</entry></row><row><entry> </entry></row><row><entry>acttcgtggc catgaagttc atcgacaaca ccctgtactt catcgccgag gacgacgaga   2280</entry></row><row><entry> </entry></row><row><entry>acatcgagac cgacatctac ttcggcaagc tggagagcaa gctgagcgtg atccggaacc   2340</entry></row><row><entry> </entry></row><row><entry>tgaacgacca ggtgctgttc atcgaccagg gcaaccggcc tctgttcgag gacatgaccg   2400</entry></row><row><entry> </entry></row><row><entry>acagcgactg ccgggacaac gctccccgga ccatcttcat catcagcatg tacaaggaca   2460</entry></row><row><entry> </entry></row><row><entry>gccagccccg gggaatggcc gtgaccatca gcgtgaagtg cgagaagatc agcaccctga   2520</entry></row><row><entry> </entry></row><row><entry>gctgcgagaa caagatcatc agcttcaagg agatgaaccc tcccgacaac atcaaggaca   2580</entry></row><row><entry> </entry></row><row><entry>ccaagagcga catcatcttc ttccagcgga gcgtgcctgg ccacgacaac aagatgcagt   2640</entry></row><row><entry> </entry></row><row><entry>tcgagagcag cagctacgag ggctacttcc tggcctgcga gaaggagcgg gacctgttca   2700</entry></row><row><entry> </entry></row><row><entry>agctgatcct gaagaaggag gacgagctgg gcgaccggag catcatgttc accgtgcaga   2760</entry></row><row><entry> </entry></row><row><entry>acgaggacta actcgaggga tccggattag tccaatttgt taaagacagg atatcagtgg   2820</entry></row><row><entry> </entry></row><row><entry>tccaggctct agttttgact caacaatatc accagctgaa gcctatagag tacgagccat   2880</entry></row><row><entry> </entry></row><row><entry>agataaaata aaagatttta tttagtctcc agaaaaaggg gggaatgaaa gaccccacct   2940</entry></row><row><entry> </entry></row><row><entry>gtaggtttgg caagctagct taagtaacgc cattttgcaa ggcatggaaa aatacataac   3000</entry></row><row><entry> </entry></row><row><entry>tgagaataga gaagttcaga tcaaggtcag gaacagatgg aacagctgaa tatgggccaa   3060</entry></row><row><entry> </entry></row><row><entry>acaggatatc tgtggtaagc agttcctgcc ccggctcagg gccaagaaca gatggaacag   3120</entry></row><row><entry> </entry></row><row><entry>ctgaatatgg gccaaacagg atatctgtgg taagcagttc ctgccccggc tcagggccaa   3180</entry></row><row><entry> </entry></row><row><entry>gaacagatgg tccccagatg cggtccagcc ctcagcagtt tctagagaac catcagatgt   3240</entry></row><row><entry> </entry></row><row><entry>ttccagggtg ccccaaggac ctgaaatgac cctgtgcctt atttgaacta accaatcagt   3300</entry></row><row><entry> </entry></row><row><entry>tcgcttctcg cttctgttcg cgcgcttctg ctccccgagc tcaataaaag agcccacaac   3360</entry></row><row><entry> </entry></row><row><entry>ccctcactcg gggcgccagt cctccgattg actgagtcgc ccgggtaccc gtgtatccaa   3420</entry></row><row><entry> </entry></row><row><entry>taaaccctct tgcagttgca tccgacttgt ggtctcgctg ttccttggga gggtctcctc   3480</entry></row><row><entry> </entry></row><row><entry>tgagtgattg actacccgtc agcgggggtc tttcacacat gcagcatgta tcaaaattaa   3540</entry></row><row><entry> </entry></row><row><entry>tttggttttt tttcttaagt atttacatta aatggccata gtacttaaag ttacattggc   3600</entry></row><row><entry> </entry></row><row><entry>ttccttgaaa taaacatgga gtattcagaa tgtgtcataa atatttctaa ttttaagata   3660</entry></row><row><entry> </entry></row><row><entry>gtatctccat tggctttcta ctttttcttt tatttttttt tgtcctctgt cttccatttg   3720</entry></row><row><entry> </entry></row><row><entry>ttgttgttgt tgtttgtttg tttgtttgtt ggttggttgg ttaatttttt tttaaagatc   3780</entry></row><row><entry> </entry></row><row><entry>ctacactata gttcaagcta gactattagc tactctgtaa cccagggtga ccttgaagtc   3840</entry></row><row><entry> </entry></row><row><entry>atgggtagcc tgctgtttta gccttcccac atctaagatt acaggtatga gctatcattt   3900</entry></row><row><entry> </entry></row><row><entry>ttggtatatt gattgattga ttgattgatg tgtgtgtgtg tgattgtgtt tgtgtgtgtg   3960</entry></row><row><entry> </entry></row><row><entry>actgtgaaaa tgtgtgtatg ggtgtgtgtg aatgtgtgta tgtatgtgtg tgtgtgagtg   4020</entry></row><row><entry> </entry></row><row><entry>tgtgtgtgtg tgtgtgcatg tgtgtgtgtg tgactgtgtc tatgtgtatg actgtgtgtg   4080</entry></row><row><entry> </entry></row><row><entry>tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtt gtgaaaaaat attctatggt   4140</entry></row><row><entry> </entry></row><row><entry>agtgagagcc aacgctccgg ctcaggtgtc aggttggttt ttgagacaga gtctttcact   4200</entry></row><row><entry> </entry></row><row><entry>tagcttggaa ttcactggcc gtcgttttac aacgtcgtga ctgggaaaac cctggcgtta   4260</entry></row><row><entry> </entry></row><row><entry>cccaacttaa tcgccttgca gcacatcccc ctttcgccag ctggcgtaat agcgaagagg   4320</entry></row><row><entry> </entry></row><row><entry>cccgcaccga tcgcccttcc caacagttgc gcagcctgaa tggcgaatgg cgcctgatgc   4380</entry></row><row><entry> </entry></row><row><entry>ggtattttct ccttacgcat ctgtgcggta tttcacaccg catatggtgc actctcagta   4440</entry></row><row><entry> </entry></row><row><entry>caatctgctc tgatgccgca tagttaagcc agccccgaca cccgccaaca cccgctgacg   4500</entry></row><row><entry> </entry></row><row><entry>cgccctgacg ggcttgtctg ctcccggcat ccgcttacag acaagctgtg accgtctccg   4560</entry></row><row><entry> </entry></row><row><entry>ggagctgcat gtgtcagagg ttttcaccgt catcaccgaa acgcgcgatg acgaaagggc   4620</entry></row><row><entry> </entry></row><row><entry>ctcgtgatac gcctattttt ataggttaat gtcatgataa taatggtttc ttagacgtca   4680</entry></row><row><entry> </entry></row><row><entry>ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattttt ctaaatacat   4740</entry></row><row><entry> </entry></row><row><entry>tcaaatatgt atccgctcat gagacaataa ccctgataaa tgcttcaata atattgaaaa   4800</entry></row><row><entry> </entry></row><row><entry>aggaagagta tgagtattca acatttccgt gtcgccctta ttcccttttt tgcggcattt   4860</entry></row><row><entry> </entry></row><row><entry>tgccttcctg tttttgctca cccagaaacg ctggtgaaag taaaagatgc tgaagatcag   4920</entry></row><row><entry> </entry></row><row><entry>ttgggtgcac gagtgggtta catcgaactg gatctcaaca gcggtaagat ccttgagagt   4980</entry></row><row><entry> </entry></row><row><entry>tttcgccccg aagaacgttt tccaatgatg agcactttta aagttctgct atgtggcgcg   5040</entry></row><row><entry> </entry></row><row><entry>gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca ctattctcag   5100</entry></row><row><entry> </entry></row><row><entry>aatgacttgg ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta   5160</entry></row><row><entry> </entry></row><row><entry>agagaattat gcagtgctgc cataaccatg agtgataaca ctgcggccaa cttacttctg   5220</entry></row><row><entry> </entry></row><row><entry>acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta   5280</entry></row><row><entry> </entry></row><row><entry>actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga cgagcgtgac   5340</entry></row><row><entry> </entry></row><row><entry>accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg cgaactactt   5400</entry></row><row><entry> </entry></row><row><entry>actctagctt cccggcaaca attaatagac tggatggagg cggataaagt tgcaggacca   5460</entry></row><row><entry> </entry></row><row><entry>cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg agccggtgag   5520</entry></row><row><entry> </entry></row><row><entry>cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta   5580</entry></row><row><entry> </entry></row><row><entry>gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgctgag   5640</entry></row><row><entry> </entry></row><row><entry>ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc atatatactt   5700</entry></row><row><entry> </entry></row><row><entry>tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat   5760</entry></row><row><entry> </entry></row><row><entry>aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta   5820</entry></row><row><entry> </entry></row><row><entry>gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa   5880</entry></row><row><entry> </entry></row><row><entry>acaaaaaaac caccgctacc agcggtggtt tgtttgccgg atcaagagct accaactctt   5940</entry></row><row><entry> </entry></row><row><entry>tttccgaagg taactggctt cagcagagcg cagataccaa atactgtcct tctagtgtag   6000</entry></row><row><entry> </entry></row><row><entry>ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta   6060</entry></row><row><entry> </entry></row><row><entry>atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg gttggactca   6120</entry></row><row><entry> </entry></row><row><entry>agacgatagt taccggataa ggcgcagcgg tcgggctgaa cggggggttc gtgcacacag   6180</entry></row><row><entry> </entry></row><row><entry>cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gcattgagaa   6240</entry></row><row><entry> </entry></row><row><entry>agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga   6300</entry></row><row><entry> </entry></row><row><entry>acaggagagc gcacgaggga gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc   6360</entry></row><row><entry> </entry></row><row><entry>gggtttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc   6420</entry></row><row><entry> </entry></row><row><entry>ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt   6480</entry></row><row><entry> </entry></row><row><entry>gctcacatgt tctttcctgc gttatcccct gattctgtgg ataaccgtat taccgccttt   6540</entry></row><row><entry> </entry></row><row><entry>gagtgagctg ataccgctcg ccgcagccga acgaccgagc gcagcgagtc agtgagcgag   6600</entry></row><row><entry> </entry></row><row><entry>gaagcggaag agcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa   6660</entry></row><row><entry> </entry></row><row><entry>tgcagctggc acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat   6720</entry></row><row><entry> </entry></row><row><entry>gtgagttagc tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg   6780</entry></row><row><entry> </entry></row><row><entry>ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac   6840</entry></row><row><entry> </entry></row><row><entry>gccaagcttt gctcttagga gtttcctaat acatcccaaa ctcaaatata taaagcattt   6900</entry></row><row><entry> </entry></row><row><entry>gacttgttct atgccctagg gggcgggggg aagctaagcc agcttttttt aacatttaaa   6960</entry></row><row><entry> </entry></row><row><entry>atgttaattc cattttaaat gcacagatgt ttttatttca taagggtttc aatgtgcatg   7020</entry></row><row><entry> </entry></row><row><entry>aatgctgcaa tattcctgtt accaaagcta gtataaataa aaatagataa acgtggaaat   7080</entry></row><row><entry> </entry></row><row><entry>tacttagagt ttctgtcatt aacgtttcct tcctcagttg acaacataaa tgcgctgctg   7140</entry></row><row><entry> </entry></row><row><entry>agcaagccag tttgcatctg tcaggatcaa tttcccatta tgccagtcat attaattact   7200</entry></row><row><entry> </entry></row><row><entry>agtcaattag ttgattttta tttttgacat atacatgtga atgaaagacc ccacctgtag   7260</entry></row><row><entry> </entry></row><row><entry>gtttggcaag ctagcttaag taacgccatt ttgcaaggca tggaaaaata cataactgag   7320</entry></row><row><entry> </entry></row><row><entry>aatagaaaag ttcagatcaa ggtcaggaac agatggaaca gctgaatatg ggccaaacag   7380</entry></row><row><entry> </entry></row><row><entry>gatatctgtg gtaagcagtt cctgccccgg ctcagggcca agaacagatg gaacagctga   7440</entry></row><row><entry> </entry></row><row><entry>atatgggcca aacaggatat ctgtggtaag cagttcctgc cccggctcag ggccaagaac   7500</entry></row><row><entry> </entry></row><row><entry>agatggtccc cagatgcggt ccagccctca gcagtttcta gagaaccatc agatgtttcc   7560</entry></row><row><entry> </entry></row><row><entry>agggtgcccc aaggacctga aatgaccctg tgccttattt gaactaacca atcagttcgc   7620</entry></row><row><entry> </entry></row><row><entry>ttctcgcttc tgttcgcgcg cttatgctcc ccgagctcaa taaaagagcc cacaacccct   7680</entry></row><row><entry> </entry></row><row><entry>cactcggggc gccagtcctc cgattgactg agtcgcccgg gtacccgtgt atccaataaa   7740</entry></row><row><entry> </entry></row><row><entry>ccctcttgca gttgcatccg acttgtggtc tcgctgttcc ttgggagggt ctcctctgag   7800</entry></row><row><entry> </entry></row><row><entry>tgattgacta cccgtcagcg ggggtctttc atttgggggc tcgtccggga tcgggagacc   7860</entry></row><row><entry> </entry></row><row><entry>cctgcccagg gaccaccgac ccaccaccgg gaggtaagct ggccagcaac ttatctgtgt   7920</entry></row><row><entry> </entry></row><row><entry>ctgtccgatt gtctagtgtc tatgactgat tttatgcgcc tgcgtcggta ctagttagct   7980</entry></row><row><entry> </entry></row><row><entry>aactagctct gtatctggcg gacccgtggt ggaactgacg agttcggaac acccggccgc   8040</entry></row><row><entry> </entry></row><row><entry>aaccctggga gacgtcccag ggacttcggg ggccgttttt gtggcccgac ctgagtccta   8100</entry></row><row><entry> </entry></row><row><entry>aaatcccgat cgtttaggac tctttggtgc acccccctta gaggagggat atgtggttct   8160</entry></row><row><entry> </entry></row><row><entry>ggtaggagac gagaacctaa aacagttccc gcctccgtct gaatttttgc tttcggtttg   8220</entry></row><row><entry> </entry></row><row><entry>ggaccgaagc cgcgccgcgc gtcttgtctg ctgcagcatc gttctgtgtt gtctctgtct   8280</entry></row><row><entry> </entry></row><row><entry>gactgtgttt ctgtatttgt ctgaaaatat gggcccgggc tagactgtta ccactccctt   8340</entry></row><row><entry> </entry></row><row><entry>aagtttgacc ttaggtcact ggaaagatgt cgagcggatc gctcacaacc agtcggtaga   8400</entry></row><row><entry> </entry></row><row><entry>tgtcaagaag agacgttggg ttaccttctg ctctgcagaa tggccaacct ttaacgtcgg   8460</entry></row><row><entry> </entry></row><row><entry>atggccgcga gacggcacct ttaaccgaga cctcatcacc caggttaaga tcaaggtctt   8520</entry></row><row><entry> </entry></row><row><entry>ttcacctggc ccgcatggac acccagacca ggtcccctac atcgtgacct gggaagcctt   8580</entry></row><row><entry> </entry></row><row><entry>ggcttttgac ccccctccct gggtcaagcc ctttgtacac cctaagcctc cgcctcctct   8640</entry></row><row><entry> </entry></row><row><entry>tcctccatcc gccccgtctc tcccccttga acctcctcgt tcgaccccgc ctcgatcctc   8700</entry></row><row><entry> </entry></row><row><entry>cctttatcca gccctcactc cttctctagg cgcccccata tggccatatg agatcttata   8760</entry></row><row><entry> </entry></row><row><entry>tggggcaccc ccgccccttg taaacttccc tgaccctgac atgacaagag ttactaacag   8820</entry></row><row><entry> </entry></row><row><entry>cccctctctc caagctcact tacaggctct ctacttagtc cagcacgaag tctggagacc   8880</entry></row><row><entry> </entry></row><row><entry>tctggcggca gcctaccaag aacaactgga ccgaccggtg gtacctcacc cttaccgagt   8940</entry></row><row><entry> </entry></row><row><entry>cggcgacaca gtgtgggtcc gccgacacca gactaagaac ctagaacctc gctggaaagg   9000</entry></row><row><entry> </entry></row><row><entry>accttacaca gtcctgctga ccacccccac cgccctcaaa gtagacggca tcgcagcttg   9060</entry></row><row><entry> </entry></row><row><entry>gatacacgcc gcccacgtga aggctgccga ccccgggggt ggaccatcct ctagactg     9118</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 108</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 885</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 108</entry></row><row><entry> </entry></row><row><entry>cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat     60</entry></row><row><entry> </entry></row><row><entry>gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc    120</entry></row><row><entry> </entry></row><row><entry>cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc    180</entry></row><row><entry> </entry></row><row><entry>tacgacgccc ttcacatgca ggccctgccc cctcgccggc ggaaacggtc tggatctggg    240</entry></row><row><entry> </entry></row><row><entry>gaaggtcggg gatctttgct cacatgtgga gatgtcgaag agaatcctgg ccctatggcc    300</entry></row><row><entry> </entry></row><row><entry>gccgagcccg tggaggacaa ctgcatcaac ttcgtggcca tgaagttcat cgacaacacc    360</entry></row><row><entry> </entry></row><row><entry>ctgtacttca tcgccgagga cgacgagaac gacgaggtgg acatctactt cggcaagctg    420</entry></row><row><entry> </entry></row><row><entry>gagagcaagc tgagcgtgat ccggaacctg aacgaccagg tgctgttcat cgaccagggc    480</entry></row><row><entry> </entry></row><row><entry>aaccggcctc tgttcgagga catgaccgac agcgactgcc gggacaacgc tccccggacc    540</entry></row><row><entry> </entry></row><row><entry>atcttcatca tcagcatgta caaggacagc cagccccggg gaatggccgt gaccatcagc    600</entry></row><row><entry> </entry></row><row><entry>gtgaagtgcg agaagatcag caccctgagc tgcgagaaca agatcatcag cttcaaggag    660</entry></row><row><entry> </entry></row><row><entry>atgaaccctc ccgacaacat caaggacacc aagagcgaca tcatcttctt ccagcggagc    720</entry></row><row><entry> </entry></row><row><entry>gtgcctggcc acgacaacaa gatgcagttc gagagcagca gctacgaggg ctacttcctg    780</entry></row><row><entry> </entry></row><row><entry>gcctgcgaga aggagcggga cctgttcaag ctgatcctga agaaggagga cgagctgggc    840</entry></row><row><entry> </entry></row><row><entry>gaccggagca tcatgttcac cgtgcagaac gaggactaac tcgag                    885</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 109</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9118</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 109</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tctggatctg gggaaggtcg gggatctttg ctcacatgtg   2160</entry></row><row><entry> </entry></row><row><entry>gagatgtcga agagaatcct ggccctatgg ccgccgagcc cgtggaggac aactgcatca   2220</entry></row><row><entry> </entry></row><row><entry>acttcgtggc catgaagttc atcgacaaca ccctgtactt catcgccgag gacgacgaga   2280</entry></row><row><entry> </entry></row><row><entry>acgacgaggt ggacatctac ttcggcaagc tggagagcaa gctgagcgtg atccggaacc   2340</entry></row><row><entry> </entry></row><row><entry>tgaacgacca ggtgctgttc atcgaccagg gcaaccggcc tctgttcgag gacatgaccg   2400</entry></row><row><entry> </entry></row><row><entry>acagcgactg ccgggacaac gctccccgga ccatcttcat catcagcatg tacaaggaca   2460</entry></row><row><entry> </entry></row><row><entry>gccagccccg gggaatggcc gtgaccatca gcgtgaagtg cgagaagatc agcaccctga   2520</entry></row><row><entry> </entry></row><row><entry>gctgcgagaa caagatcatc agcttcaagg agatgaaccc tcccgacaac atcaaggaca   2580</entry></row><row><entry> </entry></row><row><entry>ccaagagcga catcatcttc ttccagcgga gcgtgcctgg ccacgacaac aagatgcagt   2640</entry></row><row><entry> </entry></row><row><entry>tcgagagcag cagctacgag ggctacttcc tggcctgcga gaaggagcgg gacctgttca   2700</entry></row><row><entry> </entry></row><row><entry>agctgatcct gaagaaggag gacgagctgg gcgaccggag catcatgttc accgtgcaga   2760</entry></row><row><entry> </entry></row><row><entry>acgaggacta actcgaggga tccggattag tccaatttgt taaagacagg atatcagtgg   2820</entry></row><row><entry> </entry></row><row><entry>tccaggctct agttttgact caacaatatc accagctgaa gcctatagag tacgagccat   2880</entry></row><row><entry> </entry></row><row><entry>agataaaata aaagatttta tttagtctcc agaaaaaggg gggaatgaaa gaccccacct   2940</entry></row><row><entry> </entry></row><row><entry>gtaggtttgg caagctagct taagtaacgc cattttgcaa ggcatggaaa aatacataac   3000</entry></row><row><entry> </entry></row><row><entry>tgagaataga gaagttcaga tcaaggtcag gaacagatgg aacagctgaa tatgggccaa   3060</entry></row><row><entry> </entry></row><row><entry>acaggatatc tgtggtaagc agttcctgcc ccggctcagg gccaagaaca gatggaacag   3120</entry></row><row><entry> </entry></row><row><entry>ctgaatatgg gccaaacagg atatctgtgg taagcagttc ctgccccggc tcagggccaa   3180</entry></row><row><entry> </entry></row><row><entry>gaacagatgg tccccagatg cggtccagcc ctcagcagtt tctagagaac catcagatgt   3240</entry></row><row><entry> </entry></row><row><entry>ttccagggtg ccccaaggac ctgaaatgac cctgtgcctt atttgaacta accaatcagt   3300</entry></row><row><entry> </entry></row><row><entry>tcgcttctcg cttctgttcg cgcgcttctg ctccccgagc tcaataaaag agcccacaac   3360</entry></row><row><entry> </entry></row><row><entry>ccctcactcg gggcgccagt cctccgattg actgagtcgc ccgggtaccc gtgtatccaa   3420</entry></row><row><entry> </entry></row><row><entry>taaaccctct tgcagttgca tccgacttgt ggtctcgctg ttccttggga gggtctcctc   3480</entry></row><row><entry> </entry></row><row><entry>tgagtgattg actacccgtc agcgggggtc tttcacacat gcagcatgta tcaaaattaa   3540</entry></row><row><entry> </entry></row><row><entry>tttggttttt tttcttaagt atttacatta aatggccata gtacttaaag ttacattggc   3600</entry></row><row><entry> </entry></row><row><entry>ttccttgaaa taaacatgga gtattcagaa tgtgtcataa atatttctaa ttttaagata   3660</entry></row><row><entry> </entry></row><row><entry>gtatctccat tggctttcta ctttttcttt tatttttttt tgtcctctgt cttccatttg   3720</entry></row><row><entry> </entry></row><row><entry>ttgttgttgt tgtttgtttg tttgtttgtt ggttggttgg ttaatttttt tttaaagatc   3780</entry></row><row><entry> </entry></row><row><entry>ctacactata gttcaagcta gactattagc tactctgtaa cccagggtga ccttgaagtc   3840</entry></row><row><entry> </entry></row><row><entry>atgggtagcc tgctgtttta gccttcccac atctaagatt acaggtatga gctatcattt   3900</entry></row><row><entry> </entry></row><row><entry>ttggtatatt gattgattga ttgattgatg tgtgtgtgtg tgattgtgtt tgtgtgtgtg   3960</entry></row><row><entry> </entry></row><row><entry>actgtgaaaa tgtgtgtatg ggtgtgtgtg aatgtgtgta tgtatgtgtg tgtgtgagtg   4020</entry></row><row><entry> </entry></row><row><entry>tgtgtgtgtg tgtgtgcatg tgtgtgtgtg tgactgtgtc tatgtgtatg actgtgtgtg   4080</entry></row><row><entry> </entry></row><row><entry>tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtt gtgaaaaaat attctatggt   4140</entry></row><row><entry> </entry></row><row><entry>agtgagagcc aacgctccgg ctcaggtgtc aggttggttt ttgagacaga gtctttcact   4200</entry></row><row><entry> </entry></row><row><entry>tagcttggaa ttcactggcc gtcgttttac aacgtcgtga ctgggaaaac cctggcgtta   4260</entry></row><row><entry> </entry></row><row><entry>cccaacttaa tcgccttgca gcacatcccc ctttcgccag ctggcgtaat agcgaagagg   4320</entry></row><row><entry> </entry></row><row><entry>cccgcaccga tcgcccttcc caacagttgc gcagcctgaa tggcgaatgg cgcctgatgc   4380</entry></row><row><entry> </entry></row><row><entry>ggtattttct ccttacgcat ctgtgcggta tttcacaccg catatggtgc actctcagta   4440</entry></row><row><entry> </entry></row><row><entry>caatctgctc tgatgccgca tagttaagcc agccccgaca cccgccaaca cccgctgacg   4500</entry></row><row><entry> </entry></row><row><entry>cgccctgacg ggcttgtctg ctcccggcat ccgcttacag acaagctgtg accgtctccg   4560</entry></row><row><entry> </entry></row><row><entry>ggagctgcat gtgtcagagg ttttcaccgt catcaccgaa acgcgcgatg acgaaagggc   4620</entry></row><row><entry> </entry></row><row><entry>ctcgtgatac gcctattttt ataggttaat gtcatgataa taatggtttc ttagacgtca   4680</entry></row><row><entry> </entry></row><row><entry>ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattttt ctaaatacat   4740</entry></row><row><entry> </entry></row><row><entry>tcaaatatgt atccgctcat gagacaataa ccctgataaa tgcttcaata atattgaaaa   4800</entry></row><row><entry> </entry></row><row><entry>aggaagagta tgagtattca acatttccgt gtcgccctta ttcccttttt tgcggcattt   4860</entry></row><row><entry> </entry></row><row><entry>tgccttcctg tttttgctca cccagaaacg ctggtgaaag taaaagatgc tgaagatcag   4920</entry></row><row><entry> </entry></row><row><entry>ttgggtgcac gagtgggtta catcgaactg gatctcaaca gcggtaagat ccttgagagt   4980</entry></row><row><entry> </entry></row><row><entry>tttcgccccg aagaacgttt tccaatgatg agcactttta aagttctgct atgtggcgcg   5040</entry></row><row><entry> </entry></row><row><entry>gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca ctattctcag   5100</entry></row><row><entry> </entry></row><row><entry>aatgacttgg ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta   5160</entry></row><row><entry> </entry></row><row><entry>agagaattat gcagtgctgc cataaccatg agtgataaca ctgcggccaa cttacttctg   5220</entry></row><row><entry> </entry></row><row><entry>acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta   5280</entry></row><row><entry> </entry></row><row><entry>actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga cgagcgtgac   5340</entry></row><row><entry> </entry></row><row><entry>accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg cgaactactt   5400</entry></row><row><entry> </entry></row><row><entry>actctagctt cccggcaaca attaatagac tggatggagg cggataaagt tgcaggacca   5460</entry></row><row><entry> </entry></row><row><entry>cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg agccggtgag   5520</entry></row><row><entry> </entry></row><row><entry>cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta   5580</entry></row><row><entry> </entry></row><row><entry>gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgctgag   5640</entry></row><row><entry> </entry></row><row><entry>ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc atatatactt   5700</entry></row><row><entry> </entry></row><row><entry>tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat   5760</entry></row><row><entry> </entry></row><row><entry>aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta   5820</entry></row><row><entry> </entry></row><row><entry>gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa   5880</entry></row><row><entry> </entry></row><row><entry>acaaaaaaac caccgctacc agcggtggtt tgtttgccgg atcaagagct accaactctt   5940</entry></row><row><entry> </entry></row><row><entry>tttccgaagg taactggctt cagcagagcg cagataccaa atactgtcct tctagtgtag   6000</entry></row><row><entry> </entry></row><row><entry>ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta   6060</entry></row><row><entry> </entry></row><row><entry>atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg gttggactca   6120</entry></row><row><entry> </entry></row><row><entry>agacgatagt taccggataa ggcgcagcgg tcgggctgaa cggggggttc gtgcacacag   6180</entry></row><row><entry> </entry></row><row><entry>cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gcattgagaa   6240</entry></row><row><entry> </entry></row><row><entry>agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga   6300</entry></row><row><entry> </entry></row><row><entry>acaggagagc gcacgaggga gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc   6360</entry></row><row><entry> </entry></row><row><entry>gggtttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc   6420</entry></row><row><entry> </entry></row><row><entry>ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt   6480</entry></row><row><entry> </entry></row><row><entry>gctcacatgt tctttcctgc gttatcccct gattctgtgg ataaccgtat taccgccttt   6540</entry></row><row><entry> </entry></row><row><entry>gagtgagctg ataccgctcg ccgcagccga acgaccgagc gcagcgagtc agtgagcgag   6600</entry></row><row><entry> </entry></row><row><entry>gaagcggaag agcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa   6660</entry></row><row><entry> </entry></row><row><entry>tgcagctggc acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat   6720</entry></row><row><entry> </entry></row><row><entry>gtgagttagc tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg   6780</entry></row><row><entry> </entry></row><row><entry>ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac   6840</entry></row><row><entry> </entry></row><row><entry>gccaagcttt gctcttagga gtttcctaat acatcccaaa ctcaaatata taaagcattt   6900</entry></row><row><entry> </entry></row><row><entry>gacttgttct atgccctagg gggcgggggg aagctaagcc agcttttttt aacatttaaa   6960</entry></row><row><entry> </entry></row><row><entry>atgttaattc cattttaaat gcacagatgt ttttatttca taagggtttc aatgtgcatg   7020</entry></row><row><entry> </entry></row><row><entry>aatgctgcaa tattcctgtt accaaagcta gtataaataa aaatagataa acgtggaaat   7080</entry></row><row><entry> </entry></row><row><entry>tacttagagt ttctgtcatt aacgtttcct tcctcagttg acaacataaa tgcgctgctg   7140</entry></row><row><entry> </entry></row><row><entry>agcaagccag tttgcatctg tcaggatcaa tttcccatta tgccagtcat attaattact   7200</entry></row><row><entry> </entry></row><row><entry>agtcaattag ttgattttta tttttgacat atacatgtga atgaaagacc ccacctgtag   7260</entry></row><row><entry> </entry></row><row><entry>gtttggcaag ctagcttaag taacgccatt ttgcaaggca tggaaaaata cataactgag   7320</entry></row><row><entry> </entry></row><row><entry>aatagaaaag ttcagatcaa ggtcaggaac agatggaaca gctgaatatg ggccaaacag   7380</entry></row><row><entry> </entry></row><row><entry>gatatctgtg gtaagcagtt cctgccccgg ctcagggcca agaacagatg gaacagctga   7440</entry></row><row><entry> </entry></row><row><entry>atatgggcca aacaggatat ctgtggtaag cagttcctgc cccggctcag ggccaagaac   7500</entry></row><row><entry> </entry></row><row><entry>agatggtccc cagatgcggt ccagccctca gcagtttcta gagaaccatc agatgtttcc   7560</entry></row><row><entry> </entry></row><row><entry>agggtgcccc aaggacctga aatgaccctg tgccttattt gaactaacca atcagttcgc   7620</entry></row><row><entry> </entry></row><row><entry>ttctcgcttc tgttcgcgcg cttatgctcc ccgagctcaa taaaagagcc cacaacccct   7680</entry></row><row><entry> </entry></row><row><entry>cactcggggc gccagtcctc cgattgactg agtcgcccgg gtacccgtgt atccaataaa   7740</entry></row><row><entry> </entry></row><row><entry>ccctcttgca gttgcatccg acttgtggtc tcgctgttcc ttgggagggt ctcctctgag   7800</entry></row><row><entry> </entry></row><row><entry>tgattgacta cccgtcagcg ggggtctttc atttgggggc tcgtccggga tcgggagacc   7860</entry></row><row><entry> </entry></row><row><entry>cctgcccagg gaccaccgac ccaccaccgg gaggtaagct ggccagcaac ttatctgtgt   7920</entry></row><row><entry> </entry></row><row><entry>ctgtccgatt gtctagtgtc tatgactgat tttatgcgcc tgcgtcggta ctagttagct   7980</entry></row><row><entry> </entry></row><row><entry>aactagctct gtatctggcg gacccgtggt ggaactgacg agttcggaac acccggccgc   8040</entry></row><row><entry> </entry></row><row><entry>aaccctggga gacgtcccag ggacttcggg ggccgttttt gtggcccgac ctgagtccta   8100</entry></row><row><entry> </entry></row><row><entry>aaatcccgat cgtttaggac tctttggtgc acccccctta gaggagggat atgtggttct   8160</entry></row><row><entry> </entry></row><row><entry>ggtaggagac gagaacctaa aacagttccc gcctccgtct gaatttttgc tttcggtttg   8220</entry></row><row><entry> </entry></row><row><entry>ggaccgaagc cgcgccgcgc gtcttgtctg ctgcagcatc gttctgtgtt gtctctgtct   8280</entry></row><row><entry> </entry></row><row><entry>gactgtgttt ctgtatttgt ctgaaaatat gggcccgggc tagactgtta ccactccctt   8340</entry></row><row><entry> </entry></row><row><entry>aagtttgacc ttaggtcact ggaaagatgt cgagcggatc gctcacaacc agtcggtaga   8400</entry></row><row><entry> </entry></row><row><entry>tgtcaagaag agacgttggg ttaccttctg ctctgcagaa tggccaacct ttaacgtcgg   8460</entry></row><row><entry> </entry></row><row><entry>atggccgcga gacggcacct ttaaccgaga cctcatcacc caggttaaga tcaaggtctt   8520</entry></row><row><entry> </entry></row><row><entry>ttcacctggc ccgcatggac acccagacca ggtcccctac atcgtgacct gggaagcctt   8580</entry></row><row><entry> </entry></row><row><entry>ggcttttgac ccccctccct gggtcaagcc ctttgtacac cctaagcctc cgcctcctct   8640</entry></row><row><entry> </entry></row><row><entry>tcctccatcc gccccgtctc tcccccttga acctcctcgt tcgaccccgc ctcgatcctc   8700</entry></row><row><entry> </entry></row><row><entry>cctttatcca gccctcactc cttctctagg cgcccccata tggccatatg agatcttata   8760</entry></row><row><entry> </entry></row><row><entry>tggggcaccc ccgccccttg taaacttccc tgaccctgac atgacaagag ttactaacag   8820</entry></row><row><entry> </entry></row><row><entry>cccctctctc caagctcact tacaggctct ctacttagtc cagcacgaag tctggagacc   8880</entry></row><row><entry> </entry></row><row><entry>tctggcggca gcctaccaag aacaactgga ccgaccggtg gtacctcacc cttaccgagt   8940</entry></row><row><entry> </entry></row><row><entry>cggcgacaca gtgtgggtcc gccgacacca gactaagaac ctagaacctc gctggaaagg   9000</entry></row><row><entry> </entry></row><row><entry>accttacaca gtcctgctga ccacccccac cgccctcaaa gtagacggca tcgcagcttg   9060</entry></row><row><entry> </entry></row><row><entry>gatacacgcc gcccacgtga aggctgccga ccccgggggt ggaccatcct ctagactg     9118</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 110</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 718</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 110</entry></row><row><entry> </entry></row><row><entry>caccaaggtg agcagcttcg tgcactggat caagaagacc atgaagcggt accgccgcaa     60</entry></row><row><entry> </entry></row><row><entry>acgctctggg tccggagaag ggcggggatc cttgctcaca tgtggggatg ttgaagagaa    120</entry></row><row><entry> </entry></row><row><entry>tcctgggcca atggccgccg agcccgtgga ggacaactgc atcaacttcg tggccatgaa    180</entry></row><row><entry> </entry></row><row><entry>gttcatcgac aacaccctgt acttcatcgc cgaggacgac gagaacatcg agcccgacta    240</entry></row><row><entry> </entry></row><row><entry>cttcggcaag ctggagagca agctgagcgt gatccggaac ctgaacgacc aggtgctgtt    300</entry></row><row><entry> </entry></row><row><entry>catcgaccag ggcaaccggc ctctgttcga ggacatgacc gacagcgact gccgggacaa    360</entry></row><row><entry> </entry></row><row><entry>cgctccccgg accatcttca tcatcagcat gtacaaggac agccagcccc ggggaatggc    420</entry></row><row><entry> </entry></row><row><entry>cgtgaccatc agcgtgaagt gcgagaagat cagcaccctg agctgcgaga acaagatcat    480</entry></row><row><entry> </entry></row><row><entry>cagcttcaag gagatgaacc ctcccgacaa catcaaggac accaagagcg acatcatctt    540</entry></row><row><entry> </entry></row><row><entry>cttccagcgg agcgtgcctg gccacgacaa caagatgcag ttcgagagca gcagctacga    600</entry></row><row><entry> </entry></row><row><entry>gggctacttc ctggcctgcg agaaggagcg ggacctgttc aagctgatcc tgaagaagga    660</entry></row><row><entry> </entry></row><row><entry>ggacgagctg ggcgaccgga gcatcatgtt caccgtgcag aacgaggact aactcgag      718</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 111</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9937</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 111</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tccggatctg gggctacaaa cttctctctc ttgaagcagg   2160</entry></row><row><entry> </entry></row><row><entry>ccggagatgt cgaagaaaat ccaggcccta tgcagcccat cctgttgctc ctggccttcc   2220</entry></row><row><entry> </entry></row><row><entry>tcttgctgcc tcgggccgac gccggcgaga tcatcggcgg acacgaggcc aagccccaca   2280</entry></row><row><entry> </entry></row><row><entry>gcaggcccta catggcctac ctgatgatct gggaccagaa gagcctgaag cggtgcggag   2340</entry></row><row><entry> </entry></row><row><entry>gcttcctgat ccgggacgac ttcgtgctga ccgccgccca ctgctgggga agcagcatca   2400</entry></row><row><entry> </entry></row><row><entry>acgtgaccct gggcgctcac aacatcaagg agcaggagcc cacccagcag ttcatccctg   2460</entry></row><row><entry> </entry></row><row><entry>tgaagcggcc catccctcac cccgcctaca accccaagaa cttcagcaac gacatcatgc   2520</entry></row><row><entry> </entry></row><row><entry>tgctgcagct ggagcggaag gccaagcgga cccgggccgt gcagcccctg cggctgccca   2580</entry></row><row><entry> </entry></row><row><entry>gcaacaaggc ccaggtgaag cctggccaga cctgcagcgt ggccggctgg ggccagaccg   2640</entry></row><row><entry> </entry></row><row><entry>ctcccctggg caagcacagc cacaccctgc aggaggtgaa gatgaccgtg caggaggacc   2700</entry></row><row><entry> </entry></row><row><entry>ggaagtgcga gagcgacctg cggcactact acgacagcac catcgagctg tgcgtgggag   2760</entry></row><row><entry> </entry></row><row><entry>accccgagat caagaagacc agcttcaagg gcgacagcgg cggacccctg gtgtgcaaca   2820</entry></row><row><entry> </entry></row><row><entry>aggtggccca gggcatcgtg agctacggca ggaacaacgg catgccccct cgggcctgca   2880</entry></row><row><entry> </entry></row><row><entry>ccaaggtgag cagcttcgtg cactggatca agaagaccat gaagcggtac cgccgcaaac   2940</entry></row><row><entry> </entry></row><row><entry>gctctgggtc cggagaaggg cggggatcct tgctcacatg tggggatgtt gaagagaatc   3000</entry></row><row><entry> </entry></row><row><entry>ctgggccaat ggccgccgag cccgtggagg acaactgcat caacttcgtg gccatgaagt   3060</entry></row><row><entry> </entry></row><row><entry>tcatcgacaa caccctgtac ttcatcgccg aggacgacga gaacatcgag cccgactact   3120</entry></row><row><entry> </entry></row><row><entry>tcggcaagct ggagagcaag ctgagcgtga tccggaacct gaacgaccag gtgctgttca   3180</entry></row><row><entry> </entry></row><row><entry>tcgaccaggg caaccggcct ctgttcgagg acatgaccga cagcgactgc cgggacaacg   3240</entry></row><row><entry> </entry></row><row><entry>ctccccggac catcttcatc atcagcatgt acaaggacag ccagccccgg ggaatggccg   3300</entry></row><row><entry> </entry></row><row><entry>tgaccatcag cgtgaagtgc gagaagatca gcaccctgag ctgcgagaac aagatcatca   3360</entry></row><row><entry> </entry></row><row><entry>gcttcaagga gatgaaccct cccgacaaca tcaaggacac caagagcgac atcatcttct   3420</entry></row><row><entry> </entry></row><row><entry>tccagcggag cgtgcctggc cacgacaaca agatgcagtt cgagagcagc agctacgagg   3480</entry></row><row><entry> </entry></row><row><entry>gctacttcct ggcctgcgag aaggagcggg acctgttcaa gctgatcctg aagaaggagg   3540</entry></row><row><entry> </entry></row><row><entry>acgagctggg cgaccggagc atcatgttca ccgtgcagaa cgaggactaa ctcgagggat   3600</entry></row><row><entry> </entry></row><row><entry>ccggattagt ccaatttgtt aaagacagga tatcagtggt ccaggctcta gttttgactc   3660</entry></row><row><entry> </entry></row><row><entry>aacaatatca ccagctgaag cctatagagt acgagccata gataaaataa aagattttat   3720</entry></row><row><entry> </entry></row><row><entry>ttagtctcca gaaaaagggg ggaatgaaag accccacctg taggtttggc aagctagctt   3780</entry></row><row><entry> </entry></row><row><entry>aagtaacgcc attttgcaag gcatggaaaa atacataact gagaatagag aagttcagat   3840</entry></row><row><entry> </entry></row><row><entry>caaggtcagg aacagatgga acagctgaat atgggccaaa caggatatct gtggtaagca   3900</entry></row><row><entry> </entry></row><row><entry>gttcctgccc cggctcaggg ccaagaacag atggaacagc tgaatatggg ccaaacagga   3960</entry></row><row><entry> </entry></row><row><entry>tatctgtggt aagcagttcc tgccccggct cagggccaag aacagatggt ccccagatgc   4020</entry></row><row><entry> </entry></row><row><entry>ggtccagccc tcagcagttt ctagagaacc atcagatgtt tccagggtgc cccaaggacc   4080</entry></row><row><entry> </entry></row><row><entry>tgaaatgacc ctgtgcctta tttgaactaa ccaatcagtt cgcttctcgc ttctgttcgc   4140</entry></row><row><entry> </entry></row><row><entry>gcgcttctgc tccccgagct caataaaaga gcccacaacc cctcactcgg ggcgccagtc   4200</entry></row><row><entry> </entry></row><row><entry>ctccgattga ctgagtcgcc cgggtacccg tgtatccaat aaaccctctt gcagttgcat   4260</entry></row><row><entry> </entry></row><row><entry>ccgacttgtg gtctcgctgt tccttgggag ggtctcctct gagtgattga ctacccgtca   4320</entry></row><row><entry> </entry></row><row><entry>gcgggggtct ttcacacatg cagcatgtat caaaattaat ttggtttttt ttcttaagta   4380</entry></row><row><entry> </entry></row><row><entry>tttacattaa atggccatag tacttaaagt tacattggct tccttgaaat aaacatggag   4440</entry></row><row><entry> </entry></row><row><entry>tattcagaat gtgtcataaa tatttctaat tttaagatag tatctccatt ggctttctac   4500</entry></row><row><entry> </entry></row><row><entry>tttttctttt attttttttt gtcctctgtc ttccatttgt tgttgttgtt gtttgtttgt   4560</entry></row><row><entry> </entry></row><row><entry>ttgtttgttg gttggttggt taattttttt ttaaagatcc tacactatag ttcaagctag   4620</entry></row><row><entry> </entry></row><row><entry>actattagct actctgtaac ccagggtgac cttgaagtca tgggtagcct gctgttttag   4680</entry></row><row><entry> </entry></row><row><entry>ccttcccaca tctaagatta caggtatgag ctatcatttt tggtatattg attgattgat   4740</entry></row><row><entry> </entry></row><row><entry>tgattgatgt gtgtgtgtgt gattgtgttt gtgtgtgtga ctgtgaaaat gtgtgtatgg   4800</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtga atgtgtgtat gtatgtgtgt gtgtgagtgt gtgtgtgtgt gtgtgcatgt   4860</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtgt gactgtgtct atgtgtatga ctgtgtgtgt gtgtgtgtgt gtgtgtgtgt   4920</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtgt gtgtgtgttg tgaaaaaata ttctatggta gtgagagcca acgctccggc   4980</entry></row><row><entry> </entry></row><row><entry>tcaggtgtca ggttggtttt tgagacagag tctttcactt agcttggaat tcactggccg   5040</entry></row><row><entry> </entry></row><row><entry>tcgttttaca acgtcgtgac tgggaaaacc ctggcgttac ccaacttaat cgccttgcag   5100</entry></row><row><entry> </entry></row><row><entry>cacatccccc tttcgccagc tggcgtaata gcgaagaggc ccgcaccgat cgcccttccc   5160</entry></row><row><entry> </entry></row><row><entry>aacagttgcg cagcctgaat ggcgaatggc gcctgatgcg gtattttctc cttacgcatc   5220</entry></row><row><entry> </entry></row><row><entry>tgtgcggtat ttcacaccgc atatggtgca ctctcagtac aatctgctct gatgccgcat   5280</entry></row><row><entry> </entry></row><row><entry>agttaagcca gccccgacac ccgccaacac ccgctgacgc gccctgacgg gcttgtctgc   5340</entry></row><row><entry> </entry></row><row><entry>tcccggcatc cgcttacaga caagctgtga ccgtctccgg gagctgcatg tgtcagaggt   5400</entry></row><row><entry> </entry></row><row><entry>tttcaccgtc atcaccgaaa cgcgcgatga cgaaagggcc tcgtgatacg cctattttta   5460</entry></row><row><entry> </entry></row><row><entry>taggttaatg tcatgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat   5520</entry></row><row><entry> </entry></row><row><entry>gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg   5580</entry></row><row><entry> </entry></row><row><entry>agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa   5640</entry></row><row><entry> </entry></row><row><entry>catttccgtg tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac   5700</entry></row><row><entry> </entry></row><row><entry>ccagaaacgc tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac   5760</entry></row><row><entry> </entry></row><row><entry>atcgaactgg atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt   5820</entry></row><row><entry> </entry></row><row><entry>ccaatgatga gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc   5880</entry></row><row><entry> </entry></row><row><entry>gggcaagagc aactcggtcg ccgcatacac tattctcaga atgacttggt tgagtactca   5940</entry></row><row><entry> </entry></row><row><entry>ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgctgcc   6000</entry></row><row><entry> </entry></row><row><entry>ataaccatga gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag   6060</entry></row><row><entry> </entry></row><row><entry>gagctaaccg cttttttgca caacatgggg gatcatgtaa ctcgccttga tcgttgggaa   6120</entry></row><row><entry> </entry></row><row><entry>ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg   6180</entry></row><row><entry> </entry></row><row><entry>gcaacaacgt tgcgcaaact attaactggc gaactactta ctctagcttc ccggcaacaa   6240</entry></row><row><entry> </entry></row><row><entry>ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg   6300</entry></row><row><entry> </entry></row><row><entry>gctggctggt ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt   6360</entry></row><row><entry> </entry></row><row><entry>gcagcactgg ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt   6420</entry></row><row><entry> </entry></row><row><entry>caggcaacta tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag   6480</entry></row><row><entry> </entry></row><row><entry>cattggtaac tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat   6540</entry></row><row><entry> </entry></row><row><entry>ttttaattta aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct   6600</entry></row><row><entry> </entry></row><row><entry>taacgtgagt tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct   6660</entry></row><row><entry> </entry></row><row><entry>tgagatcctt tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca   6720</entry></row><row><entry> </entry></row><row><entry>gcggtggttt gtttgccgga tcaagagcta ccaactcttt ttccgaaggt aactggcttc   6780</entry></row><row><entry> </entry></row><row><entry>agcagagcgc agataccaaa tactgtcctt ctagtgtagc cgtagttagg ccaccacttc   6840</entry></row><row><entry> </entry></row><row><entry>aagaactctg tagcaccgcc tacatacctc gctctgctaa tcctgttacc agtggctgct   6900</entry></row><row><entry> </entry></row><row><entry>gccagtggcg ataagtcgtg tcttaccggg ttggactcaa gacgatagtt accggataag   6960</entry></row><row><entry> </entry></row><row><entry>gcgcagcggt cgggctgaac ggggggttcg tgcacacagc ccagcttgga gcgaacgacc   7020</entry></row><row><entry> </entry></row><row><entry>tacaccgaac tgagatacct acagcgtgag cattgagaaa gcgccacgct tcccgaaggg   7080</entry></row><row><entry> </entry></row><row><entry>agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa caggagagcg cacgagggag   7140</entry></row><row><entry> </entry></row><row><entry>cttccagggg gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca cctctgactt   7200</entry></row><row><entry> </entry></row><row><entry>gagcgtcgat ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac   7260</entry></row><row><entry> </entry></row><row><entry>gcggcctttt tacggttcct ggccttttgc tggccttttg ctcacatgtt ctttcctgcg   7320</entry></row><row><entry> </entry></row><row><entry>ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga taccgctcgc   7380</entry></row><row><entry> </entry></row><row><entry>cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga gcgcccaata   7440</entry></row><row><entry> </entry></row><row><entry>cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt   7500</entry></row><row><entry> </entry></row><row><entry>cccgactgga aagcgggcag tgagcgcaac gcaattaatg tgagttagct cactcattag   7560</entry></row><row><entry> </entry></row><row><entry>gcaccccagg ctttacactt tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga   7620</entry></row><row><entry> </entry></row><row><entry>taacaatttc acacaggaaa cagctatgac catgattacg ccaagctttg ctcttaggag   7680</entry></row><row><entry> </entry></row><row><entry>tttcctaata catcccaaac tcaaatatat aaagcatttg acttgttcta tgccctaggg   7740</entry></row><row><entry> </entry></row><row><entry>ggcgggggga agctaagcca gcttttttta acatttaaaa tgttaattcc attttaaatg   7800</entry></row><row><entry> </entry></row><row><entry>cacagatgtt tttatttcat aagggtttca atgtgcatga atgctgcaat attcctgtta   7860</entry></row><row><entry> </entry></row><row><entry>ccaaagctag tataaataaa aatagataaa cgtggaaatt acttagagtt tctgtcatta   7920</entry></row><row><entry> </entry></row><row><entry>acgtttcctt cctcagttga caacataaat gcgctgctga gcaagccagt ttgcatctgt   7980</entry></row><row><entry> </entry></row><row><entry>caggatcaat ttcccattat gccagtcata ttaattacta gtcaattagt tgatttttat   8040</entry></row><row><entry> </entry></row><row><entry>ttttgacata tacatgtgaa tgaaagaccc cacctgtagg tttggcaagc tagcttaagt   8100</entry></row><row><entry> </entry></row><row><entry>aacgccattt tgcaaggcat ggaaaaatac ataactgaga atagaaaagt tcagatcaag   8160</entry></row><row><entry> </entry></row><row><entry>gtcaggaaca gatggaacag ctgaatatgg gccaaacagg atatctgtgg taagcagttc   8220</entry></row><row><entry> </entry></row><row><entry>ctgccccggc tcagggccaa gaacagatgg aacagctgaa tatgggccaa acaggatatc   8280</entry></row><row><entry> </entry></row><row><entry>tgtggtaagc agttcctgcc ccggctcagg gccaagaaca gatggtcccc agatgcggtc   8340</entry></row><row><entry> </entry></row><row><entry>cagccctcag cagtttctag agaaccatca gatgtttcca gggtgcccca aggacctgaa   8400</entry></row><row><entry> </entry></row><row><entry>atgaccctgt gccttatttg aactaaccaa tcagttcgct tctcgcttct gttcgcgcgc   8460</entry></row><row><entry> </entry></row><row><entry>ttatgctccc cgagctcaat aaaagagccc acaacccctc actcggggcg ccagtcctcc   8520</entry></row><row><entry> </entry></row><row><entry>gattgactga gtcgcccggg tacccgtgta tccaataaac cctcttgcag ttgcatccga   8580</entry></row><row><entry> </entry></row><row><entry>cttgtggtct cgctgttcct tgggagggtc tcctctgagt gattgactac ccgtcagcgg   8640</entry></row><row><entry> </entry></row><row><entry>gggtctttca tttgggggct cgtccgggat cgggagaccc ctgcccaggg accaccgacc   8700</entry></row><row><entry> </entry></row><row><entry>caccaccggg aggtaagctg gccagcaact tatctgtgtc tgtccgattg tctagtgtct   8760</entry></row><row><entry> </entry></row><row><entry>atgactgatt ttatgcgcct gcgtcggtac tagttagcta actagctctg tatctggcgg   8820</entry></row><row><entry> </entry></row><row><entry>acccgtggtg gaactgacga gttcggaaca cccggccgca accctgggag acgtcccagg   8880</entry></row><row><entry> </entry></row><row><entry>gacttcgggg gccgtttttg tggcccgacc tgagtcctaa aatcccgatc gtttaggact   8940</entry></row><row><entry> </entry></row><row><entry>ctttggtgca ccccccttag aggagggata tgtggttctg gtaggagacg agaacctaaa   9000</entry></row><row><entry> </entry></row><row><entry>acagttcccg cctccgtctg aatttttgct ttcggtttgg gaccgaagcc gcgccgcgcg   9060</entry></row><row><entry> </entry></row><row><entry>tcttgtctgc tgcagcatcg ttctgtgttg tctctgtctg actgtgtttc tgtatttgtc   9120</entry></row><row><entry> </entry></row><row><entry>tgaaaatatg ggcccgggct agactgttac cactccctta agtttgacct taggtcactg   9180</entry></row><row><entry> </entry></row><row><entry>gaaagatgtc gagcggatcg ctcacaacca gtcggtagat gtcaagaaga gacgttgggt   9240</entry></row><row><entry> </entry></row><row><entry>taccttctgc tctgcagaat ggccaacctt taacgtcgga tggccgcgag acggcacctt   9300</entry></row><row><entry> </entry></row><row><entry>taaccgagac ctcatcaccc aggttaagat caaggtcttt tcacctggcc cgcatggaca   9360</entry></row><row><entry> </entry></row><row><entry>cccagaccag gtcccctaca tcgtgacctg ggaagccttg gcttttgacc cccctccctg   9420</entry></row><row><entry> </entry></row><row><entry>ggtcaagccc tttgtacacc ctaagcctcc gcctcctctt cctccatccg ccccgtctct   9480</entry></row><row><entry> </entry></row><row><entry>cccccttgaa cctcctcgtt cgaccccgcc tcgatcctcc ctttatccag ccctcactcc   9540</entry></row><row><entry> </entry></row><row><entry>ttctctaggc gcccccatat ggccatatga gatcttatat ggggcacccc cgccccttgt   9600</entry></row><row><entry> </entry></row><row><entry>aaacttccct gaccctgaca tgacaagagt tactaacagc ccctctctcc aagctcactt   9660</entry></row><row><entry> </entry></row><row><entry>acaggctctc tacttagtcc agcacgaagt ctggagacct ctggcggcag cctaccaaga   9720</entry></row><row><entry> </entry></row><row><entry>acaactggac cgaccggtgg tacctcaccc ttaccgagtc ggcgacacag tgtgggtccg   9780</entry></row><row><entry> </entry></row><row><entry>ccgacaccag actaagaacc tagaacctcg ctggaaagga ccttacacag tcctgctgac   9840</entry></row><row><entry> </entry></row><row><entry>cacccccacc gccctcaaag tagacggcat cgcagcttgg atacacgccg cccacgtgaa   9900</entry></row><row><entry> </entry></row><row><entry>ggctgccgac cccgggggtg gaccatcctc tagactg                            9937</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 112</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 11023</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 112</entry></row><row><entry> </entry></row><row><entry>ccatgggccc cggcgtgctg ctgctgctgc tggtggccac cgcctggcac ggccagggcg     60</entry></row><row><entry> </entry></row><row><entry>gcgtggtgag ccacttcaac gactgccctc tgagccacga cggctactgc ctgcacgacg    120</entry></row><row><entry> </entry></row><row><entry>gcgtgtgcat gtacatcgag gccctggaca agtacgcctg caactgcgtg gtgggctaca    180</entry></row><row><entry> </entry></row><row><entry>tcggcgagag atgccagtac agagacctga agtggtggga gctgagagcc gccgccccca    240</entry></row><row><entry> </entry></row><row><entry>ccaccacacc cgctcccaga ccccctaccc ctgcccccac catcgccagc cagcccctga    300</entry></row><row><entry> </entry></row><row><entry>gcctgagacc cgaggcctgc agacctgccg ccggcggagc cgtgcacacc agaggcctgg    360</entry></row><row><entry> </entry></row><row><entry>acttcgcctg cgacatctac atctgggctc ccctggccgg cacctgcggc gtgctgctgc    420</entry></row><row><entry> </entry></row><row><entry>tgagcctggt gatcaccctg tactgcaacc acaagagagg cagaaagaag ctgctgtaca    480</entry></row><row><entry> </entry></row><row><entry>tcttcaagca gcccttcatg agacccgtgc agaccaccca ggaggaggac ggctgcagct    540</entry></row><row><entry> </entry></row><row><entry>gcagattccc cgaggaggag gagggcggct gcgagctgag aagaaagaga agcggcagcg    600</entry></row><row><entry> </entry></row><row><entry>gcgagggcag aggcagcctg ctgacctgcg gcgacgtgga ggagaacccc ggacccatgg    660</entry></row><row><entry> </entry></row><row><entry>ctctcccagt gactgcccta ctgcttcccc tagcgcttct cctgcatgca gaggtgcagc    720</entry></row><row><entry> </entry></row><row><entry>tgcagcagtc tggaggaggc ttggtgcaac ctggaggatc catgaaactc tcctgtgttg    780</entry></row><row><entry> </entry></row><row><entry>cctctggatt cactttcagt aactactgga tgaactgggt ccgccagtct ccagagaagg    840</entry></row><row><entry> </entry></row><row><entry>ggcttgagtg ggttgctgaa attagattga aatctaataa ttatgcaaca cattatgcgg    900</entry></row><row><entry> </entry></row><row><entry>agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtagt gtctacctgc    960</entry></row><row><entry> </entry></row><row><entry>aaatgaacaa cttaagagct gaagacactg gcatttatta ctgtaccttt ggtaactcct   1020</entry></row><row><entry> </entry></row><row><entry>ttgcttactg gggccaaggg accacggtca ccgtctcctc aggtggaggc ggttcaggcg   1080</entry></row><row><entry> </entry></row><row><entry>gaggtggctc tggcggtggc ggatcgcagg ccgtggtcac tcaggaatct gcactcacca   1140</entry></row><row><entry> </entry></row><row><entry>catcacctgg tgaaacagtc acactcactt gtcgctcaag tactggggct gttacaacta   1200</entry></row><row><entry> </entry></row><row><entry>gtaactatgc caactgggtc caagaaaaac cagatcattt attcactggt ctaataggtg   1260</entry></row><row><entry> </entry></row><row><entry>gtaccaacaa ccgagcacca ggtgttcctg ccagattctc aggctccctg attggagaca   1320</entry></row><row><entry> </entry></row><row><entry>aggctgccct caccatcaca ggggcacaga ctgaggatga ggcaatatat ttctgtgctc   1380</entry></row><row><entry> </entry></row><row><entry>tatggtacag caaccattgg gtgttcggtg gaggaaccaa actgactgtc ctaggatcag   1440</entry></row><row><entry> </entry></row><row><entry>aggcggccgc aattgaagtt atgtatcctc ctccttacct agacaatgag aagagcaatg   1500</entry></row><row><entry> </entry></row><row><entry>gaaccattat ccatgtgaaa gggaaacacc tttgtccaag tcccctattt cccggacctt   1560</entry></row><row><entry> </entry></row><row><entry>ctaagccctt ttgggtgctg gtggtggttg gtggagtcct ggcttgctat agcttgctag   1620</entry></row><row><entry> </entry></row><row><entry>taacagtggc ctttattatt ttctgggtga ggagtaagag gagcaggctc ctgcacagtg   1680</entry></row><row><entry> </entry></row><row><entry>actacatgaa catgactccc cgccgccccg ggcccacccg caagcattac cagccctatg   1740</entry></row><row><entry> </entry></row><row><entry>ccccaccacg cgacttcgca gcctatcgct ccagagtgaa gttcagcagg agcgcagacg   1800</entry></row><row><entry> </entry></row><row><entry>cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta ggacgaagag   1860</entry></row><row><entry> </entry></row><row><entry>aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg ggaaagccga   1920</entry></row><row><entry> </entry></row><row><entry>gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag atggcggagg   1980</entry></row><row><entry> </entry></row><row><entry>cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac gatggccttt   2040</entry></row><row><entry> </entry></row><row><entry>accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg caggccctgc   2100</entry></row><row><entry> </entry></row><row><entry>cccctcgccg gcggaaacgg tccggatctg gggctacaaa cttctctctc ttgaagcagg   2160</entry></row><row><entry> </entry></row><row><entry>ccggagatgt cgaagaaaat ccaggcccta tgcagcccat cctgttgctc ctggccttcc   2220</entry></row><row><entry> </entry></row><row><entry>tcttgctgcc tcgggccgac gccggcgaga tcatcggcgg acacgaggcc aagccccaca   2280</entry></row><row><entry> </entry></row><row><entry>gcaggcccta catggcctac ctgatgatct gggaccagaa gagcctgaag cggtgcggag   2340</entry></row><row><entry> </entry></row><row><entry>gcttcctgat ccgggacgac ttcgtgctga ccgccgccca ctgctgggga agcagcatca   2400</entry></row><row><entry> </entry></row><row><entry>acgtgaccct gggcgctcac aacatcaagg agcaggagcc cacccagcag ttcatccctg   2460</entry></row><row><entry> </entry></row><row><entry>tgaagcggcc catccctcac cccgcctaca accccaagaa cttcagcaac gacatcatgc   2520</entry></row><row><entry> </entry></row><row><entry>tgctgcagct ggagcggaag gccaagcgga cccgggccgt gcagcccctg cggctgccca   2580</entry></row><row><entry> </entry></row><row><entry>gcaacaaggc ccaggtgaag cctggccaga cctgcagcgt ggccggctgg ggccagaccg   2640</entry></row><row><entry> </entry></row><row><entry>ctcccctggg caagcacagc cacaccctgc aggaggtgaa gatgaccgtg caggaggacc   2700</entry></row><row><entry> </entry></row><row><entry>ggaagtgcga gagcgacctg cggcactact acgacagcac catcgagctg tgcgtgggag   2760</entry></row><row><entry> </entry></row><row><entry>accccgagat caagaagacc agcttcaagg gcgacagcgg cggacccctg gtgtgcaaca   2820</entry></row><row><entry> </entry></row><row><entry>aggtggccca gggcatcgtg agctacggca ggaacaacgg catgccccct cgggcctgca   2880</entry></row><row><entry> </entry></row><row><entry>ccaaggtgag cagcttcgtg cactggatca agaagaccat gaagcggtac cgccgcaaac   2940</entry></row><row><entry> </entry></row><row><entry>gctctgggtc cggagaaggg cggggatcct tgctcacatg tggggatgtt gaagagaatc   3000</entry></row><row><entry> </entry></row><row><entry>ctgggccaat ggccgctcgg ctgctgctgc tgggcatcct gttgctcctg ctccctctgc   3060</entry></row><row><entry> </entry></row><row><entry>ccgtgcccgc cccctgccac accgccgccc ggagcgagtg caagcggagc cacaagttcg   3120</entry></row><row><entry> </entry></row><row><entry>tgcctggcgc ctggctggcc ggagagggcg tggacgtgac cagcctgcgg aggagcggca   3180</entry></row><row><entry> </entry></row><row><entry>gcttccctgt ggacacccag cggttcctgc ggcctgacgg cacctgcacc ctgtgcgaga   3240</entry></row><row><entry> </entry></row><row><entry>acgccctgca ggagggcacc ctgcagaggc tgcccctggc cctgaccaac tggagggccc   3300</entry></row><row><entry> </entry></row><row><entry>agggaagcgg ctgccagcgg cacgtgacca gggccaaggt gagcagcacc gaggccgtgg   3360</entry></row><row><entry> </entry></row><row><entry>cccgggacgc cgcccggagc atccggaacg actggaaggt gggcctggac gtgaccccca   3420</entry></row><row><entry> </entry></row><row><entry>agcccaccag caacgtgcac gtgagcgtgg caggcagcca cagccaggcc gccaacttcg   3480</entry></row><row><entry> </entry></row><row><entry>ccgcccagaa gacccaccag gaccagtaca gcttcagcac cgacaccgtg gagtgccggt   3540</entry></row><row><entry> </entry></row><row><entry>tctacagctt ccacgtggtg cacacacccc ctctgcaccc cgacttcaag cgggccctgg   3600</entry></row><row><entry> </entry></row><row><entry>gcgacctgcc ccaccacttc aacgccagca cccagcctgc ctacctgcgg ctgatcagca   3660</entry></row><row><entry> </entry></row><row><entry>actacggcac ccacttcatc cgggctgtgg agctgggagg caggatcagc gccctgaccg   3720</entry></row><row><entry> </entry></row><row><entry>ccctgcggac ctgcgagctg gccctggagg gcctgaccga caacgaggtg gaggactgcc   3780</entry></row><row><entry> </entry></row><row><entry>tgaccgtgga ggcccaggtg aacatcggca tccacggcag catcagcgcc gaggccaagg   3840</entry></row><row><entry> </entry></row><row><entry>cctgcgagga gaagaagaag aagcacaaga tgaccgccag cttccaccag acctaccggg   3900</entry></row><row><entry> </entry></row><row><entry>agcggcacag cgaggtggtg ggaggccacc acaccagcat caacgacctg ctgttcggca   3960</entry></row><row><entry> </entry></row><row><entry>tccaggctgg acccgagcag tacagcgcct gggtgaacag cctgcctggc agccccggac   4020</entry></row><row><entry> </entry></row><row><entry>tggtggacta caccctggag cccctgcacg tgctgctgga cagccaggac cccaggcggg   4080</entry></row><row><entry> </entry></row><row><entry>aggccctgcg gagggccctg agccagtacc tgaccgaccg ggctcggtgg cgggactgca   4140</entry></row><row><entry> </entry></row><row><entry>gcagaccctg cccccctggc aggcagaaga gccccaggga cccctgccag tgcgtgtgcc   4200</entry></row><row><entry> </entry></row><row><entry>acggcagcgc tgtgaccacc caggactgct gccccaggca gcggggactg gcccagctgg   4260</entry></row><row><entry> </entry></row><row><entry>aggtgacctt catccaggcc tggggcctgt ggggcgactg gttcaccgcc accgacgcct   4320</entry></row><row><entry> </entry></row><row><entry>acgtgaagct gttcttcgga ggccaggagc tgcggaccag caccgtgtgg gacaacaaca   4380</entry></row><row><entry> </entry></row><row><entry>accccatctg gagcgtgcgg ctggacttcg gcgacgtgct gctggccacc ggcggacccc   4440</entry></row><row><entry> </entry></row><row><entry>tgcggctgca ggtgtgggac caggacagcg gcagggacga cgacctgctg ggcacctgcg   4500</entry></row><row><entry> </entry></row><row><entry>accaggctcc caagagcggc agccacgagg tgcggtgcaa cctgaaccac ggccacctga   4560</entry></row><row><entry> </entry></row><row><entry>agttccggta ccacgccagg tgcctgcccc acctgggcgg aggcacctgc ctggactacg   4620</entry></row><row><entry> </entry></row><row><entry>tgccccagat gctgctgggc gagccccctg gcaaccggag cggcgctgtg tggtaactcg   4680</entry></row><row><entry> </entry></row><row><entry>agggatccgg attagtccaa tttgttaaag acaggatatc agtggtccag gctctagttt   4740</entry></row><row><entry> </entry></row><row><entry>tgactcaaca atatcaccag ctgaagccta tagagtacga gccatagata aaataaaaga   4800</entry></row><row><entry> </entry></row><row><entry>ttttatttag tctccagaaa aaggggggaa tgaaagaccc cacctgtagg tttggcaagc   4860</entry></row><row><entry> </entry></row><row><entry>tagcttaagt aacgccattt tgcaaggcat ggaaaaatac ataactgaga atagagaagt   4920</entry></row><row><entry> </entry></row><row><entry>tcagatcaag gtcaggaaca gatggaacag ctgaatatgg gccaaacagg atatctgtgg   4980</entry></row><row><entry> </entry></row><row><entry>taagcagttc ctgccccggc tcagggccaa gaacagatgg aacagctgaa tatgggccaa   5040</entry></row><row><entry> </entry></row><row><entry>acaggatatc tgtggtaagc agttcctgcc ccggctcagg gccaagaaca gatggtcccc   5100</entry></row><row><entry> </entry></row><row><entry>agatgcggtc cagccctcag cagtttctag agaaccatca gatgtttcca gggtgcccca   5160</entry></row><row><entry> </entry></row><row><entry>aggacctgaa atgaccctgt gccttatttg aactaaccaa tcagttcgct tctcgcttct   5220</entry></row><row><entry> </entry></row><row><entry>gttcgcgcgc ttctgctccc cgagctcaat aaaagagccc acaacccctc actcggggcg   5280</entry></row><row><entry> </entry></row><row><entry>ccagtcctcc gattgactga gtcgcccggg tacccgtgta tccaataaac cctcttgcag   5340</entry></row><row><entry> </entry></row><row><entry>ttgcatccga cttgtggtct cgctgttcct tgggagggtc tcctctgagt gattgactac   5400</entry></row><row><entry> </entry></row><row><entry>ccgtcagcgg gggtctttca cacatgcagc atgtatcaaa attaatttgg ttttttttct   5460</entry></row><row><entry> </entry></row><row><entry>taagtattta cattaaatgg ccatagtact taaagttaca ttggcttcct tgaaataaac   5520</entry></row><row><entry> </entry></row><row><entry>atggagtatt cagaatgtgt cataaatatt tctaatttta agatagtatc tccattggct   5580</entry></row><row><entry> </entry></row><row><entry>ttctactttt tcttttattt ttttttgtcc tctgtcttcc atttgttgtt gttgttgttt   5640</entry></row><row><entry> </entry></row><row><entry>gtttgtttgt ttgttggttg gttggttaat ttttttttaa agatcctaca ctatagttca   5700</entry></row><row><entry> </entry></row><row><entry>agctagacta ttagctactc tgtaacccag ggtgaccttg aagtcatggg tagcctgctg   5760</entry></row><row><entry> </entry></row><row><entry>ttttagcctt cccacatcta agattacagg tatgagctat catttttggt atattgattg   5820</entry></row><row><entry> </entry></row><row><entry>attgattgat tgatgtgtgt gtgtgtgatt gtgtttgtgt gtgtgactgt gaaaatgtgt   5880</entry></row><row><entry> </entry></row><row><entry>gtatgggtgt gtgtgaatgt gtgtatgtat gtgtgtgtgt gagtgtgtgt gtgtgtgtgt   5940</entry></row><row><entry> </entry></row><row><entry>gcatgtgtgt gtgtgtgact gtgtctatgt gtatgactgt gtgtgtgtgt gtgtgtgtgt   6000</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtgt gtgtgtgtgt gtgttgtgaa aaaatattct atggtagtga gagccaacgc   6060</entry></row><row><entry> </entry></row><row><entry>tccggctcag gtgtcaggtt ggtttttgag acagagtctt tcacttagct tggaattcac   6120</entry></row><row><entry> </entry></row><row><entry>tggccgtcgt tttacaacgt cgtgactggg aaaaccctgg cgttacccaa cttaatcgcc   6180</entry></row><row><entry> </entry></row><row><entry>ttgcagcaca tccccctttc gccagctggc gtaatagcga agaggcccgc accgatcgcc   6240</entry></row><row><entry> </entry></row><row><entry>cttcccaaca gttgcgcagc ctgaatggcg aatggcgcct gatgcggtat tttctcctta   6300</entry></row><row><entry> </entry></row><row><entry>cgcatctgtg cggtatttca caccgcatat ggtgcactct cagtacaatc tgctctgatg   6360</entry></row><row><entry> </entry></row><row><entry>ccgcatagtt aagccagccc cgacacccgc caacacccgc tgacgcgccc tgacgggctt   6420</entry></row><row><entry> </entry></row><row><entry>gtctgctccc ggcatccgct tacagacaag ctgtgaccgt ctccgggagc tgcatgtgtc   6480</entry></row><row><entry> </entry></row><row><entry>agaggttttc accgtcatca ccgaaacgcg cgatgacgaa agggcctcgt gatacgccta   6540</entry></row><row><entry> </entry></row><row><entry>tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggtgg cacttttcgg   6600</entry></row><row><entry> </entry></row><row><entry>ggaaatgtgc gcggaacccc tatttgttta tttttctaaa tacattcaaa tatgtatccg   6660</entry></row><row><entry> </entry></row><row><entry>ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa gagtatgagt   6720</entry></row><row><entry> </entry></row><row><entry>attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct tcctgttttt   6780</entry></row><row><entry> </entry></row><row><entry>gctcacccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg tgcacgagtg   6840</entry></row><row><entry> </entry></row><row><entry>ggttacatcg aactggatct caacagcggt aagatccttg agagttttcg ccccgaagaa   6900</entry></row><row><entry> </entry></row><row><entry>cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt atcccgtatt   6960</entry></row><row><entry> </entry></row><row><entry>gacgccgggc aagagcaact cggtcgccgc atacactatt ctcagaatga cttggttgag   7020</entry></row><row><entry> </entry></row><row><entry>tactcaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga attatgcagt   7080</entry></row><row><entry> </entry></row><row><entry>gctgccataa ccatgagtga taacactgcg gccaacttac ttctgacaac gatcggagga   7140</entry></row><row><entry> </entry></row><row><entry>ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg ccttgatcgt   7200</entry></row><row><entry> </entry></row><row><entry>tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac gatgcctgta   7260</entry></row><row><entry> </entry></row><row><entry>gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct agcttcccgg   7320</entry></row><row><entry> </entry></row><row><entry>caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct gcgctcggcc   7380</entry></row><row><entry> </entry></row><row><entry>cttccggctg gctggtttat tgctgataaa tctggagccg gtgagcgtgg gtctcgcggt   7440</entry></row><row><entry> </entry></row><row><entry>atcattgcag cactggggcc agatggtaag ccctcccgta tcgtagttat ctacacgacg   7500</entry></row><row><entry> </entry></row><row><entry>gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg tgcctcactg   7560</entry></row><row><entry> </entry></row><row><entry>attaagcatt ggtaactgtc agaccaagtt tactcatata tactttagat tgatttaaaa   7620</entry></row><row><entry> </entry></row><row><entry>cttcattttt aatttaaaag gatctaggtg aagatccttt ttgataatct catgaccaaa   7680</entry></row><row><entry> </entry></row><row><entry>atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa gatcaaagga   7740</entry></row><row><entry> </entry></row><row><entry>tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa aaaaccaccg   7800</entry></row><row><entry> </entry></row><row><entry>ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc gaaggtaact   7860</entry></row><row><entry> </entry></row><row><entry>ggcttcagca gagcgcagat accaaatact gtccttctag tgtagccgta gttaggccac   7920</entry></row><row><entry> </entry></row><row><entry>cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaatcct gttaccagtg   7980</entry></row><row><entry> </entry></row><row><entry>gctgctgcca gtggcgataa gtcgtgtctt accgggttgg actcaagacg atagttaccg   8040</entry></row><row><entry> </entry></row><row><entry>gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca cacagcccag cttggagcga   8100</entry></row><row><entry> </entry></row><row><entry>acgacctaca ccgaactgag atacctacag cgtgagcatt gagaaagcgc cacgcttccc   8160</entry></row><row><entry> </entry></row><row><entry>gaagggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg agagcgcacg   8220</entry></row><row><entry> </entry></row><row><entry>agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt tcgccacctc   8280</entry></row><row><entry> </entry></row><row><entry>tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg gaaaaacgcc   8340</entry></row><row><entry> </entry></row><row><entry>agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgctca catgttcttt   8400</entry></row><row><entry> </entry></row><row><entry>cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg agctgatacc   8460</entry></row><row><entry> </entry></row><row><entry>gctcgccgca gccgaacgac cgagcgcagc gagtcagtga gcgaggaagc ggaagagcgc   8520</entry></row><row><entry> </entry></row><row><entry>ccaatacgca aaccgcctct ccccgcgcgt tggccgattc attaatgcag ctggcacgac   8580</entry></row><row><entry> </entry></row><row><entry>aggtttcccg actggaaagc gggcagtgag cgcaacgcaa ttaatgtgag ttagctcact   8640</entry></row><row><entry> </entry></row><row><entry>cattaggcac cccaggcttt acactttatg cttccggctc gtatgttgtg tggaattgtg   8700</entry></row><row><entry> </entry></row><row><entry>agcggataac aatttcacac aggaaacagc tatgaccatg attacgccaa gctttgctct   8760</entry></row><row><entry> </entry></row><row><entry>taggagtttc ctaatacatc ccaaactcaa atatataaag catttgactt gttctatgcc   8820</entry></row><row><entry> </entry></row><row><entry>ctagggggcg gggggaagct aagccagctt tttttaacat ttaaaatgtt aattccattt   8880</entry></row><row><entry> </entry></row><row><entry>taaatgcaca gatgttttta tttcataagg gtttcaatgt gcatgaatgc tgcaatattc   8940</entry></row><row><entry> </entry></row><row><entry>ctgttaccaa agctagtata aataaaaata gataaacgtg gaaattactt agagtttctg   9000</entry></row><row><entry> </entry></row><row><entry>tcattaacgt ttccttcctc agttgacaac ataaatgcgc tgctgagcaa gccagtttgc   9060</entry></row><row><entry> </entry></row><row><entry>atctgtcagg atcaatttcc cattatgcca gtcatattaa ttactagtca attagttgat   9120</entry></row><row><entry> </entry></row><row><entry>ttttattttt gacatataca tgtgaatgaa agaccccacc tgtaggtttg gcaagctagc   9180</entry></row><row><entry> </entry></row><row><entry>ttaagtaacg ccattttgca aggcatggaa aaatacataa ctgagaatag aaaagttcag   9240</entry></row><row><entry> </entry></row><row><entry>atcaaggtca ggaacagatg gaacagctga atatgggcca aacaggatat ctgtggtaag   9300</entry></row><row><entry> </entry></row><row><entry>cagttcctgc cccggctcag ggccaagaac agatggaaca gctgaatatg ggccaaacag   9360</entry></row><row><entry> </entry></row><row><entry>gatatctgtg gtaagcagtt cctgccccgg ctcagggcca agaacagatg gtccccagat   9420</entry></row><row><entry> </entry></row><row><entry>gcggtccagc cctcagcagt ttctagagaa ccatcagatg tttccagggt gccccaagga   9480</entry></row><row><entry> </entry></row><row><entry>cctgaaatga ccctgtgcct tatttgaact aaccaatcag ttcgcttctc gcttctgttc   9540</entry></row><row><entry> </entry></row><row><entry>gcgcgcttat gctccccgag ctcaataaaa gagcccacaa cccctcactc ggggcgccag   9600</entry></row><row><entry> </entry></row><row><entry>tcctccgatt gactgagtcg cccgggtacc cgtgtatcca ataaaccctc ttgcagttgc   9660</entry></row><row><entry> </entry></row><row><entry>atccgacttg tggtctcgct gttccttggg agggtctcct ctgagtgatt gactacccgt   9720</entry></row><row><entry> </entry></row><row><entry>cagcgggggt ctttcatttg ggggctcgtc cgggatcggg agacccctgc ccagggacca   9780</entry></row><row><entry> </entry></row><row><entry>ccgacccacc accgggaggt aagctggcca gcaacttatc tgtgtctgtc cgattgtcta   9840</entry></row><row><entry> </entry></row><row><entry>gtgtctatga ctgattttat gcgcctgcgt cggtactagt tagctaacta gctctgtatc   9900</entry></row><row><entry> </entry></row><row><entry>tggcggaccc gtggtggaac tgacgagttc ggaacacccg gccgcaaccc tgggagacgt   9960</entry></row><row><entry> </entry></row><row><entry>cccagggact tcgggggccg tttttgtggc ccgacctgag tcctaaaatc ccgatcgttt  10020</entry></row><row><entry> </entry></row><row><entry>aggactcttt ggtgcacccc ccttagagga gggatatgtg gttctggtag gagacgagaa  10080</entry></row><row><entry> </entry></row><row><entry>cctaaaacag ttcccgcctc cgtctgaatt tttgctttcg gtttgggacc gaagccgcgc  10140</entry></row><row><entry> </entry></row><row><entry>cgcgcgtctt gtctgctgca gcatcgttct gtgttgtctc tgtctgactg tgtttctgta  10200</entry></row><row><entry> </entry></row><row><entry>tttgtctgaa aatatgggcc cgggctagac tgttaccact cccttaagtt tgaccttagg  10260</entry></row><row><entry> </entry></row><row><entry>tcactggaaa gatgtcgagc ggatcgctca caaccagtcg gtagatgtca agaagagacg  10320</entry></row><row><entry> </entry></row><row><entry>ttgggttacc ttctgctctg cagaatggcc aacctttaac gtcggatggc cgcgagacgg  10380</entry></row><row><entry> </entry></row><row><entry>cacctttaac cgagacctca tcacccaggt taagatcaag gtcttttcac ctggcccgca  10440</entry></row><row><entry> </entry></row><row><entry>tggacaccca gaccaggtcc cctacatcgt gacctgggaa gccttggctt ttgacccccc  10500</entry></row><row><entry> </entry></row><row><entry>tccctgggtc aagccctttg tacaccctaa gcctccgcct cctcttcctc catccgcccc  10560</entry></row><row><entry> </entry></row><row><entry>gtctctcccc cttgaacctc ctcgttcgac cccgcctcga tcctcccttt atccagccct  10620</entry></row><row><entry> </entry></row><row><entry>cactccttct ctaggcgccc ccatatggcc atatgagatc ttatatgggg cacccccgcc  10680</entry></row><row><entry> </entry></row><row><entry>ccttgtaaac ttccctgacc ctgacatgac aagagttact aacagcccct ctctccaagc  10740</entry></row><row><entry> </entry></row><row><entry>tcacttacag gctctctact tagtccagca cgaagtctgg agacctctgg cggcagccta  10800</entry></row><row><entry> </entry></row><row><entry>ccaagaacaa ctggaccgac cggtggtacc tcacccttac cgagtcggcg acacagtgtg  10860</entry></row><row><entry> </entry></row><row><entry>ggtccgccga caccagacta agaacctaga acctcgctgg aaaggacctt acacagtcct  10920</entry></row><row><entry> </entry></row><row><entry>gctgaccacc cccaccgccc tcaaagtaga cggcatcgca gcttggatac acgccgccca  10980</entry></row><row><entry> </entry></row><row><entry>cgtgaaggct gccgaccccg ggggtggacc atcctctaga ctg                    11023</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 113</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 9670</entry></row><row><entry>&#x3c;212&#x3e; TYPE: DNA</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polynucleotide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 113</entry></row><row><entry> </entry></row><row><entry>ggatccggat tagtccaatt tgttaaagac aggatatcag tggtccaggc tctagttttg     60</entry></row><row><entry> </entry></row><row><entry>actcaacaat atcaccagct gaagcctata gagtacgagc catagataaa ataaaagatt    120</entry></row><row><entry> </entry></row><row><entry>ttatttagtc tccagaaaaa ggggggaatg aaagacccca cctgtaggtt tggcaagcta    180</entry></row><row><entry> </entry></row><row><entry>gcttaagtaa cgccattttg caaggcatgg aaaaatacat aactgagaat agagaagttc    240</entry></row><row><entry> </entry></row><row><entry>agatcaaggt caggaacaga tggaacagct gaatatgggc caaacaggat atctgtggta    300</entry></row><row><entry> </entry></row><row><entry>agcagttcct gccccggctc agggccaaga acagatggaa cagctgaata tgggccaaac    360</entry></row><row><entry> </entry></row><row><entry>aggatatctg tggtaagcag ttcctgcccc ggctcagggc caagaacaga tggtccccag    420</entry></row><row><entry> </entry></row><row><entry>atgcggtcca gccctcagca gtttctagag aaccatcaga tgtttccagg gtgccccaag    480</entry></row><row><entry> </entry></row><row><entry>gacctgaaat gaccctgtgc cttatttgaa ctaaccaatc agttcgcttc tcgcttctgt    540</entry></row><row><entry> </entry></row><row><entry>tcgcgcgctt ctgctccccg agctcaataa aagagcccac aacccctcac tcggggcgcc    600</entry></row><row><entry> </entry></row><row><entry>agtcctccga ttgactgagt cgcccgggta cccgtgtatc caataaaccc tcttgcagtt    660</entry></row><row><entry> </entry></row><row><entry>gcatccgact tgtggtctcg ctgttccttg ggagggtctc ctctgagtga ttgactaccc    720</entry></row><row><entry> </entry></row><row><entry>gtcagcgggg gtctttcaca catgcagcat gtatcaaaat taatttggtt ttttttctta    780</entry></row><row><entry> </entry></row><row><entry>agtatttaca ttaaatggcc atagtactta aagttacatt ggcttccttg aaataaacat    840</entry></row><row><entry> </entry></row><row><entry>ggagtattca gaatgtgtca taaatatttc taattttaag atagtatctc cattggcttt    900</entry></row><row><entry> </entry></row><row><entry>ctactttttc ttttattttt ttttgtcctc tgtcttccat ttgttgttgt tgttgtttgt    960</entry></row><row><entry> </entry></row><row><entry>ttgtttgttt gttggttggt tggttaattt ttttttaaag atcctacact atagttcaag   1020</entry></row><row><entry> </entry></row><row><entry>ctagactatt agctactctg taacccaggg tgaccttgaa gtcatgggta gcctgctgtt   1080</entry></row><row><entry> </entry></row><row><entry>ttagccttcc cacatctaag attacaggta tgagctatca tttttggtat attgattgat   1140</entry></row><row><entry> </entry></row><row><entry>tgattgattg atgtgtgtgt gtgtgattgt gtttgtgtgt gtgactgtga aaatgtgtgt   1200</entry></row><row><entry> </entry></row><row><entry>atgggtgtgt gtgaatgtgt gtatgtatgt gtgtgtgtga gtgtgtgtgt gtgtgtgtgc   1260</entry></row><row><entry> </entry></row><row><entry>atgtgtgtgt gtgtgactgt gtctatgtgt atgactgtgt gtgtgtgtgt gtgtgtgtgt   1320</entry></row><row><entry> </entry></row><row><entry>gtgtgtgtgt gtgtgtgtgt gttgtgaaaa aatattctat ggtagtgaga gccaacgctc   1380</entry></row><row><entry> </entry></row><row><entry>cggctcaggt gtcaggttgg tttttgagac agagtctttc acttagcttg gaattcactg   1440</entry></row><row><entry> </entry></row><row><entry>gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgcctt   1500</entry></row><row><entry> </entry></row><row><entry>gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgcac cgatcgccct   1560</entry></row><row><entry> </entry></row><row><entry>tcccaacagt tgcgcagcct gaatggcgaa tggcgcctga tgcggtattt tctccttacg   1620</entry></row><row><entry> </entry></row><row><entry>catctgtgcg gtatttcaca ccgcatatgg tgcactctca gtacaatctg ctctgatgcc   1680</entry></row><row><entry> </entry></row><row><entry>gcatagttaa gccagccccg acacccgcca acacccgctg acgcgccctg acgggcttgt   1740</entry></row><row><entry> </entry></row><row><entry>ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag   1800</entry></row><row><entry> </entry></row><row><entry>aggttttcac cgtcatcacc gaaacgcgcg atgacgaaag ggcctcgtga tacgcctatt   1860</entry></row><row><entry> </entry></row><row><entry>tttataggtt aatgtcatga taataatggt ttcttagacg tcaggtggca cttttcgggg   1920</entry></row><row><entry> </entry></row><row><entry>aaatgtgcgc ggaaccccta tttgtttatt tttctaaata cattcaaata tgtatccgct   1980</entry></row><row><entry> </entry></row><row><entry>catgagacaa taaccctgat aaatgcttca ataatattga aaaaggaaga gtatgagtat   2040</entry></row><row><entry> </entry></row><row><entry>tcaacatttc cgtgtcgccc ttattccctt ttttgcggca ttttgccttc ctgtttttgc   2100</entry></row><row><entry> </entry></row><row><entry>tcacccagaa acgctggtga aagtaaaaga tgctgaagat cagttgggtg cacgagtggg   2160</entry></row><row><entry> </entry></row><row><entry>ttacatcgaa ctggatctca acagcggtaa gatccttgag agttttcgcc ccgaagaacg   2220</entry></row><row><entry> </entry></row><row><entry>ttttccaatg atgagcactt ttaaagttct gctatgtggc gcggtattat cccgtattga   2280</entry></row><row><entry> </entry></row><row><entry>cgccgggcaa gagcaactcg gtcgccgcat acactattct cagaatgact tggttgagta   2340</entry></row><row><entry> </entry></row><row><entry>ctcaccagtc acagaaaagc atcttacgga tggcatgaca gtaagagaat tatgcagtgc   2400</entry></row><row><entry> </entry></row><row><entry>tgccataacc atgagtgata acactgcggc caacttactt ctgacaacga tcggaggacc   2460</entry></row><row><entry> </entry></row><row><entry>gaaggagcta accgcttttt tgcacaacat gggggatcat gtaactcgcc ttgatcgttg   2520</entry></row><row><entry> </entry></row><row><entry>ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt gacaccacga tgcctgtagc   2580</entry></row><row><entry> </entry></row><row><entry>aatggcaaca acgttgcgca aactattaac tggcgaacta cttactctag cttcccggca   2640</entry></row><row><entry> </entry></row><row><entry>acaattaata gactggatgg aggcggataa agttgcagga ccacttctgc gctcggccct   2700</entry></row><row><entry> </entry></row><row><entry>tccggctggc tggtttattg ctgataaatc tggagccggt gagcgtgggt ctcgcggtat   2760</entry></row><row><entry> </entry></row><row><entry>cattgcagca ctggggccag atggtaagcc ctcccgtatc gtagttatct acacgacggg   2820</entry></row><row><entry> </entry></row><row><entry>gagtcaggca actatggatg aacgaaatag acagatcgct gagataggtg cctcactgat   2880</entry></row><row><entry> </entry></row><row><entry>taagcattgg taactgtcag accaagttta ctcatatata ctttagattg atttaaaact   2940</entry></row><row><entry> </entry></row><row><entry>tcatttttaa tttaaaagga tctaggtgaa gatccttttt gataatctca tgaccaaaat   3000</entry></row><row><entry> </entry></row><row><entry>cccttaacgt gagttttcgt tccactgagc gtcagacccc gtagaaaaga tcaaaggatc   3060</entry></row><row><entry> </entry></row><row><entry>ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct   3120</entry></row><row><entry> </entry></row><row><entry>accagcggtg gtttgtttgc cggatcaaga gctaccaact ctttttccga aggtaactgg   3180</entry></row><row><entry> </entry></row><row><entry>cttcagcaga gcgcagatac caaatactgt ccttctagtg tagccgtagt taggccacca   3240</entry></row><row><entry> </entry></row><row><entry>cttcaagaac tctgtagcac cgcctacata cctcgctctg ctaatcctgt taccagtggc   3300</entry></row><row><entry> </entry></row><row><entry>tgctgccagt ggcgataagt cgtgtcttac cgggttggac tcaagacgat agttaccgga   3360</entry></row><row><entry> </entry></row><row><entry>taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca cagcccagct tggagcgaac   3420</entry></row><row><entry> </entry></row><row><entry>gacctacacc gaactgagat acctacagcg tgagcattga gaaagcgcca cgcttcccga   3480</entry></row><row><entry> </entry></row><row><entry>agggagaaag gcggacaggt atccggtaag cggcagggtc ggaacaggag agcgcacgag   3540</entry></row><row><entry> </entry></row><row><entry>ggagcttcca gggggaaacg cctggtatct ttatagtcct gtcgggtttc gccacctctg   3600</entry></row><row><entry> </entry></row><row><entry>acttgagcgt cgatttttgt gatgctcgtc aggggggcgg agcctatgga aaaacgccag   3660</entry></row><row><entry> </entry></row><row><entry>caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca tgttctttcc   3720</entry></row><row><entry> </entry></row><row><entry>tgcgttatcc cctgattctg tggataaccg tattaccgcc tttgagtgag ctgataccgc   3780</entry></row><row><entry> </entry></row><row><entry>tcgccgcagc cgaacgaccg agcgcagcga gtcagtgagc gaggaagcgg aagagcgccc   3840</entry></row><row><entry> </entry></row><row><entry>aatacgcaaa ccgcctctcc ccgcgcgttg gccgattcat taatgcagct ggcacgacag   3900</entry></row><row><entry> </entry></row><row><entry>gtttcccgac tggaaagcgg gcagtgagcg caacgcaatt aatgtgagtt agctcactca   3960</entry></row><row><entry> </entry></row><row><entry>ttaggcaccc caggctttac actttatgct tccggctcgt atgttgtgtg gaattgtgag   4020</entry></row><row><entry> </entry></row><row><entry>cggataacaa tttcacacag gaaacagcta tgaccatgat tacgccaagc tttgctctta   4080</entry></row><row><entry> </entry></row><row><entry>ggagtttcct aatacatccc aaactcaaat atataaagca tttgacttgt tctatgccct   4140</entry></row><row><entry> </entry></row><row><entry>agggggcggg gggaagctaa gccagctttt tttaacattt aaaatgttaa ttccatttta   4200</entry></row><row><entry> </entry></row><row><entry>aatgcacaga tgtttttatt tcataagggt ttcaatgtgc atgaatgctg caatattcct   4260</entry></row><row><entry> </entry></row><row><entry>gttaccaaag ctagtataaa taaaaataga taaacgtgga aattacttag agtttctgtc   4320</entry></row><row><entry> </entry></row><row><entry>attaacgttt ccttcctcag ttgacaacat aaatgcgctg ctgagcaagc cagtttgcat   4380</entry></row><row><entry> </entry></row><row><entry>ctgtcaggat caatttccca ttatgccagt catattaatt actagtcaat tagttgattt   4440</entry></row><row><entry> </entry></row><row><entry>ttatttttga catatacatg tgaatgaaag accccacctg taggtttggc aagctagctt   4500</entry></row><row><entry> </entry></row><row><entry>aagtaacgcc attttgcaag gcatggaaaa atacataact gagaatagaa aagttcagat   4560</entry></row><row><entry> </entry></row><row><entry>caaggtcagg aacagatgga acagctgaat atgggccaaa caggatatct gtggtaagca   4620</entry></row><row><entry> </entry></row><row><entry>gttcctgccc cggctcaggg ccaagaacag atggaacagc tgaatatggg ccaaacagga   4680</entry></row><row><entry> </entry></row><row><entry>tatctgtggt aagcagttcc tgccccggct cagggccaag aacagatggt ccccagatgc   4740</entry></row><row><entry> </entry></row><row><entry>ggtccagccc tcagcagttt ctagagaacc atcagatgtt tccagggtgc cccaaggacc   4800</entry></row><row><entry> </entry></row><row><entry>tgaaatgacc ctgtgcctta tttgaactaa ccaatcagtt cgcttctcgc ttctgttcgc   4860</entry></row><row><entry> </entry></row><row><entry>gcgcttatgc tccccgagct caataaaaga gcccacaacc cctcactcgg ggcgccagtc   4920</entry></row><row><entry> </entry></row><row><entry>ctccgattga ctgagtcgcc cgggtacccg tgtatccaat aaaccctctt gcagttgcat   4980</entry></row><row><entry> </entry></row><row><entry>ccgacttgtg gtctcgctgt tccttgggag ggtctcctct gagtgattga ctacccgtca   5040</entry></row><row><entry> </entry></row><row><entry>gcgggggtct ttcatttggg ggctcgtccg ggatcgggag acccctgccc agggaccacc   5100</entry></row><row><entry> </entry></row><row><entry>gacccaccac cgggaggtaa gctggccagc aacttatctg tgtctgtccg attgtctagt   5160</entry></row><row><entry> </entry></row><row><entry>gtctatgact gattttatgc gcctgcgtcg gtactagtta gctaactagc tctgtatctg   5220</entry></row><row><entry> </entry></row><row><entry>gcggacccgt ggtggaactg acgagttcgg aacacccggc cgcaaccctg ggagacgtcc   5280</entry></row><row><entry> </entry></row><row><entry>cagggacttc gggggccgtt tttgtggccc gacctgagtc ctaaaatccc gatcgtttag   5340</entry></row><row><entry> </entry></row><row><entry>gactctttgg tgcacccccc ttagaggagg gatatgtggt tctggtagga gacgagaacc   5400</entry></row><row><entry> </entry></row><row><entry>taaaacagtt cccgcctccg tctgaatttt tgctttcggt ttgggaccga agccgcgccg   5460</entry></row><row><entry> </entry></row><row><entry>cgcgtcttgt ctgctgcagc atcgttctgt gttgtctctg tctgactgtg tttctgtatt   5520</entry></row><row><entry> </entry></row><row><entry>tgtctgaaaa tatgggcccg ggctagactg ttaccactcc cttaagtttg accttaggtc   5580</entry></row><row><entry> </entry></row><row><entry>actggaaaga tgtcgagcgg atcgctcaca accagtcggt agatgtcaag aagagacgtt   5640</entry></row><row><entry> </entry></row><row><entry>gggttacctt ctgctctgca gaatggccaa cctttaacgt cggatggccg cgagacggca   5700</entry></row><row><entry> </entry></row><row><entry>cctttaaccg agacctcatc acccaggtta agatcaaggt cttttcacct ggcccgcatg   5760</entry></row><row><entry> </entry></row><row><entry>gacacccaga ccaggtcccc tacatcgtga cctgggaagc cttggctttt gacccccctc   5820</entry></row><row><entry> </entry></row><row><entry>cctgggtcaa gccctttgta caccctaagc ctccgcctcc tcttcctcca tccgccccgt   5880</entry></row><row><entry> </entry></row><row><entry>ctctccccct tgaacctcct cgttcgaccc cgcctcgatc ctccctttat ccagccctca   5940</entry></row><row><entry> </entry></row><row><entry>ctccttctct aggcgccccc atatggccat atgagatctt atatggggca cccccgcccc   6000</entry></row><row><entry> </entry></row><row><entry>ttgtaaactt ccctgaccct gacatgacaa gagttactaa cagcccctct ctccaagctc   6060</entry></row><row><entry> </entry></row><row><entry>acttacaggc tctctactta gtccagcacg aagtctggag acctctggcg gcagcctacc   6120</entry></row><row><entry> </entry></row><row><entry>aagaacaact ggaccgaccg gtggtacctc acccttaccg agtcggcgac acagtgtggg   6180</entry></row><row><entry> </entry></row><row><entry>tccgccgaca ccagactaag aacctagaac ctcgctggaa aggaccttac acagtcctgc   6240</entry></row><row><entry> </entry></row><row><entry>tgaccacccc caccgccctc aaagtagacg gcatcgcagc ttggatacac gccgcccacg   6300</entry></row><row><entry> </entry></row><row><entry>tgaaggctgc cgaccccggg ggtggaccat cctctagact gccatggcag ctgagcctgt   6360</entry></row><row><entry> </entry></row><row><entry>ggaggacaac tgcatcaact tcgtggccat gaagttcatc gacaacaccc tgtacttcat   6420</entry></row><row><entry> </entry></row><row><entry>cgctgaggac gacgagaacg gaggcggggg tagcatccct gagagcctga gagctggtgg   6480</entry></row><row><entry> </entry></row><row><entry>gggaggtgga agcgctgccg cttacttcgg aaagctggag agcaagctga gcgtgatcag   6540</entry></row><row><entry> </entry></row><row><entry>aaacctgaac gaccaggtgc tgttcatcga ccagggcaac agacctctgt tcgaggacat   6600</entry></row><row><entry> </entry></row><row><entry>gaccgacagc gactgcagag acaacgctcc cagaaccatc ttcatcatca gcatgtacaa   6660</entry></row><row><entry> </entry></row><row><entry>ggacagccag cctagaggca tggccgtgac catcagcgtg aagtgcgaga agatcagcac   6720</entry></row><row><entry> </entry></row><row><entry>cctgagctgc gagaacaaga tcatcagctt caaggagatg aaccctcctg acaacatcaa   6780</entry></row><row><entry> </entry></row><row><entry>ggacaccaag agcgacatca tcttcttcca gagaagcgtg cctggacacg acaacaagat   6840</entry></row><row><entry> </entry></row><row><entry>gcagttcgag agcagcagct acgagggcta cttcctggct tgcgagaagg agagagacct   6900</entry></row><row><entry> </entry></row><row><entry>gttcaagctg atcctgaaga aggaggacga gctgggagac agaagcatca tgttcaccgt   6960</entry></row><row><entry> </entry></row><row><entry>gcagaacgag gacagagcta agagaagcgg atctggagct accaacttca gcctgctgaa   7020</entry></row><row><entry> </entry></row><row><entry>gcaggctgga gatgtggagg agaaccctgg acccatgggc tggctgtgtt ccggcctgct   7080</entry></row><row><entry> </entry></row><row><entry>gtttcctgtg tcctgtctgg tgctgctgca ggtggccagc tccgggaaca tgaaagtgct   7140</entry></row><row><entry> </entry></row><row><entry>gcaggagccc acatgtgtgt ccgactacat gtccatctct acatgtgagt ggaagatgaa   7200</entry></row><row><entry> </entry></row><row><entry>cggccccaca aactgctcta ccgagctgcg gctgctgtac cagctggtgt ttctgctgag   7260</entry></row><row><entry> </entry></row><row><entry>cgaggcccac acctgtatcc cagaaaataa tggcggggcc gggtgtgtgt gccacctgct   7320</entry></row><row><entry> </entry></row><row><entry>gatggatgac gtggtgtctg ccgacaatta caccctggac ctgtgggccg gacagcagct   7380</entry></row><row><entry> </entry></row><row><entry>gctgtggaag gggtccttca aaccctctga gcacgtgaag ccaagggccc ccggcaacct   7440</entry></row><row><entry> </entry></row><row><entry>gacagtgcac accaacgtgt ctgatacact gctgctgaca tggagcaatc cataccctcc   7500</entry></row><row><entry> </entry></row><row><entry>tgacaactac ctgtacaacc acctgaccta cgccgtgaat atctggagcg aaaatgatcc   7560</entry></row><row><entry> </entry></row><row><entry>tgccgacttt cggatttaca atgtgaccta tctggagccc tccctgagaa ttgccgcctc   7620</entry></row><row><entry> </entry></row><row><entry>taccctgaaa tctggaatct cctaccgcgc cagggtgcgg gcctgggccc agtgttacaa   7680</entry></row><row><entry> </entry></row><row><entry>caccacctgg tctgagtgga gcccaagcac caagtggcac aattcttatc gggagccttt   7740</entry></row><row><entry> </entry></row><row><entry>tgagcagcac ctgatcccct ggctgggaca cctgctggtg gggctgtctg gcgcctttgg   7800</entry></row><row><entry> </entry></row><row><entry>cttcatcatt ctggtgtacc tgctgatcaa ctgtaggaat acaggccctt ggctgaagaa   7860</entry></row><row><entry> </entry></row><row><entry>ggtgctgaag tgtaacaccc ccgacccctc taagttcttc agccagctgt cctctgaaca   7920</entry></row><row><entry> </entry></row><row><entry>cgggggagat gtgcagaagt ggctgtccag ccctttccca tccagctcct ttagccccgg   7980</entry></row><row><entry> </entry></row><row><entry>gggcctggcc cctgagatct ctccactgga agtgctggag cgggacaagg tgacccagct   8040</entry></row><row><entry> </entry></row><row><entry>gctgctgcag caggacaagg tgccagaacc cgcctccctg agctccaacc acagcctgac   8100</entry></row><row><entry> </entry></row><row><entry>atcttgcttt acaaatcagg gatacttctt cttccacctg cccgatgccc tggagatcga   8160</entry></row><row><entry> </entry></row><row><entry>ggcctgccag gtgtacttca cctacgatcc ctactctgag gaagacccag atgagggcgt   8220</entry></row><row><entry> </entry></row><row><entry>ggccggggcc ccaaccgggt ccagcccaca gccactgcag ccactgtccg gcgaagatga   8280</entry></row><row><entry> </entry></row><row><entry>cgcctactgc acattccctt ccagggatga cctgctgctg ttcagcccat ctctgctggg   8340</entry></row><row><entry> </entry></row><row><entry>cggaccctct cctccaagca cagccccagg gggatccggc gccggggaag agaggatgcc   8400</entry></row><row><entry> </entry></row><row><entry>ccctagcctg caggagcgcg tgcccagaga ctgggacccc cagcccctgg gccctccaac   8460</entry></row><row><entry> </entry></row><row><entry>ccctggggtg cccgacctgg tggacttcca gcctccaccc gagctggtgc tgagggaggc   8520</entry></row><row><entry> </entry></row><row><entry>cggcgaagag gtgcccgacg ccggcccccg ggagggcgtg tccttccctt ggtccagacc   8580</entry></row><row><entry> </entry></row><row><entry>tccaggacag ggcgagttcc gcgccctgaa cgccaggctg cctctgaaca ccgatgccta   8640</entry></row><row><entry> </entry></row><row><entry>cctgtctctg caggaactgc agggccagga cccaacccac ctggtgcgga gaaagcgcag   8700</entry></row><row><entry> </entry></row><row><entry>cggctccggc gagggccggg gcagcctgct gacctgcggc gacgtggaag agaaccccgg   8760</entry></row><row><entry> </entry></row><row><entry>acccatgggc ccaggagttc tgctgctcct gctggtggcc acagcttggc atggtcaggg   8820</entry></row><row><entry> </entry></row><row><entry>aggtgtggtg tcgcacttca atgactgtcc actgtcgcac gatggatact gcctccatga   8880</entry></row><row><entry> </entry></row><row><entry>tggtgtgtgc atgtacatcg aggcattgga caagtatgca tgcaactgtg tcgtcggcta   8940</entry></row><row><entry> </entry></row><row><entry>catcggagag cgatgtcagt accgagacct gaagtggtgg gaactgagag cggccgcaat   9000</entry></row><row><entry> </entry></row><row><entry>tgaagttatg tatcctcctc cttacctaga caatgagaag agcaatggaa ccattatcca   9060</entry></row><row><entry> </entry></row><row><entry>tgtgaaaggg aaacaccttt gtccaagtcc cctatttccc ggaccttcta agcccttttg   9120</entry></row><row><entry> </entry></row><row><entry>ggtgctggtg gtggttggtg gagtcctggc ttgctatagc ttgctagtaa cagtggcctt   9180</entry></row><row><entry> </entry></row><row><entry>tattattttc tgggtgagga gtaagaggag caggctcctg cacagtgact acatgaacat   9240</entry></row><row><entry> </entry></row><row><entry>gactccccgc cgccccgggc ccacccgcaa gcattaccag ccctatgccc caccacgcga   9300</entry></row><row><entry> </entry></row><row><entry>cttcgcagcc tatcgctcca gagtgaagtt cagcaggagc gcagacgccc ccgcgtacca   9360</entry></row><row><entry> </entry></row><row><entry>gcagggccag aaccagctct ataacgagct caatctagga cgaagagagg agtacgatgt   9420</entry></row><row><entry> </entry></row><row><entry>tttggacaag agacgtggcc gggaccctga gatgggggga aagccgagaa ggaagaaccc   9480</entry></row><row><entry> </entry></row><row><entry>tcaggaaggc ctgtacaatg aactgcagaa agataagatg gcggaggcct acagtgagat   9540</entry></row><row><entry> </entry></row><row><entry>tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat ggcctttacc agggtctcag   9600</entry></row><row><entry> </entry></row><row><entry>tacagccacc aaggacacct acgacgccct tcacatgcag gccctgcccc ctcgctaaca   9660</entry></row><row><entry> </entry></row><row><entry>gccactcgag                                                          9670</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 114</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 6</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 114</entry></row><row><entry> </entry></row><row><entry>Met Tyr Pro Pro Pro Tyr</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 115</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 115</entry></row><row><entry> </entry></row><row><entry>Ser Gly Ser Gly</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 116</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 116</entry></row><row><entry> </entry></row><row><entry>Asp Glu Val Asp</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 117</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 8</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 117</entry></row><row><entry> </entry></row><row><entry>Ile Pro Glu Ser Leu Arg Ala Gly</entry></row><row><entry>1               5</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 118</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 31</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: VARIANT</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (6)..(22)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /replace=&#x201c; &#x201d;</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: VARIANT</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (23)..(23)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /replace=&#x201c;Leu&#x201d;</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: VARIANT</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (24)..(24)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /replace=&#x201c;Glu&#x201d;</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: VARIANT</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (25)..(25)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /replace=&#x201c;Ser&#x201d;</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: VARIANT</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (26)..(26)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /replace=&#x201c;Asp&#x201d;</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: SITE</entry></row><row><entry>&#x3c;222&#x3e; LOCATION: (1)..(31)</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Variant residues given in the sequence</entry></row><row><entry>      have no preference with respect to those in the annotations</entry></row><row><entry>      for variant positions&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 118</entry></row><row><entry> </entry></row><row><entry>Glu Asp Asp Glu Asn Gly Gly Gly Gly Ser Ile Pro Glu Ser Leu Arg</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ala Gly Gly Gly Gly Gly Ser Ala Ala Ala Tyr Phe Gly Lys Leu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 119</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 14</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 119</entry></row><row><entry> </entry></row><row><entry>Glu Asp Asp Glu Asn Leu Glu Ser Asp Tyr Phe Gly Lys Leu</entry></row><row><entry>1               5                   10</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 120</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 31</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic polypeptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 120</entry></row><row><entry> </entry></row><row><entry>Glu Asp Asp Glu Asn Gly Gly Gly Gly Ser Ile Pro Glu Ser Leu Arg</entry></row><row><entry>1               5                   10                  15</entry></row><row><entry> </entry></row><row><entry>Ala Gly Gly Gly Gly Gly Ser Ala Ala Ala Tyr Phe Gly Lys Leu</entry></row><row><entry>            20                  25                  30</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 121</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 121</entry></row><row><entry> </entry></row><row><entry>Leu Glu Ser Asp</entry></row><row><entry>1</entry></row><row><entry> </entry></row><row><entry> </entry></row><row><entry>&#x3c;210&#x3e; SEQ ID NO 122</entry></row><row><entry>&#x3c;211&#x3e; LENGTH: 4</entry></row><row><entry>&#x3c;212&#x3e; TYPE: PRT</entry></row><row><entry>&#x3c;213&#x3e; ORGANISM: Artificial Sequence</entry></row><row><entry>&#x3c;220&#x3e; FEATURE:</entry></row><row><entry>&#x3c;221&#x3e; NAME/KEY: source</entry></row><row><entry>&#x3c;223&#x3e; OTHER INFORMATION: /note=&#x201c;Description of Artificial Sequence:</entry></row><row><entry>      Synthetic peptide&#x201d;</entry></row><row><entry> </entry></row><row><entry>&#x3c;400&#x3e; SEQUENCE: 122</entry></row><row><entry> </entry></row><row><entry>Ile Glu Thr Asp</entry></row><row><entry>1</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></tbody></tgroup></table></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000914A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221222" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000914</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17678735</doc-number><date>20220223</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>17</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>17</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0783</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>62</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>17</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>1774</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0638</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>625</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">MODIFIED CYTOTOXIC T CELLS AND METHODS OF USE THEREOF</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>PCT/US2020/056901</doc-number><date>20201022</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>17678735</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>62925111</doc-number><date>20191023</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Cue Biopharma, Inc.</orgname><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Suri</last-name><first-name>Anish</first-name><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present disclosure provides in vitro modified cytotoxic T cells (CTLs) that comprise: a) a T-cell receptor (TCR) specific for a preselected antigen in a human; and b) a nucleic acid(s) encoding a chimeric antigen receptor (CAR) specific for a cancer-associated antigen. The present disclosure provides methods of producing the modified CTLs. The present disclosure provides of treating cancer, comprising administering the modified CTLs to an individual in need thereof.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="70.02mm" wi="158.75mm" file="US20230000914A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="236.39mm" wi="123.02mm" orientation="landscape" file="US20230000914A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="236.98mm" wi="146.39mm" file="US20230000914A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="211.24mm" wi="153.67mm" file="US20230000914A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="158.24mm" wi="154.18mm" file="US20230000914A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="200.07mm" wi="153.67mm" file="US20230000914A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="231.48mm" wi="150.11mm" orientation="landscape" file="US20230000914A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="200.58mm" wi="91.78mm" orientation="landscape" file="US20230000914A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="242.74mm" wi="156.89mm" file="US20230000914A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="154.69mm" wi="154.26mm" file="US20230000914A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="242.23mm" wi="152.48mm" file="US20230000914A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="168.06mm" wi="153.84mm" file="US20230000914A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="228.52mm" wi="152.82mm" file="US20230000914A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="245.03mm" wi="154.01mm" file="US20230000914A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="229.45mm" wi="152.82mm" file="US20230000914A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="245.19mm" wi="154.01mm" file="US20230000914A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="237.57mm" wi="153.08mm" file="US20230000914A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="244.26mm" wi="154.01mm" file="US20230000914A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="245.96mm" wi="154.18mm" file="US20230000914A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="241.81mm" wi="154.09mm" file="US20230000914A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS-REFERENCE</heading><p id="p-0002" num="0001">This application claims the benefit of U.S. Provisional Patent Application No. 62/925,111, filed Oct. 23, 2019, which application is incorporated herein by reference in its entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">INTRODUCTION</heading><p id="p-0003" num="0002">An adaptive immune response involves the engagement of the T cell receptor (TCR), present on the surface of a T cell, with a small peptide antigen non-covalently presented on the surface of an antigen presenting cell (APC) by a major histocompatibility complex (MHC; also referred to in humans as a human leukocyte antigen (HLA) complex). This engagement represents the immune system's targeting mechanism and is a requisite molecular interaction for T cell modulation (activation or inhibition) and effector function. Following epitope-specific cell targeting, the targeted T cells are activated through engagement of costimulatory proteins found on the APC with counterpart costimulatory proteins the T cells. Both signals&#x2014;epitope/TCR binding and engagement of APC costimulatory proteins with T cell costimulatory proteins&#x2014;are required to drive T cell specificity and activation or inhibition. The TCR is specific for a given epitope; however, the costimulatory protein not epitope specific and instead is generally expressed on all T cells or on large T cell subsets.</p><heading id="h-0003" level="1">SUMMARY</heading><p id="p-0004" num="0003">The present disclosure provides in vitro modified cytotoxic T cells (CTLs) that comprise: a) a T-cell receptor (TCR) specific for a preselected antigen in a human; and b) a nucleic acid(s) encoding a chimeric antigen receptor (CAR) specific for a cancer-associated antigen. The present disclosure provides methods of producing the modified CTLs. The present disclosure provides methods of treating cancer, comprising administering the modified CTLs to an individual in need thereof.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0005" num="0004"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a schematic depiction of generation and use of modified CTLs according to the present disclosure.</p><p id="p-0006" num="0005"><figref idref="DRAWINGS">FIG. <b>2</b>A-<b>2</b>D</figref> provide schematic depictions of exemplary embodiments of TMMPs.</p><p id="p-0007" num="0006"><figref idref="DRAWINGS">FIGS. <b>3</b>A-<b>3</b>G</figref> provide amino acid sequences (from top to bottom SEQ ID NOs: 376-387) of immunoglobulin Fc polypeptides.</p><p id="p-0008" num="0007"><figref idref="DRAWINGS">FIG. <b>4</b></figref> provides a multiple amino acid sequence alignment of beta-2 microglobulin (&#x3b2;2M) precursors (i.e., including the leader sequence) from <i>Homo sapiens </i>(NP_004039.1; SEQ ID NO:388), <i>Pan troglodytes </i>(NP_001009066.1; SEQ ID NO:388), <i>Macaca mulatta </i>(NP_001040602.1; SEQ ID NO:389), <i>Bos taurus </i>(NP_776318.1; SEQ ID NO:390) and <i>Mus musculus </i>(NP_033865.2; SEQ ID NO:391). Amino acids 1-20 are a signal peptide.</p><p id="p-0009" num="0008"><figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>C</figref> provide amino acid sequences of full-length human HLA heavy chains of alleles A*0101 (SEQ ID NO:392), A*1101 (SEQ ID NO:393), A*2402 (SEQ ID NO:394), and A*3303 (SEQ ID NO:395) (<figref idref="DRAWINGS">FIG. <b>5</b>A</figref>); full-length human HLA heavy chain of allele B*0702 (<figref idref="DRAWINGS">FIG. <b>5</b>B</figref>; SEQ ID NO:396); and a full-length human HLA-C heavy chain (<figref idref="DRAWINGS">FIG. <b>5</b>C</figref>; SEQ ID NO:397).</p><p id="p-0010" num="0009"><figref idref="DRAWINGS">FIG. <b>6</b></figref> provides an alignment of eleven mature MHC class I heavy chain amino acid sequences without their leader sequences, transmembrane domains, and intracellular domains.</p><p id="p-0011" num="0010"><figref idref="DRAWINGS">FIGS. <b>7</b>A-<b>7</b>B</figref> provide an alignment of HLA-A heavy chain amino acid sequences (<figref idref="DRAWINGS">FIG. <b>7</b>A</figref>; from top to bottom SEQ ID NOs: 406, 185, 407-413) and a consensus sequence (<figref idref="DRAWINGS">FIG. <b>7</b>B</figref>; SEQ ID NO: 184).</p><p id="p-0012" num="0011"><figref idref="DRAWINGS">FIGS. <b>8</b>A-<b>8</b>B</figref> provide an alignment of HLA-B heavy chain amino acid sequences (<figref idref="DRAWINGS">FIG. <b>8</b>A</figref>; from top to bottom SEQ ID NOs: 195, 414-419) and a consensus sequence (<figref idref="DRAWINGS">FIG. <b>8</b>B</figref>; SEQ ID NO: 194).</p><p id="p-0013" num="0012"><figref idref="DRAWINGS">FIGS. <b>9</b>A-<b>9</b>B</figref> provide an alignment of HLA-C heavy chain amino acid sequences (<figref idref="DRAWINGS">FIG. <b>9</b>A</figref>; from top to bottom SEQ ID NOs: 420-424, 199, 425-427) and a consensus sequence (<figref idref="DRAWINGS">FIG. <b>9</b>B</figref>; SEQ ID NO: 198).</p><p id="p-0014" num="0013"><figref idref="DRAWINGS">FIG. <b>10</b></figref> provides a consensus amino acid sequence for each of HLA-E (SEQ ID NO:428), -F (SEQ ID NO:429), and -G (SEQ ID NO:430) heavy chains. Variable amino acid (aa) positions are indicated as &#x201c;X&#x201d; residues sequentially numbered; the locations of amino acids 84, 139, and 236 are double underlined.</p><p id="p-0015" num="0014"><figref idref="DRAWINGS">FIG. <b>11</b></figref> provides an alignment of consensus amino acid sequences for HLA-A (SEQ ID NO:184), -B (SEQ ID NO:194), -C(SEQ ID NO:198), -E (SEQ ID NO:431), -F (SEQ ID NO:432), and -G (SEQ ID NO:433).</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DEFINITIONS</heading><p id="p-0016" num="0015">The terms &#x201c;polynucleotide&#x201d; and &#x201c;nucleic acid,&#x201d; used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.</p><p id="p-0017" num="0016">The terms &#x201c;peptide,&#x201d; &#x201c;polypeptide,&#x201d; and &#x201c;protein&#x201d; are used interchangeably herein, and refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.</p><p id="p-0018" num="0017">A polynucleotide or polypeptide has a certain percent &#x201c;sequence identity&#x201d; to another polynucleotide or polypeptide, meaning that, when aligned, that percentage of bases or amino acids are the same, and in the same relative position, when comparing the two sequences. Sequence identity can be determined in a number of different ways. To determine sequence identity, sequences can be aligned using various convenient methods and computer programs (e.g., BLAST, T-COFFEE, MUSCLE, MAFFT, etc.), available over the world wide web at sites including ncbi.nlm.nili.gov/BLAST, ebi.ac.uk/Tools/msa/tcoffee/, ebi.ac.uk/Tools/msa/muscle/, mafft.cbrc.jp/alignment/software/. See, e.g., Altschul et al. (1990), J. Mol. Biol. 215:403-10.</p><p id="p-0019" num="0018">The term &#x201c;conservative amino acid substitution&#x201d; refers to the interchangeability in proteins of amino acid residues having similar side chains. For example, a group of amino acids having aliphatic side chains consists of glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains consists of serine and threonine; a group of amino acids having amide containing side chains consisting of asparagine and glutamine; a group of amino acids having aromatic side chains consists of phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains consists of lysine, arginine, and histidine; a group of amino acids having acidic side chains consists of glutamate and aspartate; and a group of amino acids having sulfur containing side chains consists of cysteine and methionine. Exemplary conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine-glycine, and asparagine-glutamine.</p><p id="p-0020" num="0019">The term &#x201c;immunological synapse&#x201d; or &#x201c;immune synapse&#x201d; as used herein generally refers to the natural interface between two interacting immune cells of an adaptive immune response including, e.g., the interface between an antigen-presenting cell (APC) or target cell and an effector cell, e.g., a lymphocyte, an effector T cell, a natural killer cell, and the like. An immunological synapse between an APC and a T cell is generally initiated by the interaction of a T cell antigen receptor and major histocompatibility complex molecules, e.g., as described in Bromley et al., Annu Rev Immunol. 2001; 19:375-96; the disclosure of which is incorporated herein by reference in its entirety.</p><p id="p-0021" num="0020">&#x201c;T cell&#x201d; includes all types of immune cells expressing CD3, including T-helper cells (CD4<sup>+</sup> cells), cytotoxic T-cells (CD8<sup>+</sup> cells), T-regulatory cells (Treg), and NK-T cells.</p><p id="p-0022" num="0021">The term &#x201c;immunomodulatory polypeptide&#x201d; (also referred to as a &#x201c;co-stimulatory polypeptide&#x201d;), as used herein, includes a polypeptide on an antigen presenting cell (APC) (e.g., a dendritic cell, a B cell, and the like) that specifically binds a cognate co-immunomodulatory polypeptide on a T cell, thereby providing a signal which, in addition to the primary signal provided by, for instance, binding of a TCR/CD3 complex with a major histocompatibility complex (MHC) polypeptide loaded with peptide, mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. An immunomodulatory polypeptide can include, but is not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, Fas ligand (FasL), inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3/TR6, ILT3, ILT4, HVEM, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3.</p><p id="p-0023" num="0022">As noted above, an &#x201c;immunomodulatory polypeptide&#x201d; (also referred to herein as a &#x201c;MOD&#x201d;) specifically binds a cognate co-immunomodulatory polypeptide on a T cell.</p><p id="p-0024" num="0023">An &#x201c;immunomodulatory domain&#x201d; (&#x201c;MOD&#x201d;) of a TMMP binds a cognate co-immunomodulatory polypeptide, which may be present on a target T cell.</p><p id="p-0025" num="0024">In general, a T-cell modulatory polypeptide (TMP) comprises a polypeptide that preferentially binds to and activates target T cells bearing a T cell receptor (TCR) specific for an antigen of interest. Likewise, a T-cell modulatory multimeric polypeptide (TMMP) comprises a multimeric T-cell modulatory polypeptide that preferentially binds to and activates target T cells bearing a T cell receptor (TCR) specific for an antigen of interest. For example, a TMMP can comprise at least one heterodimer comprising 2 polypeptide chains: a) a first polypeptide comprising: i) a peptide epitope (e.g., a peptide that is at least 4 amino acids in length (e.g., from 4 amino acids to about 25 amino acids in length); and ii) first MHC polypeptide; b) a second polypeptide comprising a second MHC polypeptide, and c) at least one immunomodulatory polypeptide, where the first and/or the second polypeptide comprises the immunomodulatory polypeptide. A TMP or a TMMP also may be referred to as a &#x201c;synTac&#x201d; or an &#x201c;Immuno-STAT&#x2122;.&#x201d;</p><p id="p-0026" num="0025">&#x201c;Heterologous,&#x201d; as used herein, means a nucleotide or polypeptide that is not found in the native nucleic acid or protein, respectively.</p><p id="p-0027" num="0026">The terms &#x201c;expression construct,&#x201d; or &#x201c;DNA construct&#x201d; are used interchangeably herein to refer to a DNA molecule comprising a vector and at least one insert.</p><p id="p-0028" num="0027">As used herein, the term &#x201c;affinity&#x201d; refers to the equilibrium constant for the reversible binding of two agents (e.g., an antibody and an antigen) and is expressed as a dissociation constant (K<sub>D</sub>). Affinity can be at least 1-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 20-fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, or at least 1,000-fold greater, or more, than the affinity of an antibody for unrelated amino acid sequences. Affinity of an antibody to a target protein can be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar (fM) or more. As used herein, the term &#x201c;avidity&#x201d; refers to the resistance of a complex of two or more agents to dissociation after dilution. The terms &#x201c;immunoreactive&#x201d; and &#x201c;preferentially binds&#x201d; are used interchangeably herein with respect to antibodies and/or antigen-binding fragments. Unless otherwise indicated herein, when the word &#x201c;about&#x201d; is used in reference to a numeric value, it means a range of &#xb1;10% of the stated numeric value, e.g., &#x201c;about 10&#x201d; means a value from 9 to 11.</p><p id="p-0029" num="0028">The term &#x201c;binding,&#x201d; as used herein (e.g. with reference to binding of a TMMP to a polypeptide (e.g., a T-cell receptor) on a T cell; or with reference to binding of an antigen-binding polypeptide present in a CAR to an antigen such as a cancer-associated antigen), refers to a non-covalent interaction between two molecules. Non-covalent binding refers to a direct association between two molecules, due to, for example, electrostatic, hydrophobic, ionic, and/or hydrogen-bond interactions, including interactions such as salt bridges and water bridges. Non-covalent binding interactions are generally characterized by a dissociation constant (K<sub>D</sub>) of less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;7 </sup>M, less than 10<sup>&#x2212;8 </sup>M, less than 10<sup>&#x2212;9 </sup>M, less than 10<sup>&#x2212;10 </sup>M, less than 10<sup>&#x2212;11 </sup>M, less than 10<sup>&#x2212;12 </sup>M, less than 10<sup>&#x2212;13 </sup>M, less than 10<sup>&#x2212;14 </sup>M, or less than 10<sup>&#x2212;15 </sup>M. &#x201c;Affinity&#x201d; refers to the strength of non-covalent binding, increased binding affinity being correlated with a lower K<sub>D</sub>. &#x201c;Specific binding&#x201d; generally refers to binding with an affinity of at least about 10<sup>&#x2212;7 </sup>M or greater, e.g., 5&#xd7;10<sup>&#x2212;7</sup>M, 10<sup>&#x2212;8 </sup>M, 5&#xd7;10<sup>&#x2212;8 </sup>M, 10<sup>&#x2212;9 </sup>M, and greater. &#x201c;Non-specific binding&#x201d; generally refers to binding (e.g., the binding of a ligand to a moiety other than its designated binding site or receptor) with an affinity of less than about 10<sup>&#x2212;7 </sup>M (e.g., binding with an affinity of 10<sup>&#x2212;6 </sup>M, 10<sup>&#x2212;5 </sup>M, 10<sup>&#x2212;4 </sup>M). However, in some contexts, e.g., binding between a TCR and a peptide/MHC complex, &#x201c;specific binding&#x201d; can be in the range of from 1 &#x3bc;M to 100 &#x3bc;M, or from 100 &#x3bc;M to 1 mM. &#x201c;Covalent binding&#x201d; or &#x201c;covalent bond,&#x201d; as used herein, refers to the formation of one or more covalent chemical binds between two different molecules.</p><p id="p-0030" num="0029">The terms &#x201c;treatment&#x201d;, &#x201c;treating&#x201d; and the like are used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. &#x201c;Treatment&#x201d; as used herein covers any treatment of a disease or symptom in a mammal, and includes: (a) preventing the disease or symptom from occurring in a subject which may be predisposed to acquiring the disease or symptom but has not yet been diagnosed as having it; (b) inhibiting the disease or symptom, i.e., arresting its development; and/or (c) relieving the disease, i.e., causing regression of the disease. The therapeutic agent may be administered before, during or after the onset of disease or injury. The treatment of ongoing disease, where the treatment stabilizes or reduces the undesirable clinical symptoms of the patient, is of particular interest. Such treatment is desirably performed prior to complete loss of function in the affected tissues. The subject therapy will desirably be administered during the symptomatic stage of the disease, and in some cases after the symptomatic stage of the disease.</p><p id="p-0031" num="0030">The terms &#x201c;individual,&#x201d; &#x201c;subject,&#x201d; &#x201c;host,&#x201d; and &#x201c;patient,&#x201d; are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired. Mammals include, e.g., humans, non-human primates, rodents (e.g., rats; mice), lagomorphs (e.g., rabbits), ungulates (e.g., cows, sheep, pigs, horses, goats, and the like), etc.</p><p id="p-0032" num="0031">Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.</p><p id="p-0033" num="0032">Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.</p><p id="p-0034" num="0033">Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.</p><p id="p-0035" num="0034">It must be noted that as used herein and in the appended claims, the singular forms &#x201c;a,&#x201d; &#x201c;an,&#x201d; and &#x201c;the&#x201d; include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to &#x201c;a modified T cell&#x201d; includes a plurality of such T cells and reference to &#x201c;the T-cell modulatory multimeric polypeptide&#x201d; includes reference to one or more T-cell modulatory multimeric polypeptides and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as &#x201c;solely,&#x201d; &#x201c;only&#x201d; and the like in connection with the recitation of claim elements, or use of a &#x201c;negative&#x201d; limitation.</p><p id="p-0036" num="0035">It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.</p><p id="p-0037" num="0036">The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.</p><heading id="h-0006" level="1">DETAILED DESCRIPTION</heading><p id="p-0038" num="0037">The present disclosure provides in vitro modified cytotoxic T cells (CTLs) that comprise: a) a T-cell receptor (TCR) specific for a preselected antigen in a human; and b) a nucleic acid(s) encoding a chimeric antigen receptor (CAR) specific for a cancer-associated antigen. The present disclosure provides methods of producing the modified CTLs. The present disclosure provides methods of treating cancer, comprising administering the modified CTLs to an individual in need thereof.</p><heading id="h-0007" level="2">Modified Cytotoxic T Cells</heading><p id="p-0039" num="0038">The present disclosure provides in vitro modified T cells that comprise: a) a TCR specific for a preselected antigen present in a human; and b) one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain that binds to a cancer-associated antigen. The present disclosure provides an in vitro composition comprising a quantity of (a population of) target modified T cells that comprise: a) a TCR specific for a preselected antigen present in a human; and b) one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain that binds to a cancer-associated antigen. The present disclosure provides in vitro modified CTLs that comprise: a) a TCR specific for a preselected antigen present in a human; and b) one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain that binds to a cancer-associated antigen. The present disclosure provides an in vitro composition comprising a quantity of (a population of) target modified CTLs that comprise: a) a TCR specific for a preselected antigen present in a human; and b) one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain that binds to a cancer-associated antigen.</p><p id="p-0040" num="0039">An in vitro composition of the present disclosure can comprise a population of modified T cells that may contain modified cells (e.g., T cells, such as CTLs) other than the target modified T cells (e.g., target modified CTLs). Such cells are referred to as &#x201c;non-target modified T cells,&#x201d; where non-target T cells can include non-target CTLs. Non-target modified T cells comprise a TCR that is not specific for the preselected antigen. Thus, an in vitro composition of the present disclosure can be a heterogeneous population comprising target modified T cells (e.g., target modified CTLs) and non-target modified T cells (e.g., non-target modified CTLs). In some cases, from 1% to 20% of the total number of T cells in the composition are target modified T cells (e.g., target modified CTLs). In some cases, from 1% to 5%, from 5% to 10%, from 10% to 15%, or from 15% to 20% of the total number of T cells in the composition are target modified T cells (e.g., target modified CTLs). In some cases, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or more than 99%, of the total number of T cells in the composition are target modified T cells (e.g., target modified CTLs). In some cases, from 20% to 30%, from 30% to 40%, from 40% to 50%, from 50% to 60%, from 60% to 70%, from 70% to 80%, from 80% to 90%, or from 90% to 100%, of the total number of T cells in the composition are target modified T cells (e.g., target modified CTLs). In some cases, therefore, the population of T cells in the composition is a substantially homogeneous population of target modified T cells (e.g., target modified CTLs). Unless otherwise indicated, when used herein the term &#x201c;substantially&#x201d; means &#x201c;wholly or largely but not wholly&#x201d;. Hence, for example, a &#x201c;substantially homogeneous population&#x201d; means a population that is wholly homogeneous or largely but not wholly homogeneous.</p><p id="p-0041" num="0040">As noted above, target modified T cells (e.g., target modified CTLs) comprise (e.g., express on their cell surface) a TCR specific for a preselected antigen present in a human Such antigens can be antigens of pathogens that infect humans. Such antigens can be antigens present in vaccines administered to humans. In some cases, the antigen is a viral antigen. In some cases, a viral antigen is encoded by a virus that infects a majority of the human population, where such viruses include, e.g., cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus, influenza virus, adenovirus, and the like. In some cases, the antigen is a bacterial epitope, e.g., a bacterial epitope that is included in a vaccine and to which a majority of the human population has immunity. For example, in some cases, the antigen is a tetanus antigen.</p><p id="p-0042" num="0041">Use of an in vitro composition comprising modified target T cells is depicted schematically in <figref idref="DRAWINGS">FIG. <b>1</b></figref>. The in vitro cell population is modified to express a chimeric antigen receptor (CAR) specific for a cancer-associated antigen. Target modified T cells in the population comprise TCRs specific for preselected antigens present in humans. The in vitro composition comprising target modified T cells can be administered to an individual in need thereof, e.g., an individual having a cancer. A T-cell modulatory multimeric polypeptide (TMMP) that comprises a peptide epitope that is bound by the TCR present on the modified target T cells can also be administered to the individual. The TMMP comprises an immunomodulatory polypeptide that provides for activation of T cells comprising TCRs that bind the peptide epitope present in the TMMP. The modified target T cells (e.g., modified CTLs) will target cancer cells expressing the cancer-associated antigen to which the CAR present. The TMMP will activate the modified target T cells by binding to TCRs present on the modified target T cells. Such a method takes advantage of the presence in human populations of T cells (e.g., CTLs) specific for antigens such as those associated with common human pathogens and/or commonly administered human vaccines.</p><heading id="h-0008" level="2">Chimeric Antigen Receptor</heading><p id="p-0043" num="0042">As noted above, a modified T cell is modified to express a CAR specific for a cancer-associated antigen. A CAR generally comprises: a) an extracellular domain comprising an antigen-binding domain (antigen-binding polypeptide); b) a transmembrane region; and c) a cytoplasmic domain comprising an intracellular signaling domain (intracellular signaling polypeptide). In some cases, a CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a transmembrane region; and c) a cytoplasmic domain comprising: i) one or more co-stimulatory polypeptides; and ii) an intracellular signaling domain. In some cases, a CAR comprises hinge region between the extracellular antigen-binding domain and the transmembrane domain. Thus, in some cases, a CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a hinge region; c) a transmembrane region; and d) a cytoplasmic domain comprising an intracellular signaling domain. In some cases, a CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a hinge region; c) a transmembrane region; and d) a cytoplasmic domain comprising: i) one or more co-stimulatory polypeptides; and ii) an intracellular signaling domain.</p><p id="p-0044" num="0043">Exemplary CAR structures are known in the art (See e.g., WO 2009/091826; US 20130287748; WO 2015/142675; WO 2014/055657; WO 2015/090229; and U.S. Pat. No. 9,587,020.</p><p id="p-0045" num="0044">In some cases, a CAR is a single polypeptide chain. In some cases, a CAR comprises two polypeptide chains. Generally, any CAR structure known to those skilled in the art may be used to modify T cells in order to prepare compositions as disclosed herein.</p><p id="p-0046" num="0045">CARs specific for a variety of tumor antigens are known in the art; for example CD171-specific CARs (Park et al., <i>Mol Ther </i>(2007) 15(4):825-833), EGFRvIII-specific CARs (Morgan et al., <i>Hum Gene Ther </i>(2012) 23(10):1043-1053), EGF-R-specific CARs (Kobold et al., <i>J. Natl Cancer Inst </i>(2014) 107(1):364), carbonic anhydrase IX-specific CARs (Lamers et al., <i>Biochem Soc Trans </i>(2016) 44(3):951-959), folate receptor-&#x3b1; (FR-&#x3b1;)-specific CARs (Kershaw et al., <i>Clin Cancer Res </i>(2006) 12(20):6106-6015), HER2-specific CARs (Ahmed et al., <i>J. Clin Oncol </i>(2015) 33(15)1688-1696; Nakazawa et al., <i>Mol Ther </i>(2011) 19(12):2133-2143; Ahmed et al., <i>Mol Ther </i>(2009) 17(10):1779-1787; Luo et al., <i>Cell Res </i>(2016) 26(7):850-853; Morgan et al., <i>Mol Ther </i>(2010) 18(4):843-851; Grada et al., <i>Mol Ther Nucleic Acids </i>(2013) 9(2):32), CEA-specific CARs (Katz et al., <i>Clin Cancer Res </i>(2015) 21(14):3149-3159), IL-13R&#x3b1;2-specific CARs (Brown et al., <i>Clin Cancer Res </i>(2015) 21(18):4062-4072), ganglioside GD2-specific CARs (Louis et al., <i>Blood </i>(2011) 118(23):6050-6056; Caruana et al., <i>Nat Med </i>(2015) 21(5):524-529; Yu et al. (2018) <i>J. Hematol. Oncol. </i>11:1), ErbB2-specific CARs (Wilkie et al., <i>J. Clin Immunol </i>(2012) 32(5):1059-1070), VEGF-R-specific CARs (Chinnasamy et al., <i>Cancer Res </i>(2016) 22(2):436-447), FAP-specific CARs (Wang et al., <i>Cancer Immunol Res </i>(2014) 2(2): 154-166), mesothelin (MSLN)-specific CARs (Moon et al, <i>Clin Cancer Res </i>(2011) 17(14):4719-30), NKG2D-specific CARs (VanSeggelen et al., <i>Mol Ther </i>(2015) 23(10):1600-1610), CD19-specific CARs (Axicabtagene ciloleucel (Yescarta&#x2122;) and Tisagenlecleucel (Kymriah&#x2122;). See also, Li et al., <i>J. Hematol and Oncol </i>(2018) 11:22, reviewing clinical trials of tumor-specific CARs; Heyman and Yan (2019) <i>Cancers </i>11:pii:E191; Baybutt et al. (2019) <i>Clin. Pharmacol. Ther. </i>105:71.</p><heading id="h-0009" level="2">Antigen-Binding Domain</heading><p id="p-0047" num="0046">As noted above, a CAR comprises an extracellular domain comprising an antigen-binding domain. The antigen-binding domain present in a CAR can be any antigen-binding polypeptide, a wide variety of which are known in the art. In some instances, the antigen-binding domain is a single chain Fv (scFv). Other antibody-based recognition domains (cAb VHH (camelid antibody variable domains) and humanized versions, IgNAR VH (shark antibody variable domains) and humanized versions, sdAb VH (single domain antibody variable domains) and &#x201c;camelized&#x201d; antibody variable domains are suitable. In some cases, the antigen-binding domain is a nanobody.</p><p id="p-0048" num="0047">In some cases, the antigen bound by the antigen-binding domain of a CAR is selected from: a MUC1 polypeptide, an LMP2 polypeptide, an epidermal growth factor receptor (EGFR) vIII polypeptide, a HER-2/neu polypeptide, a melanoma antigen family A, 3 (MAGE A3) polypeptide, a p53 polypeptide, a mutant p53 polypeptide, an NY-ESO-1 polypeptide, a folate hydrolase (prostate-specific membrane antigen; PSMA) polypeptide, a carcinoembryonic antigen (CEA) polypeptide, a melanoma antigen recognized by T-cells (melanA/MART1) polypeptide, a Ras polypeptide, a gp100 polypeptide, a proteinase3 (PR1) polypeptide, a bcr-abl polypeptide, a tyrosinase polypeptide, a survivin polypeptide, a prostate specific antigen (PSA) polypeptide, an hTERT polypeptide, a sarcoma translocation breakpoints polypeptide, a synovial sarcoma X (SSX) breakpoint polypeptide, an EphA2 polypeptide, an acid phosphatase, prostate (PAP) polypeptide, a melanoma inhibitor of apoptosis (ML-IAP) polypeptide, an epithelial cell adhesion molecule (EpCAM) polypeptide, an ERG (TMPRSS2 ETS fusion) polypeptide, a NA17 polypeptide, a paired-box-3 (PAX3) polypeptide, an anaplastic lymphoma kinase (ALK) polypeptide, an androgen receptor polypeptide, a cyclin B1 polypeptide, an N-myc proto-oncogene (MYCN) polypeptide, a Ras homolog gene family member C (RhoC) polypeptide, a tyrosinase-related protein-2 (TRP-2) polypeptide, a mesothelin polypeptide, a prostate stem cell antigen (PSCA) polypeptide, a melanoma associated antigen-1 (MAGE A1) polypeptide, a cytochrome P450 1B1 (CYP1B1) polypeptide, a placenta-specific protein 1 (PLAC1) polypeptide, a BORIS polypeptide (also known as CCCTC-binding factor or CTCF), an ETV6-AML polypeptide, a breast cancer antigen NY-BR-1 polypeptide (also referred to as ankyrin repeat domain-containing protein 30A), a regulator of G-protein signaling (RGS5) polypeptide, a squamous cell carcinoma antigen recognized by T-cells (SART3) polypeptide, a carbonic anhydrase IX polypeptide, a paired box-5 (PAX5) polypeptide, an OY-TES1 (testis antigen; also known as acrosin binding protein) polypeptide, a sperm protein 17 polypeptide, a lymphocyte cell-specific protein-tyrosine kinase (LCK) polypeptide, a high molecular weight melanoma associated antigen (HMW-MAA), an A-kinase anchoring protein-4 (AKAP-4), a synovial sarcoma X breakpoint 2 (SSX2) polypeptide, an X antigen family member 1 (XAGE1) polypeptide, a B7 homolog 3 (B7H3; also known as CD276) polypeptide, a legumain polypeptide (LGMN1; also known as asparaginyl endopeptidase), a tyrosine kinase with Ig and EGF homology domains-2 (Tie-2; also known as angiopoietin-1 receptor) polypeptide, a P antigen family member 4 (PAGE4) polypeptide, a vascular endothelial growth factor receptor 2 (VEGF2) polypeptide, a MAD-CT-1 polypeptide, a fibroblast activation protein (FAP) polypeptide, a platelet derived growth factor receptor beta (PDGF&#x3b2;) polypeptide, a MAD-CT-2 polypeptide, or a Fos-related antigen-1 (FOSL) polypeptide. In some cases, the antigen is a human papilloma virus (HPV) antigen. In some cases, the antigen is an alpha-feto protein (AFP) antigen. In some cases, the antigen is a Wilms tumor-1 (WT1) antigen.</p><p id="p-0049" num="0048">The antigen-binding polypeptide of a CAR can bind any of a variety of cancer-associated antigens, including, e.g., CD19, CD20, CD38, CD30, Her2/neu, ERBB2, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), EGFRvIII, vascular endothelial growth factor receptor-2 (VEGFR2), B-cell maturation antigen (BCMA), high molecular weight-melanoma associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2, GD2, and the like. Cancer-associated antigens also include, e.g., 4-1BB, 5T4, adenocarcinoma antigen, alpha-fetoprotein (AFP), BAFF, B-lymphoma cell, C242 antigen, CA-125, carbonic anhydrase 9 (CA-IX), C-MET, CCR4, CD152, CD19, CD20, CD200, CD22, CD221, CD23 (IgE receptor), CD28, CD30 (TNFRSF8), CD33, CD4, CD40, CD44 v6, CD51, CD52, CD56, CD74, CD80, CEA, CNT0888, CTLA-4, DRS, EGFR, EpCAM, CD3, FAP, fibronectin extra domain-B, folate receptor 1, GD2, GD3 ganglioside, glycoprotein 75, GPNMB, HER2/neu, HGF, human scatter factor receptor kinase, IGF-1 receptor, IGF-I, IgG1, L1-CAM, IL-13, IL-6, insulin-like growth factor I receptor, integrin &#x3b1;5&#x3b2;1, integrin &#x3b1;v&#x3b2;3, MORAb-009, MS4A1, MUC1, mucin CanAg, N-glycolylneuraminic acid, NPC-1C, PDGF-R &#x3b1;, PDL192, phosphatidylserine, prostatic carcinoma cells, RANKL, RON, ROR1, SCH 900105, SDC1, SLAMF7, TAG-72, tenascin C, TGF beta 2, TGF-&#x3b2;, TRAIL-R1, TRAIL-R2, tumor antigen CTAA16.88, VEGF-A, VEGFR-1, VEGFR2, and vimentin.</p><p id="p-0050" num="0049">In some cases, the cancer-associated antigen bound by the antigen-binding polypeptide of a CAR is selected from AFP, BCMA, CD10, CD117, CD123, CD133, CD128, CD171, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD5, CD56, CD7, CD70, CD80, CD86, CEA, CLD18, CLL-1, cMet, EGFR, EGFRvIII, EpCAM, EphA2, GD-2, glypican-3, GPC3, HER-2, kappa immunoglobulin, LeY, LMP1, mesothlin, MG7, MUC1, NKG2D ligand, PD-L1, PSCA, PSMA, ROR1, ROR1R, TACI, and VEGFR2. In some cases, the cancer-associated antigen is BCMA. In some cases, the cancer-associated antigen is MUC1. In some cases, the cancer-associated antigen is CD19. In some cases, the cancer-associated antigen is AFP.</p><p id="p-0051" num="0050">VH and VL amino acid sequences of various cancer-associated antigen-binding antibodies are known in the art, as are the light chain and heavy chain CDRs of such antibodies. See, e.g., Ling et al. (2018) <i>Frontiers Immunol. </i>9:469; WO 2005/012493; US 2019/0119375; US 2013/0066055. The following are non-limiting examples of antibodies that bind cancer-associated antigens.</p><heading id="h-0010" level="2">1) Anti-Her2</heading><p id="p-0052" num="0051">In some cases, an anti-Her2 antibody comprises: a) a light chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0053" num="0052">DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:1); and b) a heavy chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0054" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVA</entry></row><row><entry> </entry></row><row><entry>RIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSR</entry></row><row><entry> </entry></row><row><entry>WGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC</entry></row><row><entry> </entry></row><row><entry>LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL</entry></row><row><entry> </entry></row><row><entry>GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL</entry></row><row><entry> </entry></row><row><entry>FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP</entry></row><row><entry> </entry></row><row><entry>REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK</entry></row><row><entry> </entry></row><row><entry>GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN</entry></row><row><entry> </entry></row><row><entry>NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ</entry></row><row><entry> </entry></row><row><entry>KSLSLSPGK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0055" num="0053">In some cases, an anti-Her2 antibody comprises a light chain variable region (VL) present in the light chain amino acid sequence provided above; and a heavy chain variable region (VH) present in the heavy chain amino acid sequence provided above. For example, an anti-Her2 antibody can comprise: a) a VL comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGS RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:3); and b) a VH comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS (SEQ ID NO:4). In some cases, an anti-Her2 antibody comprises, in order from N-terminus to C-terminus: a) a VH comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADS VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS (SEQ ID NO:4); b) a linker; and c) a VL comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGS RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:3). Suitable linkers are described elsewhere herein and include, e.g., (GGGGS)n (SEQ ID NO:5), where n is an integer from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).</p><p id="p-0056" num="0054">In some cases, an anti-Her2 antibody comprises VL CDR1, VL CDR2, and VL CDR3 present in the light chain amino acid sequence provided above; and VH CDR1, CDR2, and CDR3 present in the heavy chain amino acid sequence provided above. In some cases, the VH and VL CDRs are as defined by Kabat (see, e.g., Table 1, above; and Kabat 1991). In some cases, the VH and VL CDRs are as defined by Chothia (see, e.g., Table 1, above; and Chothia 1987).</p><p id="p-0057" num="0055">For example, an anti-Her2 antibody can comprise a VL CDR1 having the amino acid sequence RASQDVNTAVA (SEQ ID NO:6); a VL CDR2 having the amino acid sequence SASFLY (SEQ ID NO:7); a VL CDR3 having the amino acid sequence QQHYTTPP (SEQ ID NO:8); a VH CDR1 having the amino acid sequence GFNIKDTY (SEQ ID NO:9); a VH CDR2 having the amino acid sequence IYPTNGYT (SEQ ID NO:10); and a VH CDR3 having the amino acid sequence SRWGGDGFYAMDY (SEQ ID NO:11).</p><p id="p-0058" num="0056">In some cases, an anti-Her2 antibody is a scFv antibody. For example, an anti-Her2 scFv can comprise an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0059" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVA</entry></row><row><entry> </entry></row><row><entry>RIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSR</entry></row><row><entry> </entry></row><row><entry>WGGDGFYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLS</entry></row><row><entry> </entry></row><row><entry>ASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSR</entry></row><row><entry> </entry></row><row><entry>FSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0060" num="0057">As another example, in some cases, an anti-Her2 antibody comprises: a) a light chain variable region (VL) comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0061" num="0058">DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRY TGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSD EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:13); and b) a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0062" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;14)</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVA</entry></row><row><entry> </entry></row><row><entry>DVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCAR</entry></row><row><entry> </entry></row><row><entry>NLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL</entry></row><row><entry> </entry></row><row><entry>VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG</entry></row><row><entry> </entry></row><row><entry>TQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLF</entry></row><row><entry> </entry></row><row><entry>PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR</entry></row><row><entry> </entry></row><row><entry>EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG</entry></row><row><entry> </entry></row><row><entry>QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN</entry></row><row><entry> </entry></row><row><entry>YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK</entry></row><row><entry> </entry></row><row><entry>SLSLSPG.</entry></row></tbody></tgroup></table></tables></p><p id="p-0063" num="0059">In some cases, an anti-Her2 antibody comprises a VL present in the light chain amino acid sequence provided above; and a VH present in the heavy chain amino acid sequence provided above. For example, an anti-Her2 antibody can comprise: a) a VL comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK (SEQ ID NO:15); and b) a VH comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence:</p><p id="p-0064" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;16)</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVA</entry></row><row><entry> </entry></row><row><entry>DVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCAR</entry></row><row><entry> </entry></row><row><entry>NLGPSFYFDYWGQGTLVTVSS.&#x2003;</entry></row></tbody></tgroup></table></tables></p><p id="p-0065" num="0060">In some cases, an anti-Her2 antibody comprises VL CDR1, VL CDR2, and VL CDR3 present in the light chain amino acid sequence provided above; and VH CDR1, CDR2, and CDR3 present in the heavy chain amino acid sequence provided above. In some cases, the V<sub>H </sub>and V<sub>L </sub>CDRs are as defined by Kabat (see, e.g., Table 1, above; and Kabat 1991). In some cases, the V<sub>H </sub>and V<sub>L </sub>CDRs are as defined by Chothia (see, e.g., Table 1, above; and Chothia 1987).</p><p id="p-0066" num="0061">For example, an anti-HER2 antibody can comprise a VL CDR1 having the amino acid sequence KASQDVSIGVA (SEQ ID NO:17); a VL CDR2 having the amino acid sequence SASYRY (SEQ ID NO:18); a VL CDR3 having the amino acid sequence QQYYIYPY (SEQ ID NO:19); a VH CDR1 having the amino acid sequence GFTFTDYTMD (SEQ ID NO:20); a VH CDR2 having the amino acid sequence ADVNPNSGGSIYNQRFKG (SEQ ID NO:21); and a VH CDR3 having the amino acid sequence ARNLGPSFYFDY (SEQ ID NO:22).</p><p id="p-0067" num="0062">In some cases, an anti-Her2 antibody is a scFv. For example, in some cases, an anti-Her2 scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0068" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVA</entry></row><row><entry> </entry></row><row><entry>RIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSR</entry></row><row><entry> </entry></row><row><entry>WGGDGFYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLS</entry></row><row><entry> </entry></row><row><entry>ASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSR</entry></row><row><entry> </entry></row><row><entry>FSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0011" level="2">2) Anti-CD19</heading><p id="p-0069" num="0063">Anti-CD19 antibodies are known in the art; and the VH and VL, or the VH and VL CDRs, of any anti-CD19 antibody can be included in a CAR. See e.g., WO 2005/012493.</p><p id="p-0070" num="0064">In some cases, an anti-CD19 antibody includes a VL CDR1 comprising the amino acid sequence KASQSVDYDGDSYLN (SEQ ID NO:23); a VL CDR2 comprising the amino acid sequence DASNLVS (SEQ ID NO:24); and a VL CDR3 comprising the amino acid sequence QQSTEDPWT (SEQ ID NO:25). In some cases, an anti-CD19 antibody includes a VH CDR1 comprising the amino acid sequence SYWMN (SEQ ID NO:26); a VH CDR2 comprising the amino acid sequence QIWPGDGDTNYNGKFKG (SEQ ID NO:27); and a VH CDR3 comprising the amino acid sequence RETTTVGRYYYAMDY (SEQ ID NO:28). In some cases, an anti-CD19 antibody includes a VL CDR1 comprising the amino acid sequence KASQSVDYDGDSYLN (SEQ ID NO:23); a VL CDR2 comprising the amino acid sequence DASNLVS (SEQ ID NO:24); a VL CDR3 comprising the amino acid sequence QQSTEDPWT (SEQ ID NO:25); a VH CDR1 comprising the amino acid sequence SYWMN (SEQ ID NO:26); a VH CDR2 comprising the amino acid sequence QIWPGDGDTNYNGKFKG (SEQ ID NO:27); and a VH CDR3 comprising the amino acid sequence RETTTVGRYYYAMDY (SEQ ID NO:28).</p><p id="p-0071" num="0065">In some cases, an anti-CD19 antibody is a scFv. For example, in some cases, an anti-CD19 scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0072" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;29)</entry><entry/></row><row><entry>DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRF</entry><entry/></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQ</entry></row><row><entry> </entry></row><row><entry>LQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFK</entry></row><row><entry> </entry></row><row><entry>GKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVS.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0012" level="2">3) Anti-Mesothelin</heading><p id="p-0073" num="0066">Anti-mesothelin antibodies are known in the art; and the VH and VL, or the VH and VL CDRs, of any anti-mesothelin antibody can be included in a CAR. See, e.g., U.S. 2019/0000944; WO 2009/045957; WO 2014/031476; U.S. Pat. No. 8,460,660; US 2013/0066055; and WO 2009/068204.</p><p id="p-0074" num="0067">In some cases, an anti-mesothelin antibody comprises: a) a light chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0075" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;30)</entry><entry/></row><row><entry>DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNR</entry><entry/></row><row><entry> </entry></row><row><entry>PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVLGQPKAAPSVT</entry></row><row><entry> </entry></row><row><entry>LFPPSSEELQANKATLVCLISDFYPGAVTVAWKGDSSPVKAGVETTTPSKQSNNKYAASSYLSL</entry></row><row><entry> </entry></row><row><entry>TPEQWKSHRSYSCQVTHEGSTVEKTVAPTESS;</entry></row></tbody></tgroup></table></tables><br/>and</p><p id="p-0076" num="0068">b) a heavy chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0077" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;31)</entry><entry/></row><row><entry>QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPG</entry><entry/></row><row><entry> </entry></row><row><entry>DSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLV</entry></row><row><entry> </entry></row><row><entry>TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG</entry></row><row><entry> </entry></row><row><entry>LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP</entry></row><row><entry> </entry></row><row><entry>PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT</entry></row><row><entry> </entry></row><row><entry>VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG</entry></row><row><entry> </entry></row><row><entry>FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN</entry></row><row><entry> </entry></row><row><entry>HYTQKSLSLSPGK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0078" num="0069">In some cases, an anti-mesothelin antibody comprises a VL present in the light chain amino acid sequence provided above; and a VH present in the heavy chain amino acid sequence provided above. For example, an anti-mesothelin antibody can comprise: a) a VL comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence: DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFS GSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTK (SEQ ID NO:32); and b) a VH comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence:</p><p id="p-0079" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;33)</entry><entry/></row><row><entry>QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSF</entry><entry/></row><row><entry>QGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS.</entry></row></tbody></tgroup></table></tables></p><p id="p-0080" num="0070">In some cases, an anti-mesothelin antibody comprises VL CDR1, VL CDR2, and VL CDR3 present in the light chain amino acid sequence provided above; and VH CDR1, CDR2, and CDR3 present in the heavy chain amino acid sequence provided above. In some cases, the V<sub>H </sub>and V<sub>L </sub>CDRs are as defined by Kabat (see, e.g., Table 1, above; and Kabat 1991). In some cases, the V<sub>H </sub>and V<sub>L </sub>CDRs are as defined by Chothia (see, e.g., Table 1, above; and Chothia 1987).</p><p id="p-0081" num="0071">For example, an anti-mesothelin antibody can comprise a VL CDR1 having the amino acid sequence TGTSSDIGGYNSVS (SEQ ID NO:34); a VL CDR2 having the amino acid sequence LMIYGVNNRPS (SEQ ID NO:35); a VL CDR3 having the amino acid sequence SSYDIESATP (SEQ ID NO:36); a VH CDR1 having the amino acid sequence GYSFTSYWIG (SEQ ID NO:37); a VH CDR2 having the amino acid sequence WMGIIDPGDSRTRYSP (SEQ ID NO:38); and a VH CDR3 having the amino acid sequence GQLYGGTYMDG (SEQ ID NO:39).</p><p id="p-0082" num="0072">An anti-mesothelin antibody can be a scFv. As one non-limiting example, an anti-mesothelin scFv can comprise the following amino acid sequence:</p><p id="p-0083" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;40)</entry><entry/></row><row><entry>QVQLQQSGAEVKKPGASVKVSCKAS<u style="single">GYTFTGYYMH</u>WVRQAPGQGLEWMG<u style="single">RINPNSGGTNYA</u></entry><entry/></row><row><entry> </entry></row><row><entry><u style="single">QKFQ</u>GRVTMTRDTSISTAYMELSRLRSEDTAVYYCAR<u style="single">GRYYGMDV</u>WGQGTMVTVSSGGGGS</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATISC<u style="single"><b>RASQSVSSNFA</b></u>WYQQRPGQAPRLLIY<u style="single"><b>D</b></u></entry></row><row><entry> </entry></row><row><entry><u style="single"><b>ASNRAT</b></u>GIPPRFSGSGSGTDFTLTISSLEPEDFAAYYC<u style="single"><b>HQRSNWLYT</b></u>FGQGTKVDIK,</entry></row></tbody></tgroup></table></tables><br/>where VH CDR1, CDR2, and CDR3 are underlined; and VL CDR1, CDR2, and CDR3 are bolded and underlined.</p><p id="p-0084" num="0073">As one non-limiting example, an anti-mesothelin scFv can comprise the following amino acid sequence:</p><p id="p-0085" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;41)</entry><entry/></row><row><entry>QVQLVQSGAEVKKPGASVKVSCKAS<u style="single">GYTFTGYYMH</u>WVRQAPGQGLEWMG<u style="single">WINPNSGGTNY</u></entry><entry/></row><row><entry> </entry></row><row><entry><u style="single">AQKFQ</u>GRVTMTRDTSISTAYMELSRLRSDDTAVYYCAR<u style="single">DLRRTVVTPRAYYGMDV</u>WGQGTTV</entry></row><row><entry> </entry></row><row><entry>TVSSGGGGSGGGGSGGGGSGGGGSDIQLTQSPSTLSASVGDRVTITC<u style="single"><b>QASQDISNSLN</b></u>WYQQKA</entry></row><row><entry> </entry></row><row><entry>GKAPKLLIY<u style="single"><b>DASTLET</b></u>GVPSRFSGSGSGTDFSF</entry></row><row><entry> </entry></row><row><entry>TISSLQPEDIATYYC<u style="single"><b>QQHDNLPL</b></u>TFGOGTKVEIK,</entry></row></tbody></tgroup></table></tables><br/>where VH CDR1, CDR2, and CDR3 are underlined; and VL CDR1, CDR2, and CDR3 are bolded and underlined.</p><heading id="h-0013" level="2">4) Anti-BCMA</heading><p id="p-0086" num="0074">Anti-BCMA (B-cell maturation antigen) antibodies are known in the art; and the VH and VL, or the VH and VL CDRs, of any anti-BCMA antibody can be included in a CAR. See, e.g., WO 2014/089335; US 2019/0153061; and WO 2017/093942.</p><p id="p-0087" num="0075">In some cases, an anti-BCMA antibody comprises: a) a light chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0088" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;42)</entry><entry/></row><row><entry>QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIFNYHQRP</entry><entry/></row><row><entry> </entry></row><row><entry>SGVPDRFSGSKSGSSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVLGQPKAAPSV</entry></row><row><entry> </entry></row><row><entry>TLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPDSKQSNNKYAASSYL</entry></row><row><entry> </entry></row><row><entry>SLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS;</entry></row></tbody></tgroup></table></tables><br/>and</p><p id="p-0089" num="0076">b) a heavy chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0090" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;43)</entry><entry/></row><row><entry>EVQLVESGGGLVKPGGSLRLSCAASGFTFGDYALSWFRQAPGKGLEWVGVSRSKAYGGTTDY</entry><entry/></row><row><entry> </entry></row><row><entry>AASVKGRFTISRDDSKSTAYLQMNSLKTEDTAVYYCASSGYSSGWTPFDYWGQGTLVTVSSAS</entry></row><row><entry> </entry></row><row><entry>TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD</entry></row><row><entry> </entry></row><row><entry>TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ</entry></row><row><entry> </entry></row><row><entry>DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS</entry></row><row><entry> </entry></row><row><entry>DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ</entry></row><row><entry> </entry></row><row><entry>KSLSLSPGK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0091" num="0077">In some cases, an anti-BCMA antibody comprises a VL present in the light chain amino acid sequence provided above; and a VH present in the heavy chain amino acid sequence provided above. For example, an anti-BCMA antibody can comprise: a) a VL comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence:</p><p id="p-0092" num="0078">QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIFNYHQRP SGVPDRFSGSKSGSSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVLG (SEQ ID NO:44); and b) a VH comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence:</p><p id="p-0093" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;45)</entry><entry/></row><row><entry>EVQLVESGGGLVKPGGSLRLSCAASGFTFGDYALSWFRQAPGKGLEWVGVSRS</entry><entry/></row><row><entry>KAYGGTTDYAASVKGRFTISRDDSKSTAYLQMNSLKTEDTAVYYCASSGYSSGWTPFDYWGQ</entry></row><row><entry>GTLVTVSSASTKGPSV.</entry></row></tbody></tgroup></table></tables></p><p id="p-0094" num="0079">In some cases, an anti-BCMA antibody comprises VL CDR1, VL CDR2, and VL CDR3 present in the light chain amino acid sequence provided above; and VH CDR1, CDR2, and CDR3 present in the heavy chain amino acid sequence provided above. In some cases, the V<sub>H </sub>and V<sub>L </sub>CDRs are as defined by Kabat (see, e.g., Table 1, above; and Kabat 1991). In some cases, the V<sub>H </sub>and V<sub>L </sub>CDRs are as defined by Chothia (see, e.g., Table 1, above; and Chothia 1987).</p><p id="p-0095" num="0080">For example, an anti-BCMA antibody can comprise a VL CDR1 having the amino acid sequence SSNIGSNT (SEQ ID NO:46), a VL CDR2 having the amino acid sequence NYH, a VL CDR3 having the amino acid sequence AAWDDSLNGWV (SEQ ID NO:47)), a VH CDR1 having the amino acid sequence GFTFGDYA (SEQ ID NO:48), a VH CDR2 having the amino acid sequence SRSKAYGGTT (SEQ ID NO:49), and a VH CDR3 having the amino acid sequence ASSGYSSGWTPFDY (SEQ ID NO:50).</p><p id="p-0096" num="0081">An anti-BCMA antibody can be a scFv. As one non-limiting example, an anti-BCMA scFv can comprise the following amino acid sequence:</p><p id="p-0097" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/></row><row><entry>QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYY</entry><entry/></row><row><entry> </entry></row><row><entry>NQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLDNWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKR.</entry></row></tbody></tgroup></table></tables></p><p id="p-0098" num="0082">As another example, an anti-BCMA scFv can comprise the following amino acid sequence:</p><p id="p-0099" num="0000"><tables id="TABLE-US-00016" num="00016"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry/></row><row><entry>DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGS</entry><entry/></row><row><entry> </entry></row><row><entry>GSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYN</entry></row><row><entry> </entry></row><row><entry>QKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLDNWGQGTLVTVSS.</entry></row><row><entry> </entry></row></tbody></tgroup></table></tables></p><p id="p-0100" num="0083">In some cases, an anti-BCMA antibody can comprise a VL CDR1 having the amino acid sequence SASQDISNYLN (SEQ ID NO:53); a VL CDR2 having the amino acid sequence YTSNLHS (SEQ ID NO:54); a VL CDR3 having the amino acid sequence QQYRKLPWT (SEQ ID NO:55); a VH CDR1 having the amino acid sequence NYWMH (SEQ ID NO:56); a VH CDR2 having the amino acid sequence ATYRGHSDTYYNQKFKG (SEQ ID NO:57); and a VH CDR3 having the amino acid sequence GAIYNGYDVLDN (SEQ ID NO:58).</p><p id="p-0101" num="0084">In some cases, an anti-BCMA antibody comprises: a) a light chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0102" num="0000"><tables id="TABLE-US-00017" num="00017"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;59)</entry><entry/></row><row><entry>DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGS</entry><entry/></row><row><entry>GSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKR.</entry></row></tbody></tgroup></table></tables></p><p id="p-0103" num="0085">In some cases, an anti-BCMA antibody comprises: a) a heavy chain comprising an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0104" num="0000"><tables id="TABLE-US-00018" num="00018"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;60)</entry><entry/></row><row><entry>QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYY</entry><entry/></row><row><entry>NQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS.</entry></row></tbody></tgroup></table></tables></p><p id="p-0105" num="0086">In some cases, an anti-BCMA antibody (e.g., an antibody referred to in the literature as belantamab) comprises a light chain comprising the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKR (SEQ ID NO:59); and a heavy chain comprising the amino acid sequence:</p><p id="p-0106" num="0000"><tables id="TABLE-US-00019" num="00019"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;60)</entry><entry/></row><row><entry>QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYY</entry><entry/></row><row><entry>NQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS.</entry></row></tbody></tgroup></table></tables></p><p id="p-0107" num="0087">In some cases, the anti-BCMA antibody has a cancer chemotherapeutic agent linked to the antibody. For example, in some cases, the anti-BCMA antibody is GSK2857916 (belantamab-mafodotin), where monomethyl auristatin F (MMAF) is linked via a maleimidocaproyl linker to the anti-BCMA antibody belantamab.</p><heading id="h-0014" level="2">5) Anti-MUC1</heading><p id="p-0108" num="0088">In some cases, an antigen-binding polypeptide present in a CAR is a single-chain Fv specific for MUC1. See, e.g., Singh et al. (2007) <i>Mol. Cancer Ther. </i>6:562; Thie et al. (2011) <i>PLoSOne </i>6:e15921; Imai et al. (2004) <i>Leukemia </i>18:676; Posey et al. (2016) <i>Immunity </i>44:1444; EP3130607; EP3164418; WO 2002/044217; and US 2018/0112007. In some cases, an antigen-binding polypeptide present in a CAR is a scFv specific for the MUC1 peptide VTSAPDTRPAPGSTAPPAHG (SEQ ID NO:61). In some cases, a TTP is a scFv specific for the MUC1 peptide SNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRY (SEQ ID NO:62). In some cases, an antigen-binding polypeptide present in a CAR is a scFv specific for the MUC1 peptide SVVVQLTLAFREGTINVHDVETQFNQYKTEAASRY (SEQ ID NO:63). In some cases, a TTP is a scFv specific for the MUC1 peptide LAFREGTINVHDVETQFNQY (SEQ ID NO:64). In some cases, an antigen-binding polypeptide present in a CAR is a scFv specific for the MUC1 peptide SNIKFRPGSVVVQLTLAAFREGTIN (SEQ ID NO:65).</p><p id="p-0109" num="0089">As an example, an anti-MUC1 antibody can comprise: a VH CDR1 having the amino acid sequence RYGMS (SEQ ID NO:66); a VH CDR2 having the amino acid sequence TISGGGTYIYYPDSVKG (SEQ ID NO:67); a VH CDR3 having the amino acid sequence DNYGRNYDYGMDY (SEQ ID NO:68); a VL CDR1 having the amino acid sequence SATSSVSYIH (SEQ ID NO:69); a VL CDR2 having the amino acid sequence STSNLAS (SEQ ID NO:70); and a VL CDR3 having the amino acid sequence QQRSSSPFT (SEQ ID NO:71). See, e.g., US 2018/0112007.</p><p id="p-0110" num="0090">As another example, an anti-MUC1 antibody can comprise a VH CDR1 having the amino acid sequence GYAMS (SEQ ID NO:72); a VH CDR2 having the amino acid sequence TISSGGTYIYYPDSVKG (SEQ ID NO:73); a VH CDR3 having the amino acid sequence LGGDNYYEYFDV (SEQ ID NO:74); a VL CDR1 having the amino acid sequence RASKSVSTSGYSYMH (SEQ ID NO:75); a VL CDR2 having the amino acid sequence LASNLES (SEQ ID NO:76); and a VL CDR3 having the amino acid sequence QHSRELPFT (SEQ ID NO:77). See, e.g., US 2018/0112007.</p><p id="p-0111" num="0091">As another example, an anti-MUC1 antibody can comprise a VH CDR1 having the amino acid sequence DYAMN (SEQ ID NO:78); a VH CDR2 having the amino acid sequence VISTFSGNINFNQKFKG (SEQ ID NO:79); a VH CDR3 having the amino acid sequence SDYYGPYFDY (SEQ ID NO:80); a VL CDR1 having the amino acid sequence RSSQTIVHSNGNTYLE (SEQ ID NO:81); a VL CDR2 having the amino acid sequence KVSNRFS (SEQ ID NO:82); and a VL CDR3 having the amino acid sequence (FQGSHVPFT (SEQ ID NO:83). See, e.g., US 2018/0112007.</p><p id="p-0112" num="0092">As another example, an anti-MUC1 antibody can comprise a VH CDR1 having the amino acid sequence GYAMS (SEQ ID NO:72); a VH CDR2 having the amino acid sequence TISSGGTYIYYPDSVKG (SEQ ID NO:73); a VH CDR3 having the amino acid sequence LGGDNYYEY (SEQ ID NO:84); a VL CDR1 having the amino acid sequence TASKSVSTSGYSYMH (SEQ ID NO:85); a VL CDR2 having the amino acid sequence LVSNLES (SEQ ID NO:86); and a VL CDR3 having the amino acid sequence QHIRELTRSE (SEQ ID NO:87). See, e.g., US 2018/0112007. 6) Anti-MUC16</p><p id="p-0113" num="0093">In some cases, an antigen-binding polypeptide present in a CAR is specific for a MUC16 polypeptide present on a cancer cell. See, e.g., US 2018/0118848; and US 2018/0112008. In some cases, a MUC16-specific antigen-binding polypeptide is a scFv. In some cases, a MUC16-specific antigen-binding polypeptide is a nanobody.</p><p id="p-0114" num="0094">As one example, an anti-MUC16 antibody can comprise a VH CDR1 having the amino acid sequence GFTFSNYY (SEQ ID NO:88); a VH CDR2 having the amino acid sequence ISGRGSTI (SEQ ID NO:89); a VH CDR3 having the amino acid sequence VKDRGGYSPY (SEQ ID NO:90); a VL CDR1 having the amino acid sequence QSISTY (SEQ ID NO:91); a VL CDR2 having the amino acid sequence TAS; and a VL CDR3 having the amino acid sequence QQSYSTPPIT (SEQ ID NO:92). See, e.g., US 2018/0118848.</p><heading id="h-0015" level="2">7) Examples of Antigen-Binding Domains</heading><p id="p-0115" num="0095">In some cases, a suitable CAR comprises a scFv specific for CD19. For example, in some cases, an anti-CD19 scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0116" num="0000"><tables id="TABLE-US-00020" num="00020"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;29)</entry><entry/></row><row><entry>DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRF</entry><entry/></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQ</entry></row><row><entry> </entry></row><row><entry>LQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFK</entry></row><row><entry> </entry></row><row><entry>GKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVS.</entry></row></tbody></tgroup></table></tables></p><p id="p-0117" num="0096">In some cases, a suitable CAR comprises a scFv specific for mesothelin. For example, in some cases, an anti-mesothelin scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0118" num="0000"><tables id="TABLE-US-00021" num="00021"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;40)</entry></row><row><entry>QVQLQQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMG</entry></row><row><entry> </entry></row><row><entry>RINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSEDTAVYYCAR</entry></row><row><entry> </entry></row><row><entry>GRYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPAT</entry></row><row><entry> </entry></row><row><entry>LSLSPGERATISCRASQSVSSNFAWYQQRPGQAPRLLIYDASNRATGIP</entry></row><row><entry> </entry></row><row><entry>PRFSGSGSGTDFTLTISSLEPEDFAAYYCHQRSNWLYTFGQGTKVDIK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0119" num="0097">In some cases, an anti-mesothelin scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0120" num="0000"><tables id="TABLE-US-00022" num="00022"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;41)</entry></row><row><entry>QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMG</entry></row><row><entry> </entry></row><row><entry>WINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAR</entry></row><row><entry> </entry></row><row><entry>DLRRTVVTPRAYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSGGGGSD</entry></row><row><entry> </entry></row><row><entry>IQLTQSPSTLSASVGDRVTITCQASQDISNSLNWYQQKAGKAPKLLIYD</entry></row><row><entry> </entry></row><row><entry>ASTLETGVPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQHDNLPLTFG</entry></row><row><entry> </entry></row><row><entry>QGTKVEIK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0121" num="0098">In some cases, a suitable CAR comprises a scFv specific for B-cell maturation antigen (BCMA). For example, in some cases, an anti-BCMA scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0122" num="0000"><tables id="TABLE-US-00023" num="00023"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry></row><row><entry>QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMG</entry></row><row><entry> </entry></row><row><entry>ATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAR</entry></row><row><entry> </entry></row><row><entry>GAIYNGYDVLDNWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQ</entry></row><row><entry> </entry></row><row><entry>SPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLH</entry></row><row><entry> </entry></row><row><entry>SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKL</entry></row><row><entry> </entry></row><row><entry>EIKR.</entry></row></tbody></tgroup></table></tables></p><p id="p-0123" num="0099">In some cases, an anti-BCMA scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following amino acid sequence:</p><p id="p-0124" num="0000"><tables id="TABLE-US-00024" num="00024"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry></row><row><entry>DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIY</entry></row><row><entry> </entry></row><row><entry>YTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTF</entry></row><row><entry> </entry></row><row><entry>GQGTKLEIKRGGGGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVK</entry></row><row><entry> </entry></row><row><entry>VSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRV</entry></row><row><entry> </entry></row><row><entry>TITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLDNWGQGTLV</entry></row><row><entry> </entry></row><row><entry>TVSS.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0016" level="2">Hinge Region</heading><p id="p-0125" num="0100">As noted above, a CAR can include a hinge region between the extracellular domain and the transmembrane domain. As used herein, the term &#x201c;hinge region&#x201d; refers to a flexible polypeptide connector region (also referred to herein as &#x201c;hinge&#x201d; or &#x201c;spacer&#x201d;) providing structural flexibility and spacing to flanking polypeptide regions and can consist of natural or synthetic polypeptides. The hinge region can include complete hinge region derived from an antibody of a different class or subclass from that of the CH1 domain. The term &#x201c;hinge region&#x201d; can also include regions derived from CD8 and other receptors that provide a similar function in providing flexibility and spacing to flanking regions.</p><p id="p-0126" num="0101">The hinge region can have a length of from about 4 amino acids to about 50 amino acids, e.g., from about 4 aa to about 10 aa, from about 10 aa to about 15 aa, from about 15 aa to about 20 aa, from about 20 aa to about 25 aa, from about 25 aa to about 30 aa, from about 30 aa to about 40 aa, or from about 40 aa to about 50 aa.</p><p id="p-0127" num="0102">As non-limiting examples, an immunoglobulin hinge region can include one of the following amino acid sequences: DKTHT (SEQ ID NO:93); CPPC (SEQ ID NO:94); CPEPKSCDTPPPCPR (SEQ ID NO:95); ELKTPLGDTTHT (SEQ ID NO:96); KSCDKTHTCP (SEQ ID NO:97); KCCVDCP (SEQ ID NO:98); KYGPPCP (SEQ ID NO:99); EPKSCDKTHTCPPCP (SEQ ID NO:100) (human IgG1 hinge); ERKCCVECPPCP (SEQ ID NO:101) (human IgG2 hinge); ELKTPLGDTTHTCPRCP (SEQ ID NO:102) (human IgG3 hinge); SPNMVPHAHHAQ (SEQ ID NO:103) (human IgG4 hinge); and the like. The hinge region can comprise an amino acid sequence derived from human CD8; e.g., the hinge region can comprise the amino acid sequence: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO:104), or a variant thereof.</p><heading id="h-0017" level="2">Transmembrane Domain</heading><p id="p-0128" num="0103">Any transmembrane (TM) domain that provides for insertion of a polypeptide into the cell membrane of a eukaryotic (e.g., mammalian) cell is suitable for use. The transmembrane region of a CAR can be derived from (i.e. comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8 alpha, CD8 beta), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R.alpha., ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, and PAG/Cbp. The transmembrane domain can be synthetic, in which case it can comprise predominantly hydrophobic residues such as leucine and valine. In some cases, a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain.</p><p id="p-0129" num="0104">As one non-limiting example, the TM sequence IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO:105) can be used. Additional non-limiting examples of suitable TM sequences include: a) CD8 beta derived TM: LGLLVAGVLVLLVSLGVAIHLCC (SEQ ID NO:106); b) CD4 derived TM: ALIVLGGVAGLLLFIGLGIFFCVRC (SEQ ID NO:107); c) CD3 zeta derived TM: LCYLLDGILFIYGVILTALFLRV (SEQ ID NO:108); d) CD28 derived TM: WVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO:109); e) CD134 (OX40) derived TM: VAAILGLGLVLGLLGPLAILLALYLL (SEQ ID NO:110); and f) CD7 derived TM: ALPAALAVISFLLGLGLGVACVLA (SEQ ID NO:111).</p><heading id="h-0018" level="2">Intracellular Domain&#x2014;Co-Stimulatory Polypeptide</heading><p id="p-0130" num="0105">The intracellular portion (cytoplasmic domain) of a CAR can comprise one or more co-stimulatory polypeptides. Non-limiting examples of suitable co-stimulatory polypeptides include, but are not limited to, 4-1BB (CD137), CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM. Suitable co-stimulatory polypeptides include, e.g.: 1) a 4-1BB polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO:112); 2) a CD28 polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: FWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO:113); 3) an ICOS polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: TKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL (SEQ ID NO:114); 4) an OX40 polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI (SEQ ID NO:115); 5) a BTLA polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: CCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEASTRQNSQVLLSETGIYDNDPDLCFRMQEG SEVYSNPCLEENKPGIVYASLNHSVIGPNSRLARNVKEAPTEYASICVRS (SEQ ID NO:116); 6) a CD27 polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: HQRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP (SEQ ID NO:117); 7) a CD30 polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: RRACRKRIRQKLHLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGLMSQPLMETC HSVGAAYLESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIMKADTVIVGTVKAELPEG RGLAGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK (SEQ ID NO:118); 8) a GITR polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: HIWQLRSQCMWPRETQLLLEVPPSTEDARSCQFPEEERGERSAEEKGRLGDLWV (SEQ ID NO:119); and 9) an HVEM polypeptide having at least 90%, at least 95%, at least 98%, or 100%, amino acid sequence identity to the following amino acid sequence: CVKRRKPRGDVVKVIVSVQRKRQEAEGEATVIEALQAPPDVTTVAVEETIPSFTGRSPNH (SEQ ID NO:120). The co-stimulatory polypeptide can have a length of from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, from about 60 aa to about 65 aa, or from about 65 aa to about 70 aa.</p><heading id="h-0019" level="2">Intracellular Domain&#x2014;Signaling Polypeptide</heading><p id="p-0131" num="0106">The intracellular portion of a CAR can comprise a signaling polypeptide. Suitable signaling polypeptides include, e.g., an immunoreceptor tyrosine-based activation motif (ITAM)-containing intracellular signaling polypeptide. An ITAM motif is YX<sub>1</sub>X<sub>2</sub>L/I, (SEQ ID NO: 121) where X<sub>1 </sub>and X<sub>2 </sub>are independently any amino acid. In some cases, the intracellular signaling domain of a subject CAR comprises 1, 2, 3, 4, or 5 ITAM motifs. In some cases, an ITAM motif is repeated twice in an intracellular signaling domain, where the first and second instances of the ITAM motif are separated from one another by 6 to 8 amino acids, e.g., (YX<sub>1</sub>X<sub>2</sub>L/I)(X<sub>3</sub>)<sub>n</sub>(YX<sub>1</sub>X<sub>2</sub>L/I) (SEQ ID NO:122), where n is an integer from 6 to 8, and each of the 6-8 X<sub>3 </sub>can be any amino acid. In some cases, the intracellular signaling domain of a CAR comprises 3 ITAM motifs.</p><p id="p-0132" num="0107">A suitable intracellular signaling domain can be an ITAM motif-containing portion that is derived from a polypeptide that contains an ITAM motif. For example, a suitable intracellular signaling domain can be an ITAM motif-containing domain from any ITAM motif-containing protein. Thus, a suitable intracellular signaling domain need not contain the entire sequence of the entire protein from which it is derived. Examples of suitable ITAM motif-containing polypeptides include, but are not limited to: DAP12; FCER1G (Fc epsilon receptor I gamma chain); CD3D (CD3 delta); CD3E (CD3 epsilon); CD3G (CD3 gamma); CD3Z (CD3 zeta); and CD79A (antigen receptor complex-associated protein alpha chain).</p><heading id="h-0020" level="2">TCR</heading><p id="p-0133" num="0108">As noted above, target modified T cells (e.g., target modified CTLs) comprise (e.g., express on their cell surface) a TCR specific for a preselected antigen present in a human Such antigens can be antigens of pathogens that infect humans. Such antigens can be antigens present in vaccines administered to humans. In some cases, the antigen is a viral antigen. In some cases, a viral antigen is encoded by a virus that infects a majority of the human population, where such viruses include, e.g., cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus, influenza virus, adenovirus, and the like. In some cases, the antigen is a bacterial epitope, e.g., a bacterial epitope that is included in a vaccine and to which a majority of the human population has immunity. For example, in some cases, the antigen is a tetanus antigen.</p><heading id="h-0021" level="2">CMV Peptides</heading><p id="p-0134" num="0109">In some cases, the TCR present on the surface of a target modified T cell binds a CMV peptide. In some cases, the TCR present on the surface of a target modified T cell binds a peptide from CMV pp65. In some cases, the TCR present on the surface of a target modified T cell binds a peptide from CMV gB (glycoprotein B).</p><p id="p-0135" num="0110">For example, in some cases, the TCR present on the surface of a target modified T cell binds a CMV polypeptide having a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length), and comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following CMV pp65 amino acid sequence:</p><p id="p-0136" num="0000"><tables id="TABLE-US-00025" num="00025"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;123)</entry><entry/></row><row><entry>MESRGRRCPE&#x2003;MISVLGPISG&#x2003;HVLKAVFSRG&#x2003;DTPVLPHETR&#x2003;LLQTGIHVRV</entry><entry/></row><row><entry> </entry></row><row><entry>SQPSLILVSQ&#x2003;YTPDSTPCHR&#x2003;GDNQLQVQHT&#x2003;YFTGSEVENV&#x2003;SVNVHNPTGR&#x2003;SICPSQEPMS</entry></row><row><entry> </entry></row><row><entry>IYVYALPLKM&#x2003;LNIPSINVHH&#x2003;YPSAAERKHR&#x2003;HLPVADAVIH&#x2003;ASGKQMWQAR&#x2003;LTVSGLAWTR</entry></row><row><entry> </entry></row><row><entry>QQNQWKEPDV&#x2003;YYTSAFVFPT&#x2003;KDVALRHVVC&#x2003;AHELVCSMEN&#x2003;TRATKMQVIG&#x2003;DQYVKVYLES</entry></row><row><entry> </entry></row><row><entry>FCEDVPSGKL&#x2003;FMHVTLGSDV&#x2003;EEDLTMTRNP&#x2003;QPFMRPHERN&#x2003;GFTVLCPKNM&#x2003;IIKPGKISHI</entry></row><row><entry> </entry></row><row><entry>MLDVAFTSHE&#x2003;HFGLLCPKSI&#x2003;PGLSISGNLL&#x2003;MNGQQIFLEV&#x2003;QAIRETVELR&#x2003;QYDPVAALFF</entry></row><row><entry> </entry></row><row><entry>FDIDLLLQRG&#x2003;PQYSEHPTFT&#x2003;SQYRIQGKLE&#x2003;YRHTWDRHDE&#x2003;GAAQGDDDVW&#x2003;TSGSDSDEEL</entry></row><row><entry> </entry></row><row><entry>VTTERKTPRV&#x2003;TGGGAMAGAS&#x2003;TSAGRKRKSA&#x2003;SSATACTSGV&#x2003;MTRGRLKAES&#x2003;TVAPEEDTDE</entry></row><row><entry> </entry></row><row><entry>DSDNEIHNPA&#x2003;VFTWPPWQAG&#x2003;ILARNLVPMV&#x2003;ATVQGQNLKY&#x2003;QEFFWDANDI&#x2003;YRIFAELEGV</entry></row><row><entry> </entry></row><row><entry>WQPAAQPKRR&#x2003;RHRQDALPGP&#x2003;CIASTPKKHR&#x2003;G.</entry></row></tbody></tgroup></table></tables></p><p id="p-0137" num="0111">As one non-limiting example, the TCR present on the surface of a target modified T cell binds a peptide having the amino acid sequence NLVPMVATV (SEQ ID NO:172) and having a length of 9 amino acids.</p><p id="p-0138" num="0112">In some cases, the TCR present on the surface of a target modified T cell binds a peptide having a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length) of a CMV polypeptide comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following CMV gB amino acid sequence:</p><p id="p-0139" num="0000"><tables id="TABLE-US-00026" num="00026"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;123)</entry><entry/></row><row><entry>MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQ</entry><entry/></row><row><entry> </entry></row><row><entry>HVTSSEAVSHRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINED</entry></row><row><entry> </entry></row><row><entry>LDEGIMVVYKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQ</entry></row><row><entry> </entry></row><row><entry>CYSSYSRVIGGTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCN</entry></row><row><entry> </entry></row><row><entry>LNCMLTITTARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPN</entry></row><row><entry> </entry></row><row><entry>AAPETHRLVAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSK</entry></row><row><entry> </entry></row><row><entry>KQEVNMSDSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVE</entry></row><row><entry> </entry></row><row><entry>LERLANRSSLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAW</entry></row><row><entry> </entry></row><row><entry>CVDQRRTLEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESP</entry></row><row><entry> </entry></row><row><entry>GRCYSRPVVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRM</entry></row><row><entry> </entry></row><row><entry>IDLSSISTVDSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRVKYVEDKVV</entry></row><row><entry> </entry></row><row><entry>DPLPPYLKGLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVII</entry></row><row><entry> </entry></row><row><entry>TYLIYTRQRRLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSD</entry></row><row><entry> </entry></row><row><entry>ASTAAPPYTNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNG</entry></row><row><entry> </entry></row><row><entry>YRHLKDSDEEENV.</entry></row></tbody></tgroup></table></tables></p><p id="p-0140" num="0113">In some cases, the TCR present on the surface of a target modified T cell binds a CMV peptide when presented with an HLA complex comprising an MHC class I heavy chain selected from HLA-A*0101, A*0201, A*0301, A*1101, A*2301, A*2402, A*2407, A*3303, and A*3401. In some cases, the TCR present on the surface of a target modified T cell binds a CMV peptide that is restricted to HLA-B*0702, B*0801, B*1502, B*3802, B*4001, B*4601, and/or B*5301. In some cases, the TCR present on the surface of a target modified T cell binds a CMV peptide that is restricted to C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*702, C*0801, and/or C*1502. As one example, in some cases, the TCR present on the surface of a target modified T cell binds a peptide epitope having amino acid sequence NLVPMVATV (SEQ ID NO:172) and having a length of 9 amino acids; where the CMV peptide is presented in a complex comprising: i) an HLA-A*0201 class I heavy chain polypeptide; and ii) a &#x3b2;2M polypeptide.</p><heading id="h-0022" level="2">HPV Peptides</heading><p id="p-0141" num="0114">In some cases, the TCR present on the surface of a target modified T cell binds a peptide of an HPV E6 polypeptide or an HPV E7 polypeptide. The HPV epitope can be an epitope of HPV of any of a variety of genotypes, including, e.g., HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV68, HPV73, or HPV82. In some cases, the epitope is an HPV E6 epitope. In some cases, the epitope is an HPV E7 epitope.</p><p id="p-0142" num="0115">Examples of HPV E6 peptides that can be bound by the TCR present on the surface of a target modified T cell include, but are not limited to, E6 18-26 (KLPQLCTEL; SEQ ID NO:124); E6 26-34 (LQTTIHDII; SEQ ID NO:125); E6 49-57 (VYDFAFRDL; SEQ ID NO:126); E6 52-60 (FAFRDLCIV; SEQ ID NO:127); E6 75-83 (KFYSKISEY; SEQ ID NO:128); and E6 80-88 (ISEYRHYCY; SEQ ID NO:129).</p><p id="p-0143" num="0116">Examples of HPV E7 peptides that can be bound by the TCR present on the surface of a target modified T cell include, but are not limited to, E7 7-15 (TLHEYMLDL; SEQ ID NO:130); E7 11-19 (YMLDLQPET; SEQ ID NO:131); E7 44-52 (QAEPDRAHY; SEQ ID NO:132); E7 49-57 (RAHYNIVTF (SEQ ID NO:133); E7 61-69 (CDSTLRLCV; SEQ ID NO:134); and E7 67-76 (LCVQSTHVDI; SEQ ID NO:135); E7 82-90 (LLMGTLGIV; SEQ ID NO:136); E7 86-93 (TLGIVCPI; SEQ ID NO:137); and E7 92-93 (LLMGTLGIVCPI; SEQ ID NO:138).</p><p id="p-0144" num="0117">In some cases, the TCR present on the surface of a target modified T cell binds an HPV peptide, where the HPV peptide is an HPV E6 peptide that is bound to an MHC complex comprising a &#x3b2;2M polypeptide and an HLA-A24 heavy chain. Non-limiting examples of such HPV E6 peptides include: VYDFAFRDL (SEQ ID NO:126); CYSLYGTTL (SEQ ID NO:139); EYRHYCYSL (SEQ ID NO:140); KLPQLCTEL (SEQ ID NO:124); DPQERPRKL (SEQ ID NO:141); HYCYSLYGT (SEQ ID NO:142); DFAFRDLCI (SEQ ID NO:143); LYGTTLEQQY (SEQ ID NO:144); HYCYSLYGTT (SEQ ID NO:145); EVYDFAFRDL (SEQ ID NO:146); EYRHYCYSLY (SEQ ID NO:147); VYDFAFRDLC (SEQ ID NO:148); YCYSIYGTTL (SEQ ID NO:149); VYCKTVLEL (SEQ ID NO:150); VYGDTLEKL (SEQ ID NO:151); and LTNTGLYNLL (SEQ ID NO:152).</p><p id="p-0145" num="0118">In some cases, the TCR present on the surface of a target modified T cell binds an HPV peptide selected from the group consisting of: DLQPETTDL (SEQ ID NO:153); TLHEYMLDL (SEQ ID NO:130); TPTLHEYML (SEQ ID NO:154); RAHYNIVTF (SEQ ID NO:133); GTLGIVCPI (SEQ ID NO:155); EPDRAHYNI (SEQ ID NO:156); QLFLNTLSF (SEQ ID NO:157); FQQLFLNTL (SEQ ID NO:158); and AFQQLFLNTL (SEQ ID NO:159).</p><p id="p-0146" num="0119">In some cases, the TCR present on the surface of a target modified T cell binds an HPV peptide that presents an HLA-A*2401-restricted epitope. Non-limiting examples of HPV peptides presenting an HLA-A*2401-restricted epitope are: VYDFAFRDL (SEQ ID NO:127); RAHYNIVTF (SEQ ID NO:160); CDSTLRLCV (SEQ ID NO:134); and LCVQSTHVDI (SEQ ID NO:135). In some cases, the TCR present on the surface of a target modified T cell binds the peptide VYDFAFRDL (SEQ ID NO:126). In some cases, the TCR present on the surface of a target modified T cell binds the peptide RAHYNIVTF (SEQ ID NO:133). In some cases, the TCR present on the surface of a target modified T cell binds the peptide CDSTLRLCV (SEQ ID NO:134). In some cases, the TCR present on the surface of a target modified T cell binds the peptide LCVQSTHVDI (SEQ ID NO:135).</p><heading id="h-0023" level="2">Influenza Virus Peptides</heading><p id="p-0147" num="0120">Influenza virus peptides that can be bound by the TCR present on the surface of a target modified T cell include peptides of from 4 amino acids to 25 amino acids in length of an influenza polypeptide, e.g., an influenza polypeptide that is included in a vaccine, or that is present in an influenza virus that infects a human. As one example, the TCR present on the surface of a target modified T cell binds an influenza virus peptide of from 4 amino acids to 25 amino acids in length of an influenza virus nucleoprotein. As another example, the TCR present on the surface of a target modified T cell binds a peptide of from 4 amino acids to 25 amino acids in length of an influenza virus hemagglutinin polypeptide. As another example, the TCR present on the surface of a target modified T cell binds a peptide of from 4 amino acids to 25 amino acids in length of an influenza A virus Matrix protein 1. As another example, the TCR present on the surface of a target modified T cell binds a peptide of from 4 amino acids to 25 amino acids in length of an influenza virus neuraminidase polypeptide. In some cases, the peptide is a peptide that presents an immunodominant influenza virus protein epitope. One non-limiting example of a suitable influenza peptide is a peptide having the sequence GILGFVFTL (SEQ ID NO:160) and having a length of 9 amino acids.</p><heading id="h-0024" level="2">Tetanus Peptides</heading><p id="p-0148" num="0121">In some cases, the TCR present on the surface of a target modified T cell binds a tetanus peptide (e.g., a peptide of an antigen present in a tetanus vaccine). Tetanus peptides that can be bound by the TCR present on the surface of a target modified T cell include peptides of from 4 amino acids to 25 amino acids in length of a tetanus toxin. Examples of such tetanus peptides include, but are not limited to, QYIKANSKFIGIFE (SEQ ID NO:161); QYIKANSKFIGITE (SEQ ID NO:162); ILMQYIKANSKFIGI (SEQ ID NO:163); VNNESSE (SEQ ID NO:164); PGINGKAIHLVNNESSE (SEQ ID NO:165); PNRDIL (SEQ ID NO:166); FIGITEL (SEQ ID NO:167); SYFPSV (SEQ ID NO:168); NSVDDALINSTKIYSYFPSV (SEQ ID NO:169); and IDKISDVSTIVPYIGPALNI (SEQ ID NO:170).</p><heading id="h-0025" level="2">Methods of Making a Modified CTL</heading><p id="p-0149" num="0122">The present disclosure provides a method of making an in vitro composition of cells of the present disclosure. In some cases, the method comprises: a) providing a composition comprising a quantity of T cells, wherein the quantity comprises target T cells having a TCR specific for a preselected antigen; b) at least partially separating target T cells from non-target T cells comprising a TCR that is not specific for the preselected antigen, thereby generating an enriched target T cell population; and c) modifying the target T cells in the enriched target T cell population by introducing into the target T cells one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen. In some cases, the method comprises: a) at least partially separating target T cells having a TCR specific for a preselected antigen from non-target T cells comprising a TCR that is not specific for the preselected antigen present in a heterogeneous population of T cells, thereby generating an enriched target T cell population; and b) modifying the target T cells in the enriched target T cell population by introducing into the target T cells one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen.</p><heading id="h-0026" level="2">Cell Separation</heading><p id="p-0150" num="0123">Target T cells (e.g., CTLs) having a TCR specific for a preselected antigen) can be enriched from a quantity of cells (a &#x201c;starting cell population&#x201d;; or &#x201c;heterogeneous cell population&#x201d;; or &#x201c;heterogeneous starting cell population&#x201d;) obtained from an individual, e.g., a patient who has been vaccinated with a particular antigen of interest or who has been infected with a virus. The starting cell population can be whole blood, peripheral blood mononuclear cells (PBMCs), cells obtained by leukapheresis, or other starting cell population that includes leukocytes.</p><p id="p-0151" num="0124">The starting cell population comprises cells having a TCR specific for a preselected antigen (e.g., a viral antigen; a bacterial antigen; as described above). T cells having a TCR specific for a preselected antigen are collectively referred to as &#x201c;target T cells.&#x201d; The starting cell population also comprises T cells having a TCR specific for an antigen other than the preselected antigen; such cells are referred to as &#x201c;non-target T cells.&#x201d; Thus, the starting cell population comprises both target T cells and non-target T cells.</p><p id="p-0152" num="0125">The proportion of target T cells in the starting T cell population generally will be low, e.g., well less than 1%, but it also can be higher, e.g., if a patient is experiencing an active infection such as the flu that causes a natural increase in target T cells that are specific for a flu antigen. Hence, the proportion can range, e.g., from less than 0.01% to about 10% or higher. For example, the proportion of target T cells in the starting cell population can be from less than 0.01% to 0.01%, from 0.01% to 0.05%, from 0.05% to 0.1%, from 0.1% to 0.5%, from 0.5% to 1%, from 1% to 2%, from 2% to 5%, or from 5% to 10%. The proportion of target T cells in the starting cell population can be more than 10% (e.g., from 10% to about 50%).</p><p id="p-0153" num="0126">The proportion of target T cells in the enriched target T cell population typically will be higher than 10 percent, but can be lower, e.g., less than 1%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8% about 9%, or 10%. As noted, however, the proportion of target T cells in the enriched target T cell population typically will be higher than 10 percent and often much higher, however, e.g. at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%. In some cases, therefore, the population of T cells in the composition is a substantially homogeneous population of target modified T cells (e.g., target modified CTLs). The proportion of target T cells in the enriched target T cell population can be from 10% to 15%, from 15% to 20%, from 20% to 25%, from 25% to 30%, from 30% to 35%, from 35% to 40%, from 40% to 45%, from 45% to 50%, from 50% to 55%, from 55% to 60%, from 60% to 65%, from 65% to 70%, from 70% to 75%, from 75% to 80%, from 80% to 85% from 85% to 90%, from 90% to 95%, or from 95% to 100%. The proportion of target T cells in the enriched target T cell population can be from 10% to 25%, from 25% to 50%, from 50% to 75%, from 75% to 95%, or from 95% to 100%, e.g. 96%, 97%, 98% or 99%.</p><p id="p-0154" num="0127">In some cases, the separation step provides for a fold enrichment (an increase in the proportion of total cells in the enriched target T cell population that are target T cells, compared to the proportion of total cells in the starting cell population that are target T cells) of at least 2-fold, at least 2.5-fold, at least 5-fold, at least 10-fold, at least 25-fold, at least 50-fold, at least 100-fold, at least 250-fold, at least 500-fold, at least 1000-fold, at least 1500-fold, or at least 2000-fold.</p><p id="p-0155" num="0128">Sorting or positively selecting antigen-specific T cells (e.g., antigen-specific CTLs) can be carried out using peptide-loaded MHC multimers (e.g., trimers; tetramers; or pentamers); peptide/MHC-coated magnetic beads; or antibody-coated magnetic beads; or some combination of the foregoing. See, e.g., US 2002/0151690; Altman et al. (1996) <i>Science </i>274:94; Tubb et al. (2018) <i>J. Immunother. Cancer </i>6:70; Cobbold et al. (2005) <i>J. Exp. Med. </i>202:379; and Luxembourg et al. (1998) <i>Nat. Biotechnol. </i>16:281.</p><p id="p-0156" num="0129">Antigen-specific T cells (e.g., antigen-specific CTLs) can additionally be positively selected by contacting a starting population of cells, or a population of cells that has been enriched for specificity for a pre-selected antigen, with antibodies specific for T cell markers (e.g., where the antibody is attached to a bead, such as a magnetic bead). Antibodies that can be used include, but are not limited to, anti-CD3, anti-CD8, anti-CD25, anti-CD54, anti-CD69, anti-CD38, anti-CD45RO, anti-CD49d, anti-CD40L, anti-CD137, and anti-CD134 antibodies. In some cases, a starting population of cells is enriched for CD8<sup>+</sup> T cells. Thus, in some cases, a method of the present disclosure comprises: a) at least partially separating target T cells from non-target T cells, thereby generating an enriched target T cell population; b) optionally, at least partially separating CD8<sup>+</sup> T cells from CD8<sup>&#x2212;</sup> T cells in the enriched target T cell population, thereby generating a CD8<sup>+</sup> enriched target T cell population; and c) genetically modifying the enriched target T cells or CD8<sup>+</sup> enriched target T cells with one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen. In some cases, a method of the present disclosure comprises: a) at least partially separating CD8<sup>+</sup> T cells from CD8<sup>&#x2212;</sup> T cells in a starting cell population, thereby generating an enriched CD8<sup>+</sup> cell population; b) at least partially separating target T cells from non-target T cells present in the enriched CD8<sup>+</sup> cell population, thereby generating a CD8<sup>+</sup> enriched target T cell population; and c) genetically modifying the CD8<sup>+</sup> enriched target T cells with one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen.</p><p id="p-0157" num="0130">MHC multimers, and methods for generating such multimers, are known in the art. For example, an MHC class I heavy chain can be modified to include biotin. The MHC class I heavy chain is allowed to form a complex with a &#x3b2;2M polypeptide. The biotinylated MHC class I heavy chain/&#x3b2;2M complex is multimerized by contacting the complex with avidin or streptavidin. MHC multimers can be modified to include, e.g., phycoerythrin. For example, a biotinylated MHC class I heavy chain/&#x3b2;2M complex can be multimerized by contacting the complex with PE-labeled avidin or streptavidin. See, e.g., Altman et al. (1996) <i>Science </i>274:94.</p><p id="p-0158" num="0131">As one non-limiting example, a population of PBMCs is obtained from a CMV-seropositive individual. This starting population of PBMCs contains less than 0.1% CMV-specific T cells. CMV has a prevalence of 50% to 90% in human adults. Magnetic beads are coated with HLA-A*0201 heavy chains. Class I MHC complexes are formed by contacting the coated beads with &#x3b2;2M polypeptides, forming magnetic beads coated with an MHC complex comprising HLA-A*0201 heavy chain/&#x3b2;2M heterodimers. The peptide NLMPMVATV (SEQ ID NO:171) is loaded onto the magnetic beads coated with the MHC complexes, forming magnetic beads coated with MHC/peptide. The MHC/peptide-coated magnetic beads are mixed with PBMCs. Application of a magnetic field provides for separation of CMV-specific T cells from the starting population, generating an enriched CMV-specific T cell population. The enriched CMV-specific T cell population can include over 90% CMV-specific T cells.</p><p id="p-0159" num="0132">As another non-limiting example, a population of PBMCs is obtained from a CMV-seropositive individual. This starting population of PBMCs contains less than 0.1% CMV-specific T cells. The starting population of PBMCs is coated with MHC multimers (e.g., trimers; tetramers; pentamers) loaded with the CMV peptide NLMPMVATV (SEQ ID NO:171), generating a population of MHC/peptide-coated PBMCs. The MHC multimers comprises multiple copies of HLA-A*0201 heavy chain/&#x3b2;2M heterodimers loaded with the CMV peptide. Magnetic beads are coated with antibody specific for the MHC heavy chain present in the MHC multimers. The antibody-coated magnetic beads are mixed with the MHC/peptide-coated PBMCs. Application of a magnetic field provides for separation of CMV-specific T cells from the starting population, generating an enriched CMV-specific T cell population. The enriched CMV-specific T cell population can include over 90% CMV-specific T cells.</p><p id="p-0160" num="0133">As another non-limiting example, a population of PBMCs is obtained from a CMV-seropositive individual. This starting population of PBMCs contains less than 0.1% CMV-specific T cells. The starting population of PBMCs is coated with phycoerythrin (PE)-labeled MHC multimers (e.g., trimers; tetramers; pentamers) loaded with the CMV peptide NLMPMVATV (SEQ ID NO:171), generating a population of MHC/peptide-coated PBMCs. The CMV peptide-loaded, PE-labeled MHC multimers comprises multiple copies of HLA-A*0201 heavy chain/&#x3b2;2M heterodimers loaded with the CMV peptide. Magnetic beads are coated with antibody specific for PE. The antibody-coated magnetic beads are mixed with the MHC/peptide-coated PBMCs. Application of a magnetic field provides for separation of CMV-specific T cells from the starting population, generating an enriched CMV-specific T cell population. The enriched CMV-specific T cell population can include over 90% CMV-specific T cells.</p><p id="p-0161" num="0000">Contacting with a TMMP</p><p id="p-0162" num="0134">In the methods described below, the patient's blood optionally may be pre-screened to determine if it contains an appropriate target T cell for modification with a CAR. For example, the patient's blood may be drawn and T cells screened using the methods described above to determine if the patient already has T cells that are specific for a particular antigen, e.g., CMV, EBD, HPV, tetanus, influenza, etc.</p><p id="p-0163" num="0135">In some cases, prior to the step of at least partially separating target T cells from non-target T cells, the composition comprising a quantity of T cells is contacted in vitro or in vivo with a composition comprising a T-cell modulatory polypeptide (e.g., a TMMP, as described herein) that binds to and activates substantially only the T cells comprising a TCR specific for the preselected antigen. A TMMP that binds to and activates substantially only the T cells comprising a TCR specific for the preselected antigen is thus a TMMP that either wholly or largely (but not wholly) binds to and activates only the T cells comprising a TCR specific for the preselected antigen. That is, a TMMP that binds to and activates substantially only the T cells comprising a TCR specific for the preselected antigen may bind to and activate a relatively small percentage of T cells that are non-target T cells. As used herein, the term &#x201c;in vitro&#x201d; is intended to connote any process, system, container, apparatus, equipment, etc. that is outside of the patient, i.e., ex vivo, for making, holding and/or delivering to the patient the mCTLs described herein.</p><p id="p-0164" num="0136">In some cases, the starting cell population is obtained from an individual to be treated with a composition of the present disclosure, where the composition comprises a quantity of modified T cells (e.g., modified CTLs), and where, before the starting cell population is obtained from the individual, one or more doses of a TMMP, as described herein, has been administered to the individual. Administration of a TMMP to the individual, before obtaining the starting cell population from the individual, can increase the number of target T cells in the individual and therefore can increase the proportion of target T cells in the starting cell population. For example, a TMMP comprising a peptide epitope is administered to an individual; and, at a time after such administration (e.g., 2-3 weeks), a starting cell population is obtained from the individual, where the starting cell population comprises target T cells comprising a TCR specific for the peptide epitope present in the TMMP. Thus, in some cases, a method of the present disclosure for making an in vitro composition of cells of the present disclosure comprises: a) administering to an individual a TMMP comprising a peptide epitope; b) obtaining from the individual a composition comprising a quantity of T cells, where the quantity comprises target T cells having a TCR specific for the peptide epitope (a peptide epitope present in a preselected antigen); c) at least partially separating target T cells from non-target T cells comprising a TCR that is not specific for the peptide epitope, thereby generating an enriched target T cell population; and d) modifying the target T cells in the enriched target T cell population by introducing into the target T cells one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen.</p><p id="p-0165" num="0137">In some cases, a method of the present disclosure for making an in vitro composition of cells of the present disclosure comprises: a) administering to an individual a TMMP comprising a peptide epitope; b) at least partially separating target T cells having a TCR specific for the peptide epitope (a peptide epitope present in a preselected antigen) from non-target T cells comprising a TCR that is not specific for the peptide epitope present in a heterogeneous population of T cells obtained from the individual, thereby generating an enriched target T cell population; and c) modifying the target T cells in the enriched target T cell population by introducing into the target T cells one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen. In some cases, the TMMP is administered to the individual at a period of time of from 1 day to 1 month (e.g., from 1 day to 4 days, from 4 days to 7 days, from 1 week to 2 weeks, from 2 weeks to 3 weeks, or from 3 weeks to 1 month) before the starting cell population is obtained from the individual. In some cases, multiple doses of the TMMP are administered to the individual before the starting cell population is obtained from the individual.</p><p id="p-0166" num="0138">In some cases, prior to step (ii) (i.e., prior to the step of at least partially separating target T cells from non-target T cells), the composition comprising a quantity of T cells is contacted in vitro with a composition comprising a TMMP that binds to and activates substantially only the T cells comprising a TCR specific for the preselected antigen. Suitable TMMPs are described elsewhere herein. Contacting the T cells with a TMMP that binds to and activates substantially only the target T cells comprising a TCR specific for the preselected antigen stimulates proliferation of the target T cells, thereby increasing the number of target T cells.</p><heading id="h-0027" level="2">Modifying Target T Cells</heading><p id="p-0167" num="0139">As noted above, a method of the present disclosure for making an in vitro composition of cells of the present disclosure comprises modifying the target T cells in the enriched target T cell population by introducing into the target T cells one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen. Any method known to those skilled in the art may be used to introduce into the target T cells one or more nucleic acids comprising nucleotide sequences encoding a CAR. A discussion of some known materials and methods is provided below.</p><p id="p-0168" num="0140">A nucleic acid comprising a nucleotide sequence encoding a CAR can be an expression vector, e.g., recombinant expression vector. In some cases, the recombinant expression vector is a viral construct, e.g., a recombinant adeno-associated virus (AAV) construct, a recombinant adenoviral construct, a recombinant lentiviral construct, a recombinant retroviral construct, etc. In some cases, a nucleic acid comprising a nucleotide sequence encoding a CAR is a recombinant lentivirus vector. In some cases, a nucleic acid comprising a nucleotide sequence encoding a CAR is a recombinant AAV vector.</p><p id="p-0169" num="0141">The nucleotide sequences encoding the CAR can be operably linked to a transcriptional control element such as a promoter. The transcriptional control element (e.g., a promoter) is one that is functional in a T cell. Suitable promoters include constitutive promoters and regulatable (e.g., inducible) promoters.</p><p id="p-0170" num="0142">One example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of an operably linked nucleotide sequence. Another example of a suitable promoter is Elongation Growth Factor-1&#x3b1; (EF-1&#x3b1;). However, other constitutive promoter sequences may also be used, including, but not limited to, the simian virus 40 (SV40) early promoter, MND (myeloproliferative sarcoma virus) promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, Moloney Murine Leukemia Virus (MoMuLV) promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. Examples of inducible promoters include, but are not limited to, a metallothionine promoter, a glucocorticoid-inducible promoter, a progesterone-inducible promoter, and a tetracycline-inducible promoter.</p><p id="p-0171" num="0143">In some cases, the promoter is a CD8 cell-specific promoter, a CD4 cell-specific promoter, a neutrophil-specific promoter, or an NK-specific promoter. For example, a CD4 gene promoter can be used; see, e.g., Salmon et al. (1993) <i>Proc. Natl. Acad. Sci. USA </i>90: 7739; and Marodon et al. (2003) <i>Blood </i>101:3416. As another example, a CD8 gene promoter can be used. NK cell-specific expression can be achieved by use of an Ncr1 (p46) promoter; see, e.g., Eckelhart et al. (2011) <i>Blood </i>117:1565.</p><p id="p-0172" num="0144">Any method of introducing nucleic acids into cells can be used to introduce nucleic acid(s) encoding a CAR into target T cells. Suitable methods include viral transfection (e.g., where the nucleic acid is a lentiviral vector or other viral vector comprising a nucleotide sequence encoding a CAR), electroporation, diethylaminoethyl (DEAE)-dextran-mediated transfection, lipofection, and the like.</p><heading id="h-0028" level="2">Use of Allogeneic T Cells</heading><p id="p-0173" num="0145">While the methods and compositions described above involve the removal of T cells from a patient and the introduction of target modified T cells back into the same patient, it also is expressly contemplated that allogeneic T cells can be used instead of (or in addition to) T cells removed from the patient. If a heterogenous population of allogeneic T cells is employed as a starting material, then an enriched population optionally can be prepared as described above. The target modified T cells made from allogeneic T cells thus can contain both a TCR specific for a preselected antigen (including such TCRs expressed as a result of gene-editing), as well as one or more nucleic acids comprising nucleotide sequences encoding a CAR, where the CAR comprises an antigen-binding domain specific for a cancer-associated antigen. The target modified T cells prepared from allogeneic T cells then would be employed for treatment in the same manner as described herein for patient-derived target modified T cells.</p><heading id="h-0029" level="2">Methods of Treating Cancer</heading><p id="p-0174" num="0146">The present disclosure provides a method of treating cancer in an individual having a cancer. The method comprises: (a) administering to the individual a composition comprising a quantity of genetically modified CTLs of the present disclosure (e.g., modified CTLs prepared according to a method of the present disclosure), where the genetically modified CTLs express a CAR on their cell surface, where the CAR comprises an antigen-binding domain (e.g., an antibody) specific for a cancer-associated peptide; and (b) administering to the individual a composition comprising a TMMP. The TMMP selectively binds to and activates T cells comprising a TCR specific for the preselected antigen. T cells comprising a TCR specific for the preselected antigen will in many cases be genetically modified CTLs as described herein. By activating genetically modified CTLs, the number and activity of such cells is increased, such that activated, genetically modified CTLs target and kill tumor cells that bear on their surface the cancer-associated epitope for which the CAR is specific.</p><p id="p-0175" num="0147">A method of the present disclosure comprises administering an effective amount of a modified CTL of the present disclosure and an effective amount of a TMMP.</p><p id="p-0176" num="0148">In some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof, lead to a reduction in the number of cancer cells in the individual. The amount that is an effective amount may depend on whether the patient is receiving additional treatments in combination with the modified CTL, including additional treatments with TMMPs as discussed herein.</p><p id="p-0177" num="0149">For example, in some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof, leads to a reduction in the number of cancer cells in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, compared to the number of cancer cells in the individual before administration of the modified CTL and the TMMP, or in the absence of administration with the modified CTL and the TMMP. In some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof, leads to a reduction in the number of cancer cells in the individual to undetectable levels.</p><p id="p-0178" num="0150">In some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof, leads to a reduction in the tumor mass in the individual. For example, in some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof (an individual having a tumor), leads to a reduction in the tumor mass in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, compared to the tumor mass in the individual before administration of the modified CTL and the TMMP, or in the absence of administration of the modified CTL and the TMP. In some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof (an individual having a tumor), leads to a reduction in the tumor volume in the individual. For example, in some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof (an individual having a tumor), reduces the tumor volume in the individual by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, compared to the tumor volume in the individual before administration of the modified CTL and the TMMP, or in the absence of administration with the modified CTL and the TMMP. In some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof, leads to an increase in survival time of the individual. For example, in some cases, &#x201c;effective amounts&#x201d; of a modified CTL of the present disclosure and a TMMP are amounts that, when administered in one or more doses to an individual in need thereof, leads to an increase in survival time of the individual by at least 1 month, at least 2 months, at least 3 months, from 3 months to 6 months, from 6 months to 1 year, from 1 year to 2 years, from 2 years to 5 years, from 5 years to 10 years, or more than 10 years, compared to the expected survival time of the individual in the absence of administration with the modified CTL and the TMMP.</p><p id="p-0179" num="0151">In some cases, the modified CTL and the TMMP are administered at the same time. In some cases, the modified CTL and the TMMP are administered to an individual within about 1 minute to about 24 hours (e.g., within about 1 minute, within about 5 minutes, within about 15 minutes, within about 30 minutes, within about 1 hour, within about 4 hours, within about 8 hours, within about 12 hours, or within about 24 hours) of one another.</p><p id="p-0180" num="0152">In some cases, a method of the present disclosure comprises: a) administering a TMMP; and b) after a period of time, administering a modified CTL. For example, in some cases, a TMMP is administered from 1 week to 4 weeks (e.g., 1 week, 2 weeks, 3 weeks, or 4 weeks) before the modified CTL is administered. In some cases, multiple doses of a TMMP are administered to an individual before a modified CTL is administered to the individual. For example, in some cases, a method of the present disclosure comprises: a) administering multiple doses of a TMMP; and b) after a period of time, administering a modified CTL.</p><p id="p-0181" num="0153">In some cases, a method of the present disclosure comprises: a) administering a modified CTL; and b) after a period of time, administering a TMMP. For example, in some cases, a modified CTL is administered from 1 week to 4 weeks (e.g., 1 week, 2 weeks, 3 weeks, or 4 weeks) before the TMMP is administered. In some cases, multiple doses of a TMMP are administered to an individual after the modified CTL is administered to the individual. For example, in some cases, a method of the present disclosure comprises: a) administering a modified CTL; and b) after a period of time, administering multiple doses of a TMMP to the individual.</p><p id="p-0182" num="0154">In some cases, a method of the present disclosure comprises: a) a) administering a TMMP; b) after a period of time, administering a modified CTL; and c) after a period of time, administering the TMMP. For example, in some cases, a TMMP is administered from 1 week to 4 weeks (e.g., 1 week, 2 weeks, 3 weeks, or 4 weeks) before the modified CTL is administered; and, after the CTL is administered, one or more additional doses of the TMMP is administered to the individual. In some cases, multiple doses of a TMMP are administered to an individual before a modified CTL is administered to the individual; and multiple doses of the TMMP are administered to the individual after the modified CTL is administered.</p><p id="p-0183" num="0155">Cancers that can be treated with a method of the present disclosure include any cancer that can be targeted with a CAR. Cancers that can be treated with a method of the present disclosure include carcinomas, sarcomas, melanoma, leukemias, and lymphomas. Cancers that can be treated with a method of the present disclosure include solid tumors. Cancers that can be treated with a method of the present disclosure include metastatic cancers.</p><p id="p-0184" num="0156">Carcinomas that can treated by a method disclosed herein include, but are not limited to, esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma (a form of skin cancer), squamous cell carcinoma (various tissues), bladder carcinoma, including transitional cell carcinoma (a malignant neoplasm of the bladder), bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelial carcinoma, and nasopharyngeal carcinoma.</p><p id="p-0185" num="0157">Sarcomas that can be treated by a method disclosed herein include, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.</p><p id="p-0186" num="0158">Other solid tumors that can be treated by a method disclosed herein include, but are not limited to, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.</p><p id="p-0187" num="0159">Leukemias that can be amenable to therapy by a method disclosed herein include, but are not limited to, a) chronic myeloproliferative syndromes (neoplastic disorders of multipotential hematopoietic stem cells); b) acute myelogenous leukemias (neoplastic transformation of a multipotential hematopoietic stem cell or a hematopoietic cell of restricted lineage potential; c) chronic lymphocytic leukemias (CLL; clonal proliferation of immunologically immature and functionally incompetent small lymphocytes), including B-cell CLL, T-cell CLL prolymphocytic leukemia, and hairy cell leukemia; and d) acute lymphoblastic leukemias (characterized by accumulation of lymphoblasts). Lymphomas that can be treated using a subject method include, but are not limited to, B-cell lymphomas (e.g., Burkitt's lymphoma); Hodgkin's lymphoma; non-Hodgkin's lymphoma, and the like.</p><p id="p-0188" num="0160">Other cancers that can be treated according to the methods disclosed herein include atypical meningioma, islet cell carcinoma, medullary carcinoma of the thyroid, mesenchymoma, hepatocellular carcinoma, hepatoblastoma, clear cell carcinoma of the kidney, and neurofibroma mediastinum.</p><heading id="h-0030" level="2">Formulations</heading><p id="p-0189" num="0161">Suitable formulations comprising a modified CTL, or a TMMP, include a pharmaceutically acceptable excipient. In some cases, a suitable formulation comprises: a) a modified CTL of the present disclosure; and b) a pharmaceutically acceptable excipient. In some cases, a suitable formulation comprises: a) a TMMP; and b) a pharmaceutically acceptable excipient. The composition may comprise a pharmaceutically acceptable excipient, a variety of which are known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, &#x201c;Remington: The Science and Practice of Pharmacy&#x201d;, 19<sup>th </sup>Ed. (1995), or latest edition, Mack Publishing Co; A. Gennaro (2000) &#x201c;Remington: The Science and Practice of Pharmacy&#x201d;, 20th edition, Lippincott, Williams, &#x26; Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H. C. Ansel et al., eds 7<sup>th </sup>ed., Lippincott, Williams, &#x26; Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H. Kibbe et al., eds., 3<sup>rd </sup>ed. Amer. Pharmaceutical Assoc.</p><p id="p-0190" num="0162">A pharmaceutical composition can comprise a modified CTL of the present disclosure, and a pharmaceutically acceptable excipient; or can comprise a TMMP and a pharmaceutically acceptable excipient. In some cases, a subject pharmaceutical composition will be suitable for administration to a subject, e.g., will be sterile. For example, in some cases, a subject pharmaceutical composition will be suitable for administration to a human subject, e.g., where the composition is sterile and is free of detectable pyrogens and/or other toxins.</p><heading id="h-0031" level="2">Dosages</heading><p id="p-0191" num="0163">A suitable dosage of a TMMP or a modified CTL can be determined by an attending physician or other qualified medical personnel, based on various clinical factors. As is well known in the medical arts, dosages for any one patient depend upon many factors, including the patient's size, body surface area, age, the particular TMMP or modified CTL to be administered, sex of the patient, time, and route of administration, general health, and other drugs being administered concurrently.</p><p id="p-0192" num="0164">A TMMP may be administered in amounts between 1 ng/kg body weight and 20 mg/kg body weight per dose, e.g. between 0.1 mg/kg body weight to 10 mg/kg body weight, e.g. between 0.1 mg/kg body weight and 4 mg/kg body weight, between 0.5 mg/kg body weight and 2 mg/kg body weight, or between 0.5 mg/kg body weight and 5 mg/kg body weight; however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. If the regimen is a continuous infusion, it can also be in the range of 1 &#x3bc;g to 10 mg per kilogram of body weight per minute. A TMMP can be administered in an amount of from about 1 mg/kg body weight to 50 mg/kg body weight, e.g., from about 1 mg/kg body weight to about 5 mg/kg body weight, from about 5 mg/kg body weight to about 10 mg/kg body weight, from about 10 mg/kg body weight to about 15 mg/kg body weight, from about 15 mg/kg body weight to about 20 mg/kg body weight, from about 20 mg/kg body weight to about 25 mg/kg body weight, from about 25 mg/kg body weight to about 30 mg/kg body weight, from about 30 mg/kg body weight to about 35 mg/kg body weight, from about 35 mg/kg body weight to about 40 mg/kg body weight, or from about 40 mg/kg body weight to about 50 mg/kg body weight.</p><p id="p-0193" num="0165">In some cases, a suitable dose of a TMMP is from 0.01 &#x3bc;g to 100 g per kg of body weight, from 0.1 &#x3bc;g to 10 g per kg of body weight, from 1 &#x3bc;g to 1 g per kg of body weight, from 10 &#x3bc;g to 100 mg per kg of body weight, from 100 &#x3bc;g to 10 mg per kg of body weight, or from 100 &#x3bc;g to 1 mg per kg of body weight. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the administered agent in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein a TMMP is administered in maintenance doses, ranging from 0.01 &#x3bc;g to 100 g per kg of body weight, from 0.1 &#x3bc;g to 10 g per kg of body weight, from 1 &#x3bc;g to 1 g per kg of body weight, from 10 &#x3bc;g to 100 mg per kg of body weight, from 100 &#x3bc;g to 10 mg per kg of body weight, or from 100 &#x3bc;g to 1 mg per kg of body weight.</p><p id="p-0194" num="0166">In some cases, a suitable dose of modified CTLs that is equal to or less than a number selected from the group consisting of 10 cells/kg body weight, 10<sup>2 </sup>cells/kg body weight, 10<sup>3 </sup>cells/kg body weight, 10<sup>4 </sup>cells/kg body weight, 10<sup>5 </sup>cells/kg body weight, 10<sup>6 </sup>cells/kg body weight, 10<sup>7 </sup>cells/kg body weight, 10<sup>8 </sup>cells/kg body weight, and 10<sup>9 </sup>cells/kg body weight. In some cases, a suitable dose of modified CTLs is from about 10 cells/kg body weight to about 10<sup>2 </sup>cells/kg body weight, from about 10<sup>2 </sup>cells/kg body weight to about 10<sup>3 </sup>cells/kg body weight, from about 10<sup>3 </sup>cells/kg body weight to about 10<sup>4 </sup>cells/kg body weight, from about 10<sup>4 </sup>cells/kg body weight to about 10<sup>5 </sup>cells/kg body weight, from about 10<sup>5 </sup>cells/kg body weight to about 10<sup>6 </sup>cells/kg body weight, from about 10<sup>6 </sup>cells/kg body weight to about 10<sup>7 </sup>cells/kg body weight, from about 10<sup>7 </sup>cells/kg body weight to about 10<sup>8 </sup>cells/kg body weight, or from about 10<sup>8 </sup>cells/kg body weight to about 10<sup>9 </sup>cells/kg body weight. In some cases, lower doses of modified CTLs can be employed, e.g., less than about 10<sup>7 </sup>cells/kg body weight, less than about 10<sup>6 </sup>cells/kg body weight, less than about 10<sup>5 </sup>cells/kg body weight, less than about 10<sup>4 </sup>cells/kg body weight or less than about 10<sup>3 </sup>cells/kg body weight.</p><p id="p-0195" num="0167">Those of skill will readily appreciate that dose levels can vary as a function of the specific TMMP or the modified CTL, the severity of the symptoms, and the susceptibility of the subject to side effects. Preferred dosages for a given TMMP or modified CTL are readily determinable by those of skill in the art by a variety of means.</p><heading id="h-0032" level="2">Routes of Administration</heading><p id="p-0196" num="0168">An active agent (a modified CTL; a TMMP) is administered to an individual using any available method and route suitable for drug delivery, including in vivo and ex vivo methods, as well as systemic and localized routes of administration.</p><p id="p-0197" num="0169">Conventional and pharmaceutically acceptable routes of administration include intratumoral, peritumoral, intramuscular, intralymphatic, intratracheal, intracranial, subcutaneous, intradermal, topical application, intravenous, intraarterial, rectal, nasal, oral, and other enteral and parenteral routes of administration. Routes of administration may be combined, if desired, or adjusted depending upon the TMMP, the modified CTL, and/or the desired effect. A modified CTL of the present disclosure can be administered in a single dose or in multiple doses. Similarly, a TMMP can be administered in a single dose or in multiple doses. A modified CTL can be administered via the same route of administration as the TMMP. A modified CTL can be administered via a different route of administration from the TMMP.</p><p id="p-0198" num="0170">In some cases, a modified CTL of the present disclosure is administered intravenously. In some cases, a modified CTL of the present disclosure is administered intralymphatically. In some cases, a modified CTL of the present disclosure is administered locally. In some cases, a modified CTL of the present disclosure is administered intratumorally. In some cases, a modified CTL of the present disclosure is administered peritumorally. In some cases, a modified CTL of the present disclosure is administered intracranially.</p><p id="p-0199" num="0171">In some cases, a TMMP is administered intravenously. In some cases, a TMMP is administered intramuscularly. In some cases, a TMMP is administered intralymphatically. In some cases, a TMMP is administered locally. In some cases, a TMMP is administered intratumorally. In some cases, a TMMP is administered peritumorally. In some cases, a TMMP is administered intracranially. In some cases, a TMMP is administered subcutaneously.</p><heading id="h-0033" level="2">Combination Therapies</heading><p id="p-0200" num="0172">In some cases, a method of the present disclosure for treating cancer in an individual comprises: a) administering a modified CTL of the present disclosure; b) administering a TMMP; and c) administering at least one additional therapeutic agent or therapeutic treatment. Suitable additional therapeutic agents include, but are not limited to, small molecule cancer chemotherapeutic agents, biologic anti-cancer agents, e.g., antibodies, fusion proteins and bi-specific antibodies, and immune checkpoint inhibitors. Suitable additional therapeutic treatments include, e.g., radiation, surgery (e.g., surgical resection of a tumor), and the like.</p><p id="p-0201" num="0173">As an example, a treatment method of the present disclosure can comprise co-administration of: a) a modified CTL of the present disclosure; b) a TMMP; and c) an immune checkpoint inhibitor, such as an antibody specific for an immune checkpoint. In some cases, a modified CTL of the present disclosure and a TMMP are administered to an individual who is undergoing treatment with, or who has undergone treatment with, an antibody or other agent specific for an immune checkpoint.</p><p id="p-0202" num="0174">Exemplary immune checkpoint inhibitors include inhibitors that target immune checkpoint polypeptides such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, CD122, PD-1, PD-L1, and PD-L2. In some cases, the immune checkpoint polypeptide is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, CD122 and CD137. In some cases, the immune checkpoint polypeptide is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA.</p><p id="p-0203" num="0175">In some cases, the immune checkpoint inhibitor is an antibody specific for an immune checkpoint. In some cases, the anti-immune checkpoint antibody is a monoclonal antibody. In some cases, the anti-immune checkpoint antibody is humanized, or de-immunized such that the antibody substantially does not elicit an immune response in a human, or elicits an immune response that is acceptable for at least some percentage of patients. In some cases, the anti-immune checkpoint antibody is a humanized monoclonal antibody. In some cases, the anti-immune checkpoint antibody is a de-immunized monoclonal antibody. In some cases, the anti-immune checkpoint antibody is a fully human monoclonal antibody. In some cases, the anti-immune checkpoint antibody inhibits binding of the immune checkpoint polypeptide to a ligand for the immune checkpoint polypeptide. In some cases, the anti-immune checkpoint antibody inhibits binding of the immune checkpoint polypeptide to a receptor for the immune checkpoint polypeptide.</p><p id="p-0204" num="0176">Suitable anti-immune checkpoint antibodies include, but are not limited to, nivolumab (Bristol-Myers Squibb), pembrolizumab (Merck), pidilizumab (Curetech), AMP-224 (GlaxoSmithKline/Amplimmune), MPDL3280A (Roche), MDX-1105 (Medarex, Inc./Bristol Myer Squibb), MEDI-4736 (Medimmune/AstraZeneca), arelumab (Merck Serono), ipilimumab (YERVOY, (Bristol-Myers Squibb), tremelimumab (Pfizer), pidilizumab (CureTech, Ltd.), IMP321 (Immutep S.A.), MGA271 (Macrogenics), BMS-986016 (Bristol-Meyers Squibb), lirilumab (Bristol-Myers Squibb), urelumab (Bristol-Meyers Squibb), PF-05082566 (Pfizer), IPH2101 (Innate Pharma/Bristol-Myers Squibb), MEDI-6469 (MedImmune/AZ), CP-870,893 (Genentech), Mogamulizumab (Kyowa Hakko Kirin), Varlilumab (CelIDex Therapeutics), Avelumab (EMD Serono), Galiximab (Biogen Idec), AMP-514 (Amplimmune/AZ), AUNP 12 (Aurigene and Pierre Fabre), Indoximod (NewLink Genetics), NLG-919 (NewLink Genetics), INCB024360 (Incyte); KN035; and combinations thereof. For example, in some cases, the immune checkpoint inhibitor is an anti-PD-1 antibody. Suitable anti-PD-1 antibodies include, e.g., nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, and AMP-224. In some cases, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab or PDR001. Suitable anti-PD1 antibodies are described in U.S. Patent Publication No. 2017/0044259. For pidilizumab, see, e.g., Rosenblatt et al. (2011) <i>J. Immunother. </i>34:409-18. In some cases, the immune checkpoint inhibitor is an anti-CTLA-4 antibody. In some cases, the anti-CTLA-4 antibody is ipilimumab or tremelimumab. For tremelimumab, see, e.g., Ribas et al. (2013) <i>J. Clin. Oncol. </i>31:616-22. In some cases, the immune checkpoint inhibitor is an anti-PD-L1 antibody. In some cases, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), KN035, or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab). For durvalumab, see, e.g., WO 2011/066389. For atezolizumab, see, e.g., U.S. Pat. No. 8,217,149.</p><heading id="h-0034" level="2">Subjects Suitable for Treatment</heading><p id="p-0205" num="0177">Subjects suitable for treatment with a method of the present disclosure include individuals who have cancer, including individuals who have been diagnosed as having cancer but have not yet undergone treatment, individuals who have been treated for cancer but who failed to respond to the treatment, and individuals who have been treated for cancer and who initially responded but subsequently became refractory to the treatment. In some cases, the individual already will have been treated with an immune checkpoint inhibitor, e.g., nivolumab or pembrolizumab, as described above.</p><p id="p-0206" num="0178">In some cases, the individual being treated according to a method of the present disclosure has not undergone a lymphodepleting regimen prior to administration of a modified CTL of the present disclosure and/or prior to administration of a TMMP. In some cases, the individual being treated according to a method of the present disclosure has undergone a lymphodepleting regimen prior to administration of a modified CTL of the present disclosure and/or prior to administration of a TMMP. In some cases, the lymphodepletion regimen is a non-myeloablative lymphodepletion regimen. Lymphodepletion can be accomplished by administering to the individual: i) cyclophosphamide/fludarabine combination; or ii) cyclophosphamide alone.</p><heading id="h-0035" level="2">TMMP</heading><p id="p-0207" num="0179">A TMMP suitable for use in a method of the present disclosure comprises a heterodimer comprising: a) a first polypeptide comprising: i) a peptide epitope, wherein the peptide epitope is a peptide having a length of at least 4 amino acids (e.g., from 4 amino acids to about 25 amino acids); and ii) a first major histocompatibility complex (MHC) polypeptide; b) a second polypeptide comprising a second MHC polypeptide; and c) at least one immunomodulatory polypeptide, where the first and/or the second polypeptide comprises the at least one immunomodulatory polypeptide. The TMMP optionally also includes an immunoglobulin (Ig) Fc polypeptide or a non-Ig scaffold, where the first and/or the second polypeptide comprises the Ig Fc polypeptide or the non-Ig scaffold.</p><p id="p-0208" num="0180">As used herein, the term &#x201c;peptide epitope&#x201d; means a peptide that, when complexed with MHC polypeptides, presents an epitope to a TCR. A peptide epitope has a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length). When complexed with MHC polypeptides, a peptide epitope can present one or more epitopes to one or more TCRs. In some cases, the peptide epitope present in a TMMP presents an infectious disease-associated epitope (e.g., a virus-encoded peptide).</p><p id="p-0209" num="0181">As noted above, a TMMP comprises a heterodimeric polypeptide comprising: a) a first polypeptide comprising: i) a peptide epitope; and ii) a first MHC polypeptide; b) a second polypeptide comprising a second MHC polypeptide; c) at least one immunomodulatory polypeptide, where the first and/or the second polypeptide comprises the at least one (i.e., one or more) immunomodulatory polypeptide; and, optionally, d) an Ig Fc polypeptide or a non-Ig scaffold, where the first and/or the second polypeptide comprises the Ig Fc polypeptide or the non-Ig scaffold. In some cases, the at least one immunomodulatory polypeptide is wild-type, i.e., comprises an amino acid sequence of a naturally-occurring immunomodulatory polypeptide.</p><p id="p-0210" num="0182">In some cases, at least one of the one or more immunomodulatory polypeptides is a variant immunomodulatory polypeptide that exhibits reduced affinity to a cognate co-immunomodulatory polypeptide compared to the affinity of a corresponding wild-type immunomodulatory polypeptide for the cognate co-immunomodulatory polypeptide. In some cases, the peptide epitope present in a TMMP of the present disclosure binds to a T-cell receptor (TCR) on a T cell with an affinity of at least 100 &#x3bc;M (e.g., at least 10 &#x3bc;M, at least 1 &#x3bc;M, at least 100 nM, at least 10 nM, or at least 1 nM). In some cases, a TMMP of the present disclosure binds to a first T cell with an affinity that is at least 25% higher than the affinity with which the TMMP binds a second T cell, where the first T cell expresses on its surface the cognate co-immunomodulatory polypeptide and a TCR that binds the epitope with an affinity of at least 100 &#x3bc;M, and where the second T cell expresses on its surface the cognate co-immunomodulatory polypeptide but does not express on its surface a TCR that binds the epitope with an affinity of at least 100 &#x3bc;M (e.g., at least 10 &#x3bc;M, at least 1 &#x3bc;M, at least 100 nM, at least 10 nM, or at least 1 nM).</p><p id="p-0211" num="0183">In some cases, a TMMP is:</p><p id="p-0212" num="0184">A) a heterodimer comprising: a) a first polypeptide comprising a first MHC polypeptide; and b) a second polypeptide comprising a second MHC polypeptide, wherein the first polypeptide or the second polypeptide comprises a peptide epitope, wherein the first polypeptide and/or the second polypeptide comprises one or more immunomodulatory polypeptides that can be the same or different, and wherein at least one of the one or more immunomodulatory polypeptides may be a wild-type immunomodulatory polypeptide or a variant of a wild-type immunomodulatory polypeptide, wherein the variant immunomodulatory polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions compared to the amino acid sequence of the corresponding wild-type immunomodulatory polypeptide; wherein the first polypeptide and/or the second polypeptide comprises an Ig Fc polypeptide or a non-Ig scaffold; or</p><p id="p-0213" num="0185">B) a heterodimer comprising: a) a first polypeptide comprising a first MHC polypeptide; and b) a second polypeptide comprising a second MHC polypeptide, wherein the first polypeptide or the second polypeptide comprises an epitope; wherein the first polypeptide and/or the second polypeptide comprises one or more immunomodulatory polypeptides that can be the same or different,</p><p id="p-0214" num="0186">wherein at least one of the one or more immunomodulatory polypeptides is a variant of a wild-type immunomodulatory polypeptide, wherein the variant immunomodulatory polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions compared to the amino acid sequence of the corresponding wild-type immunomodulatory polypeptide,</p><p id="p-0215" num="0187">wherein at least one of the one or more immunomodulatory domains is a variant immunomodulatory polypeptide that exhibits reduced affinity to a cognate co-immunomodulatory polypeptide compared to the affinity of a corresponding wild-type immunomodulatory polypeptide for the cognate co-immunomodulatory polypeptide, and wherein the epitope binds to a TCR on a T cell with an affinity of at least 10<sup>&#x2212;7 </sup>M, such that: i) the TMMP polypeptide binds to a first T cell with an affinity that is at least 25% higher than the affinity with which the TMMP binds a second T cell, wherein the first T cell expresses on its surface the cognate co-immunomodulatory polypeptide and a TCR that binds the epitope with an affinity of at least 10<sup>&#x2212;7 </sup>M, and wherein the second T cell expresses on its surface the cognate co-immunomodulatory polypeptide but does not express on its surface a TCR that binds the epitope with an affinity of at least 10<sup>&#x2212;7 </sup>M; and/or ii) the ratio of the binding affinity of a control TMMP, wherein the control comprises a wild-type immunomodulatory polypeptide, to a cognate co-immunomodulatory polypeptide to the binding affinity of the TMMP comprising a variant of the wild-type immunomodulatory polypeptide to the cognate co-immunomodulatory polypeptide, when measured by bio-layer interferometry, is in a range of from 1.5:1 to 10<sup>6</sup>:1; and wherein the variant immunomodulatory polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions compared to the amino acid sequence of the corresponding wild-type immunomodulatory polypeptide; and</p><p id="p-0216" num="0188">wherein the first polypeptide and/or the second polypeptide comprises an Ig Fc polypeptide or a non-Ig scaffold; or</p><p id="p-0217" num="0189">C) a heterodimer comprising: a) a first polypeptide comprising, in order from N-terminus to C-terminus: i) an epitope; ii) a first MHC polypeptide; and b) a second polypeptide comprising, in order from N-terminus to C-terminus: i) a second MHC polypeptide; and ii) optionally an immunoglobulin (Ig) Fc polypeptide or a non-Ig scaffold, wherein the TMMP comprises one or more immunomodulatory domains that can be the same or different, wherein at least one of the one or more immunomodulatory domain is A) at the C-terminus of the first polypeptide; B) at the N-terminus of the second polypeptide; C) at the C-terminus of the second polypeptide; or D) at the C-terminus of the first polypeptide and at the N-terminus of the second polypeptide, and wherein at least one of the one or more immunomodulatory domains may be a wild-type immunomodulatory polypeptide or a variant of a wild-type immunomodulatory polypeptide, wherein the variant immunomodulatory polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions compared to the amino acid sequence of the corresponding wild-type immunomodulatory polypeptide; and</p><p id="p-0218" num="0190">optionally wherein at least one of the one or more immunomodulatory domains is a variant immunomodulatory polypeptide that exhibits reduced affinity to a cognate co-immunomodulatory polypeptide compared to the affinity of a corresponding wild-type immunomodulatory polypeptide for the cognate co-immunomodulatory polypeptide, and wherein the epitope binds to a TCR on a T cell with an affinity of at least 10<sup>&#x2212;7 </sup>M, such that: i) the TMMP binds to a first T cell with an affinity that is at least 25% higher than the affinity with which the TMMP binds a second T cell, wherein the first T cell expresses on its surface the cognate co-immunomodulatory polypeptide and a TCR that binds the epitope with an affinity of at least 10<sup>&#x2212;7 </sup>M, and wherein the second T cell expresses on its surface the cognate co-immunomodulatory polypeptide but does not express on its surface a TCR that binds the epitope with an affinity of at least 10<sup>&#x2212;7 </sup>M; and/or ii) the ratio of the binding affinity of a control TMMP, wherein the control comprises a wild-type immunomodulatory polypeptide, to a cognate co-immunomodulatory polypeptide to the binding affinity of the TMMP comprising a variant of the wild-type immunomodulatory polypeptide to the cognate co-immunomodulatory polypeptide, when measured by bio-layer interferometry, is in a range of from 1.5:1 to 10<sup>6</sup>:1; and wherein the variant immunomodulatory polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions compared to the amino acid sequence of the corresponding wild-type immunomodulatory polypeptide.</p><p id="p-0219" num="0191">In some cases, the epitope present in a TMMP binds to a TCR on a T cell with an affinity of from about 10<sup>&#x2212;4 </sup>M to about 5&#xd7;10<sup>&#x2212;4 </sup>M, from about 5&#xd7;10<sup>&#x2212;4 </sup>M to about 10<sup>&#x2212;5 </sup>M, from about 10<sup>&#x2212;5 </sup>M to 5&#xd7;10<sup>&#x2212;5 </sup>M, from about 5&#xd7;10<sup>&#x2212;5 </sup>M to 10<sup>&#x2212;6 </sup>M, from about 10<sup>&#x2212;6 </sup>M to about 5&#xd7;10<sup>&#x2212;6 </sup>M, from about 5&#xd7;10<sup>&#x2212;6 </sup>M to about 10<sup>&#x2212;7 </sup>M, from about 10<sup>&#x2212;7 </sup>M to about 5&#xd7;10<sup>&#x2212;7 </sup>M, from about 5&#xd7;10<sup>&#x2212;7 </sup>M to about 10<sup>&#x2212;8 </sup>M, or from about 10<sup>&#x2212;8</sup>M to about 10<sup>&#x2212;9 </sup>M. Expressed another way, in some cases, the epitope present in a TMMP of the present disclosure binds to a TCR on a T cell with an affinity of from about 1 nM to about 5 nM, from about 5 nM to about 10 nM, from about 10 nM to about 50 nM, from about 50 nM to about 100 nM, from about 0.1 &#x3bc;M to about 0.5 &#x3bc;M, from about 0.5 &#x3bc;M to about 1 &#x3bc;M, from about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><p id="p-0220" num="0192">In some cases, an immunomodulatory polypeptide present in a TMMP comprises a wild-type (naturally-occurring) amino acid sequence.</p><p id="p-0221" num="0193">In some cases, an immunomodulatory polypeptide present in a TMMP binds to its cognate co-immunomodulatory polypeptide with an affinity that it at least 10% less, at least 15% less, at least 20% less, at least 25% less, at least 30% less, at least 35% less, at least 40% less, at least 45% less, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than the affinity of a corresponding wild-type immunomodulatory polypeptide for the cognate co-immunomodulatory polypeptide.</p><p id="p-0222" num="0194">In some cases, a variant immunomodulatory polypeptide present in a TMMP has a binding affinity for a cognate co-immunomodulatory polypeptide that is from 1 nM to 100 nM, or from 100 nM to 100 &#x3bc;M. For example, in some cases, a variant immunomodulatory polypeptide present in a TMMP has a binding affinity for a cognate co-immunomodulatory polypeptide that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M. In some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure has a binding affinity for a cognate co-immunomodulatory polypeptide that is from about 1 nM to about 5 nM, from about 5 nM to about 10 nM, from about 10 nM to about 50 nM, from about 50 nM to about 100 nM</p><p id="p-0223" num="0195">The combination of the reduced affinity of the immunomodulatory polypeptide for its cognate co-immunomodulatory polypeptide, and the affinity of the epitope for a TCR, provides for enhanced selectivity of a TMMP. For example, in some cases, a TMMP binds selectively to a first T cell that displays both: i) a TCR specific for the epitope present in the TMMP; and ii) a co-immunomodulatory polypeptide that binds to the immunomodulatory polypeptide present in the TMMP, compared to binding to a second T cell that displays: i) a TCR specific for an epitope other than the epitope present in the TMMP; and ii) a co-immunomodulatory polypeptide that binds to the immunomodulatory polypeptide present in the TMMP. For example, in some cases, a TMMP binds to the first T cell with an affinity that is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2-fold, at least 2.5-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, at least 100-fold, or more than 100-fold, higher than the affinity to which it binds the second T cell.</p><p id="p-0224" num="0196">In some cases, a TMMP, when administered to an individual in need thereof, induces both an epitope-specific T cell response and an epitope non-specific T cell response. In other words, in some cases, a TMMP, when administered to an individual in need thereof, induces an epitope-specific T cell response by modulating the activity of a first T cell that displays both: i) a TCR specific for the epitope present in the TMMP; ii) a co-immunomodulatory polypeptide that binds to the immunomodulatory polypeptide present in the TMMP; and induces an epitope non-specific T cell response by modulating the activity of a second T cell that displays: i) a TCR specific for an epitope other than the epitope present in the TMMP; and ii) a co-immunomodulatory polypeptide that binds to the immunomodulatory polypeptide present in the TMMP. The ratio of the epitope-specific T cell response to the epitope-non-specific T cell response is at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, or at least 100:1. The ratio of the epitope-specific T cell response to the epitope-non-specific T cell response is from about 2:1 to about 5:1, from about 5:1 to about 10:1, from about 10:1 to about 15:1, from about 15:1 to about 20:1, from about 20:1 to about 25:1, from about 25:1 to about 50:1, or from about 50:1 to about 100:1, or more than 100:1. &#x201c;Modulating the activity&#x201d; of a T cell can include one or more of: i) activating a cytotoxic (e.g., CD8<sup>+</sup>) T cell; ii) inducing cytotoxic activity of a cytotoxic (e.g., CD8<sup>+</sup>) T cell; iii) inducing production and release of a cytotoxin (e.g., a perforin; a granzyme; a granulysin) by a cytotoxic (e.g., CD8<sup>+</sup>) T cell; iv) inhibiting activity of an autoreactive T cell; and the like.</p><p id="p-0225" num="0197">The combination of the reduced affinity of the immunomodulatory polypeptide for its cognate co-immunomodulatory polypeptide, and the affinity of the epitope for a TCR, provides for enhanced selectivity of a TMMP. Thus, for example, a TMMP binds with higher avidity to a first T cell that displays both: i) a TCR specific for the epitope present in the TMMP; and ii) a co-immunomodulatory polypeptide that binds to the immunomodulatory polypeptide present in the TMMP, compared to the avidity to which it binds to a second T cell that displays: i) a TCR specific for an epitope other than the epitope present in the TMMP; and ii) a co-immunomodulatory polypeptide that binds to the immunomodulatory polypeptide present in the TMMP.</p><p id="p-0226" num="0198">Binding affinity between an immunomodulatory polypeptide and its cognate co-immunomodulatory polypeptide can be determined by bio-layer interferometry (BLI) using purified immunomodulatory polypeptide and purified cognate co-immunomodulatory polypeptide. Binding affinity between a TMMP and its cognate co-immunomodulatory polypeptide can be determined by BLI using purified TMMP and the cognate co-immunomodulatory polypeptide. BLI methods are well known to those skilled in the art. See, e.g., Lad et al. (2015) <i>J. Biomol. Screen. </i>20(4):498-507; and Shah and Duncan (2014) <i>J. Vis. Exp. </i>18:e51383.</p><p id="p-0227" num="0199">A BLI assay can be carried out using an Octet RED 96 (Pal Fort&#xe9;Bio) instrument, or a similar instrument, as follows. A TMMP (e.g., a TMMP of the present disclosure; a control TMMP (where a control TMMP comprises a wild-type immunomodulatory polypeptide)) is immobilized onto an insoluble support (a &#x201c;biosensor&#x201d;). The immobilized TMMP is the &#x201c;target&#x201d; Immobilization can be effected by immobilizing a capture antibody onto the insoluble support, where the capture antibody immobilizes the TMMP. For example, immobilization can be effected by immobilizing anti-Fc (e.g., anti-human IgG Fc) antibodies onto the insoluble support, where the immobilized anti-Fc antibodies bind to and immobilize the TMMP (where the TMMP comprises an IgFc polypeptide). A co-immunomodulatory polypeptide is applied, at several different concentrations, to the immobilized TMMP, and the instrument's response recorded. Assays are conducted in a liquid medium comprising 25 mM HEPES pH 6.8, 5% poly(ethylene glycol) 6000, 50 mM KCl, 0.1% bovine serum albumin, and 0.02% Tween 20 nonionic detergent. Binding of the co-immunomodulatory polypeptide to the immobilized TMMP is conducted at 30&#xb0; C. As a positive control for binding affinity, an anti-MHC Class I monoclonal antibody can be used. For example, anti-HLA Class I monoclonal antibody W6/32 (American Type Culture Collection No. HB-95; Parham et al. (1979) <i>J. Immunol. </i>123:342), which has a K<sub>D </sub>of 7 nM, can be used. A standard curve can be generated using serial dilutions of the anti-MHC Class I monoclonal antibody. The co-immunomodulatory polypeptide, or the anti-MHC Class I mAb, is the &#x201c;analyte.&#x201d; BLI analyzes the interference pattern of white light reflected from two surfaces: i) from the immobilized polypeptide (&#x201c;target&#x201d;); and ii) an internal reference layer. A change in the number of molecules (&#x201c;analyte&#x201d;; e.g., co-immunomodulatory polypeptide; anti-HLA antibody) bound to the biosensor tip causes a shift in the interference pattern; this shift in interference pattern can be measured in real time. The two kinetic terms that describe the affinity of the target/analyte interaction are the association constant (k<sub>a</sub>) and dissociation constant (k<sub>d</sub>). The ratio of these two terms (k<sub>d/a</sub>) gives rise to the affinity constant K<sub>D</sub>.</p><p id="p-0228" num="0200">The BLI assay is carried out in a multi-well plate. To run the assay, the plate layout is defined, the assay steps are defined, and biosensors are assigned in Octet Data Acquisition software. The biosensor assembly is hydrated. The hydrated biosensor assembly and the assay plate are equilibrated for 10 minutes on the Octet instrument. Once the data are acquired, the acquired data are loaded into the Octet Data Analysis software. The data are processed in the Processing window by specifying method for reference subtraction, y-axis alignment, inter-step correction, and Savitzky-Golay filtering. Data are analyzed in the Analysis window by specifying steps to analyze (Association and Dissociation), selecting curve fit model (1:1), fitting method (global), and window of interest (in seconds). The quality of fit is evaluated. K<sub>D </sub>values for each data trace (analyte concentration) can be averaged if within a 3-fold range. K<sub>D </sub>error values should be within one order of magnitude of the affinity constant values; R<sup>2 </sup>values should be above 0.95. See, e.g., Abdiche et al. (2008) <i>J. Anal. Biochem. </i>377:209.</p><p id="p-0229" num="0201">Unless otherwise stated herein, the affinity of a TMMP for a cognate co-immunomodulatory polypeptide, or the affinity of a control TMMP (where a control TMMP comprises a wild-type immunomodulatory polypeptide) for a cognate co-immunomodulatory polypeptide, is determined using BLI, as described above.</p><p id="p-0230" num="0202">In some cases, the ratio of: i) the binding affinity of a control TMMP (where the control comprises a wild-type immunomodulatory polypeptide) to a cognate co-immunomodulatory polypeptide to ii) the binding affinity of a TMMP of the present disclosure comprising a variant of the wild-type immunomodulatory polypeptide to the cognate co-immunomodulatory polypeptide, when measured by BLI (as described above), is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at least 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1. In some cases, the ratio of: i) the binding affinity of a control TMMP (where the control comprises a wild-type immunomodulatory polypeptide) to a cognate co-immunomodulatory polypeptide to ii) the binding affinity of a TMMP comprising a variant of the wild-type immunomodulatory polypeptide to the cognate co-immunomodulatory polypeptide, when measured by BLI, is in a range of from 1.5:1 to 10<sup>6</sup>:1, e.g., from 1.5:1 to 10:1, from 10:1 to 50:1, from 50:1 to 10<sup>2</sup>:1, from 10<sup>2</sup>:1 to 10<sup>3</sup>:1, from 10<sup>3</sup>:1 to 10<sup>4</sup>:1, from 10<sup>4</sup>:1 to 10<sup>5</sup>:1, or from 10<sup>5</sup>:1 to 10<sup>6</sup>:1.</p><p id="p-0231" num="0203">As an example, where a control TMMP comprises a wild-type IL-2 polypeptide, and where a TMMP comprises a variant IL-2 polypeptide (comprising from 1 to 10 amino acid substitutions relative to the amino acid sequence of the wild-type IL-2 polypeptide) as the immunomodulatory polypeptide, the ratio of: i) the binding affinity of the control TMMP to an IL-2 receptor (i.e., the cognate co-immunomodulatory polypeptide) to ii) the binding affinity of the TMMP of the present disclosure to the IL-2 receptor, when measured by BLI, is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at least 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1. In some cases, where a control TMMP comprises a wild-type IL-2 polypeptide, and where a TMMP comprises a variant IL-2 polypeptide (comprising from 1 to 10 amino acid substitutions relative to the amino acid sequence of the wild-type IL-2 polypeptide) as the immunomodulatory polypeptide, the ratio of: i) the binding affinity of the control TMMP to an IL-2 receptor (i.e., the cognate co-immunomodulatory polypeptide) to ii) the binding affinity of the TMMP to the IL-2 receptor, when measured by BLI, is in a range of from 1.5:1 to 10<sup>6</sup>:1, e.g., from 1.5:1 to 10:1, from 10:1 to 50:1, from 50:1 to 10<sup>2</sup>:1, from 10<sup>2</sup>:1 to 10<sup>3</sup>:1, from 10<sup>3</sup>:1 to 10<sup>4</sup>:1, from 10<sup>4</sup>:1 to 10<sup>5</sup>:1, or from 10<sup>5</sup>:1 to 10<sup>6</sup>:1.</p><p id="p-0232" num="0204">As another example, where a control TMMP comprises a wild-type CD80 polypeptide, and where a TMMP of the present disclosure comprises a variant CD80 polypeptide (comprising from 1 to 10 amino acid substitutions relative to the amino acid sequence of the wild-type CD80 polypeptide) as the immunomodulatory polypeptide, the ratio of: i) the binding affinity of the control TMMP to a CTLA4 polypeptide (i.e., the cognate co-immunomodulatory polypeptide) to ii) the binding affinity of the TMMP of the present disclosure to the CTLA4 polypeptide, when measured by BLI, is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at least 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1.</p><p id="p-0233" num="0205">As another example, where a control TMMP comprises a wild-type CD80 polypeptide, and where a TMMP of the present disclosure comprises a variant CD80 polypeptide (comprising from 1 to 10 amino acid substitutions relative to the amino acid sequence of the wild-type CD80 polypeptide) as the immunomodulatory polypeptide, the ratio of: i) the binding affinity of the control TMMP to a CD28 polypeptide (i.e., the cognate co-immunomodulatory polypeptide) to ii) the binding affinity of the TMMP of the present disclosure to the CD28 polypeptide, when measured by BLI, is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at least 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1.</p><p id="p-0234" num="0206">As another example, where a control TMMP comprises a wild-type 4-1BBL polypeptide, and where a TMMP of the present disclosure comprises a variant 4-1BBL polypeptide (comprising from 1 to 10 amino acid substitutions relative to the amino acid sequence of the wild-type 4-1BBL polypeptide) as the immunomodulatory polypeptide, the ratio of: i) the binding affinity of the control TMMP to a 4-1BB polypeptide (i.e., the cognate co-immunomodulatory polypeptide) to ii) the binding affinity of the TMMP of the present disclosure to the 4-1BB polypeptide, when measured by BLI, is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at least 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1.</p><p id="p-0235" num="0207">As another example, where a control TMMP comprises a wild-type CD86 polypeptide, and where a TMMP of the present disclosure comprises a variant CD86 polypeptide (comprising from 1 to 10 amino acid substitutions relative to the amino acid sequence of the wild-type CD86 polypeptide) as the immunomodulatory polypeptide, the ratio of: i) the binding affinity of the control TMMP to a CD28 polypeptide (i.e., the cognate co-immunomodulatory polypeptide) to ii) the binding affinity of the TMMP of the present disclosure to the CD28 polypeptide, when measured by BLI, is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at least 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1.</p><p id="p-0236" num="0208">Binding affinity of a TMMP of the present disclosure to a target T cell can be measured in the following manner A) contacting a TMMP of the present disclosure with a target T-cell expressing on its surface: i) a cognate co-immunomodulatory polypeptide that binds the parental wild-type immunomodulatory polypeptide; and ii) a T-cell receptor that binds to the epitope, where the TMMP comprises an epitope tag, such that the TMMP binds to the target T-cell; B) contacting the target T-cell-bound TMMP with a fluorescently labeled binding agent (e.g., a fluorescently labeled antibody) that binds to the epitope tag, generating a TMMP/target T-cell/binding agent complex; C) measuring the mean fluorescence intensity (MFI) of the TMMP/target T-cell/binding agent complex using flow cytometry. The epitope tag can be, e.g., a FLAG tag, a hemagglutinin tag, a c-myc tag, a poly(histidine) tag, etc. The MFI measured over a range of concentrations of the TMMP library member provides a measure of the affinity. The MFI measured over a range of concentrations of the TMMP library member provides a half maximal effective concentration (EC<sub>50</sub>) of the TMMP. In some cases, the EC<sub>50 </sub>of a TMMP of the present disclosure for a target T cell is in the nM range; and the EC<sub>50 </sub>of the TMMP for a control T cell (where a control T cell expresses on its surface: i) a cognate co-immunomodulatory polypeptide that binds the parental wild-type immunomodulatory polypeptide; and ii) a T-cell receptor that does not bind to the epitope present in the TMMP) is in the &#x3bc;M range. In some cases, the ratio of the EC<sub>50 </sub>of a TMMP of the present disclosure for a control T cell to the EC<sub>50 </sub>of the TMMP for a target T cell is at least 1.5:1, at least 2:1, at least 5:1, at least 10:1, at least 15:1, at least 20:1, at least 25:1, at least 50:1, at least 100:1, at least 500:1, at least 10<sup>2</sup>:1, at least 5&#xd7;10<sup>2</sup>:1, at least 10<sup>3</sup>:1, at least 5&#xd7;10<sup>3</sup>:1, at least 10<sup>4</sup>:1, at lease 10<sup>5</sup>:1, or at least 10<sup>6</sup>:1. The ratio of the EC<sub>50 </sub>of a TMMP of the present disclosure for a control T cell to the EC<sub>50 </sub>of the TMMP for a target T cell is an expression of the selectivity of the TMMP.</p><p id="p-0237" num="0209">In some cases, when measured as described in the preceding paragraph, a TMMP exhibits selective binding to target T-cell, compared to binding of the TMMP library member to a control T cell that comprises: i) the cognate co-immunomodulatory polypeptide that binds the parental wild-type immunomodulatory polypeptide; and ii) a T-cell receptor that binds to an epitope other than the epitope present in the TMMP library member.</p><heading id="h-0036" level="2">Epitopes</heading><p id="p-0238" num="0210">A peptide epitope present in a TMMP can have a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids in length (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 amino acids, from 6 to 18 amino acids, from 8 to 15 amino acids, from 8 to 12 amino acids, from 5 to 10 amino acids, from 10 to 20 amino acids, and from 15 to 25 amino acids in length).</p><p id="p-0239" num="0211">A TMMP can comprise any of a variety of peptide epitopes. As discussed above, a peptide epitope present in a TMMP is a peptide that, when complexed with MHC polypeptides, presents an epitope to a T-cell receptor (TCR). An epitope-specific T cell binds an epitope having a given amino acid sequence, i.e., a &#x201c;reference&#x201d; amino acid sequence, but substantially does not bind an epitope that differs from the reference amino acid sequence, or if it binds at all, binds an epitope that differs from the reference amino acid sequence with only low affinity, e.g., less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;5 </sup>M, or less than 10<sup>&#x2212;4 </sup>M. For example, an epitope-specific T cell binds an epitope that differs from the reference amino acid sequence, if at all, with an affinity that is less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;5 </sup>M, or less than 10<sup>&#x2212;4 </sup>M. An epitope-specific T cell can bind an epitope having a reference amino acid sequence, i.e., for which it is specific, with an affinity of at least 10<sup>&#x2212;7 </sup>M, at least 10<sup>&#x2212;8</sup>M, at least 10<sup>&#x2212;9 </sup>M, or at least 10<sup>&#x2212;10 </sup>M.</p><p id="p-0240" num="0212">In some cases, the epitope peptide present in a TMMP presents an epitope specific to an HLA-A, -B, -C, -E, -F, or -G allele. In an embodiment, the epitope peptide present in a TMMP presents an epitope restricted to HLA-A*0101, A*0201, A*0301, A*1101, A*2301, A*2402, A*2407, A*3303, and/or A*3401. In an embodiment, the epitope peptide present in a TMMP presents an epitope restricted to HLA-B*0702, B*0801, B*1502, B*3802, B*4001, B*4601, and/or B*5301. In an embodiment, the epitope peptide present in a TMMP presents an epitope restricted to C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*702, C*0801, and/or C*1502.</p><p id="p-0241" num="0213">In some cases, the peptide epitope is a viral epitope. In some cases, a viral epitope is an epitope present in a viral antigen encoded by a virus that infects a majority of the human population, where such viruses include, e.g., cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus, influenza virus, adenovirus, and the like. In some cases, the peptide epitope is a bacterial epitope, e.g., a bacterial epitope that is included in a vaccine and to which a majority of the human population has immunity.</p><heading id="h-0037" level="2">1) CMV Peptide Epitopes</heading><p id="p-0242" num="0214">In some cases, a TMMP comprises a CMV peptide epitope, i.e., a peptide that when in an MHC/peptide complex (e.g., an HLA/peptide complex), presents a CMV epitope (i.e., an epitope present in a CMV antigen) to a T cell. As with other peptide epitopes of this disclosure, a CMV peptide epitope has a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length).</p><p id="p-0243" num="0215">A given CMV epitope-specific T cell binds an epitope having a reference amino acid sequence of a given CMV epitope, but substantially does not bind an epitope that differs from the reference amino acid sequence, or if it binds at all, binds an epitope that differs from the reference amino acid sequence with only low affinity, e.g., less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;5 </sup>M, or less than 10<sup>&#x2212;4 </sup>M. For example, a given CMV epitope-specific T cell binds a CMV epitope having a reference amino acid sequence, and binds an epitope that differs from the reference amino acid sequence, if at all, with an affinity that is less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;5 </sup>M, or less than 10<sup>&#x2212;4 </sup>M. A given CMV epitope-specific T cell can bind an epitope for which it is specific with an affinity of at least 10<sup>&#x2212;7 </sup>M, at least 10<sup>&#x2212;8 </sup>M, at least 10<sup>&#x2212;9 </sup>M, or at least 10<sup>&#x2212;10 </sup>M.</p><p id="p-0244" num="0216">In some cases, a CMV peptide epitope present in a TMMP is a peptide from CMV pp65. In some cases, a CMV peptide epitope present in a TMMP is a peptide from CMV gB (glycoprotein B).</p><p id="p-0245" num="0217">For example, in some cases, a CMV peptide epitope present in a TMMP is a peptide of a CMV polypeptide having a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length), and comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following CMV pp65 amino acid sequence:</p><p id="p-0246" num="0000"><tables id="TABLE-US-00027" num="00027"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;123)</entry><entry/></row><row><entry>MESRGRRCPE&#x2003;MISVLGPISG&#x2003;HVLKAVFSRG&#x2003;DTPVLPHETR&#x2003;LLQTGIHVRV</entry><entry/></row><row><entry> </entry></row><row><entry>SQPSLILVSQ&#x2003;YTPDSTPCHR&#x2003;GDNQLQVQHT&#x2003;YFTGSEVENV&#x2003;SVNVHNPTGR&#x2003;SICPSQEPMS</entry></row><row><entry> </entry></row><row><entry>IYVYALPLKM&#x2003;LNIPSINVHH&#x2003;YPSAAERKHR&#x2003;HLPVADAVIH&#x2003;ASGKQMWQAR&#x2003;LTVSGLAWTR</entry></row><row><entry> </entry></row><row><entry>QQNQWKEPDV&#x2003;YYTSAFVFPT&#x2003;KDVALRHVVC&#x2003;AHELVCSMEN&#x2003;TRATKMQVIG&#x2003;DQYVKVYLES</entry></row><row><entry> </entry></row><row><entry>FCEDVPSGKL&#x2003;FMHVTLGSDV&#x2003;EEDLTMTRNP&#x2003;QPFMRPHERN&#x2003;GFTVLCPKNM&#x2003;IIKPGKISHI</entry></row><row><entry> </entry></row><row><entry>MLDVAFTSHE&#x2003;HFGLLCPKSI&#x2003;PGLSISGNLL&#x2003;MNGQQIFLEV&#x2003;QAIRETVELR&#x2003;QYDPVAALFF</entry></row><row><entry> </entry></row><row><entry>FDIDLLLQRG&#x2003;PQYSEHPTFT&#x2003;SQYRIQGKLE&#x2003;YRHTWDRHDE&#x2003;GAAQGDDDVW&#x2003;TSGSDSDEEL</entry></row><row><entry> </entry></row><row><entry>VTTERKTPRV&#x2003;TGGGAMAGAS&#x2003;TSAGRKRKSA&#x2003;SSATACTSGV&#x2003;MTRGRLKAES&#x2003;TVAPEEDTDE</entry></row><row><entry> </entry></row><row><entry>DSDNEIHNPA&#x2003;VFTWPPWQAG&#x2003;ILARNLVPMV&#x2003;ATVQGQNLKY&#x2003;QEFFWDANDI&#x2003;YRIFAELEGV</entry></row><row><entry> </entry></row><row><entry>WQPAAQPKRR&#x2003;RHRQDALPGP&#x2003;CIASTPKKHR&#x2003;G.</entry></row></tbody></tgroup></table></tables></p><p id="p-0247" num="0218">As one non-limiting example, a CMV peptide epitope present in a TMMP has the amino acid sequence NLVPMVATV (SEQ ID NO:172) and has a length of 9 amino acids.</p><p id="p-0248" num="0219">In some cases, a CMV peptide epitope present in a TMMP is a peptide having a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length) of a CMV polypeptide comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following CMV gB amino acid sequence:</p><p id="p-0249" num="0000"><tables id="TABLE-US-00028" num="00028"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;173)</entry><entry/></row><row><entry>MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQ</entry><entry/></row><row><entry> </entry></row><row><entry>HVTSSEAVSHRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINED</entry></row><row><entry> </entry></row><row><entry>LDEGIMVVYKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQ</entry></row><row><entry> </entry></row><row><entry>CYSSYSRVIGGTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCN</entry></row><row><entry> </entry></row><row><entry>LNCMLTITTARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPN</entry></row><row><entry> </entry></row><row><entry>AAPETHRLVAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSK</entry></row><row><entry> </entry></row><row><entry>KQEVNMSDSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVE</entry></row><row><entry> </entry></row><row><entry>LERLANRSSLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAW</entry></row><row><entry> </entry></row><row><entry>CVDQRRTLEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESP</entry></row><row><entry> </entry></row><row><entry>GRCYSRPVVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRM</entry></row><row><entry> </entry></row><row><entry>IDLSSISTVDSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRVKYVEDKVV</entry></row><row><entry> </entry></row><row><entry>DPLPPYLKGLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVII</entry></row><row><entry> </entry></row><row><entry>TYLIYTRQRRLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSD</entry></row><row><entry> </entry></row><row><entry>ASTAAPPYTNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNG</entry></row><row><entry> </entry></row><row><entry>YRHLKDSDEEENV.</entry></row></tbody></tgroup></table></tables></p><p id="p-0250" num="0220">In some cases, the CMV epitope present in a TMMP presents an epitope specific to an HLA-A, -B, -C, -E, -F, or -G allele. In some cases, the epitope peptide present in a TMMP presents an epitope restricted to HLA-A*0101, A*0201, A*0301, A*1101, A*2301, A*2402, A*2407, A*3303, and/or A*3401. In some cases, the CMV epitope present in a TMMP presents an epitope restricted to HLA-B*0702, B*0801, B*1502, B*3802, B*4001, B*4601, and/or B*5301. In some cases, the CMV epitope present in a TMMP presents an epitope restricted to C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*702, C*0801, and/or C*1502. As one example, in some cases, a TMMP comprises: a) a CMV peptide epitope having amino acid sequence NLVPMVATV (SEQ ID NO:172) and having a length of 9 amino acids; b) an HLA-A*0201 class I heavy chain polypeptide; and c) a &#x3b2;2M polypeptide.</p><heading id="h-0038" level="2">2) HPV Epitopes</heading><p id="p-0251" num="0221">An HPV peptide suitable for inclusion in a TMMP can be a peptide of an HPV E6 polypeptide or an HPV E7 polypeptide. The HPV epitope can be an epitope of HPV of any of a variety of genotypes, including, e.g., HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV68, HPV73, or HPV82. In some cases, the epitope is an HPV E6 epitope. In some cases, the epitope is an HPV E7 epitope.</p><p id="p-0252" num="0222">An HPV epitope present in a TMMP is a peptide specifically bound by a T-cell, i.e., the epitope is specifically bound by an HPV epitope-specific T cell. An epitope-specific T cell binds an epitope having a reference amino acid sequence, but substantially does not bind an epitope that differs from the reference amino acid sequence, or if it binds at all, binds an epitope that differs from the reference amino acid sequence with only low affinity, e.g., less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;5 </sup>M, or less than 10<sup>&#x2212;4 </sup>M. For example, an epitope-specific T cell binds an epitope having a reference amino acid sequence, and binds an epitope that differs from the reference amino acid sequence, if at all, with an affinity that is less than 10<sup>&#x2212;6 </sup>M, less than 10<sup>&#x2212;5 </sup>M, or less than 10<sup>&#x2212;4 </sup>M. An epitope-specific T cell can bind an epitope for which it is specific with an affinity of at least 10<sup>&#x2212;7 </sup>M, at least 10<sup>&#x2212;8</sup>M, at least 10<sup>&#x2212;9 </sup>M, or at least 10<sup>&#x2212;10 </sup>M.</p><p id="p-0253" num="0223">Examples of HPV E6 peptides suitable for inclusion in a TMMP include, but are not limited to, E6 18-26 (KLPQLCTEL; SEQ ID NO:124); E6 26-34 (LQTTIHDII; SEQ ID NO:125); E6 49-57 (VYDFAFRDL; SEQ ID NO:126); E6 52-60 (FAFRDLCIV; SEQ ID NO:127); E6 75-83 (KFYSKISEY; SEQ ID NO:128); and E6 80-88 (ISEYRHYCY; SEQ ID NO:129).</p><p id="p-0254" num="0224">Examples of HPV E7 peptides suitable for inclusion in a TMMP include, but are not limited to, E7 7-15 (TLHEYMLDL; SEQ ID NO:130); E7 11-19 (YMLDLQPET; SEQ ID NO:131); E7 44-52 (QAEPDRAHY; SEQ ID NO:132); E7 49-57 (RAHYNIVTF (SEQ ID NO:132); E7 61-69 (CDSTLRLCV; SEQ ID NO:133); and E7 67-76 (LCVQSTHVDI; SEQ ID NO:134); E7 82-90 (LLMGTLGIV; SEQ ID NO:135); E7 86-93 (TLGIVCPI; SEQ ID NO:136); and E7 92-93 (LLMGTLGIVCPI; SEQ ID NO:137).</p><p id="p-0255" num="0225">In some cases, a suitable HPV peptide is an HPV E6 peptide that binds HLA-A24 (e.g., is an HLA-A2401-restricted epitope). Non-limiting examples include: VYDFAFRDL (SEQ ID NO:126); CYSLYGTTL (SEQ ID NO:139); EYRHYCYSL (SEQ ID NO:140); KLPQLCTEL (SEQ ID NO:124); DPQERPRKL (SEQ ID NO:141); HYCYSLYGT (SEQ ID NO:142); DFAFRDLCI (SEQ ID NO:143); LYGTTLEQQY (SEQ ID NO:144); HYCYSLYGTT (SEQ ID NO:145); EVYDFAFRDL (SEQ ID NO:146); EYRHYCYSLY (SEQ ID NO:147); VYDFAFRDLC (SEQ ID NO:148); YCYSIYGTTL (SEQ ID NO:149); VYCKTVLEL (SEQ ID NO:150); VYGDTLEKL (SEQ ID NO:151); and LTNTGLYNLL (SEQ ID NO:152).</p><p id="p-0256" num="0226">In some cases, a suitable HPV peptide is selected from the group consisting of: DLQPETTDL (SEQ ID NO:153); TLHEYMLDL (SEQ ID NO:130); TPTLHEYML (SEQ ID NO:154); RAHYNIVTF (SEQ ID NO:133); GTLGIVCPI (SEQ ID NO:155); EPDRAHYNI (SEQ ID NO:156); QLFLNTLSF (SEQ ID NO:157); FQQLFLNTL (SEQ ID NO:158); and AFQQLFLNTL (SEQ ID NO:159).</p><p id="p-0257" num="0227">In some cases, a suitable HPV peptide presents an HLA-A*2401-restricted epitope. Non-limiting examples of HPV peptides presenting an HLA-A*2401-restricted epitope are: VYDFAFRDL (SEQ ID NO:126); RAHYNIVTF (SEQ ID NO:133); CDSTLRLCV (SEQ ID NO:134); and LCVQSTHVDI (SEQ ID NO:135). In some cases, an HPV peptide suitable for inclusion in a TMMP is VYDFAFRDL (SEQ ID NO:126). In some cases, an HPV peptide suitable for inclusion in a TMMP is RAHYNIVTF (SEQ ID NO:133). In some cases, an HPV peptide suitable for inclusion in a TMMP is CDSTLRLCV (SEQ ID NO:134). In some cases, an HPV peptide suitable for inclusion in a TMMP is LCVQSTHVDI (SEQ ID NO:135).</p><heading id="h-0039" level="2">3) Influenza Virus Epitopes</heading><p id="p-0258" num="0228">Influenza virus peptides that are suitable for inclusion as a peptide epitope of a TMMP include peptides of from 4 amino acids to 25 amino acids in length of an influenza polypeptide, e.g., an influenza polypeptide that is included in a vaccine, or that is present in an influenza virus that infects a human. As one example, a peptide suitable for inclusion as a peptide epitope of a TMMP is an influenza virus peptide of from 4 amino acids to 25 amino acids in length of an influenza virus nucleoprotein. As another example, a peptide suitable for inclusion as a peptide epitope of a TMMP is a peptide of from 4 amino acids to 25 amino acids in length of an influenza virus hemagglutinin polypeptide. As another example, a peptide suitable for inclusion as a peptide epitope of a TMMP is a peptide of from 4 amino acids to 25 amino acids in length of an influenza A virus Matrix protein 1. As another example, a peptide suitable for inclusion as a peptide epitope of a TMMP is a peptide of from 4 amino acids to 25 amino acids in length of an influenza virus neuraminidase polypeptide. In some cases, the peptide is a peptide that presents an immunodominant influenza virus protein epitope. One non-limiting example of a suitable influenza peptide is a peptide having the sequence GILGFVFTL (SEQ ID NO:160) and having a length of 9 amino acids.</p><heading id="h-0040" level="2">4) Tetanus Epitopes</heading><p id="p-0259" num="0229">Tetanus peptides that are suitable for inclusion as a peptide epitope of a TMMP include peptides of from 4 amino acids to 25 amino acids in length of a tetanus toxin. Examples of suitable tetanus peptides include, but are not limited to, QYIKANSKFIGIFE (SEQ ID NO:161); QYIKANSKFIGITE (SEQ ID NO:162); ILMQYIKANSKFIGI (SEQ ID NO:163); VNNESSE (SEQ ID NO:164); PGINGKAIHLVNNESSE (SEQ ID NO:165); PNRDIL (SEQ ID NO:166); FIGITEL (SEQ ID NO:167); SYFPSV (SEQ ID NO:168); NSVDDALINSTKIYSYFPSV (SEQ ID NO:169); and IDKISDVSTIVPYIGPALNI (SEQ ID NO:170).</p><heading id="h-0041" level="2">MHC Polypeptides</heading><p id="p-0260" num="0230">As noted above, a TMMP includes MHC polypeptides. For the purposes of the instant disclosure, the term &#x201c;major histocompatibility complex (MHC) polypeptides&#x201d; is meant to include MHC polypeptides of various species, including human MHC (also referred to as human leukocyte antigen (HLA)) polypeptides, rodent (e.g., mouse, rat, etc.) MHC polypeptides, and MHC polypeptides of other mammalian species (e.g., lagomorphs, non-human primates, canines, felines, ungulates (e.g., equines, bovines, ovines, caprines, etc.), and the like. The term &#x201c;MHC polypeptide&#x201d; is meant to include Class I MHC polypeptides (e.g., 13-2 microglobulin and MHC class I heavy chain).</p><p id="p-0261" num="0231">In some cases, the first MHC polypeptide is an MHC Class I &#x3b2;2M (&#x3b2;2M) polypeptide, and the second MHC polypeptide is an MHC Class I heavy chain (H chain) (&#x201c;MHC-H&#x201d;)). In other instances, the first MHC polypeptide is an MHC Class I heavy chain polypeptide; and the second MHC polypeptide is a &#x3b2;2M polypeptide. In some cases, both the &#x3b2;2M and MHC-H chain are of human origin; i.e., the MHC-H chain is an HLA heavy chain, or a variant thereof. Unless expressly stated otherwise, a TMMP of the present disclosure does not include membrane anchoring domains (transmembrane regions) of an MHC Class I heavy chain, or a part of MHC Class I heavy chain sufficient to anchor the resulting TMMP to a cell (e.g., eukaryotic cell such as a mammalian cell) in which it is expressed. In some cases, the MHC Class I heavy chain present in a TMMP of the present disclosure does not include a signal peptide, a transmembrane domain, or an intracellular domain (cytoplasmic tail) associated with a native MHC Class I heavy chain. Thus, e.g., in some cases, the MHC Class I heavy chain present in a TMMP of the present disclosure includes only the &#x3b1;1, &#x3b1;2, and &#x3b1;3 domains of an MHC Class I heavy chain. In some cases, the MHC Class I heavy chain present in a TMMP of the present disclosure has a length of from about 270 amino acids (aa) to about 290 aa. In some cases, the MHC Class I heavy chain present in a TMMP of the present disclosure has a length of 270 aa, 271 aa, 272 aa, 273 aa, 274 aa, 275 aa, 276 aa, 277 aa, 278 aa, 279 aa, 280 aa, 281 aa, 282 aa, 283 aa, 284 aa, 285 aa, 286 aa, 287 aa, 288 aa, 289 aa, or 290 aa.</p><p id="p-0262" num="0232">In some cases, an MHC polypeptide of a TMMP is a human MHC polypeptide, where human MHC polypeptides are also referred to as &#x201c;human leukocyte antigen&#x201d; (&#x201c;HLA&#x201d;) polypeptides. In some cases, an MHC polypeptide of a TMMP is a Class I HLA polypeptide, e.g., a &#x3b2;2-microglobulin polypeptide, or a Class I HLA heavy chain polypeptide. Class I HLA heavy chain polypeptides include HLA-A heavy chain polypeptides, HLA-B heavy chain polypeptides, HLA-C heavy chain polypeptides, HLA-E heavy chain polypeptides, HLA-F heavy chain polypeptides, and HLA-G heavy chain polypeptides.</p><heading id="h-0042" level="2">MHC Class I Heavy Chains</heading><p id="p-0263" num="0233">In some cases, an MHC Class I heavy chain polypeptide present in a TMMP of the present disclosure comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of the amino acid sequence of any of the human HLA heavy chain polypeptides depicted in <figref idref="DRAWINGS">FIGS. <b>5</b>-<b>11</b></figref>. In some cases, the MHC Class I heavy chain has a length of 270 aa, 271 aa, 272 aa, 273 aa, 274 aa, 275 aa, 276 aa, 277 aa, 278 aa, 279 aa, 280 aa, 281 aa, 282 aa, 283 aa, 284 aa, 285 aa, 286 aa, 287 aa, 288 aa, 289 aa, or 290 aa. In some cases, an MHC Class I heavy chain polypeptide present in a TMMP of the present disclosure comprises 1-30, 1-5, 5-10, 10-15, 15-20, 20-25 or 25-30 amino acid insertions, deletions, and/or substitutions (in addition to those locations indicated as being variable in the heavy chain consensus sequences) of any one of the amino acid sequences depicted in <figref idref="DRAWINGS">FIGS. <b>5</b>-<b>11</b></figref>. In some cases, the MHC Class I heavy chain does not include transmembrane or cytoplasmic domains. As an example, a MHC Class I heavy chain polypeptide of a TMMP of the present disclosure can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to amino acids 25-300 (lacking all, or substantially all, of the leader, transmembrane and cytoplasmic sequence) or amino acids 25-365 (lacking the leader) of a human HLA-A heavy chain polypeptides depicted in any one of <figref idref="DRAWINGS">FIGS. <b>5</b>A, <b>5</b>B, and <b>5</b>C</figref>.</p><p id="p-0264" num="0234"><figref idref="DRAWINGS">FIGS. <b>5</b>A, <b>5</b>B and <b>5</b>C</figref> provide amino acid sequences of human leukocyte antigen (HLA) Class I heavy chain polypeptides. Signal sequences, amino acids 1-24, are bolded and underlined. <figref idref="DRAWINGS">FIG. <b>5</b>A</figref> entry: 3A.1 is the HLA-A heavy chain (HLA-A*01:01:01:01 or A*0101) (NCBI accession NP_001229687.1), SEQ ID NO:392; entry 3A.2 is from HLA-A*1101 SEQ ID NO:393; entry 3A.3 is from HLA-A*2402 SEQ ID NO:394 and entry 3A.4 is from HLA-A*3303 SEQ ID NO:395. <figref idref="DRAWINGS">FIG. <b>5</b>B</figref> provides the sequence HLA-B*07:02:01 (HLA-B*0702) NCBI GenBank Accession NP_005505.2 (see also GenBank Accession AUV50118.1.). <figref idref="DRAWINGS">FIG. <b>5</b>C</figref> provides the sequence HLA-C*0701 (GenBank Accession NP_001229971.1) (HLA-C*07:01:01:01 or HLA-Cw*070101, HLA-Cw*07 see GenBank Accession CA078194.1).</p><p id="p-0265" num="0235"><figref idref="DRAWINGS">FIG. <b>6</b></figref> provides an alignment of eleven mature MHC class I heavy chain amino acid sequences without their leader sequences or transmembrane domains or intracellular domains. The aligned sequences are human HLA-A, HLA-B, and HLA-C, a mouse H2K protein sequence, three variants of HLA-A (var.1, var. 2C, and var.2CP), and 3 human HLA-A variants (HLA-A*1101; HLA-A*2402; and HLA-A*3303). Indicated in the alignment are the locations (84 and 139 of the mature proteins) where cysteine residues may be introduced (e.g., by substitution) for the formation of a disulfide bond to stabilize the MHC H chain&#x2014;&#x3b2;2M complex. Also shown in the alignment is position 236 (of the mature polypeptide), which may be substituted by a cysteine residue that can form an inter-chain disulfide bond with &#x3b2;2M (e.g., at aa 12). An arrow appears above each of those locations and the residues are bolded. The seventh HLA-A sequence shown in the alignment (var. 2c), shows the sequence of variant 2 substituted with C residues at positions 84, 139 and 236. The boxes flanking residues 84, 139 and 236 show the groups of five amino acids on either sides of those six sets of five residues, denoted aac1 (for &#x201c;amino acid cluster 1&#x201d;), aac2 (for &#x201c;amino acid cluster 2&#x201d;), aac3 (for &#x201c;amino acid cluster 3&#x201d;), aac4 (for &#x201c;amino acid cluster 4&#x201d;), aac5 (for &#x201c;amino acid cluster 5&#x201d;), and aac6 (for &#x201c;amino acid cluster 6&#x201d;), that may be replaced by 1 to 5 amino acids selected independently from (i) any naturally occurring amino acid or (ii) any naturally occurring amino acid except proline or glycine.</p><p id="p-0266" num="0236">With regard to <figref idref="DRAWINGS">FIG. <b>6</b></figref>, in some cases: i) aac1 (amino acid cluster 1) may be the amino acid sequence GTLRG (SEQ ID NO:174) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., L replaced by I, V, A or F); ii) aac2 (amino acid cluster 2) may be the amino acid sequence YNQSE (SEQ ID NO:175) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., N replaced by Q, Q replaced by N, and/or E replaced by D); iii) aac3 (amino acid cluster 3) may be the amino acid sequence TAADM (SEQ ID NO:176) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., T replaced by S, A replaced by G, D replaced by E, and/or M replaced by L, V, or I); iv) aac4 (amino acid cluster 4) may be the amino acid sequence AQTTK (SEQ ID NO:177) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., A replaced by G, Q replaced by N, or T replaced by S, and/or K replaced by R or Q); v) aac5 (amino acid cluster 5) may be the amino acid sequence VETRP (SEQ ID NO:178) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., V replaced by I or L, E replaced by D, T replaced by S, and/or R replaced by K); and/or vi) aac6 (amino acid cluster 6) may be the amino acid sequence GDGTF (SEQ ID NO:179) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., D replaced by E, T replaced by S, or F replaced by L, W, or Y).</p><p id="p-0267" num="0237"><figref idref="DRAWINGS">FIGS. <b>7</b>-<b>9</b></figref> provide alignments of mature HLA class I heavy chain amino acid sequences (without leader sequences or transmembrane domains or intracellular domains). The aligned amino acid sequences in <figref idref="DRAWINGS">FIG. <b>7</b>A</figref> are HLA-A class I heavy chains of the following alleles: A*0101, A*0201, A*0301, A*1101, A*2301, A*2402, A*2407, A*3303, and A*3401. The aligned amino acid sequences in <figref idref="DRAWINGS">FIG. <b>8</b>A</figref> are HLA-B class I heavy chains of the following alleles: B*0702, B*0801, B*1502, B*3802, B*4001, B*4601, and B*5301. The aligned amino acid sequences in <figref idref="DRAWINGS">FIG. <b>9</b>A</figref> are HLA-C class I heavy chains of the following alleles: C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*0801, and C*1502. Indicated in the alignments are the locations (84 and 139 of the mature proteins) where cysteine residues may be introduced (e.g., by substitution) for the formation of a disulfide bond to stabilize the HLA H chain&#x2014;&#x3b2;2M complex. Also shown in the alignment is position 236 (of the mature polypeptide), which may be substituted by a cysteine residue that can form an inter-chain disulfide bond with &#x3b2;2M (e.g., at aa 12). The boxes flanking residues 84, 139 and 236 show the groups of five amino acids on either sides of those six sets of five residues, denoted aac1 (for &#x201c;amino acid cluster 1&#x201d;), aac2 (for &#x201c;amino acid cluster 2&#x201d;), aac3 (for &#x201c;amino acid cluster 3&#x201d;), aac4 (for &#x201c;amino acid cluster 4&#x201d;), aac5 (for &#x201c;amino acid cluster 5&#x201d;), and aac6 (for &#x201c;amino acid cluster 6&#x201d;), that may be replaced by 1 to 5 amino acids selected independently from (i) any naturally occurring amino acid or (ii) any naturally occurring amino acid except proline or glycine.</p><p id="p-0268" num="0238"><figref idref="DRAWINGS">FIGS. <b>7</b>A, <b>8</b>A, and <b>9</b>A</figref> provide alignments of the amino acid sequences of mature HLA-A, &#x2014;B, and -C class I heavy chains, respectively. The sequences are provided for the extracellular portion of the mature protein (without leader sequences or transmembrane domains or intracellular domains). As described in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, the positions of aa residues 84, 139, and 236 and their flanking residues (aac1 to aac6) that may be replaced by 1 to 5 amino acids selected independently from (i) any naturally occurring amino acid or (ii) any naturally occurring amino acid except proline or glycine ae also shown. <figref idref="DRAWINGS">FIGS. <b>7</b>B, <b>8</b>B, and <b>9</b>B</figref> provide consensus amino acid sequences for the HLA-A, &#x2014;B, and -C sequences, respectively, provide in <figref idref="DRAWINGS">FIGS. <b>7</b>A, <b>8</b>A, and <b>9</b>A</figref>. The consensus sequences show the variable amino acid positions as &#x201c;X&#x201d; residues sequentially numbered and the locations of amino acids 84, 139 and 236 double underlined.</p><p id="p-0269" num="0239">With regard to <figref idref="DRAWINGS">FIG. <b>7</b>A</figref>, in some cases: i) aac1 (amino acid cluster 1) may be the amino acid sequence GTLRG (SEQ ID NO:174) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., L replaced by I, V, A or F); ii) aac2 (amino acid cluster 2) may be the amino acid sequence YNQSE (SEQ ID NO:175) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., N replaced by Q, Q replaced by N, and/or E replaced by D); iii) aac3 (amino acid cluster 3) may be the amino acid sequence TAADM (SEQ ID NO:176) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., T replaced by S, A replaced by G, D replaced by E, and/or M replaced by L, V, or I); iv) aac4 (amino acid cluster 4) may be the amino acid sequence AQTTK (SEQ ID NO:177) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., A replaced by G, Q replaced by N, or T replaced by S, and or K replaced by R or Q); v) aac5 (amino acid cluster 5) may be the amino acid sequence VETRP (SEQ ID NO:178) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., V replaced by I or L, E replaced by D, T replaced by S, and/or R replaced by K); and/or vi) aac6 (amino acid cluster 6) may be the amino acid sequence GDGTF (SEQ ID NO:179) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., D replaced by E, T replaced by S, or F replaced by L, W, or Y).</p><p id="p-0270" num="0240">With regard to <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>, in some cases: i) aac1 (amino acid cluster 1) may be the amino acid sequence RNLRG (SEQ ID NO:180) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., N replaced by T or I; and/or L replaced by A; and/or the second R replaced by L; and/or the G replaced by R); ii) aac2 (amino acid cluster 2) may be the amino acid sequence YNQSE (SEQ ID NO:175) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., N replaced by Q, Q replaced by N, and/or E replaced by D); iii) aac3 (amino acid cluster 3) may be the amino acid sequence TAADT (SEQ ID NO:181) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., the first T replaced by S; and/or A replaced by G; and/or D replaced by E; and/or the second T replaced by S); iv) aac4 (amino acid cluster 4) may be the amino acid sequence AQITQ (SEQ ID NO:182) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., A replaced by G; and/or the first Q replaced by N; and/or I replaced by L or V; and/or the T replaced by S; and/or the second Q replaced by N); v) aac5 (amino acid cluster 5) may be the amino acid sequence VETRP (SEQ ID NO:178) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., V replaced by I or L, E replaced by D, T replaced by S, and/or R replaced by K); and/or vi) aac6 (amino acid cluster 6) may be the amino acid sequence GDRTF (SEQ ID NO:183) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., D replaced by E; and/or T replaced by S; and/or R replaced by K or H; and/or F replaced by L, W, or Y).</p><p id="p-0271" num="0241">With regard to <figref idref="DRAWINGS">FIG. <b>9</b>A</figref>, in some cases: i) aac1 (amino acid cluster 1) may be the amino acid sequence RNLRG (SEQ ID NO:180) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., N replaced by K; and/or L replaced by A or I; and/or the second R replaced by H; and/or the G replaced by T or S); ii) aac2 (amino acid cluster 2) may be the amino acid sequence YNQSE (SEQ ID NO:175) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., N replaced by Q, Q replaced by N, and/or E replaced by D); iii) aac3 (amino acid cluster 3) may be the amino acid sequence TAADT (SEQ ID NO:181) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., the first T replaced by S; and/or A replaced by G; and/or D replaced by E; and/or the second T replaced by S); iv) aac4 (amino acid cluster 4) may be the amino acid sequence AQITQ (SEQ ID NO:182) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., A replaced by G; and/or the first Q replaced by N; and/or I replaced by L; and/or the second Q replaced by N or K); v) aac5 (amino acid cluster 5) may be the amino acid sequence VETRP (SEQ ID NO:178) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., V replaced by I or L, E replaced by D, T replaced by S, and/or R replaced by K or H); and/or vi) aac6 (amino acid cluster 6) may be the amino acid sequence GDGTF (SEQ ID NO:179) or that sequence with one or two amino acids deleted or substituted with other naturally occurring amino acids (e.g., D replaced by E; and/or T replaced by S; and/or F replaced by L, W, or Y).</p><heading id="h-0043" level="2">1) HLA-A</heading><p id="p-0272" num="0242">In some cases, a TMMP of the present disclosure comprises an HLA-A heavy chain polypeptide. The HLA-A heavy chain peptide sequences, or portions thereof, that may be that may be incorporated into a TMMP of the present disclosure include, but are not limited to, the alleles: A*0101, A*0201, A*0301, A*1101, A*2301, A*2402, A*2407, A*3303, and A*3401, which are aligned without all, or substantially all, of the leader, transmembrane and cytoplasmic sequences in <figref idref="DRAWINGS">FIG. <b>7</b>A</figref>. Any of those alleles may comprise a mutation at one or more of positions 84, 139 and/or 236 (as shown in <figref idref="DRAWINGS">FIG. <b>7</b>A</figref>) selected from: a tyrosine to alanine at position 84 (Y84A); a tyrosine to cysteine at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C). In addition, HLA-A sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%) or 100% amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of the sequence of those HLA-A alleles may also be employed (e.g., it may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions).</p><p id="p-0273" num="0243">In some cases, a TMMP of the present disclosure comprises an HLA-A heavy chain polypeptide comprising the following HLA-A consensus amino acid sequence:</p><p id="p-0274" num="0000"><tables id="TABLE-US-00029" num="00029"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="294pt" align="right"/><colspec colname="2" colwidth="147pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;184)</entry><entry/></row><row><entry>GSHSMRYF<u style="single"><b>X1</b></u>TSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQ<u style="single"><b>X2</b></u>MEPRAPWI</entry><entry/></row><row><entry> </entry></row><row><entry>EQEGPEYWD<u style="single"><b>X3X4</b></u>T<u style="single"><b>X5X6X7</b></u>KA<u style="single"><b>X8</b></u>SQ<u style="single"><b>X9X10</b></u>R<u style="single"><b>X11X12</b></u>L<u style="single"><b>X13X14X15X16X17</b></u>YYNQSE<u style="single"><b>X18</b></u>GSHT</entry></row><row><entry> </entry></row><row><entry><u style="single"><b>X19</b></u>Q<u style="single"><b>X20</b></u>M<u style="single"><b>X21</b></u>GCDVG<u style="single"><b>X22</b></u>D<u style="single"><b>X23</b></u>RFLRGY<u style="single"><b>X24</b></u>Q<u style="single"><b>X25</b></u>AYDGKDYIAL<u style="single"><b>X26</b></u>EDLRSWTAADMAAQ</entry></row><row><entry> </entry></row><row><entry><u style="single"><b>X27</b></u>T<u style="single"><b>X28X29</b></u>KWE<u style="single"><b>X30X31X32</b></u>EAEQ<u style="single"><b>X33</b></u>R<u style="single"><b>X34</b></u>YL<u style="single"><b>X35</b></u>G<u style="single"><b>X36</b></u>CV<u style="single"><b>X37X38</b></u>LRRYLENGKETLQRTD<u style="single"><b>X39</b></u></entry></row><row><entry> </entry></row><row><entry>PKTHMTHH<u style="single"><b>X40X41</b></u>SDHEATLRCWAL<u style="single"><b>X42</b></u>FYPAEITLTWQRDGEDQTQDTELVETRPAGDGTF</entry></row><row><entry> </entry></row><row><entry>QKWA<u style="single"><b>X43</b></u>VVVPSG<u style="single"><b>X44</b></u>EQRYTCHVQHEGLPKPLTLRWE<u style="single"><b>X45</b></u>,</entry></row></tbody></tgroup></table></tables><br/>wherein X1 is Y, S, or T; X2 is K or R; X3 is Q, G, E, or R; X4 is N or E; X5 is R or G; X6 is N or K; X7 is M or V; X8 is H or Q; X9 is T or I; X10 is D or H; X11 is A, V, or E; X12 is N or D; X13 is G or R; X14 is T or I; X15 is L or A; X16 is R or L; X17 is G or R; X18 is A or D; X19 is I, L, or V; X20 is I, R or M; X21 is F or Y; X22 is S or P; X23 is W or G; X24 is R, H, or Q; X25 is D or Y; X26 is N or K; X27 is T or I; X28 is K or Q; X29 is R or H; X30 is A or T; X31 is A or V; X32 is H or R; X33 is R, L, Q, or W; X34 is V or A; X35 is D or E; X36 is R or T; X37 is D or E; X38 is W or G; X39 is P or A; X40 is P or A; X41 is V or I; X42 is S or G; X43 is A or S; X44 is Q or E; and X45 is P or L.</p><p id="p-0275" num="0244">As one example, an MHC Class I heavy chain polypeptide of a TMMP can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A heavy chain amino acid sequence:</p><p id="p-0276" num="0000"><tables id="TABLE-US-00030" num="00030"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;185)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWEP.</entry></row></tbody></tgroup></table></tables></p><p id="p-0277" num="0245">In some cases, an HLA-A heavy chain polypeptide suitable for inclusion in a TMMP of the present disclosure comprises the following amino acid sequence: GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET RKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVV VPSGQEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:185). This HLA-A heavy chain polypeptide is also referred to as &#x201c;HLA-A*0201&#x201d; or simply &#x201c;HLA-A02.&#x201d; In some cases, the C-terminal Pro is not included in a TMMP of the present disclosure. For example, in some cases, an HLA-A02 polypeptide suitable for inclusion in a TMMP of the present disclosure comprises the following amino acid sequence:</p><p id="p-0278" num="0000"><tables id="TABLE-US-00031" num="00031"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;186)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWE.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0044" level="2">2) HLA-A (Y84A; A236C)</heading><p id="p-0279" num="0246">In some cases, the MHC Class I heavy chain polypeptide comprises Y84A and A236C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A heavy chain (Y84A; A236C) amino acid sequence: GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET RKVKAHSQTHRVDLGTLRG<u style="single">A</u>YNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRP<u style="single">C</u>GDGTFQKWAAVV VPSGQEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:187), where amino acid 84 is Ala and amino acid 236 is Cys. In some cases, the Cys-236 forms an interchain disulfide bond with Cys-12 of a variant &#x3b2;2M polypeptide that comprises an R12C substitution.</p><p id="p-0280" num="0247">In some cases, an HLA-A heavy chain polypeptide suitable for inclusion in a TMMP of the present disclosure is an HLA-A02 (Y84A; A236C) polypeptide comprising the following amino acid sequence:</p><p id="p-0281" num="0000"><tables id="TABLE-US-00032" num="00032"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;187)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRGAYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPCGDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWEP.</entry></row></tbody></tgroup></table></tables></p><p id="p-0282" num="0248">In some cases, an HLA-A heavy chain polypeptide suitable for inclusion in a TMMP of the present disclosure is an HLA-A02 (Y84A; A236C) polypeptide comprising the following amino acid sequence:</p><p id="p-0283" num="0000"><tables id="TABLE-US-00033" num="00033"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;188)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRGAYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPCGDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWE.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0045" level="2">3) HLA-A (Y84C; A139C)</heading><p id="p-0284" num="0249">In some cases, the MHC Class I heavy chain polypeptide comprises Y84C and A139C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A heavy chain (Y84C; A139C) amino acid sequence: GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET RKVKAHSQTHRVDLGTLRG<u style="single">C</u>YNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA LKEDLRSWTAADM<u style="single">C</u>AQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVV VPSGQEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:189), where amino acid 84 is Cys and amino acid 139 is Cys. In some cases, Cys-84 forms an intrachain disulfide bond with Cys-139.</p><heading id="h-0046" level="2">4) HLA-A11 (HLA-A*1101)</heading><p id="p-0285" num="0250">As one non-limiting example, an MHC Class I heavy chain polypeptide of a TMMP can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A11 heavy chain amino acid sequence: GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQE TRNVKAQSQTDRVDLGTLRGYYNQSEDGSHTIQIMYGCDVGPDGRFLRGYRQDAYDGKDYIA LNEDLRSWTAADMAAQITKRKWEAAHAAEQQRAYLEGTCVEWLRRYLENGKETLQRTDPPKT HMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVV PSGEEQRYTCHVQHEGLPKPLTLRWE (SEQ ID NO:190). Such an MHC Class I heavy chain may be prominent in Asian populations, including populations of individuals of Asian descent.</p><heading id="h-0047" level="2">5) HLA-A11 (Y84A; A236C)</heading><p id="p-0286" num="0251">As one non-limiting example, in some cases, the MHC Class I heavy chain polypeptide is an HLA-A11 allele that comprises Y84A and A236C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A All heavy chain (Y84A; A236C) amino acid sequence: GSHSMRYFYTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQE TRNVKAQSQTDRVDLGTLRG<u style="single">A</u>YNQSEDGSHTIQIMYGCDVGPDGRFLRGYRQDAYDGKDYIA LNEDLRSWTAADMAAQITKRKWEAAHAAEQQRAYLEGTCVEWLRRYLENGKETLQRTDPPKT HMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRP<u style="single">C</u>GDGTFQKWAAVVV PSGEEQRYTCHVQHEGLPKPLTLRWE (SEQ ID NO:191), where amino acid 84 is Ala and amino acid 236 is Cys. In some cases, the Cys-236 forms an interchain disulfide bond with Cys-12 of a variant &#x3b2;2M polypeptide that comprises an R12C substitution.</p><heading id="h-0048" level="2">6) HLA-A24 (HLA-A*2402)</heading><p id="p-0287" num="0252">As one non-limiting example, an MHC Class I heavy chain polypeptide of a TMMP of the present disclosure can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A24 heavy chain amino acid sequence: GSHSMRYFSTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDEET GKVKAHSQTDRENLRIALRYYNQSEAGSHTLQMMFGCDVGSDGRFLRGYHQYAYDGKDYIAL KEDLRSWTAADMAAQITKRKWEAAHVAEQQRAYLEGTCVDGLRRYLENGKETLQRTDPPKT HMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVV PSGEEQRYTCHVQHEGLPKPLTLRWEPSSQPTVPIVGIIAGLVLLGAVITGAVVAAVMWRRNSS DRKGGSYSQAASSDSAQGSDVSLTACKV (SEQ ID NO:192). Such an MHC Class I heavy chain may be prominent in Asian populations, including populations of individuals of Asian descent. In some cases, amino acid 84 is an Ala. In some cases, amino acid 84 is a Cys. In some cases, amino acid 236 is a Cys. In some cases, amino acid 84 is an Ala and amino acid 236 is a Cys. In some cases, amino acid 84 is an Cys and amino acid 236 is a Cys.</p><heading id="h-0049" level="2">7) HLA-A33 (HLA-A*3303)</heading><p id="p-0288" num="0253">As one non-limiting example, an MHC Class I heavy chain polypeptide of a TMMP of the present disclosure can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-A33 heavy chain amino acid sequence: GSHSMRYFTTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDRN TRNVKAHSQIDRVDLGTLRGYYNQSEAGSHTIQMMYGCDVGSDGRFLRGYQQDAYDGKDYIA LNEDLRSWTAADMAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDPPKT HMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWASVVV PSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAVFAGAVVAAVRWRRKSSD RKGGSYSQAASSDSAQGSDMSLTACKV (SEQ ID NO:193). Such an MHC Class I heavy chain may be prominent in Asian populations, including populations of individuals of Asian descent. In some cases, amino acid 84 is an Ala. In some cases, amino acid 84 is a Cys. In some cases, amino acid 236 is a Cys. In some cases, amino acid 84 is an Ala and amino acid 236 is a Cys. In some cases, amino acid 84 is an Cys and amino acid 236 is a Cys.</p><heading id="h-0050" level="2">8) HLA-B</heading><p id="p-0289" num="0254">In some cases, a TMMP of the present disclosure comprises an HLA-B heavy chain polypeptide. The HLA-B heavy chain peptide sequences, or portions thereof, that may be that may be incorporated into a TMMP of the present disclosure include, but are not limited to, the alleles: B*0702, B*0801, B*1502, B*3802, B*4001, B*4601, and B*5301, which are aligned without all, or substantially all, of the leader, transmembrane and cytoplasmic sequences in <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>. Any of those alleles may comprise a mutation at one or more of positions 84, 139 and/or 236 (as shown in <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>) selected from: a tyrosine to alanine at position 84 (Y84A); a tyrosine to cysteine at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C). In addition, a HLA-B polypeptide comprising an amino acid sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%) or 100% amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of the sequence of those HLA-B alleles may also be employed (e.g., it may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions).</p><p id="p-0290" num="0255">In some cases, a TMMP of the present disclosure comprises an HLA-B heavy chain polypeptide comprising the following HLA-B consensus amino acid sequence:</p><p id="p-0291" num="0000"><tables id="TABLE-US-00034" num="00034"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="294pt" align="right"/><colspec colname="2" colwidth="147pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;194)</entry><entry/></row><row><entry>GSHSMRYF<u style="single"><b>X1</b></u>T<u style="single"><b>X2X3</b></u>SRPGRGEPRFI<u style="single"><b>X4</b></u>VGYVDDT<u style="single"><b>X5</b></u>FVRFDSDA<u style="single"><b>X6</b></u>SPR<u style="single"><b>X7X8</b></u>PR</entry><entry/></row><row><entry> </entry></row><row><entry>APWIEQEGPEYWDR<u style="single"><b>X9</b></u>TQ<u style="single"><b>X10X11</b></u>KT<u style="single"><b>X12X13</b></u>TQ<u style="single"><b>X14</b></u>Y<u style="single"><b>X15X16</b></u>NL<u style="single"><b>X17X18X19X20</b></u>YYNQSEAGS</entry></row><row><entry> </entry></row><row><entry>H<u style="single"><b>X21X22QX23</b></u>MYGCDLGPDGRLLRGHDQSAYDGKDYIALNEDL<u style="single"><b>X24</b></u>SWTAADTAAQI<u style="single"><b>X25</b></u>QRK</entry></row><row><entry> </entry></row><row><entry><u style="single"><b>X26</b></u>EAAR<u style="single"><b>X27</b></u>AEQ<u style="single"><b>X28</b></u>R<u style="single"><b>X29</b></u>YLEG<u style="single"><b>X30</b></u>CVEWLRRYLENGK<u style="single"><b>X31X32</b></u>L<u style="single"><b>X33</b></u>RADPPKTHVTHHP<u style="single"><b>X34</b></u></entry></row><row><entry> </entry></row><row><entry>SDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQR</entry></row><row><entry> </entry></row><row><entry>YTCHVQHEGLPKPLTLRWEP,</entry></row></tbody></tgroup></table></tables><br/>wherein X1 is H, Y, or D; X2 is A or S; X3 is M or V; X4 is A, S, or T; X5 is Q or L; X6 is A or T; X7 is E, M K, or T; X8 is A or T; X9 is E or N; X10 is I or K; X11 is Y, F, S, or C; X12 is N or Q; X13 is A or T; X14 is D or Y; X15 is E or V; X16 is S or N; X17 is T, N, or I; X18 is A or L; X19 is L, or R; X20 is R or G; X21 is T or I; X22 is L or I; X23 is R or S; X24 is R or S; X25 is S or T; X26 is L or W; X27 is E OR V; X28 is R, D, L or W; X29 is A or T; X30 is L, E or T; X31 is E or D; X32 is K or T; X33 is E or Q; and X34 is I or V.</p><p id="p-0292" num="0256">As an example, an MHC Class I heavy chain polypeptide of a TMMP of the present disclosure can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-B heavy chain amino acid sequence:</p><p id="p-0293" num="0000"><tables id="TABLE-US-00035" num="00035"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;195)</entry><entry/></row><row><entry>GSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNT</entry><entry/></row><row><entry> </entry></row><row><entry>QIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIAL</entry></row><row><entry> </entry></row><row><entry>NEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTH</entry></row><row><entry> </entry></row><row><entry>VTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPS</entry></row><row><entry> </entry></row><row><entry>GEEQRYTCHVQHEGLPKPLTLRWEP.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0051" level="2">9) HLA-B (Y84A; A236C)</heading><p id="p-0294" num="0257">As one non-limiting example, in some cases, the MHC Class I heavy chain polypeptide is an HLA-B polypeptide that comprises Y84A and A236C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-B heavy chain (Y84A; A236C) amino acid sequence: GSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNT QIYKAQAQTDRESLRNLRG<u style="single">A</u>YNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIAL NEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTH VTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRP<u style="single">C</u>GDRTFQKWAAVVVPS GEEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:196), where amino acid 84 is Ala and amino acid 236 is Cys. In some cases, the Cys-236 forms an interchain disulfide bond with Cys-12 of a variant &#x3b2;2M polypeptide that comprises an R12C substitution.</p><heading id="h-0052" level="2">10) HLA-B (Y84C; A139C)</heading><p id="p-0295" num="0258">In some cases, the MHC Class I heavy chain polypeptide comprises Y84C and A139C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-B heavy chain (Y84C; A139C) amino acid sequence: GSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNT QIYKAQAQTDRESLRNLRG<u style="single">C</u>YNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIAL NEDLRSWTAADT<u style="single">C</u>AQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTH VTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPS GEEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:197), where amino acid 84 is Cys and amino acid 139 is Cys. In some cases, Cys-84 forms an intrachain disulfide bond with Cys-139.</p><heading id="h-0053" level="2">11) HLA-B*0702</heading><p id="p-0296" num="0259">As an example, in some cases, a MHC Class I heavy chain polypeptide present in a TMMP of the present disclosure comprises an amino acid sequence of HLA-B*0702 (SEQ ID NO:195) in <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>, or a sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%) or 100%, amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of that sequence (e.g., it may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions). In some cases, where the HLA-B heavy chain polypeptide of TMMP of the present disclosure has less than 100% identity to the sequence labeled HLA-B in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, or labeled &#x201c;B*0702 in <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>, it may comprise a mutation at one or more of positions 84, 139 and/or 236 selected from: a tyrosine to alanine substitution at position 84 (Y84A); a tyrosine to cysteine substitution at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C). In some cases, the HLA-B heavy chain polypeptide of TMMP of the present disclosure comprises Y84A and A236C substitutions. In some cases, the HLA-B*0702 heavy chain polypeptide of TMMP of the present disclosure comprises Y84C and A139C substitutions. In some cases, the HLA-B heavy chain polypeptide of TMMP of the present disclosure comprises Y84C, A139C, and A236C substitutions.</p><heading id="h-0054" level="2">12) HLA-C</heading><p id="p-0297" num="0260">In some cases, a TMMP of the present disclosure comprises an HLA-C heavy chain polypeptide. The HLA-C heavy chain polypeptide, or portions thereof, that may be that may be incorporated into a TMMP of the present disclosure include, but are not limited to, the alleles: C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*0801, and C*1502, which are aligned without all, or substantially all, of the leader, transmembrane and cytoplasmic sequences in <figref idref="DRAWINGS">FIG. <b>9</b>A</figref>. Any of those alleles may comprise a mutation at one or more of positions 84, 139 and/or 236 (as shown in <figref idref="DRAWINGS">FIG. <b>9</b>A</figref>) selected from: a tyrosine to alanine substitution at position 84 (Y84A); a tyrosine to cysteine substitution at position 84 (Y84C); an alanine to cysteine substitution at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C). In addition, an HLA-C polypeptide comprising an amino acid sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%) or 100% amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of the sequence of those HLA-C alleles may also be employed (e.g., it may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions).</p><p id="p-0298" num="0261">In some cases, a TMMP of the present disclosure comprises an HLA-C heavy chain polypeptide comprising the following HLA-C consensus amino acid sequence:</p><p id="p-0299" num="0000"><tables id="TABLE-US-00036" num="00036"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;198)</entry><entry/></row><row><entry><u style="single"><b>X1</b></u>SHSM<u style="single"><b>X2</b></u>YF<u style="single"><b>X3</b></u>TAVS<u style="single"><b>X4</b></u>PGRGEP<u style="single"><b>X5</b></u>FI<u style="single"><b>X6</b></u>VGYVDDTQFV<u style="single"><b>X7</b></u>FDSDAASPRGEPR</entry><entry/></row><row><entry> </entry></row><row><entry><u style="single"><b>X8</b></u>PWVEQEGPEYWDRETQ<u style="single"><b>X9</b></u>YKRQAQ<u style="single"><b>X10</b></u>DRV<u style="single"><b>X11</b></u>LR<u style="single"><b>X12</b></u>LRGYYNQSE<u style="single"><b>X13X14</b></u>SH<u style="single"><b>X15X16</b></u>Q</entry></row><row><entry> </entry></row><row><entry><u style="single"><b>X17</b></u>M<u style="single"><b>X18</b></u>GCD<u style="single"><b>X19</b></u>GPDGRLLRG<u style="single"><b>X20X21</b></u>Q<u style="single"><b>X22</b></u>AYDGKDYIALNEDLRSWTAADTAAQITQRK<u style="single"><b>X23</b></u>E</entry></row><row><entry> </entry></row><row><entry>AAR<u style="single"><b>X24</b></u>AEQ<u style="single"><b>X25</b></u>RAYLEG<u style="single"><b>X26</b></u>CVEWLRRYL<u style="single"><b>X27</b></u>NGK<u style="single"><b>X28</b></u>TLQRAE<u style="single"><b>X29</b></u>PKTHVTHHP<u style="single"><b>X30</b></u>SDHEA</entry></row><row><entry> </entry></row><row><entry>TLRCWALGFYPAEITLTWQ<u style="single"><b>X31</b></u>DGEDQTQDTELVETRPAGDGTFQKWAAV<u style="single"><b>X32</b></u>VPSG<u style="single"><b>X33</b></u>EQRY</entry></row><row><entry> </entry></row><row><entry>TCH<u style="single"><b>X34</b></u>QHEGL<u style="single"><b>X35</b></u>EPLTL<u style="single"><b>X36</b></u>W<u style="single"><b>X37</b></u>P,</entry></row></tbody></tgroup></table></tables><br/>wherein X1 is C or G; X2 is R or K; X3 is F, Y, S, or D; X4 is R or W; X5 is H or R; X6 is A or S; X7 is Q or R; X8 is A or E; X9 is N or K; X10 is T or A; X11 is S or N; X12 is N or K; X13 is A or D; X14 is G or R; X15 is T or I; X16 is L or I; X17 is W or R; X18 is C, Y, F, or S; X19 is L, or V; X20 is Y or H; X21 is D or N; X22 is Y, F, S, or L; X23 is L or W; X24 is E, A, Or T; X25 is R, L, or W; X26 is L or T; X27 is E OR K; X28 is E or K; X29 is H or P; X30 is R or V; X31 is W or R; X32 is V or M; X33 is E or Q; X34 is M or V; X35 is P or Q; X36 is R or S; and X37 is P or G.</p><p id="p-0300" num="0262">As an example, an MHC Class I heavy chain polypeptide of a TMMP of the present disclosure can comprise an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-C heavy chain amino acid sequence:</p><p id="p-0301" num="0000"><tables id="TABLE-US-00037" num="00037"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;199)</entry><entry/></row><row><entry>CSHSMRYFDTAVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPRGEPRAPWVEQEGPEYWDRE</entry><entry/></row><row><entry> </entry></row><row><entry>TQNYKRQAQADRVSLRNLRGYYNQSEDGSHTLQRMYGCDLGPDGRLLRGYDQSAYDGKDYI</entry></row><row><entry> </entry></row><row><entry>ALNEDLRSWTAADTAAQITQRKLEAARAAEQLRAYLEGTCVEWLRRYLENGKETLQRAEPPKT</entry></row><row><entry> </entry></row><row><entry>HVTHHPLSDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVV</entry></row><row><entry> </entry></row><row><entry>PSGQEQRYTCHMQHEGLQEPLTLSWEP.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0055" level="2">13) HLA-C(Y84A; A236C)</heading><p id="p-0302" num="0263">As one non-limiting example, in some cases, the MHC Class I heavy chain polypeptide is an HLA-C polypeptide that comprises Y84A and A236C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-C heavy chain (Y84A; A236C) amino acid sequence: CSHSMRYFDTAVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPRGEPRAPWVEQEGPEYWDRE TQNYKRQAQADRVSLRNLRGAYNQSEDGSHTLQRMYGCDLGPDGRLLRGYDQSAYDGKDYI ALNEDLRSWTAADTAAQITQRKLEAARAAEQLRAYLEGTCVEWLRRYLENGKETLQRAEPPKT HVTHHPLSDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPCGDGTFQKWAAVVV PSGQEQRYTCHMQHEGLQEPLTLSWEP (SEQ ID NO:200), where amino acid 84 is Ala and amino acid 236 is Cys. In some cases, the Cys-236 forms an interchain disulfide bond with Cys-12 of a variant &#x3b2;2M polypeptide that comprises an R12C substitution. 14) HLA-C(Y84C; A139C)</p><p id="p-0303" num="0264">In some cases, the MHC Class I heavy chain polypeptide comprises Y84C and A139C substitutions. For example, in some cases, the MHC Class I heavy chain polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human HLA-C heavy chain (Y84C; A139C) amino acid sequence: CSHSMRYFDTAVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPRGEPRAPWVEQEGPEYWDRE TQNYKRQAQADRVSLRNLRGCYNQSEDGSHTLQRMYGCDLGPDGRLLRGYDQSAYDGKDYI ALNEDLRSWTAADTCAQITQRKLEAARAAEQLRAYLEGTCVEWLRRYLENGKETLQRAEPPKT HVTHHPLSDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVV PSGQEQRYTCHMQHEGLQEPLTLSWEP (SEQ ID NO:201), where amino acid 84 is Cys and amino acid 139 is Cys. In some cases, Cys-84 forms an intrachain disulfide bond with Cys-139.</p><heading id="h-0056" level="2">15) HLA-C*0701</heading><p id="p-0304" num="0265">In some cases, a MHC Class I heavy chain polypeptide of a TMMP of the present disclosure comprises an amino acid sequence of HLA-C*0701 of <figref idref="DRAWINGS">FIG. <b>9</b>A</figref> (labeled HLA-C in <figref idref="DRAWINGS">FIG. <b>6</b></figref>), or an amino acid sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%) or 100% amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of that sequence (e.g., it may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions). In some cases, where the HLA-C heavy chain polypeptide of a TMMP of the present disclosure has less than 100% identity to the sequence labeled HLA-C*0701 in <figref idref="DRAWINGS">FIG. <b>9</b>A</figref>, it may comprise a mutation at one or more of positions 84, 139 and/or 236 selected from: a tyrosine to alanine substitution at position 84 (Y84A); a tyrosine to cysteine substitution at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C). In some cases, the HLA-C heavy chain polypeptide of a TMMP of the present disclosure comprises Y84A and A236C substitutions. In some cases, the HLA-C*0701 heavy chain polypeptide of a T-Cell-MMP or its epitope conjugate comprises Y84C and A139C substitutions. In some cases, the HLA-C heavy chain polypeptide of a TMMP of the present disclosure comprises Y84C, A139C, and A236C substitutions.</p><heading id="h-0057" level="2">Non-Classical HLA-E, -F, and -G MHC Class I Heavy Chains</heading><p id="p-0305" num="0266">In some cases, a TMMP of the present disclosure comprises a non-classical MHC Class I heavy chain polypeptide. Among the non-classical HLA heavy chain polypeptides, or portions thereof, that may be that may be incorporated into a TMMP of the present disclosure include, but are not limited to, those of HLA-E, -F, and -G alleles Amino acid sequences for HLA-E, -F, and -G heavy chain polypeptides, (and the HLA-A, B and C alleles) may be found on the world wide web hla.alleles.org/nomenclature/index.html, the European Bioinformatics Institute (www(dot)ebi(dot)ac(dot)uk), which is part of the European Molecular Biology Laboratory(EMBL), and at the National Center for Biotechnology Information (www(dot)ncbi(dot)nlm(dot)nih(dot)gov).</p><p id="p-0306" num="0267">Non-limiting examples of suitable HLA-E alleles include, but are not limited to, HLA-E*0101 (HLA-E*01:01:01:01), HLA-E*01:03(HLA-E*01:03:01:01), HLA-E*01:04, HLA-E*01:05, HLA-E*01:06, HLA-E*01:07, HLA-E*01:09, and HLA-E*01:10. Non-limiting examples of suitable HLA-F alleles include, but are not limited to, HLA-F*0101 (HLA-F*01:01:01:01), HLA-F*01:02, HLA-F*01:03(HLA-F*01:03:01:01), HLA-F*01:04, HLA-F*01:05, and HLA-F*01:06. Non-limiting examples of suitable HLA-G alleles include, but are not limited to, HLA-G*0101 (HLA-G*01:01:01:01), HLA-G*01:02, HLA-G*01:03(HLA-G*01:03:01:01), HLA-G*01:04 (HLA-G*01:04:01:01), HLA-G*01:06, HLA-G*01:07, HLA-G*01:08, HLA-G*01:09: HLA-G*01:10, HLA-G*01:10, HLA-G*01:11, HLA-G*01:12, HLA-G*01:14, HLA-G*01:15, HLA-G*01:16, HLA-G*01:17, HLA-G*01:18: HLA-G*01:19, HLA-G*01:20, and HLA-G*01:22. Consensus sequences for those HLA E, -F and -G alleles without all, or substantially all, of the leader, transmembrane and cytoplasmic sequences are provided in <figref idref="DRAWINGS">FIG. <b>10</b></figref>, and aligned with consensus sequences of the above-mentioned HLA-A, &#x2014;B and -C alleles in <figref idref="DRAWINGS">FIG. <b>11</b></figref>.</p><p id="p-0307" num="0268"><figref idref="DRAWINGS">FIG. <b>11</b></figref> provides a consensus sequence for each of HLA-E, &#x2014;F, and -G with the variable aa positions indicated as &#x201c;X&#x201d; residues sequentially numbered and the locations of aas 84, 139 and 236 double underlined.</p><p id="p-0308" num="0269"><figref idref="DRAWINGS">FIG. <b>11</b></figref> provides an alignment of the consensus amino acid sequences for HLA-A, &#x2014;B, -C, -E, &#x2014;F, and -G, which are given in <figref idref="DRAWINGS">FIGS. <b>7</b>-<b>11</b></figref>. Variable residues in each sequence are listed as &#x201c;X&#x201d; with the sequential numbering removed. As indicated in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, the locations of aas 84, 139 and 236 are indicated with their flanking five-amino acid clusters that may be replaced by 1 to 5 amino acids selected independently from (i) any naturally occurring amino acid or (ii) any naturally occurring amino acid except proline or glycine are also shown.</p><p id="p-0309" num="0270">Any of the above-mentioned HLA-E, &#x2014;F, and/or -G alleles may comprise a substitution at one or more of positions 84, 139 and/or 236 as shown in <figref idref="DRAWINGS">FIG. <b>11</b></figref> for the consensus sequences. In some cases, the substitutions may be selected from a: position 84 tyrosine to alanine (Y84A) or cysteine (Y84C), or, in the case of HLA-F, an R84A or R84C substitution; a position 139 alanine to cysteine (A139C), or, in the case of HLA-F, a V139C; and an alanine to cysteine substitution at position 236 (A236C). In addition, an HLA-E, -F and/or -G sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%) or 100% amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of any of the consensus sequences of set forth in <figref idref="DRAWINGS">FIG. <b>11</b></figref> may also be employed (e.g., the sequences may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions in addition to changes at variable residues listed therein).</p><heading id="h-0058" level="2">Mouse H2K</heading><p id="p-0310" num="0271">In some cases, a MHC Class I heavy chain polypeptide present in a TMMP of the present disclosure comprises an amino acid sequence of MOUSE H2K (SEQ ID NO:401) (MOUSE H2K in <figref idref="DRAWINGS">FIG. <b>6</b></figref>), or a sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% amino acid sequence identity to all or part (e.g., 50, 75, 100, 150, 200, or 250 contiguous amino acids) of that sequence (e.g., it may comprise 1-25, 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 amino acid insertions, deletions, and/or substitutions). In some cases, where the MOUSE H2K heavy chain polypeptide of a TMMP of the present disclosure has less than 100% identity to the sequence labeled MOUSE H2K in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, it may comprise a mutation at one or more of positions 84, 139 and/or 236 selected from: a tyrosine to alanine at position 84 (Y84A); a tyrosine to cysteine at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C). In some cases, the MOUSE H2K heavy chain polypeptide of a TMMP of the present disclosure comprises Y84A and A236C substitutions. In some cases, the MOUSE H2K heavy chain polypeptide of a TMMP of the present disclosure comprises Y84C and A139C substitutions. In some cases, the MOUSE H2K heavy chain polypeptide of a TMMP of the present disclosure comprises Y84C, A139C and A236C substitutions.</p><heading id="h-0059" level="2">Exemplary Combinations</heading><p id="p-0311" num="0272">Table 2, below, presents various combinations of MHC Class I heavy chain sequence modifications that can be incorporated in a TMMP of the present disclosure.</p><p id="p-0312" num="0000"><tables id="TABLE-US-00038" num="00038"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><colspec colname="4" colwidth="91pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 2</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry/><entry>Specific Substitutions </entry></row><row><entry/><entry>HLA Heavy</entry><entry/><entry>at aa positions </entry></row><row><entry>Entry</entry><entry>Chain Sequence</entry><entry>Sequence Identity Range&#x2002;<img id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="1.44mm" file="US20230000914A1-20230105-P00001.TIF" alt="custom-character" img-content="character" img-format="tif"/> </entry><entry>84, 139 and/or 236</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="28pt" align="char" char="."/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="133pt" align="center"/><colspec colname="4" colwidth="91pt" align="center"/><tbody valign="top"><row><entry>1</entry><entry>HLA-A</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>Consensus</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>(FIG. 7B)</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry/><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry/><entry>and/or substitutions (not counting</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry/><entry/><entry>variable residues)</entry><entry/></row><row><entry>2</entry><entry>A*0101, A*0201,</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>A*0301, A*1101,</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>A*2402, A*2301,</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry>A*2402, A*2407,</entry><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry>A*3303, or</entry><entry>and/or substitutions</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry/><entry>A*3401</entry><entry/><entry/></row><row><entry/><entry>(FIG. 7A)</entry><entry/><entry/></row><row><entry>3</entry><entry>HLA-B</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>Consensus</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>(FIG. 8B)</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry/><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry/><entry>and/or substitutions (not counting</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry/><entry/><entry>variable residues)</entry><entry/></row><row><entry>4</entry><entry>B*0702, B*0801,</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>B*1502, B*3802,</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>B*4001, B*4601,</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry>or B*5301</entry><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry>(FIG. 8A)</entry><entry>and/or substitutions</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry>5</entry><entry>HLA-C</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>Consensus</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>(FIG. 9B)</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry/><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry/><entry>and/or substitutions (not counting</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry/><entry/><entry>variable residues)</entry><entry/></row><row><entry>6</entry><entry>C*0102, C*0303,</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>C*0304, C*0401,</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>C*0602, C*0701,</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry>C*0801, or</entry><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry>C*1502</entry><entry>and/or substitutions</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry/><entry>(FIG. 9A)</entry><entry/><entry/></row><row><entry>7</entry><entry>HLA-E, F, or G</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>Consensus</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry>(FIG. 10)</entry><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry/><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry/><entry>and/or substitutions (not counting</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry/><entry/><entry>variable residues)</entry><entry/></row><row><entry>8</entry><entry>MOUSE H2K</entry><entry>75%-99.8%, 80%-99.8%, 85%-99.8%,</entry><entry>None; Y84C; Y84A;</entry></row><row><entry/><entry>(FIG. 6)</entry><entry>90%-99.8%, 95%-99.8%, 98%-99.8%,</entry><entry>A139C; A236C;</entry></row><row><entry/><entry/><entry>or 99%-99.8%; or 1-25, 1-5, 5-10, 10-15,</entry><entry>(Y84A &#x26; A236C);</entry></row><row><entry/><entry/><entry>15-20, or 20-25 aa insertions, deletions,</entry><entry>(Y84C &#x26; A139C); or</entry></row><row><entry/><entry/><entry>and/or substitutions</entry><entry>(Y84C, A139C &#x26; A236C)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry namest="1" nameend="4" align="left" id="FOO-00001"><img id="CUSTOM-CHARACTER-00002" he="2.46mm" wi="1.44mm" file="US20230000914A1-20230105-P00001.TIF" alt="custom-character" img-content="character" img-format="tif"/> The Sequence Identity Range is the permissible range in sequence identity of an MHC-H polypeptide sequence incorporated into a TMMP relative to the corresponding portion of the sequences listed in FIG. 6-11 not counting the variable residues in the consensus sequences.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0060" level="2">Beta-2 Microglobulin</heading><p id="p-0313" num="0273">A &#x3b2;2-microglobulin (&#x3b2;2M) polypeptide of a TMMP of the present disclosure can be a human &#x3b2;2M polypeptide, a non-human primate &#x3b2;2M polypeptide, a murine &#x3b2;2M polypeptide, and the like. In some instances, a &#x3b2;2M polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to a &#x3b2;2M amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>4</b></figref>. In some instances, a &#x3b2;2M polypeptide comprises an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to amino acids 21 to 119 of a &#x3b2;2M amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>4</b></figref>.</p><p id="p-0314" num="0274">In some cases, a suitable &#x3b2;2M polypeptide comprises the following amino acid sequence:</p><p id="p-0315" num="0000"><tables id="TABLE-US-00039" num="00039"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="196pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;202)</entry></row><row><entry/><entry>IQRTPKIQVY&#x2003;SCHPAENGKS&#x2003;NFLNCYVSGF</entry></row><row><entry/><entry>HPSDIEVDLLKNGERIEKVE&#x2003;HSDLSFSKDW&#x2003;SFYLLYYTEF</entry></row><row><entry/><entry>TPTEKDEYAC&#x2003;RVNHVTLSQP&#x2003;KIVKWDRDM;</entry></row></tbody></tgroup></table></tables><br/>and the HLA Class I heavy chain polypeptide comprises the following amino acid sequence:</p><p id="p-0316" num="0275">GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQ EGPEYWDGETRKVKAHSQTHRVDL(aa1) {C} (aa2)AGSHTVQRMYGCDVGSDWRFLRGYHQYA YDGKDYIALKEDLRSW(aa3) C (aa4))HKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQ RTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTEL(aa5)I(aa6)QKWAA VVVPSGQEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:203), where the cysteine residues indicated as {C} form an disulfide bond between the a1 and a2-1 helices and t11 residue forms a disulfide bond with the &#x3b2;2M polypeptide cysteine at position 12. In the sequence above, &#x201c;aa1&#x201d; is &#x201c;amino acid cluster 1&#x201d;; &#x201c;aa2&#x201d; is &#x201c;amino acid cluster 2&#x201d;; &#x201c;aa3&#x201d; is &#x201c;amino acid cluster 3&#x201d;; &#x201c;aa4&#x201d; is &#x201c;amino acid cluster 4&#x201d;; &#x201c;aa5&#x201d; is &#x201c;amino acid cluster 5&#x201d;; and &#x201c;aa6&#x201d; is &#x201c;amino acid cluster 6&#x201d;; see, e.g., <figref idref="DRAWINGS">FIG. <b>6</b></figref>. Each occurrence of aa1, aa2, aa3, aa4, aa5, and aa6 is and independently selected to be 1-5 amino acid residues, wherein the amino acid residues are i) selected independently from any naturally occurring (e.g., encoded) amino acid or ii) any naturally occurring amino acid except proline or glycine.</p><p id="p-0317" num="0276">In some cases, an MHC polypeptide comprises a single amino acid substitution relative to a reference MHC polypeptide (where a reference MHC polypeptide can be a wild-type MHC polypeptide), where the single amino acid substitution substitutes an amino acid with a cysteine (Cys) residue. Such cysteine residues, when present in an MHC polypeptide of a first polypeptide of a TMMP of the present disclosure, can form a disulfide bond with a cysteine residue present in a second polypeptide chain of a TMMP of the present disclosure.</p><p id="p-0318" num="0277">In some cases, a first MHC polypeptide in a first polypeptide of a TMMP of the present disclosure, and/or the second MHC polypeptide in the second polypeptide of a TMMP of the present disclosure, includes an amino acid substitution to substitute an amino acid with a cysteine, where the substituted cysteine in the first MHC polypeptide forms a disulfide bond with a cysteine in the second MHC polypeptide, where a cysteine in the first MHC polypeptide forms a disulfide bond with the substituted cysteine in the second MHC polypeptide, or where the substituted cysteine in the first MHC polypeptide forms a disulfide bond with the substituted cysteine in the second MHC polypeptide.</p><p id="p-0319" num="0278">For example, in some cases, one of following pairs of residues in an HLA &#x3b2;2-microglobulin and an HLA Class I heavy chain is substituted with cysteines (where residue numbers are those of the mature polypeptide): 1) &#x3b2;2M residue 12, HLA Class I heavy chain residue 236; 2) &#x3b2;2M residue 12, HLA Class I heavy chain residue 237; 3) &#x3b2;2M residue 8, HLA Class I heavy chain residue 234; 4) &#x3b2;2M residue 10, HLA Class I heavy chain residue 235; 5) &#x3b2;2M residue 24, HLA Class I heavy chain residue 236; 6) &#x3b2;2M residue 28, HLA Class I heavy chain residue 232; 7) &#x3b2;2M residue 98, HLA Class I heavy chain residue 192; 8) &#x3b2;2M residue 99, HLA Class I heavy chain residue 234; 9) &#x3b2;2M residue 3, HLA Class I heavy chain residue 120; 10) &#x3b2;2M residue 31, HLA Class I heavy chain residue 96; 11) &#x3b2;2M residue 53, HLA Class I heavy chain residue 35; 12) &#x3b2;2M residue 60, HLA Class I heavy chain residue 96; 13) &#x3b2;2M residue 60, HLA Class I heavy chain residue 122; 14) &#x3b2;2M residue 63, HLA Class I heavy chain residue 27; 15) &#x3b2;2M residue Arg3, HLA Class I heavy chain residue Gly120; 16) &#x3b2;2M residue His31, HLA Class I heavy chain residue Gln96; 17) &#x3b2;2M residue Asp53, HLA Class I heavy chain residue Arg35; 18) &#x3b2;2M residue Trp60, HLA Class I heavy chain residue Gln96; 19) &#x3b2;2M residue Trp60, HLA Class I heavy chain residue Asp122; 20) &#x3b2;2M residue Tyr63, HLA Class I heavy chain residue Tyr27; 21) &#x3b2;2M residue Lys6, HLA Class I heavy chain residue Glu232; 22) &#x3b2;2M residue Gln8, HLA Class I heavy chain residue Arg234; 23) &#x3b2;2M residue Tyr10, HLA Class I heavy chain residue Pro235; 24) &#x3b2;2M residue Ser11, HLA Class I heavy chain residue Gln242; 25) &#x3b2;2M residue Asn24, HLA Class I heavy chain residue Ala236; 26) &#x3b2;2M residue Ser28, HLA Class I heavy chain residue Glu232; 27) &#x3b2;2M residue Asp98, HLA Class I heavy chain residue His192; and 28) &#x3b2;2M residue Met99, HLA Class I heavy chain residue Arg234. The amino acid numbering of the MHC/HLA Class I heavy chain is in reference to the mature MHC/HLA Class I heavy chain, without a signal peptide. For example, in some cases, residue 236 of the mature HLA-A amino acid sequence is substituted with a Cys. In some cases, residue 236 of the mature HLA-B amino acid sequence is substituted with a Cys. In some cases, residue 236 of the mature HLA-C amino acid sequence is substituted with a Cys. In some cases, residue 32 (corresponding to Arg-12 of mature &#x3b2;2M) of an amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>4</b></figref> is substituted with a Cys.</p><p id="p-0320" num="0279">In some cases, a &#x3b2;2M polypeptide comprises the amino acid sequence: IQRTPKIQVY SRHPAENGKS NFLNCYVSGF HPSDIEVDLLKNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM (SEQ ID NO:204). In some cases, a &#x3b2;2M polypeptide comprises the amino acid sequence: IQRTPKIQVY SCHPAENGKS NFLNCYVSGF HPSDIEVDLLKNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM (SEQ ID NO:202).</p><p id="p-0321" num="0280">In some cases, an HLA Class I heavy chain polypeptide comprises the amino acid sequence:</p><p id="p-0322" num="0000"><tables id="TABLE-US-00040" num="00040"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;185)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRP<u style="single"><b>A</b></u>GDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWEP&#x2003;.</entry></row></tbody></tgroup></table></tables></p><p id="p-0323" num="0281">In some cases, an HLA Class I heavy chain polypeptide comprises the amino acid sequence:</p><p id="p-0324" num="0000"><tables id="TABLE-US-00041" num="00041"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;205)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRP<u style="single"><b>C</b></u>GDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWEP.</entry></row></tbody></tgroup></table></tables></p><p id="p-0325" num="0282">In some cases, an HLA Class I heavy chain polypeptide comprises the amino acid sequence:</p><p id="p-0326" num="0000"><tables id="TABLE-US-00042" num="00042"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;188)</entry><entry/></row><row><entry>GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGET</entry><entry/></row><row><entry> </entry></row><row><entry>RKVKAHSQTHRVDLGTLRG<u style="single"><b>A</b></u>YNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIA</entry></row><row><entry> </entry></row><row><entry>LKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPK</entry></row><row><entry> </entry></row><row><entry>THMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRP<u style="single"><b>C</b></u>GDGTFQKWAAVV</entry></row><row><entry> </entry></row><row><entry>VPSGQEQRYTCHVQHEGLPKPLTLRWE.</entry></row></tbody></tgroup></table></tables></p><p id="p-0327" num="0283">In some cases, the &#x3b2;2M polypeptide comprises the following amino acid sequence:</p><p id="p-0328" num="0284">IQRTPKIQVY SCHPAENGKS NFLNCYVSGF HPSDIEVDLLKNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM (SEQ ID NO:202); and the HLA Class I heavy chain polypeptide of a TMMP of the present disclosure comprises the following amino acid sequence:</p><p id="p-0329" num="0285">GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQ EGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQ YAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENG KETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPCGD GTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEP (SEQ ID NO:205), where the Cys residues that are underlined and in bold form a disulfide bond with one another in the TMMP.</p><p id="p-0330" num="0286">In some cases, the &#x3b2;2M polypeptide comprises the amino acid sequence:</p><p id="p-0331" num="0000"><tables id="TABLE-US-00043" num="00043"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="right"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;202)</entry><entry/></row><row><entry>IQRTPKIQVYS<u style="single"><b>C</b></u>HPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLL</entry><entry/></row><row><entry>YYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM.</entry></row></tbody></tgroup></table></tables></p><p id="p-0332" num="0287">in some cases, the first polypeptide and the second polypeptide of a TMMP of the present disclosure are disulfide linked to one another through: i) a Cys residue present in a linker connecting the peptide epitope and a &#x3b2;2M polypeptide in the first polypeptide chain; and ii) a Cys residue present in an MHC Class I heavy chain in the second polypeptide chain. In some cases, the Cys residue present in the MHC Class I heavy chain is a Cys introduce as a Y84C substitution. In some cases, the linker connecting the peptide epitope and the &#x3b2;2M polypeptide in the first polypeptide chain is GCGGS(G4S)n (SEQ ID NO:206), where n is 1, 2, 3, 4, 5, 6, 7, 8, or 9. For example, in some cases, the linker comprises the amino acid sequence GCGGSGGGGSGGGGSGGGGS (SEQ ID NO:207). As another example, the linker comprises the amino acid sequence GCGGSGGGGSGGGGS (SEQ ID NO:208). Examples of disulfide-linked first and second polypeptides of a TMMP of the present disclosure are depicted schematically in <figref idref="DRAWINGS">FIG. <b>1</b>A-<b>1</b>B</figref>.</p><heading id="h-0061" level="2">Immunomodulatory Polypeptides</heading><p id="p-0333" num="0288">In some cases, an immunomodulatory polypeptide present in a TMMP is a wild-type immunomodulatory polypeptide. In other cases, an immunomodulatory polypeptide present in a TMMP of the present disclosure is a variant immunomodulatory polypeptide that has reduced affinity for a co-immunomodulatory polypeptide, compared to the affinity of a corresponding wild-type immunomodulatory polypeptide for the co-immunomodulatory polypeptide. Suitable immunomodulatory domains that exhibit reduced affinity for a co-immunomodulatory domain can have from 1 amino acid (aa) to 20 aa differences from a wild-type immunomodulatory domain. For example, in some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure differs in amino acid sequence by 1 aa, 2 aa, 3 aa, 4 aa, 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, or 10 aa, from a corresponding wild-type immunomodulatory polypeptide. As another example, in some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure differs in amino acid sequence by 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, or 20 aa, from a corresponding wild-type immunomodulatory polypeptide. As an example, in some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes a single amino acid substitution compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 2 amino acid substitutions (e.g., no more than 2 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 3 amino acid substitutions (e.g., no more than 3 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 4 amino acid substitutions (e.g., no more than 4 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 5 amino acid substitutions (e.g., no more than 5 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 6 amino acid substitutions (e.g., no more than 6 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 7 amino acid substitutions (e.g., no more than 7 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 8 amino acid substitutions (e.g., no more than 8 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 9 amino acid substitutions (e.g., no more than 9 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide. In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 10 amino acid substitutions (e.g., no more than 10 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0334" num="0289">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 11 amino acid substitutions (e.g., no more than 11 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0335" num="0290">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 12 amino acid substitutions (e.g., no more than 12 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0336" num="0291">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 13 amino acid substitutions (e.g., no more than 13 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0337" num="0292">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 14 amino acid substitutions (e.g., no more than 14 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0338" num="0293">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 15 amino acid substitutions (e.g., no more than 15 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0339" num="0294">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 16 amino acid substitutions (e.g., no more than 16 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0340" num="0295">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 17 amino acid substitutions (e.g., no more than 17 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0341" num="0296">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 18 amino acid substitutions (e.g., no more than 18 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0342" num="0297">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 19 amino acid substitutions (e.g., no more than 19 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0343" num="0298">In some cases, variant immunomodulatory polypeptide present in a TMMP of the present disclosure includes 20 amino acid substitutions (e.g., no more than 20 amino acid substitutions) compared to a corresponding reference (e.g., wild-type) immunomodulatory polypeptide.</p><p id="p-0344" num="0299">As discussed above, a variant immunomodulatory polypeptide suitable for inclusion in a TMMP of the present disclosure exhibits reduced affinity for a cognate co-immunomodulatory polypeptide, compared to the affinity of a corresponding wild-type immunomodulatory polypeptide for the cognate co-immunomodulatory polypeptide.</p><p id="p-0345" num="0300">Exemplary pairs of immunomodulatory polypeptide and cognate co-immunomodulatory polypeptide include, but are not limited to:</p><p id="p-0346" num="0301">a) 4-1BBL (immunomodulatory polypeptide) and 4-1BB (cognate co-immunomodulatory polypeptide);</p><p id="p-0347" num="0302">b) PD-L1 (immunomodulatory polypeptide) and PD1 (cognate co-immunomodulatory polypeptide);</p><p id="p-0348" num="0303">c) IL-2 (immunomodulatory polypeptide) and IL-2 receptor (cognate co-immunomodulatory polypeptide);</p><p id="p-0349" num="0304">d) CD80 (immunomodulatory polypeptide) and CD86 (cognate co-immunomodulatory polypeptide);</p><p id="p-0350" num="0305">e) CD86 (immunomodulatory polypeptide) and CD28 (cognate co-immunomodulatory polypeptide);</p><p id="p-0351" num="0306">f) OX40L (CD252) (immunomodulatory polypeptide) and OX40 (CD134) (cognate co-immunomodulatory polypeptide);</p><p id="p-0352" num="0307">g) Fas ligand (immunomodulatory polypeptide) and Fas (cognate co-immunomodulatory polypeptide);</p><p id="p-0353" num="0308">h) ICOS-L (immunomodulatory polypeptide) and ICOS (cognate co-immunomodulatory polypeptide);</p><p id="p-0354" num="0309">i) ICAM (immunomodulatory polypeptide) and LFA-1 (cognate co-immunomodulatory polypeptide);</p><p id="p-0355" num="0310">j) CD30L (immunomodulatory polypeptide) and CD30 (cognate co-immunomodulatory polypeptide);</p><p id="p-0356" num="0311">k) CD40 (immunomodulatory polypeptide) and CD40L (cognate co-immunomodulatory polypeptide);</p><p id="p-0357" num="0312">l) CD83 (immunomodulatory polypeptide) and CD83L (cognate co-immunomodulatory polypeptide);</p><p id="p-0358" num="0313">m) HVEM (CD270) (immunomodulatory polypeptide) and CD160 (cognate co-immunomodulatory polypeptide);</p><p id="p-0359" num="0314">n) JAG1 (CD339) (immunomodulatory polypeptide) and Notch (cognate co-immunomodulatory polypeptide);</p><p id="p-0360" num="0315">o) JAG1 (immunomodulatory polypeptide) and CD46 (cognate co-immunomodulatory polypeptide);</p><p id="p-0361" num="0316">p) CD80 (immunomodulatory polypeptide) and CTLA4 (cognate co-immunomodulatory polypeptide);</p><p id="p-0362" num="0317">q) CD86 (immunomodulatory polypeptide) and CTLA4 (cognate co-immunomodulatory polypeptide); and</p><p id="p-0363" num="0318">r) CD70 (immunomodulatory polypeptide) and CD27 (cognate co-immunomodulatory polypeptide).</p><p id="p-0364" num="0319">In some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure has a binding affinity for a cognate co-immunomodulatory polypeptide that is from 100 nM to 100 &#x3bc;M. For example, in some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure has a binding affinity for a cognate co-immunomodulatory polypeptide that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><p id="p-0365" num="0320">A variant immunomodulatory polypeptide present in a TMMP of the present disclosure exhibits reduced affinity for a cognate co-immunomodulatory polypeptide. Similarly, a TMMP of the present disclosure that comprises a variant immunomodulatory polypeptide exhibits reduced affinity for a cognate co-immunomodulatory polypeptide. Thus, for example, a TMMP of the present disclosure that comprises a variant immunomodulatory polypeptide has a binding affinity for a cognate co-immunomodulatory polypeptide that is from 100 nM to 100 &#x3bc;M. For example, in some cases, a TMMP of the present disclosure that comprises a variant immunomodulatory polypeptide has a binding affinity for a cognate co-immunomodulatory polypeptide that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><heading id="h-0062" level="2">CD80 Variants</heading><p id="p-0366" num="0321">In some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure is a variant CD80 polypeptide. Wild-type CD80 binds to CD28. Wild-type CD80 also binds to CD86.</p><p id="p-0367" num="0322">A wild-type amino acid sequence of the ectodomain of human CD80 can be as follows:</p><p id="p-0368" num="0000"><tables id="TABLE-US-00044" num="00044"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;435)</entry><entry/></row><row><entry>VIHVTK&#x2003;EVKEVATLSC&#x2003;GHNVSVEELA&#x2003;QTRIYWQKEK&#x2003;KMVLTMMSGD</entry><entry/></row><row><entry> </entry></row><row><entry>MNIWPEYKNR&#x2003;TIFDITNNLS&#x2003;IVILALRPSD&#x2003;EGTYECVVLK&#x2003;YEKDAFKREH&#x2003;LAEVTLSVKA</entry></row><row><entry> </entry></row><row><entry>DFPTPSISDF&#x2003;EIPTSNIRRIICSTSGGFPE&#x2003;PHLSWLENGE&#x2003;ELNAINTTVS&#x2003;QDPETELYAV</entry></row><row><entry> </entry></row><row><entry>SSKLDFNMTT&#x2003;NHSFMCLIKY&#x2003;GHLRVNQTFN&#x2003;WNTTKQEHFP&#x2003;DN.</entry></row></tbody></tgroup></table></tables></p><p id="p-0369" num="0323">A wild-type CD28 amino acid sequence can be as follows: MLRLLLALNL FPSIQVTGNK ILVKQSPMLV AYDNAVNLSC KYSYNLFSRE FRASLHKGLD SAVEVCVVYG NYSQQLQVYS KTGFNCDGKL GNESVTFYLQ NLYVNQTDIY FCKIEVMYPP PYLDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS (SEQ ID NO:436). In some cases, where a TMMP of the present disclosure comprises a variant CD80 polypeptide, a &#x201c;cognate co-immunomodulatory polypeptide&#x201d; is a CD28 polypeptide comprising the amino acid sequence of SEQ ID NO:5.</p><p id="p-0370" num="0324">A wild-type CD28 amino acid sequence can be as follows: MLRLLLALNL FPSIQVTGNK ILVKQSPMLV AYDNAVNLSW KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRS (SEQ ID NO:437)</p><p id="p-0371" num="0325">A wild-type CD28 amino acid sequence can be as follows: MLRLLLALNL FPSIQVTGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR S (SEQ ID NO:438).</p><p id="p-0372" num="0326">In some cases, a variant CD80 polypeptide exhibits reduced binding affinity to CD28, compared to the binding affinity of a CD80 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:4 for CD28. For example, in some cases, a variant CD80 polypeptide binds CD28 with a binding affinity that is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than the binding affinity of a CD80 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:4 for CD28 (e.g., a CD28 polypeptide comprising the amino acid sequence set forth in one of SEQ ID NO:436, 437, or 438).</p><p id="p-0373" num="0327">In some cases, a variant CD80 polypeptide has a binding affinity to CD28 that is from 100 nM to 100 &#x3bc;M. As another example, in some cases, a variant CD80 polypeptide of the present disclosure has a binding affinity for CD28 (e.g., a CD28 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7) that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><p id="p-0374" num="0328">In some cases, a variant CD80 polypeptide has a single amino acid substitution compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has from 2 to 10 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 2 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 3 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 4 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 5 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 6 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 7 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 8 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 9 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435. In some cases, a variant CD80 polypeptide has 10 amino acid substitutions compared to the CD80 amino acid sequence set forth in SEQ ID NO:435.</p><p id="p-0375" num="0329">Suitable CD80 variants include a polypeptide that comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the following amino acid sequences:</p><p id="p-0376" num="0330">VIHVTK EVKEVATLSC GH<u style="single">X</u>VSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:209), where X is any amino acid other than Asn. In some cases, X is Ala;</p><p id="p-0377" num="0331">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDIT<u style="single">X</u>NLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:210), where X is any amino acid other than Asn. In some cases, X is Ala;</p><p id="p-0378" num="0332">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS <u style="single">X</u>VILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:211), where X is any amino acid other than Ile. In some cases, X is Ala;</p><p id="p-0379" num="0333">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVL<u style="single">X</u>YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:212), where X is any amino acid other than Lys. In some cases, X is Ala;</p><p id="p-0380" num="0334">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS <u style="single">X</u>DPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:213), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0381" num="0335">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS Q<u style="single">X</u>PETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:214), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0382" num="0336">VIHVTK EVKEVATLSC GHNVSVEE<u style="single">X</u>A QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:215), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0383" num="0337">VIHVTK EVKEVATLSC GHNVSVEELA QTRI<u style="single">X</u>WQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:216), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0384" num="0338">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYW<u style="single">X</u>KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:217), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0385" num="0339">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK K<u style="single">X</u>VLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:218), where X is any amino acid other than Met. In some cases, X is Ala;</p><p id="p-0386" num="0340">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KM<u style="single">X</u>LTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:219), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0387" num="0341">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MN<u style="single">X</u>WPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:220), where X is any amino acid other than Ile. In some cases, X is Ala;</p><p id="p-0388" num="0342">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPE<u style="single">X</u>KNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:221), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0389" num="0343">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIF<u style="single">X</u>IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:222), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0390" num="0344">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA D<u style="single">X</u>PTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:223), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0391" num="0345">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTV<u style="single">X</u>QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:224), where X is any amino acid other than Ser. In some cases, X is Ala; and</p><p id="p-0392" num="0346">VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPT<u style="single">X</u>SISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:225), where X is any amino acid other than Pro. In some cases, X is Ala.</p><heading id="h-0063" level="2">CD86 Variants</heading><p id="p-0393" num="0347">In some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure is a variant CD86 polypeptide. Wild-type CD86 binds to CD28. In some cases, where a TMMP of the present disclosure comprises a variant CD86 polypeptide, a &#x201c;cognate co-immunomodulatory polypeptide&#x201d; is a CD28 polypeptide comprising the amino acid sequence of SEQ ID NO:5.</p><p id="p-0394" num="0348">The amino acid sequence of the full ectodomain of a wild-type human CD86 can be as follows:</p><p id="p-0395" num="0000"><tables id="TABLE-US-00045" num="00045"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="294pt" align="right"/><colspec colname="2" colwidth="147pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;226)</entry><entry/></row><row><entry>APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYM<u style="single"><b>N</b></u>RTSF<u style="single"><b>D</b></u>SDS<u style="single"><b>W</b></u></entry><entry/></row><row><entry> </entry></row><row><entry>TLRLHNLQIKDKGLYQCII<u style="single"><b>H</b></u>HKKPTGMIRIHQMNSELSV<b>L</b>ANFSQPEIVPISNITENVYINLTCSSIHGY</entry></row><row><entry> </entry></row><row><entry>PEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFS</entry></row><row><entry> </entry></row><row><entry>IELEDPQPPPDHIP.</entry></row></tbody></tgroup></table></tables></p><p id="p-0396" num="0349">The amino acid sequence of the IgV domain of a wild-type human CD86 can be as follows:</p><p id="p-0397" num="0000"><tables id="TABLE-US-00046" num="00046"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="294pt" align="right"/><colspec colname="2" colwidth="147pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;227)</entry><entry/></row><row><entry>APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYM<u style="single"><b>N</b></u>RTSF<u style="single"><b>D</b></u>SDS<u style="single"><b>W</b></u></entry><entry/></row><row><entry>TLRLHNLQIKDKGLYQCII<u style="single"><b>H</b></u>HKKPTGMIRIHQMNSELSVL.</entry></row></tbody></tgroup></table></tables></p><p id="p-0398" num="0350">In some cases, a variant CD86 polypeptide exhibits reduced binding affinity to CD28, compared to the binding affinity of a CD86 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:226 or SEQ ID NO:227 for CD28. For example, in some cases, a variant CD86 polypeptide binds CD28 with a binding affinity that is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than the binding affinity of a CD86 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:226 or SEQ ID NO:227 for CD28 (e.g., a CD28 polypeptide comprising the amino acid sequence set forth in one of SEQ ID NO:436, 437, or 438).</p><p id="p-0399" num="0351">In some cases, a variant CD86 polypeptide has a binding affinity to CD28 that is from 100 nM to 100 &#x3bc;M. As another example, in some cases, a variant CD86 polypeptide of the present disclosure has a binding affinity for CD28 (e.g., a CD28 polypeptide comprising the amino acid sequence set forth in one of SEQ ID NOs:5, 6, or 7) that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><p id="p-0400" num="0352">In some cases, a variant CD86 polypeptide has a single amino acid substitution compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has from 2 to 10 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 2 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 3 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 4 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 5 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 6 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 7 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 8 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 9 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226. In some cases, a variant CD86 polypeptide has 10 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:226.</p><p id="p-0401" num="0353">In some cases, a variant CD86 polypeptide has a single amino acid substitution compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has from 2 to 10 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 2 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 3 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 4 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 5 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 6 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 7 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 8 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 9 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227. In some cases, a variant CD86 polypeptide has 10 amino acid substitutions compared to the CD86 amino acid sequence set forth in SEQ ID NO:227.</p><p id="p-0402" num="0354">Suitable CD86 variants include a polypeptide that comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the following amino acid sequences:</p><p id="p-0403" num="0355">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY M<u style="single">X</u>RTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:228), where X is any amino acid other than Asn. In some cases, X is Ala;</p><p id="p-0404" num="0356">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSF<u style="single">X</u>SDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:229), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0405" num="0357">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDS<u style="single">X</u>TLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:230), where X is any amino acid other than Trp. In some cases, X is Ala;</p><p id="p-0406" num="0358">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIH<u style="single">X</u>KKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:231), where X is any amino acid other than His. In some cases, X is Ala;</p><p id="p-0407" num="0359">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY M<u style="single">X</u>RTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:232), where X is any amino acid other than Asn. In some cases, X is Ala;</p><p id="p-0408" num="0360">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSF<u style="single">X</u>SDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:233), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0409" num="0361">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDS<u style="single">X</u>TLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:234), where X is any amino acid other than Trp. In some cases, X is Ala;</p><p id="p-0410" num="0362">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIH<u style="single">X</u>KKPTGMIRIHQMNSELSVL (SEQ ID NO:235), where X is any amino acid other than His. In some cases, X is Ala;</p><p id="p-0411" num="0363">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENL<u style="single">X</u>LNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:236), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0412" num="0364">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENL<u style="single">X</u>LNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:237), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0413" num="0365">APLKIQAYFNETADLPCQFANSQNQSLSELVVFW<u style="single">X</u>DQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:238), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0414" num="0366">APLKIQAYFNETADLPCQFANSQNQSLSELVVFW<u style="single">X</u>DQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:239), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0415" num="0367">APLKIQAYFNETADLPCQFANSQNQSLSELVV<u style="single">X</u>WQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:240), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0416" num="0368">APLKIQAYFNETADLPCQFANSQNQSLSELVV<u style="single">X</u>WQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:241), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0417" num="0369">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWT<u style="single">X</u>RLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:242), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0418" num="0370">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSFDSDSWT<u style="single">X</u>RLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:243), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0419" num="0371">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSK<u style="single">X</u> MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:244), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0420" num="0372">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSK<u style="single">X</u> MNRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVL (SEQ ID NO:245), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0421" num="0373">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MXRTSFDSDSWTLRLHNLQIKDKGLYQCIIH<u style="single">X</u>KKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVY INLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILET DKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:246), where the first X is any amino acid other than Asn and the second X is any amino acid other than His. In some cases, the first and the second X are both Ala;</p><p id="p-0422" num="0374">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY M<u style="single">X</u>RTSFDSDSWTLRLHNLQIKDKGLYQCIIH<u style="single">X</u>KKPTGMIRIHQMNSELSVL (SEQ ID NO:247), where the first X is any amino acid other than Asn and the second X is any amino acid other than His. In some cases, the first and the second X are both Ala;</p><p id="p-0423" num="0375">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSF<u style="single">X</u><sub>1</sub>SDSWTLRLHNLQIKDKGLYQCIIH<u style="single">X</u><sub>2</sub>KKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENV YINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILE TDKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:248), where X<sub>1 </sub>is any amino acid other than Asp, and X<sub>2 </sub>is any amino acid other than His. In some cases, X<sub>1 </sub>is Ala and X<sub>2 </sub>is Ala;</p><p id="p-0424" num="0376">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MNRTSF<u style="single">X</u><sub>1</sub>SDSWILRLHNLQIKDKGLYQCIIH<u style="single">X</u><sub>2</sub>KKPTGMIRIHQMNSELSVL (SEQ ID NO:249), where the first X is any amino acid other than Asn and the second X is any amino acid other than His. In some cases, the first and the second X are both Ala;</p><p id="p-0425" num="0377">APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY M<u style="single">X</u><sub>1</sub>RTSF<u style="single">X</u><sub>2</sub>SDSWITRLHNLQIKDKGLYQCIIH<u style="single">X</u><sub>3</sub>KKPTGMIRIHQMNSELSVLANFSQPEIVPISNITEN VYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCIL ETDKTRLLSSPFSIELEDPQPPPDHIP (SEQ ID NO:250), where X<sub>1 </sub>is any amino acid other than Asn, X<sub>2 </sub>is any amino acid other than Asp, and X<sub>3 </sub>is any amino acid other than His. In some cases, X<sub>1 </sub>is Ala, X<sub>2 </sub>is Ala, and X<sub>3 </sub>is Ala; and</p><p id="p-0426" num="0000"><tables id="TABLE-US-00047" num="00047"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;251)</entry></row><row><entry>APLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKE</entry></row><row><entry>KFDSVHSKYM<u style="single"><b>X</b><sub>1</sub></u>RTSF<u style="single"><b>X</b><sub>2</sub></u>SDSWTLRLHNLQIKDKGLYQCIIH<u style="single"><b>X</b><sub>3</sub></u>KKPTGMI</entry></row><row><entry>RIHQMNSELSVL,</entry></row></tbody></tgroup></table></tables><br/>where X<sub>1 </sub>is any amino acid other than Asn, X<sub>2 </sub>is any amino acid other than Asp, and X<sub>3 </sub>is any amino acid other than His. In some cases, X<sub>1 </sub>is Ala, X<sub>2 </sub>is Ala, and X<sub>3 </sub>is Ala.</p><heading id="h-0064" level="2">4-1BBL Variants</heading><p id="p-0427" num="0378">In some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure is a variant 4-1BBL polypeptide. Wild-type 4-1BBL binds to 4-1BB (CD137).</p><p id="p-0428" num="0379">A wild-type 4-1BBL amino acid sequence can be as follows:</p><p id="p-0429" num="0000"><tables id="TABLE-US-00048" num="00048"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="right"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;252)</entry><entry/></row><row><entry>MEYASDASLD</entry><entry/></row><row><entry> </entry></row><row><entry>PEAPWPPAPR&#x2003;ARACRVLP<u style="single">WA</u>&#x2003;<u style="single">LVAGLLLLLL&#x2003;LAAACAVFL</u>A&#x2003;CPWAVSGARA&#x2003;SPGSAASPRL</entry></row><row><entry> </entry></row><row><entry>REGPELSPDD&#x2003;PAGLLDLRQG&#x2003;MFAQLVAQNV&#x2003;LLIDGPLSWY&#x2003;SDPGLAGVSL&#x2003;TGGLSYKEDT</entry></row><row><entry> </entry></row><row><entry>KELVVAKAGV&#x2003;YYVFFQLELR&#x2003;RVVAGEGSGS&#x2003;VSLALHLQPL&#x2003;RSAAGAAALA&#x2003;LTVDLPPASS</entry></row><row><entry> </entry></row><row><entry>EARNSAFGFQ&#x2003;GRLLHLSAGQ&#x2003;RLGVHLHTEA&#x2003;RARHAWQLTQ&#x2003;GATVLGLFRV&#x2003;TPEIPAGLPS</entry></row><row><entry> </entry></row><row><entry>PRSE.</entry></row></tbody></tgroup></table></tables></p><p id="p-0430" num="0380">In some cases, a variant 4-1BBL polypeptide is a variant of the tumor necrosis factor (TNF) homology domain (THD) of human 4-1BBL.</p><p id="p-0431" num="0381">A wild-type amino acid sequence of the THD of human 4-1BBL can be, e.g., one of SEQ ID NOs:253-255, as follows:</p><p id="p-0432" num="0000"><tables id="TABLE-US-00049" num="00049"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="287pt" align="right"/><colspec colname="2" colwidth="154pt" align="left"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;253)</entry><entry/></row><row><entry>PAGLLDLRQG&#x2003;MFAQLVAQNV&#x2003;LLIDGPLSWY&#x2003;SDPGLAGVSL&#x2003;TGGLSYKEDT</entry><entry/></row><row><entry> </entry></row><row><entry>KELVVAKAGV&#x2003;YYVFFQLELR&#x2003;RVVAGEGSGS&#x2003;VSLALHLQPL&#x2003;RSAAGAAALA&#x2003;LTVDLPPASS</entry></row><row><entry> </entry></row><row><entry>EARNSAFGFQ&#x2003;GRLLHLSAGQ&#x2003;RLGVHLHTEA&#x2003;RARHAWQLTQ&#x2003;GATVLGLFRV&#x2003;TPEIPAGLPS</entry></row><row><entry> </entry></row><row><entry>PRSE.</entry></row><row><entry> </entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;254)</entry><entry/></row><row><entry>D&#x2003;PAGLLDLRQG&#x2003;MFAQLVAQNV&#x2003;LLIDGPLSWY&#x2003;SDPGLAGVSL&#x2003;TGGLSYKEDT</entry><entry/></row><row><entry> </entry></row><row><entry>KELVVAKAGV&#x2003;YYVFFQLELR&#x2003;RVVAGEGSGS&#x2003;VSLALHLQPL&#x2003;RSAAGAAALA&#x2003;LTVDLPPASS</entry></row><row><entry> </entry></row><row><entry>EARNSAFGFQ&#x2003;GRLLHLSAGQ&#x2003;RLGVHLHTEA&#x2003;RARHAWQLTQ&#x2003;GATVLGLFRV&#x2003;TPEIPAGLPS</entry></row><row><entry> </entry></row><row><entry>PRSE.</entry></row><row><entry> </entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;255)</entry><entry/></row><row><entry>D&#x2003;PAGLLDLRQG&#x2003;MFAQLVAQNV&#x2003;LLIDGPLSWY&#x2003;SDPGLAGVSL&#x2003;TGGLSYKEDT</entry><entry/></row><row><entry> </entry></row><row><entry>KELVVAKAGV&#x2003;YYVFFQLELR&#x2003;RVVAGEGSGS&#x2003;VSLALHLQPL&#x2003;RSAAGAAALA&#x2003;LTVDLPPASS</entry></row><row><entry> </entry></row><row><entry>EARNSAFGFQ&#x2003;GRLLHLSAGQ&#x2003;RLGVHLHTEA&#x2003;RARHAWQLTQ&#x2003;GATVLGLFRV&#x2003;TPEIPA.</entry></row></tbody></tgroup></table></tables></p><p id="p-0433" num="0382">A wild-type 4-1BB amino acid sequence can be as follows: MGNSCYNIVA TLLLVLNFER TRSLQDPCSN CPAGTFCDNN RNQICSPCPP NSFSSAGGQR TCDICRQCKG VFRTRKECSS TSNAECDCTP GFHCLGAGCS MCEQDCKQGQ ELTKKGCKDC CFGTFNDQKR GICRPWTNCS LDGKSVLVNG TKERDVVCGP SPADLSPGAS SVTPPAPARE PGHSPQIISF FLALTSTALL FLLFFLTLRF SVVKRGRKKL LYIFKQPFMR PVQTTQEEDG CSCRFPEEEE GGCEL (SEQ ID NO:434). In some cases, where a TMMP of the present disclosure comprises a variant 4-1BBL polypeptide, a &#x201c;cognate co-immunomodulatory polypeptide&#x201d; is a 4-1BB polypeptide comprising the amino acid sequence of SEQ ID NO:434.</p><p id="p-0434" num="0383">In some cases, a variant 4-1BBL polypeptide exhibits reduced binding affinity to 4-1BB, compared to the binding affinity of a 4-1BBL polypeptide comprising the amino acid sequence set forth in one of SEQ ID NOs:252-255. For example, in some cases, a variant 4-1BBL polypeptide of the present disclosure binds 4-1BB with a binding affinity that is at least 10% less, at least 15% less, at least 20% less, at least 25%, at least 30% less, at least 35% less, at least 40% less, at least 45% less, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than the binding affinity of a 4-1BBL polypeptide comprising the amino acid sequence set forth in one of SEQ ID NOs:252-255 for a 4-1BB polypeptide (e.g., a 4-1BB polypeptide comprising the amino acid sequence set forth in SEQ ID NO:434), when assayed under the same conditions.</p><p id="p-0435" num="0384">In some cases, a variant 4-1BBL polypeptide has a binding affinity to 4-1BB that is from 100 nM to 100 &#x3bc;M. As another example, in some cases, a variant 4-1BBL polypeptide has a binding affinity for 4-1BB (e.g., a 4-1BB polypeptide comprising the amino acid sequence set forth in SEQ ID NO:14) that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><p id="p-0436" num="0385">In some cases, a variant 4-1BBL polypeptide has a single amino acid substitution compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has from 2 to 10 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 2 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:10-13. In some cases, a variant 4-1BBL polypeptide has 3 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 4 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 5 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 6 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 7 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 8 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 9 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255. In some cases, a variant 4-1BBL polypeptide has 10 amino acid substitutions compared to the 4-1BBL amino acid sequence set forth in one of SEQ ID NOs:252-255.</p><p id="p-0437" num="0386">Suitable 4-1BBL variants include a polypeptide that comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the following amino acid sequences:</p><p id="p-0438" num="0387">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSY<u style="single">X</u>EDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:256), where X is any amino acid other than Lys. In some cases, X is Ala;</p><p id="p-0439" num="0388">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAW<u style="single">X</u>LTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:257), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0440" num="0389">PAGLLDLRQG <u style="single">X</u>FAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:258), where X is any amino acid other than Met. In some cases, X is Ala;</p><p id="p-0441" num="0390">PAGLLDLRQG M<u style="single">X</u>AQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:259), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0442" num="0391">PAGLLDLRQG MFA<u style="single">X</u>LVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:260), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0443" num="0392">PAGLLDLRQG MFAQ<u style="single">X</u>VAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:261), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0444" num="0393">PAGLLDLRQG MFAQL<u style="single">X</u>AQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:262), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0445" num="0394">PAGLLDLRQG MFAQLVA<u style="single">X</u>NV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:263), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0446" num="0395">PAGLLDLRQG MFAQLVAQ<u style="single">X</u>V LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:264), where X is any amino acid other than Asn. In some cases, X is Ala;</p><p id="p-0447" num="0396">PAGLLDLRQG MFAQLVAQN<u style="single">X</u> LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:265), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0448" num="0397">PAGLLDLRQG MFAQLVAQNV <u style="single">X</u>LIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:266), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0449" num="0398">PAGLLDLRQG MFAQLVAQNV L<u style="single">X</u>IDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:267), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0450" num="0399">PAGLLDLRQG MFAQLVAQNV LL<u style="single">X</u>DGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:268), where X is any amino acid other than Ile. In some cases, X is Ala;</p><p id="p-0451" num="0400">PAGLLDLRQG MFAQLVAQNV LLI<u style="single">X</u>GPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:269), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0452" num="0401">PAGLLDLRQG MFAQLVAQNV LLID<u style="single">X</u>PLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:270), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0453" num="0402">PAGLLDLRQG MFAQLVAQNV LLIDG<u style="single">X</u>LSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:271), where X is any amino acid other than Pro. In some cases, X is Ala;</p><p id="p-0454" num="0403">PAGLLDLRQG MFAQLVAQNV LLIDGP<u style="single">X</u>SWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:272), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0455" num="0404">PAGLLDLRQG MFAQLVAQNV LLIDGPL<u style="single">X</u>WY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:273), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0456" num="0405">PAGLLDLRQG MFAQLVAQNV LLIDGPLS<u style="single">X</u>Y SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:274), where X is any amino acid other than Trp. In some cases, X is Ala;</p><p id="p-0457" num="0406">PAGLLDLRQG MFAQLVAQNV LLIDGPLSW<u style="single">X</u> SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:275), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0458" num="0407">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY <u style="single">X</u>DPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:276), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0459" num="0408">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY S<u style="single">X</u>PGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:277), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0460" num="0409">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SD<u style="single">X</u>GLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:278), where X is any amino acid other than Pro. In some cases, X is Ala;</p><p id="p-0461" num="0410">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDP<u style="single">X</u>LAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:279), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0462" num="0411">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPG<u style="single">X</u>AGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:280), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0463" num="0412">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLA<u style="single">X</u>VSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:281), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0464" num="0413">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAG<u style="single">X</u>SL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:282), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0465" num="0414">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGV<u style="single">X</u>L TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:283), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0466" num="0415">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVS<u style="single">X</u> TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:284), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0467" num="0416">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL <u style="single">X</u>GGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:285), where X is any amino acid other than Thr. In some cases, X is Ala;</p><p id="p-0468" num="0417">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL T<u style="single">X</u>GLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:286), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0469" num="0418">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TG<u style="single">X</u>LSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:287), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0470" num="0419">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGG<u style="single">X</u>SYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:288), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0471" num="0420">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGL<u style="single">X</u>YKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:289), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0472" num="0421">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLS<u style="single">X</u>KEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:290), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0473" num="0422">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYK<u style="single">X</u>DT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:291), where X is any amino acid other than Glu. In some cases, X is Ala;</p><p id="p-0474" num="0423">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKE<u style="single">X</u>T KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:292), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0475" num="0424">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKED<u style="single">X</u> KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:293), where X is any amino acid other than Thr. In some cases, X is Ala;</p><p id="p-0476" num="0425">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT <u style="single">X</u>ELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:294), where X is any amino acid other than Lys. In some cases, X is Ala;</p><p id="p-0477" num="0426">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT K<u style="single">X</u>LVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:295), where X is any amino acid other than Glu. In some cases, X is Ala;</p><p id="p-0478" num="0427">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYV<u style="single">X</u>FQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:296), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0479" num="0428">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVF<u style="single">X</u>QLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:297), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0480" num="0429">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFF<u style="single">X</u>LELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:298), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0481" num="0430">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQ<u style="single">X</u>ELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:299), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0482" num="0431">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQL<u style="single">X</u>LR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:300), where X is any amino acid other than Glu. In some cases, X is Ala;</p><p id="p-0483" num="0432">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLE<u style="single">X</u>R RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:301), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0484" num="0433">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLEL<u style="single">X</u> RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:302), where X is any amino acid other than Arg. In some cases, X is Ala;</p><p id="p-0485" num="0434">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR <u style="single">X</u>VVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:303), where X is any amino acid other than Arg. In some cases, X is Ala;</p><p id="p-0486" num="0435">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR R<u style="single">X</u>VAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:304), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0487" num="0436">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RV<u style="single">X</u>AGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:305), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0488" num="0437">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVA<u style="single">X</u>EGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:306), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0489" num="0438">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAG<u style="single">X</u>GSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:307), where X is any amino acid other than Glu. In some cases, X is Ala;</p><p id="p-0490" num="0439">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGE<u style="single">X</u>SGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:308), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0491" num="0440">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEG<u style="single">X</u>GS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:309), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0492" num="0441">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTV<u style="single">X</u>LPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:310), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0493" num="0442">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVD<u style="single">X</u>PPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:311), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0494" num="0443">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDL<u style="single">X</u>PASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:312), where X is any amino acid other than Pro. In some cases, X is Ala;</p><p id="p-0495" num="0444">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPA<u style="single">X</u>S EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:313), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0496" num="0445">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPAS<u style="single">X</u> EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:314), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0497" num="0446">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS <u style="single">X</u>ARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:315), where X is any amino acid other than Glu. In some cases, X is Ala;</p><p id="p-0498" num="0447">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EA<u style="single">X</u>NSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:316), where X is any amino acid other than Arg. In some cases, X is Ala;</p><p id="p-0499" num="0448">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EAR<u style="single">X</u>SAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:317), where X is any amino acid other than Asn. In some cases, X is Ala;</p><p id="p-0500" num="0449">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARN<u style="single">X</u>AFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:318), where X is any amino acid other than Ser. In some cases, X is Ala;</p><p id="p-0501" num="0450">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSA<u style="single">X</u>GFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:319), where X is any amino acid other than Phe. In some cases, X is Ala;</p><p id="p-0502" num="0451">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAG<u style="single">X</u> RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:320), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0503" num="0452">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ <u style="single">X</u>LGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:321), where X is any amino acid other than Arg. In some cases, X is Ala;</p><p id="p-0504" num="0453">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ R<u style="single">X</u>GVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:322), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0505" num="0454">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RL<u style="single">X</u>VHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:323), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0506" num="0455">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLG<u style="single">X</u>HLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:324), where X is any amino acid other than Val. In some cases, X is Ala;</p><p id="p-0507" num="0456">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGV<u style="single">X</u>LHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:325), where X is any amino acid other than His. In some cases, X is Ala;</p><p id="p-0508" num="0457">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVH<u style="single">X</u>HTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:326), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0509" num="0458">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHL<u style="single">X</u>TEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:327), where X is any amino acid other than His. In some cases, X is Ala;</p><p id="p-0510" num="0459">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLH<u style="single">X</u>EA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:328), where X is any amino acid other than Thr. In some cases, X is Ala;</p><p id="p-0511" num="0460">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHT<u style="single">X</u>A RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:329), where X is any amino acid other than Glu. In some cases, X is Ala;</p><p id="p-0512" num="0461">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA <u style="single">X</u>ARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:330), where X is any amino acid other than Arg. In some cases, X is Ala;</p><p id="p-0513" num="0462">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RA<u style="single">X</u>HAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:331), where X is any amino acid other than Arg. In some cases, X is Ala;</p><p id="p-0514" num="0463">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RAR<u style="single">X</u>AWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:332), where X is any amino acid other than His. In some cases, X is Ala;</p><p id="p-0515" num="0464">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHA<u style="single">X</u>QLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:333), where X is any amino acid other than Trp. In some cases, X is Ala;</p><p id="p-0516" num="0465">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQ<u style="single">X</u>TQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:334), where X is any amino acid other than Leu. In some cases, X is Ala;</p><p id="p-0517" num="0466">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQL<u style="single">X</u>Q GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:335), where X is any amino acid other than Thr. In some cases, X is Ala;</p><p id="p-0518" num="0467">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLT<u style="single">X</u> GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:336), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0519" num="0468">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ <u style="single">X</u>ATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:337), where X is any amino acid other than Gly. In some cases, X is Ala;</p><p id="p-0520" num="0469">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GA<u style="single">X</u>VLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:338), where X is any amino acid other than Thr. In some cases, X is Ala; and</p><p id="p-0521" num="0470">PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYKEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GAT<u style="single">X</u>LGLFRV TPEIPAGLPS PRSE (SEQ ID NO:339), where X is any amino acid other than Val. In some cases, X is Ala.</p><heading id="h-0065" level="2">IL-2 Variants</heading><p id="p-0522" num="0471">In some cases, a variant immunomodulatory polypeptide present in a TMMP of the present disclosure is a variant IL-2 polypeptide. Wild-type IL-2 binds to IL-2 receptor (IL-2R), i.e., a heterotrimeric polypeptide comprising IL-2R&#x3b1;, IL-2R&#x3b2;, and IL-2R&#x3b3;.</p><p id="p-0523" num="0472">A wild-type IL-2 amino acid sequence can be as follows: APTSSSTKKT QLQL<u style="single">EH</u>LLL<u style="single">D</u> LQMILNGINN YKNPKLTRML T<u style="single">F</u>KF<u style="single">Y</u>MPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFC<u style="single">Q</u>SIIS TLT (SEQ ID NO:340).</p><p id="p-0524" num="0473">Wild-type IL2 binds to an IL2 receptor (IL2R) on the surface of a cell. An IL2 receptor is in some cases a heterotrimeric polypeptide comprising an alpha chain (IL-2R&#x3b1;; also referred to as CD25), a beta chain (IL-2R&#x3b2;; also referred to as CD122: and a gamma chain (IL-2R&#x3b3;; also referred to as CD132). Amino acid sequences of human IL-2R&#x3b1;, IL2R&#x3b2;, and IL-2Ry can be as follows.</p><p id="p-0525" num="0000"><tables id="TABLE-US-00050" num="00050"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="280pt" align="left"/><colspec colname="2" colwidth="161pt" align="left"/><tbody valign="top"><row><entry>Human&#x2003;IL-2R&#x3b1;:</entry><entry/></row><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;341)</entry><entry/></row><row><entry>ELCDDDPPE&#x2003;IPHATFKAMA&#x2003;YKEGTMLNCE&#x2003;CKRGFRRIKS</entry><entry/></row><row><entry> </entry></row><row><entry>GSLYMLCTGN&#x2003;SSHSSWDNQC&#x2003;QCTSSATRNT&#x2003;TKQVTPQPEE&#x2003;QKERKTTEMQ&#x2003;SPMQPVDQAS</entry></row><row><entry> </entry></row><row><entry>LPGHCREPPP&#x2003;WENEATERIY&#x2003;HFVVGQMVYY&#x2003;QCVQGYRALH&#x2003;RGPAESVCKM&#x2003;THGKTRWTQP</entry></row><row><entry> </entry></row><row><entry>QLICTGEMET&#x2003;SQFPGEEKPQ&#x2003;ASPEGRPESE&#x2003;TSCLVTTTDF&#x2003;QIQTEMAATM&#x2003;ETSIFTTEYQ</entry></row><row><entry> </entry></row><row><entry>VAVAGCVFLL&#x2003;ISVLLLSGLT&#x2003;WQRRQRKSRR&#x2003;TI.</entry></row><row><entry> </entry></row><row><entry>Human&#x2003;IL-2R&#x3b2;:</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;342)</entry><entry/></row><row><entry>VNG&#x2003;TSQFTCFYNS&#x2003;RANISCVWSQ&#x2003;DGALQDTSCQ</entry><entry/></row><row><entry> </entry></row><row><entry>VHAWPDRRRW&#x2003;NQTCELLPVS&#x2003;QASWACNLIL&#x2003;GAPDSQKLTT&#x2003;VDIVTLRVLC&#x2003;REGVRWRVMA</entry></row><row><entry> </entry></row><row><entry>IQDFKPFENL&#x2003;RLMAPISLQV&#x2003;VHVETHRCNI&#x2003;SWEISQASHY&#x2003;FERHLEFEAR&#x2003;TLSPGHTWEE</entry></row><row><entry> </entry></row><row><entry>APLLTLKQKQ&#x2003;EWICLETLTP&#x2003;DTQYEFQVRV&#x2003;KPLQGEFTTW&#x2003;SPWSQPLAFR&#x2003;TKPAALGKDT</entry></row><row><entry> </entry></row><row><entry>IPWLGHLLVG&#x2003;LSGAFGFIIL&#x2003;VYLLINCRNT&#x2003;GPWLKKVLKC&#x2003;NTPDPSKFFS&#x2003;QLSSEHGGDV</entry></row><row><entry> </entry></row><row><entry>QKWLSSPFPS&#x2003;SSFSPGGLAP&#x2003;EISPLEVLER&#x2003;DKVTQLLLQQ&#x2003;DKVPEPASLS&#x2003;SNHSLTSCFT</entry></row><row><entry> </entry></row><row><entry>NQGYFFFHLP&#x2003;DALEIEACQV&#x2003;YFTYDPYSEE&#x2003;DPDEGVAGAP&#x2003;TGSSPQPLQP&#x2003;LSGEDDAYCT</entry></row><row><entry> </entry></row><row><entry>FPSRDDLLLF&#x2003;SPSLLGGPSP&#x2003;PSTAPGGSGA&#x2003;GEERMPPSLQ&#x2003;ERVPRDWDPQ&#x2003;PLGPPTPGVP</entry></row><row><entry> </entry></row><row><entry>DLVDFQPPPE&#x2003;LVLREAGEEV&#x2003;PDAGPREGVS&#x2003;FPWSRPPGQG&#x2003;EFRALNARLP&#x2003;LNTDAYLSLQ</entry></row><row><entry> </entry></row><row><entry>ELQGQDPTHL&#x2003;V.</entry></row><row><entry> </entry></row><row><entry>Human&#x2003;IL-2R&#x3b3;:</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;343)</entry><entry/></row><row><entry>LNTTILTP&#x2003;NGNEDTTADF&#x2003;FLTTMPTDSL&#x2003;SVSTLPLPEV</entry><entry/></row><row><entry> </entry></row><row><entry>QCFVFNVEYM&#x2003;NCTWNSSSEP&#x2003;QPTNLTLHYW&#x2003;YKNSDNDKVQ&#x2003;KCSHYLFSEE&#x2003;ITSGCQLQKK</entry></row><row><entry> </entry></row><row><entry>EIHLYQTFVV&#x2003;QLQDPREPRR&#x2003;QATQMLKLQN&#x2003;LVIPWAPENL&#x2003;TLHKLSESQL&#x2003;ELNWNNRFLN</entry></row><row><entry> </entry></row><row><entry>HCLEHLVQYR&#x2003;TDWDHSWTEQ&#x2003;SVDYRHKFSL&#x2003;PSVDGQKRYT&#x2003;FRVRSRFNPL&#x2003;CGSAQHWSEW</entry></row><row><entry> </entry></row><row><entry>SHPIHWGSNT&#x2003;SKENPFLFAL&#x2003;EAVVISVGSM&#x2003;GLIISLLCVY&#x2003;FWLERTMPRI&#x2003;PTLKNLEDLV</entry></row><row><entry> </entry></row><row><entry>TEYHGNFSAW&#x2003;SGVSKGLAES&#x2003;LQPDYSERLC&#x2003;LVSEIPPKGG&#x2003;ALGEGPGASP&#x2003;CNQHSPYWAP</entry></row><row><entry> </entry></row><row><entry>PCYTLKPET.</entry></row></tbody></tgroup></table></tables></p><p id="p-0526" num="0474">In some cases, where a TMMP of the present disclosure comprises a variant IL-2 polypeptide, a &#x201c;cognate co-immunomodulatory polypeptide&#x201d; is an IL-2R comprising polypeptides comprising the amino acid sequences of SEQ ID NO:16, 17, and 18.</p><p id="p-0527" num="0475">In some cases, a variant IL-2 polypeptide exhibits reduced binding affinity to IL-2R, compared to the binding affinity of a IL-2 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:15. For example, in some cases, a variant IL-2 polypeptide binds IL-2R with a binding affinity that is at least 10% less, at least 15% less, at least 20% less, at least 25%, at least 30% less, at least 35% less, at least 40% less, at least 45% less, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than the binding affinity of an IL-2 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:340 for an IL-2R (e.g., an IL-2R comprising polypeptides comprising the amino acid sequence set forth in SEQ ID NOs:341-343), when assayed under the same conditions.</p><p id="p-0528" num="0476">In some cases, a variant IL-2 polypeptide has a binding affinity to IL-2R that is from 100 nM to 100 &#x3bc;M. As another example, in some cases, a variant IL-2 polypeptide has a binding affinity for IL-2R (e.g., an IL-2R comprising polypeptides comprising the amino acid sequence set forth in SEQ ID NOs:16-18) that is from about 100 nM to 150 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM, from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 &#x3bc;M, to about 1 &#x3bc;M to about 5 &#x3bc;M, from about 5 &#x3bc;M to about 10 &#x3bc;M, from about 10 &#x3bc;M to about 15 &#x3bc;M, from about 15 &#x3bc;M to about 20 &#x3bc;M, from about 20 &#x3bc;M to about 25 &#x3bc;M, from about 25 &#x3bc;M to about 50 &#x3bc;M, from about 50 &#x3bc;M to about 75 &#x3bc;M, or from about 75 &#x3bc;M to about 100 &#x3bc;M.</p><p id="p-0529" num="0477">In some cases, a variant IL-2 polypeptide has a single amino acid substitution compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has from 2 to 10 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 2 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 3 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 4 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 5 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 6 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 7 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 8 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 9 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340. In some cases, a variant IL-2 polypeptide has 10 amino acid substitutions compared to the IL-2 amino acid sequence set forth in SEQ ID NO:340.</p><p id="p-0530" num="0478">Suitable IL-2 variants include a polypeptide that comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the following amino acid sequences:</p><p id="p-0531" num="0479">APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML T<u style="single">X</u>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:344), where X is any amino acid other than Phe. In some cases, X is Ala. In some cases, X is Met. In some cases, X is Pro. In some cases, X is Ser. In some cases, X is Thr. In some cases, X is Trp. In some cases, X is Tyr. In some cases, X is Val. In some cases, X is His;</p><p id="p-0532" num="0480">APTSSSTKKT QLQLEHLLL<u style="single">X</u> LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:345), where X is any amino acid other than Asp. In some cases, X is Ala;</p><p id="p-0533" num="0481">APTSSSTKKT QLQL<u style="single">X</u>HLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:346), where X is any amino acid other than Glu. In some cases, X is Ala.</p><p id="p-0534" num="0482">APTSSSTKKT QLQLE<u style="single">X</u>LLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:347), where X is any amino acid other than His. In some cases, X is Ala. In some cases, X is Thr. In some cases, X is Asn. In some cases, X is Cys. In some cases, X is Gln. In some cases, X is Met. In some cases, X is Val. In some cases, X is Trp;</p><p id="p-0535" num="0483">APTSSSTKKT QLQLE<u style="single">X</u>LLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:348), where X is any amino acid other than His. In some cases, X is Ala. In some cases, X is Arg. In some cases, X is Asn. In some cases, X is Asp. In some cases, X is Cys. In some cases, X is Glu. In some cases, X is Gln. In some cases, X is Gly. In some cases, X is Ile. In some cases, X is Lys. In some cases, X is Leu. In some cases, X is Met. In some cases, X is Phe. In some cases, X is Pro. In some cases, X is Ser. In some cases, X is Thr. In some cases, X is Tyr. In some cases, X is Trp. In some cases, X is Val;</p><p id="p-0536" num="0484">APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKF<u style="single">X</u>MPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:349), where X is any amino acid other than Tyr. In some cases, X is Ala;</p><p id="p-0537" num="0485">APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFC<u style="single">X</u>SIIS TLT (SEQ ID NO:350), where X is any amino acid other than Gln. In some cases, X is Ala;</p><p id="p-0538" num="0486">APTSSSTKKT QLQLE<u style="single">X</u><sub>1</sub>LLLD LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>2</sub>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:351), where X<sub>1 </sub>is any amino acid other than His, and where X<sub>2 </sub>is any amino acid other than Phe. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; and X<sub>2 </sub>is Ala. In some cases, X<sub>1 </sub>is Thr; and X<sub>2 </sub>is Ala;</p><p id="p-0539" num="0487">APTSSSTKKT QLQLEHLLL<u style="single">X</u><sub>1 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>2</sub>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:352), where X<sub>1 </sub>is any amino acid other than Asp; and where X<sub>2 </sub>is any amino acid other than Phe. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; and X<sub>2 </sub>is Ala;</p><p id="p-0540" num="0488">APTSSSTKKT QLQL<u style="single">X</u><sub>1</sub>HLLL<u style="single">X</u><sub>2 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>3</sub>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:353), where X<sub>1 </sub>is any amino acid other than Glu; where X<sub>2 </sub>is any amino acid other than Asp; and where X<sub>3 </sub>is any amino acid other than Phe. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; and X<sub>3 </sub>is Ala;</p><p id="p-0541" num="0489">APTSSSTKKT QLQLE<u style="single">X</u><sub>1</sub>LLL<u style="single">X</u><sub>2 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>3</sub>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:354), where X<sub>1 </sub>is any amino acid other than His; where X<sub>2 </sub>is any amino acid other than Asp; and where X<sub>3 </sub>is any amino acid other than Phe. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; and X<sub>3 </sub>is Ala;</p><p id="p-0542" num="0490">APTSSSTKKT QLQLEHLLL<u style="single">X</u><sub>1 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>2</sub>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCX<sub>3</sub>SIIS TLT (SEQ ID NO:355), where X<sub>1 </sub>is any amino acid other than Asp; where X<sub>2 </sub>is any amino acid other than Phe; and where X<sub>3 </sub>is any amino acid other than Gln. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; and X<sub>3 </sub>is Ala;</p><p id="p-0543" num="0491">APTSSSTKKT QLQLEHLLL<u style="single">X</u><sub>1 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>2</sub>KF<u style="single">X</u><sub>3</sub>MPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:356), where X<sub>1 </sub>is any amino acid other than Asp; where X<sub>2 </sub>is any amino acid other than Phe; and where X<sub>3 </sub>is any amino acid other than Tyr. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; and X<sub>3 </sub>is Ala;</p><p id="p-0544" num="0492">APTSSSTKKT QLQLE<u style="single">X</u><sub>1</sub>LLL<u style="single">X</u><sub>2 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>3</sub>KF<u style="single">X</u><sub>4</sub>MPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:357), where X<sub>1 </sub>is any amino acid other than His; where X<sub>2 </sub>is any amino acid other than Asp; where X<sub>3 </sub>is any amino acid other than Phe; and where X<sub>4 </sub>is any amino acid other than Tyr. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>4 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; X<sub>3 </sub>is Ala; and X<sub>4 </sub>is Ala;</p><p id="p-0545" num="0493">APTSSSTKKT QLQLEHLLL<u style="single">X</u><sub>1 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>2</sub>KF<u style="single">X</u><sub>3</sub>MPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFC<u style="single">X</u><sub>4</sub>SIIS TLT (SEQ ID NO:358), where X<sub>1 </sub>is any amino acid other than Asp; where X<sub>2 </sub>is any amino acid other than Phe; where X<sub>3 </sub>is any amino acid other than Tyr; and where X<sub>4 </sub>is any amino acid other than Gln. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>4 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; X<sub>3 </sub>is Ala; and X<sub>4 </sub>is Ala;</p><p id="p-0546" num="0494">APTSSSTKKT QLQLE<u style="single">X</u><sub>1</sub>LLL<u style="single">X</u><sub>2 </sub>LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>3</sub>KF<u style="single">X</u><sub>4</sub>MPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFC<u style="single">X</u><sub>5</sub>SIIS TLT (SEQ ID NO:359), where X<sub>1 </sub>is any amino acid other than His; where X<sub>2 </sub>is any amino acid other than Asp; where X<sub>3 </sub>is any amino acid other than Phe; where X<sub>4 </sub>is any amino acid other than Tyr; and where X<sub>5 </sub>is any amino acid other than Gln. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>4 </sub>is Ala. In some cases, X<sub>5 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; X<sub>3 </sub>is Ala; X<sub>4 </sub>is Ala; X<sub>5 </sub>is Ala; and</p><p id="p-0547" num="0495">APTSSSTKKT QLQLE<u style="single">X</u><sub>1</sub>LLLD LQMILNGINN YKNPKLTRML T<u style="single">X</u><sub>2</sub>KFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFC<u style="single">X</u><sub>3</sub>SIIS TLT (SEQ ID NO:360), where X<sub>1 </sub>is any amino acid other than His; where X<sub>2 </sub>is any amino acid other than Phe; and where X<sub>3 </sub>is any amino acid other than Gln. In some cases, X<sub>1 </sub>is Ala. In some cases, X<sub>2 </sub>is Ala. In some cases, X<sub>3 </sub>is Ala. In some cases, X<sub>1 </sub>is Ala; X<sub>2 </sub>is Ala; and X<sub>3 </sub>is Ala.</p><heading id="h-0066" level="2">Scaffold Polypeptides</heading><p id="p-0548" num="0496">A TMMP of the present disclosure can comprise an Fc polypeptide, or can comprise another suitable scaffold polypeptide.</p><p id="p-0549" num="0497">Suitable scaffold polypeptides include antibody-based scaffold polypeptides and non-antibody-based scaffolds. Non-antibody-based scaffolds include, e.g., albumin, an XTEN (extended recombinant) polypeptide, transferrin, an Fc receptor polypeptide, an elastin-like polypeptide (see, e.g., Hassouneh et al. (2012) <i>Methods Enzymol. </i>502:215; e.g., a polypeptide comprising a pentapeptide repeat unit of (Val-Pro-Gly-X-Gly; SEQ ID NO:361), where X is any amino acid other than proline), an albumin-binding polypeptide, a silk-like polypeptide (see, e.g., Valluzzi et al. (2002) <i>Philos Trans R Soc Lond B Biol Sci. </i>357:165), a silk-elastin-like polypeptide (SELP; see, e.g., Megeed et al. (2002) <i>Adv Drug Deliv Rev. </i>54:1075), and the like. Suitable XTEN polypeptides include, e.g., those disclosed in WO 2009/023270, WO 2010/091122, WO 2007/103515, US 2010/0189682, and US 2009/0092582; see also Schellenberger et al. (2009) <i>Nat Biotechnol. </i>27:1186). Suitable albumin polypeptides include, e.g., human serum albumin.</p><p id="p-0550" num="0498">Suitable scaffold polypeptides will in some cases be a half-life extending polypeptides. Thus, in some cases, a suitable scaffold polypeptide increases the in vivo half-life (e.g., the serum half-life) of the TMMP, compared to a control TMMP lacking the scaffold polypeptide. For example, in some cases, a scaffold polypeptide increases the in vivo half-life (e.g., the serum half-life) of the TMMP, compared to a control TMMP lacking the scaffold polypeptide, by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 25-fold, at least about 50-fold, at least about 100-fold, or more than 100-fold. As an example, in some cases, an Fc polypeptide increases the in vivo half-life (e.g., the serum half-life) of the TMMP, compared to a control TMMP lacking the Fc polypeptide, by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 25-fold, at least about 50-fold, at least about 100-fold, or more than 100-fold.</p><heading id="h-0067" level="2">Fc Polypeptides</heading><p id="p-0551" num="0499">In some cases, the first and/or the second polypeptide chain of a TMMP of the present disclosure comprises an Fc polypeptide. The Fc polypeptide of a TMMP of the present disclosure can be a human IgG1 Fc, a human IgG2 Fc, a human IgG3 Fc, a human IgG4 Fc, etc. In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to an amino acid sequence of an Fc region depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A-<b>3</b>G</figref>. In some cases, the Fc region comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgG1 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>. In some cases, the Fc region comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgG1 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>; and comprises a substitution of N77; e.g., the Fc polypeptide comprises an N77A substitution. In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgG2 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>; e.g., the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to amino acids 99-325 of the human IgG2 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>. In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgG3 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>; e.g., the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to amino acids 19-246 of the human IgG3 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>. In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgM Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>; e.g., the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to amino acids 1-276 to the human IgM Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>. In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgA Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>; e.g., the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to amino acids 1-234 to the human IgA Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>.</p><p id="p-0552" num="0500">In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the human IgG4 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>. In some cases, the Fc polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to amino acids 100 to 327 of the human IgG4 Fc polypeptide depicted in <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>.</p><p id="p-0553" num="0501">In some cases, the IgG4 Fc polypeptide comprises the following amino acid sequence:</p><p id="p-0554" num="0000"><tables id="TABLE-US-00051" num="00051"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;362)</entry></row><row><entry>PPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPE</entry></row><row><entry> </entry></row><row><entry>VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKC</entry></row><row><entry> </entry></row><row><entry>KVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK</entry></row><row><entry> </entry></row><row><entry>GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE</entry></row><row><entry> </entry></row><row><entry>GNVFSCSVMHEALHNHYTQKSLSLSPG.</entry></row></tbody></tgroup></table></tables></p><p id="p-0555" num="0502">In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc). In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc), except for a substitution of N297 (N77 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with an amino acid other than asparagine. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>C</figref> (human IgG1 Fc comprising an N297A substitution, which is N77 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>). In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc), except for a substitution of L234 (L14 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with an amino acid other than leucine. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc), except for a substitution of L235 (L15 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with an amino acid other than leucine.</p><p id="p-0556" num="0503">In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>E</figref>. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>F</figref>. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>5</b>G</figref> (human IgG1 Fc comprising an L234A substitution and an L235A substitution, corresponding to positions 14 and 15 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>G</figref>). In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc), except for a substitution of P331 (P111 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with an amino acid other than proline; in some cases, the substitution is a P331S substitution. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc), except for substitutions at L234 and L235 (L14 and L15 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with amino acids other than leucine. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> (human IgG1 Fc), except for substitutions at L234 and L235 (L14 and L15 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with amino acids other than leucine, and a substitution of P331 (P111 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) with an amino acid other than proline. In some cases, the Fc polypeptide present in a TMMP comprises the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>E</figref> (human IgG1 Fc comprising L234F, L235E, and P331S substitutions (corresponding to amino acid positions 14, 15, and 111 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>E</figref>). In some cases, the Fc polypeptide present in a TMMP is an IgG1 Fc polypeptide that comprises L234A and L235A substitutions (substitutions of L14 and L15 of the amino acid sequence depicted in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> with Ala), as depicted in <figref idref="DRAWINGS">FIG. <b>3</b>G</figref>.</p><heading id="h-0068" level="2">Linkers</heading><p id="p-0557" num="0504">A TMMP of the present disclosure can include one or more linkers, where the one or more linkers are between one or more of: i) an MHC Class I polypeptide and an Ig Fc polypeptide, where such a linker is referred to herein as &#x201c;L1&#x201d;; ii) an immunomodulatory polypeptide and an MHC Class I polypeptide, where such a linker is referred to herein as &#x201c;L2&#x201d;; iii) a first immunomodulatory polypeptide and a second immunomodulatory polypeptide, where such a linker is referred to herein as &#x201c;L3&#x201d;; iv) a peptide antigen (&#x201c;epitope&#x201d;) and an MHC Class I polypeptide; v) an MHC Class I polypeptide and a dimerization polypeptide (e.g., a first or a second member of a dimerizing pair); and vi) a dimerization polypeptide (e.g., a first or a second member of a dimerizing pair) and an IgFc polypeptide.</p><p id="p-0558" num="0505">Suitable linkers (also referred to as &#x201c;spacers&#x201d;) can be readily selected and can be of any of a number of suitable lengths, such as from 1 amino acid to 25 amino acids, from 3 amino acids to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids. A suitable linker can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. In some cases, a linker has a length of from 25 amino acids to 50 amino acids, e.g., from 25 to 30, from 30 to 35, from 35 to 40, from 40 to 45, or from 45 to 50 amino acids in length.</p><p id="p-0559" num="0506">Exemplary linkers include glycine polymers (G)<sub>n</sub>, glycine-serine polymers (including, for example, (GS)<sub>n</sub>, (GSGGS)<sub>n </sub>(SEQ ID NO:363) and (GGGS)<sub>n </sub>(SEQ ID NO:364), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers can be used; both Gly and Ser are relatively unstructured, and therefore can serve as a neutral tether between components. Glycine polymers can be used; glycine accesses significantly more phi-psi space than even alanine, and is much less restricted than residues with longer side chains (see Scheraga, <i>Rev. Computational Chem. </i>11173-142 (1992)). Exemplary linkers can comprise amino acid sequences including, but not limited to, GGSG (SEQ ID NO:365), GGSGG (SEQ ID NO:366), GSGSG (SEQ ID NO:367), GSGGG (SEQ ID NO:368), GGGSG (SEQ ID NO:369), GSSSG (SEQ ID NO:370), and the like. Exemplary linkers can include, e.g., Gly(Ser<sub>4</sub>)n (SEQ ID NO:371), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some cases, a linker comprises the amino acid sequence (GSSSS)n (SEQ ID NO:371), where n is 4. In some cases, a linker comprises the amino acid sequence (GSSSS)n (SEQ ID NO:371), where n is 5. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 1. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 2. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 3. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 4. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 5. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 6. In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 7, In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 8, In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 9, In some cases, a linker comprises the amino acid sequence (GGGGS)n (SEQ ID NO:5), where n is 10. In some cases, a linker comprises the amino acid sequence AAAGG (SEQ ID NO:372).</p><p id="p-0560" num="0507">In some cases, a linker polypeptide, present in a first polypeptide of a TMMP of the present disclosure, includes a cysteine residue that can form a disulfide bond with a cysteine residue present in a second polypeptide of a TMMP of the present disclosure. In some cases, for example, a suitable linker comprises the amino acid sequence GCGGSGGGGSGGGGS (SEQ ID NO:208). As another example, a suitable linker can comprise the amino acid sequence GCGGS(G4S)n (SEQ ID NO:206), where n is 1, 2, 3, 4, 5, 6, 7, 8, or 9. For example, in some cases, the linker comprises the amino acid sequence GCGGSGGGGSGGGGSGGGGS (SEQ ID NO:207). As another example, the linker comprises the amino acid sequence GCGGSGGGGSGGGGS (SEQ ID NO:208).</p><heading id="h-0069" level="2">Multiple Disulfide Bonded TMMPs</heading><p id="p-0561" num="0508">In some cases, the first polypeptide and the second polypeptide of a TMMP of the present disclosure are linked to one another by at least two disulfide bonds (Le two interchain disulfide bonds). Examples of such multiple disulfide-linked TMMP are depicted schematically in <figref idref="DRAWINGS">FIGS. <b>2</b>A and <b>2</b>B</figref>. In addition, where a TMMP of the present disclosure comprises an IgFc polypeptide, a heterodimeric TMMP can be dimerized, such that disulfide bonds link the IgFc polypeptides in the two heterodimeric TMMPs. Such an arrangement is depicted schematically in <figref idref="DRAWINGS">FIGS. <b>2</b>A and <b>2</b>B</figref>, where disulfide bonds are represented by dashed lines. Unless otherwise stated, the at least two disulfide bonds described in the multiple disulfide-linked TMMPPs in this section are not referring to disulfide bonds linking IgFc polypeptides in dimerized TMMPs.</p><p id="p-0562" num="0509">As noted above, in some cases, the first polypeptide and the second polypeptide of a TMMP of the present disclosure are linked to one another by at least two disulfide bonds (i.e., two interchain disulfide bonds). For example, in some instances, the first polypeptide and the second polypeptide of a TMMP of the present disclosure are linked to one another by 2 interchain disulfide bonds. As another example, in some instances, the first polypeptide and the second. polypeptide of a TMMP of the present disclosure are linked to one another by 3 interchain disulfide bonds. As another example, in some instances, the first polypeptide and the second polypeptide of a TMMP of the present disclosure are linked to one another by 4 interchain disulfide bonds.</p><p id="p-0563" num="0510">In some cases where a peptide epitope in a first polypeptide of a TMMP of the present disclosure is linked to a &#x3b2;2M polypeptide by a linker comprising a Cys, at least one of the at least two disulfide bonds links a Cys in the linker to a Cys in an MHC Class 1 heavy chain in the second polypeptide. In some cases, where a peptide epitope in a first polypeptide of a TMMP of the present disclosure is linked to an MHC Class I heavy chain polypeptide by a linker, at least one of the at least two disulfide bonds links a Cys in the linker to a Cys in a &#x3b2;2M polypeptide present in the second polypeptide.</p><p id="p-0564" num="0511">A multiple disulfide-linked TMMP of the present disclosure (e.g., a double disulfide-linked TMMP) can comprise, for example: a) a first polypeptide comprising: i) a peptide epitope (e.g., a peptide of from 4 amino acids to about 25 amino acids in length, that is bound by a TCR when the peptide is complexed with MHC polypeptides); and ii) a first MHC polypeptide, where the first polypeptide comprises a peptide linker between the KRAS peptide and the first MHC polypeptide, where the peptide linker comprises a Cys residue, and where the first MHC polypeptide is a &#x3b2;2M polypeptide that comprises an amino acid substitution that introduces a Cys residue; b) and a second polypeptide comprising a second MHC polypeptide, where the second MHC polypeptide is a Class I heavy chain comprising a Y84C substitution and an A236C substitution, based on the amino acid numbering of HLA-A*0201 (depicted in <figref idref="DRAWINGS">FIG. <b>7</b>A</figref>), or at corresponding positions in another Class I heavy chain allele, where the TMMP comprises a disulfide bond between the Cys residue in the peptide linker and the Cys residue at amino acid position 84 of the Class I heavy chain or corresponding position of another Class I heavy chain allele, and where the TMMP comprises a disulfide bond between the introduced Cys residue in the &#x3b2;2M polypeptide and the Cys at amino acid position 236 of the Class I heavy chain or corresponding position of another Class I heavy chain allele; and c) at least one immunomodulatory polypeptide, where the first and/or the second polypeptide comprises the at least one immunomodulatory polypeptide.</p><p id="p-0565" num="0512">In some cases, the peptide linker comprises the amino acid sequence GCGGS (SEQ ID NO:373). In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is an integer from 1 to 10. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 1. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 2. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 3. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 4. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 5. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 6. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 7. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 8. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 9. In some cases, the peptide linker comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:206), where n is 10.</p><p id="p-0566" num="0513">In some cases, the peptide linker comprises the amino acid sequence CGGGS (SEQ ID NO:374). In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is an integer from 1 to 10. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 1. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 2. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 3. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 4. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 5. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 6. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 7. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 8. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 9. In some cases, the peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:375), where n is 10.</p><heading id="h-0070" level="2">Dimerized TMMPs</heading><p id="p-0567" num="0514">A TMMP can be dimerized. For example, a dimeric TMMP can comprise two heterodimeric TMMPs. A dimeric TMMP can comprise: A) a first heterodimer comprising: a) a first polypeptide comprising: i) a peptide epitope; and ii) a first major histocompatibility complex (MHC) polypeptide; and b) a second polypeptide comprising: i) a second MHC polypeptide, wherein the first heterodimer comprises one or more immunomodulatory polypeptides; and B) a second heterodimer comprising: a) a first polypeptide comprising: i) a peptide epitope; and ii) a first MHC polypeptide; and b) a second polypeptide comprising: i) a second MHC polypeptide, wherein the second heterodimer comprises one or more immunomodulatory polypeptides, and wherein the first heterodimer and the second heterodimer are covalently linked to one another.</p><p id="p-0568" num="0515">In some cases, the two TMMPs are identical to one another in amino acid sequence. In some cases, the first heterodimer and the second heterodimer are covalently linked to one another via a C-terminal region of the second polypeptide of the first heterodimer and a C-terminal region of the second polypeptide of the second heterodimer. In some cases, first heterodimer and the second heterodimer are covalently linked to one another via the C-terminal amino acid of the second polypeptide of the first heterodimer and the C-terminal region of the second polypeptide of the second heterodimer; for example, in some cases, the C-terminal amino acid of the second polypeptide of the first heterodimer and the C-terminal region of the second polypeptide of the second heterodimer are linked to one another, either directly or via a linker. The linker can be a peptide linker. The peptide linker can have a length of from 1 amino acid to 200 amino acids (e.g., from 1 amino acid (aa) to 5 aa, from 5 aa to 10 aa, from 10 aa to 25 aa, from 25 aa to 50 aa, from 50 aa to 100 aa, from 100 aa to 150 aa, or from 150 aa to 200 aa). In some cases, the peptide epitope of the first heterodimer and the peptide epitope of the second heterodimer comprise the same amino acid sequence. In some cases, the first MHC polypeptide of the first and the second heterodimer is an MHC Class I&#x3b2;2-microglobulin, and wherein the second MHC polypeptide of the first and the second heterodimer is an MHC Class I heavy chain. In some cases, the immunomodulatory polypeptide of the first heterodimer and the immunomodulatory polypeptide of the second heterodimer comprise the same amino acid sequence. In some cases, the immunomodulatory polypeptide of the first heterodimer and the immunomodulatory polypeptide of the second heterodimer are variant immunomodulatory polypeptides that comprise from 1 to 10 amino acid substitutions compared to a corresponding parental wild-type immunomodulatory polypeptide, and wherein the from 1 to 10 amino acid substitutions result in reduced affinity binding of the variant immunomodulatory polypeptide to a cognate co-immunomodulatory polypeptide. In some cases, the immunomodulatory polypeptide of the first heterodimer and the immunomodulatory polypeptide of the second heterodimer are each independently selected from the group consisting of IL-2, 4-1BBL, PD-L1, CD80, CD86, ICOS-L, OX-40L, FasL, JAG1 (CD339), TGF&#x3b2;, CD70, and ICAM. Examples, of suitable MHC polypeptides, immunomodulatory polypeptides, and peptide epitopes are described below. The first and/or the second polypeptide comprises: i) an Ig Fc polypeptide or a non-Ig scaffold; and ii) a tumor-targeting polypeptide.</p><heading id="h-0071" level="2">Examples of Non-Limiting Aspects of the Disclosure</heading><p id="p-0569" num="0516">Aspects, including embodiments, of the present subject matter described above may be beneficial alone or in combination, with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the disclosure numbered 1-90 are provided below. As will be apparent to those of skill in the art upon reading this disclosure, each of the individually numbered aspects may be used or combined with any of the preceding or following individually numbered aspects. This is intended to provide support for all such combinations of aspects and is not limited to combinations of aspects explicitly provided below:</p><p id="p-0570" num="0517">Aspect 1. An in vitro composition comprising a quantity of modified cytotoxic T cells (&#x201c;mCTLs&#x201d;), wherein the quantity comprises target mCTLs that comprise: a) a T-cell receptor (TCR) specific for a preselected antigen present in a human; and b) one or more nucleic acids comprising nucleotide sequences encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cancer-associated antigen, and wherein the percentage of target mCTLs cells in the composition exceeds at least 1% of the total number of T cells in the composition.</p><p id="p-0571" num="0518">Aspect 2. A composition according to aspect 1, wherein the preselected antigen is an antigen encoded by a virus or a bacterium.</p><p id="p-0572" num="0519">Aspect 3. A composition according to aspect 2, wherein the preselected antigen is an antigen encoded by a virus or bacteria selected from the group consisting of cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus (HPV), adenovirus, influenza virus, and <i>Clostridium tetani. </i></p><p id="p-0573" num="0520">Aspect 4. A composition according to aspect 3, wherein the preselected antigen is a CMV polypeptide.</p><p id="p-0574" num="0521">Aspect 5. A composition according to aspect 4, wherein the CMV antigen is a CMV pp65 polypeptide.</p><p id="p-0575" num="0522">Aspect 6. A composition according to any one of aspects 1-5, wherein the CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a transmembrane region; and c) a cytoplasmic domain comprising an intracellular signaling domain.</p><p id="p-0576" num="0523">Aspect 7. A composition according to aspect 6, wherein the cytoplasmic domain comprises one or more costimulatory polypeptides.</p><p id="p-0577" num="0524">Aspect 8. A composition according to aspect 7, wherein the costimulatory polypeptide is selected from CD28, 4-1BB, and OX-40.</p><p id="p-0578" num="0525">Aspect 9. A composition according to any one of aspects 6-8, wherein the intracellular signaling domain comprises a signaling domain from the zeta chain of human CD3.</p><p id="p-0579" num="0526">Aspect 10. A composition according to any one of aspects 1-9, wherein the antigen-binding domain is a single-chain Fv polypeptide or a nanobody.</p><p id="p-0580" num="0527">Aspect 11. A composition according to any one of aspects 1-10, wherein the CAR is a single polypeptide chain CAR.</p><p id="p-0581" num="0528">Aspect 12. A composition according to any one of aspects 1-10, wherein the CAR comprises at least two polypeptide chains.</p><p id="p-0582" num="0529">Aspect 13. A composition according to any one of aspects 1-12, wherein the cancer-associated antigen is selected from AFP, BCMA, CD10, CD117, CD123, CD133, CD128, CD171, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD5, CD56, CD7, CD70, CD80, CD86, CEA, CLD18, CLL-1, cMet, EGFR, EGFRvIII, EpCAM, EphA2, GD-2, glypican-3, GPC3, HER-2, kappa immunoglobulin, LeY, LMP1, mesothelin, MG7, MUC1, NKG2D ligand, PD-L1, PSCA, PSMA, ROR1, ROR1R, TACI, and VEGFR2.</p><p id="p-0583" num="0530">Aspect 14. A composition according to any one of aspects 1-13, wherein the percentage of total number of T cells in the composition that are target mCTLs is selected from the group consisting of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and 100%.</p><p id="p-0584" num="0531">Aspect 15. A composition according to any one of aspects 1-14, wherein the target mCTLs are CD8<sup>+</sup> T cells.</p><p id="p-0585" num="0532">Aspect 16. A pharmaceutical composition comprising a composition according to any one of aspects 1-15.</p><p id="p-0586" num="0533">Aspect 17. A pharmaceutical composition according to aspect 16 comprising a pharmaceutically acceptable carrier.</p><p id="p-0587" num="0534">Aspect 18. A pharmaceutical composition according to aspect 17, wherein the pharmaceutically acceptable carrier comprises saline.</p><p id="p-0588" num="0535">Aspect 19. A pharmaceutical composition according to any one of aspects 16-18, wherein the target mCTLs are present in the composition in a concentration of from about 10<sup>6 </sup>cells/mL to about 10<sup>9 </sup>cells/mL.</p><p id="p-0589" num="0536">Aspect 20. A method of making an in vitro composition according to any one of aspects 1-15, comprising the steps of:</p><p id="p-0590" num="0537">(i) providing a composition comprising a quantity of T cells, wherein the quantity comprises target T cells having a T-cell receptor (TCR) specific for the preselected antigen;</p><p id="p-0591" num="0538">(ii) at least partially separating target T cells from non-target T cells comprising a T-cell receptor (TCR) that is not specific for the preselected antigen, thereby generating a quantity of at least partially separated target T cells; and</p><p id="p-0592" num="0539">(iii) modifying the at least partially separated target T cells by introducing into the at least partially separated target T cells one or more nucleic acids comprising nucleotide sequences encoding a chimeric antigen receptor (CAR) that comprises an antigen-binding domain specific for a cancer-associated antigen.</p><p id="p-0593" num="0540">Aspect 21. A method according to aspect 20, wherein step of at least partially separating target T cells comprises binding the target T cells to a polypeptide that binds to the TCR of the target T cells.</p><p id="p-0594" num="0541">Aspect 22. A method according to aspect 21, wherein said polypeptide that binds to the TCR of the target T cells is on a surface.</p><p id="p-0595" num="0542">Aspect 23. A method according to aspect 22, wherein the polypeptide that binds to the TCR of the target T cells is present on the surface of a bead.</p><p id="p-0596" num="0543">Aspect 24. A method according to aspect 23, wherein the polypeptide that binds to the TCR is a peptide-loaded MHC multimer.</p><p id="p-0597" num="0544">Aspect 25. A method according to any of aspects 20-24, wherein the preselected antigen present in a human is an antigen encoded by a virus or a bacterium.</p><p id="p-0598" num="0545">Aspect 26. A method according to any of aspects 20-24, wherein the preselected antigen is an antigen encoded by a virus or bacterium selected from the group consisting of cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus (HPV), adenovirus, influenza virus, and <i>Clostridium tetani. </i></p><p id="p-0599" num="0546">Aspect 27. A method according to aspect 26, wherein the preselected antigen is a CMV polypeptide.</p><p id="p-0600" num="0547">Aspect 28. A method according to aspect 27, wherein the CMV polypeptide is a CMV pp65 polypeptide.</p><p id="p-0601" num="0548">Aspect 29. A method according to any of aspects 20-28, wherein the CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a transmembrane region; and c) a cytoplasmic domain comprising an intracellular signaling domain.</p><p id="p-0602" num="0549">Aspect 30. A method according to aspect 29, wherein the intracellular signaling domain comprises a signaling domain from the zeta chain of human CD3.</p><p id="p-0603" num="0550">Aspect 31. A method according to aspect 29 or 30, wherein the cytoplasmic domain comprises one or more costimulatory polypeptides.</p><p id="p-0604" num="0551">Aspect 32. A method according to aspect 31, wherein the costimulatory polypeptide is selected from CD28, 4-1BB, and OX-40.</p><p id="p-0605" num="0552">Aspect 33. A method according to any one of aspects 20-32, wherein the antigen-binding domain is a single-chain Fv polypeptide or a nanobody.</p><p id="p-0606" num="0553">Aspect 34. A method according to any one of aspects 20-33, wherein the CAR is a single polypeptide chain CAR.</p><p id="p-0607" num="0554">Aspect 35. A method according to any one of aspects 20-33, wherein the CAR comprises two polypeptide chains.</p><p id="p-0608" num="0555">Aspect 36. A method according to any one of aspects 20-35, wherein the cancer-associated antigen is selected from AFP, BCMA, CD10, CD117, CD123, CD133, CD128, CD171, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD5, CD56, CD7, CD70, CD80, CD86, CEA, CLD18, CLL-1, cMet, EGFR, EGFRvIII, EpCAM, EphA2, GD-2, glypican-3, GPC3, HER-2, kappa immunoglobulin, LeY, LMP1, mesothelin, MG7, MUC1, NKG2D ligand, PD-L1, PSCA, PSMA, ROR1, ROR1R, TACI, and VEGFR2.</p><p id="p-0609" num="0556">Aspect 37. A method according to any one of aspects 20-36, wherein the percentage of total number of T cells in the composition that are target CTLs is selected from the group consisting of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and 100%.</p><p id="p-0610" num="0557">Aspect 38. A method according to any one of aspects 20-37, wherein prior to step (ii), the composition comprising a quantity of T cells is contacted in vitro or in vivo with a composition comprising a T-cell modulatory polypeptide that binds to and activates substantially only the T cells comprising a T-cell receptor (TCR) specific for the preselected antigen.</p><p id="p-0611" num="0558">Aspect 39. A method according to aspect 38, wherein the T-cell modulatory polypeptide is a T cell multimeric polypeptide (TMMP) that comprises at least one heterodimer, said heterodimer comprising:</p><p id="p-0612" num="0559">(i) a first polypeptide comprising a peptide epitope and a first major histocompatibility complex (MHC) polypeptide, wherein the peptide epitope is a peptide having a length of from 4 amino acids to about 25 amino acids, and wherein the peptide epitope is an epitope of the preselected antigen;</p><p id="p-0613" num="0560">(ii) a second polypeptide comprising a second MHC polypeptide; and</p><p id="p-0614" num="0561">(iii) at least one immunomodulatory polypeptide that activates T cells comprising a T-cell receptor (TCR) specific for the preselected antigen,</p><p id="p-0615" num="0562">wherein the first and/or the second polypeptide comprises the immunomodulatory polypeptide, and</p><p id="p-0616" num="0563">optionally, wherein the multimeric polypeptide comprises an immunoglobulin (Ig) Fc polypeptide or a non-Ig scaffold.</p><p id="p-0617" num="0564">Aspect 40. A method according to aspect 39, wherein the TMMP comprises two heterodimers, wherein both heterodimers comprise an Ig Fc polypeptide, and wherein the heterodimers are covalently bound by one or more disulfide bonds between the Ig Fc polypeptides of the first and second heterodimers.</p><p id="p-0618" num="0565">Aspect 41. A method according to aspect 39, wherein the TMMP comprises:</p><p id="p-0619" num="0566">a1) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0567">i) a peptide epitope; and</li>        <li id="ul0002-0002" num="0568">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0620" num="0569">b1) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0570">i) at least one immunomodulatory polypeptide;</li>        <li id="ul0004-0002" num="0571">ii) a second MHC polypeptide; and</li>        <li id="ul0004-0003" num="0572">iii) an immunoglobulin (Ig) Fc polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0621" num="0573">a2) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0000">    <ul id="ul0006" list-style="none">        <li id="ul0006-0001" num="0574">i) a peptide epitope;</li>        <li id="ul0006-0002" num="0575">ii) a first MHC polypeptide; and</li>        <li id="ul0006-0003" num="0576">iii) at least one immunomodulatory polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0622" num="0577">b2) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0007" list-style="none">    <li id="ul0007-0001" num="0000">    <ul id="ul0008" list-style="none">        <li id="ul0008-0001" num="0578">i) a second MHC polypeptide; and</li>        <li id="ul0008-0002" num="0579">ii) an Ig Fc polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0623" num="0580">a3) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0009" list-style="none">    <li id="ul0009-0001" num="0000">    <ul id="ul0010" list-style="none">        <li id="ul0010-0001" num="0581">i) a peptide epitope; and</li>        <li id="ul0010-0002" num="0582">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0624" num="0583">b3) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0011" list-style="none">    <li id="ul0011-0001" num="0000">    <ul id="ul0012" list-style="none">        <li id="ul0012-0001" num="0584">i) a second MHC polypeptide; and</li>        <li id="ul0012-0002" num="0585">ii) an Ig Fc polypeptide; and</li>        <li id="ul0012-0003" num="0586">iii) at least one immunomodulatory polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0625" num="0587">a4) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0013" list-style="none">    <li id="ul0013-0001" num="0000">    <ul id="ul0014" list-style="none">        <li id="ul0014-0001" num="0588">i) a peptide epitope; and</li>        <li id="ul0014-0002" num="0589">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0626" num="0590">b4) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0015" list-style="none">    <li id="ul0015-0001" num="0000">    <ul id="ul0016" list-style="none">        <li id="ul0016-0001" num="0591">i) a second MHC polypeptide; and</li>        <li id="ul0016-0002" num="0592">ii) at least one immunomodulatory polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0627" num="0593">a5) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0017" list-style="none">    <li id="ul0017-0001" num="0000">    <ul id="ul0018" list-style="none">        <li id="ul0018-0001" num="0594">i) a peptide epitope; and</li>        <li id="ul0018-0002" num="0595">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0628" num="0596">b5) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0019" list-style="none">    <li id="ul0019-0001" num="0000">    <ul id="ul0020" list-style="none">        <li id="ul0020-0001" num="0597">i) at least one immunomodulatory polypeptide; and</li>        <li id="ul0020-0002" num="0598">ii) a second MHC polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0629" num="0599">a6) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0021" list-style="none">    <li id="ul0021-0001" num="0000">    <ul id="ul0022" list-style="none">        <li id="ul0022-0001" num="0600">i) a peptide epitope;</li>        <li id="ul0022-0002" num="0601">ii) a first MHC polypeptide; and</li>        <li id="ul0022-0003" num="0602">iii) at least one immunomodulatory polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0630" num="0603">b6) a second polypeptide comprising:<ul id="ul0023" list-style="none">    <li id="ul0023-0001" num="0000">    <ul id="ul0024" list-style="none">        <li id="ul0024-0001" num="0604">i) a second MHC polypeptide.</li>    </ul>    </li></ul></p><p id="p-0631" num="0605">Aspect 42. A method according to any one of aspects 39-41, wherein the at least one immunomodulatory polypeptide is a naturally occurring polypeptide, a variant of a naturally occurring polypeptide, or a fragment of a naturally occurring or variant polypeptide, and wherein the polypeptide is selected from the group consisting of a 4-1BBL polypeptide, a B7-1 polypeptide; a B7-2 polypeptide, an ICOS-L polypeptide, an OX-40L polypeptide, a CD80 polypeptide, a CD86 polypeptide, a PD-L1 polypeptide, a FasL polypeptide, a cytokine, a PD-L2 polypeptide, and combinations thereof.</p><p id="p-0632" num="0606">Aspect 43. A method according to aspect 42, wherein the at least one immunomodulatory polypeptide is a naturally occurring cytokine, a variant of a naturally occurring cytokine, or a fragment of a naturally occurring cytokine.</p><p id="p-0633" num="0607">Aspect 44. A method according to aspect 42, wherein the cytokine is IL-2.</p><p id="p-0634" num="0608">Aspect 45. A method of any of aspects 39-44, wherein the at least one immunomodulatory polypeptide is a naturally occurring polypeptide, a variant of a naturally occurring polypeptide, or a fragment of a naturally occurring or variant polypeptide, wherein the at least one immunomodulatory polypeptide is selected from a 4-1BBL polypeptide and a CD80 polypeptide.</p><p id="p-0635" num="0609">Aspect 46. A method according to any one of aspects 39-45, wherein the TMMP comprises 2 or more immunomodulatory polypeptides.</p><p id="p-0636" num="0610">Aspect 47. A method according to aspect 46, wherein the 2 or more immunomodulatory polypeptides are in tandem.</p><p id="p-0637" num="0611">Aspect 48. A method according to any one of aspects 45-47, wherein the multimeric polypeptide comprises:</p><p id="p-0638" num="0612">a1) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0025" list-style="none">    <li id="ul0025-0001" num="0000">    <ul id="ul0026" list-style="none">        <li id="ul0026-0001" num="0613">i) a peptide epitope; and</li>        <li id="ul0026-0002" num="0614">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0639" num="0615">b1) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0027" list-style="none">    <li id="ul0027-0001" num="0000">    <ul id="ul0028" list-style="none">        <li id="ul0028-0001" num="0616">i) at least one immunomodulatory polypeptide;</li>        <li id="ul0028-0002" num="0617">ii) a second MHC polypeptide; and</li>        <li id="ul0028-0003" num="0618">iii) an immunoglobulin (Ig) Fc polypeptide.</li>    </ul>    </li></ul></p><p id="p-0640" num="0619">Aspect 49. A method according to any one of aspects 45-47, wherein the multimeric polypeptide comprises:</p><p id="p-0641" num="0620">a3) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0029" list-style="none">    <li id="ul0029-0001" num="0000">    <ul id="ul0030" list-style="none">        <li id="ul0030-0001" num="0621">i) a peptide epitope; and</li>        <li id="ul0030-0002" num="0622">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0642" num="0623">b3) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0031" list-style="none">    <li id="ul0031-0001" num="0000">    <ul id="ul0032" list-style="none">        <li id="ul0032-0001" num="0624">i) a second MHC polypeptide; and</li>        <li id="ul0032-0002" num="0625">ii) an Ig Fc polypeptide; and</li>        <li id="ul0032-0003" num="0626">iii) at least one immunomodulatory polypeptide.</li>    </ul>    </li></ul></p><p id="p-0643" num="0627">Aspect 50. A method according to any one of aspects 45-47, wherein the multimeric polypeptide comprises:</p><p id="p-0644" num="0628">a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0033" list-style="none">    <li id="ul0033-0001" num="0000">    <ul id="ul0034" list-style="none">        <li id="ul0034-0001" num="0629">i) a peptide epitope; and</li>        <li id="ul0034-0002" num="0630">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0645" num="0631">b4) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0035" list-style="none">    <li id="ul0035-0001" num="0000">    <ul id="ul0036" list-style="none">        <li id="ul0036-0001" num="0632">i) a second MHC polypeptide; and</li>        <li id="ul0036-0002" num="0633">ii) at least one immunomodulatory polypeptide.</li>    </ul>    </li></ul></p><p id="p-0646" num="0634">Aspect 51. A method according to any one of aspects 45-50, wherein the first polypeptide and the second polypeptide are linked to one another by a disulfide bond.</p><p id="p-0647" num="0635">Aspect 52. A method according to any of aspects 45-51, wherein the first MHC polypeptide is a &#x3b2;2M polypeptide, and the second MHC polypeptide is a class I MHC heavy chain.</p><p id="p-0648" num="0636">Aspect 53. A method according to aspect 52, wherein the &#x3b2;2M polypeptide and the MHC heavy chain polypeptide are joined by a disulfide bond that joins a Cys residue in the &#x3b2;2M polypeptide and a Cys residue in the MHC heavy chain polypeptide.</p><p id="p-0649" num="0637">Aspect 54. A method according to aspect 53, wherein a Cys at amino acid residue 12 of the &#x3b2;2M polypeptide is disulfide bonded to a Cys at amino acid residue 236 of the MHC heavy chain polypeptide.</p><p id="p-0650" num="0638">Aspect 55. A method according to any of aspects 51-54, wherein the first polypeptide chain comprises a linker between the peptide epitope and the &#x3b2;2M polypeptide.</p><p id="p-0651" num="0639">Aspect 56. A method according to any of aspects 51-54, wherein the first polypeptide chain comprises a linker between the peptide epitope and the &#x3b2;2M polypeptide, and wherein the disulfide bond links a Cys substituted for Gly2 in the linker with a Cys substituted for Tyr84 of the MHC heavy chain polypeptide.</p><p id="p-0652" num="0640">Aspect 57. A method according to any one of aspects 39-56, wherein the immunomodulatory polypeptide is an activating polypeptide.</p><p id="p-0653" num="0641">Aspect 58. A method according to any one of aspects 39-57, wherein at least 50% of the target T cells are CD8<sup>+</sup> T cells.</p><p id="p-0654" num="0642">Aspect 59. A method according to any one of aspects 20-57, comprising, between steps (i) and (ii), enriching the T cells for CD8<sup>+</sup> T cells.</p><p id="p-0655" num="0643">Aspect 60. A method according to any one of aspects 20-57, comprising, between steps (ii) and (iii), enriching the T cells for CD8<sup>+</sup> T cells.</p><p id="p-0656" num="0644">Aspect 61. A method of treating a cancer in an individual, the method comprising introducing into the individual: i) a composition comprising a quantity of modified cytotoxic T cells according to any one of aspects 1-15; ii) a pharmaceutical composition according to any one of aspects 16-19; or iii) a composition prepared according to the method of any one of aspects 20-60.</p><p id="p-0657" num="0645">Aspect 62. A method of treating cancer according to aspect 61, further comprising administering to the individual a composition comprising a T-cell modulatory polypeptide, wherein the T-cell modulatory polypeptide largely binds to and activates only the T cells comprising a T-cell receptor (TCR) specific for the preselected antigen.</p><p id="p-0658" num="0646">Aspect 63. A method according to aspect 61 or aspect 62, wherein said administering a composition comprising a quantity of genetically modified cytotoxic T cells comprises administering a quantity of genetically modified cytotoxic T cells that is equal to or less than a number selected from the group consisting of 10 cells/kg body weight, 10<sup>2 </sup>cells/kg body weight, 10<sup>3 </sup>cells/kg body weight, 10<sup>4 </sup>cells/kg body weight, 10<sup>5 </sup>cells/kg body weight, 10<sup>6 </sup>cells/kg body weight, 10<sup>7 </sup>cells/kg body weight, 10<sup>8 </sup>cells/kg body weight and 10<sup>9 </sup>cells/kg body weight.</p><p id="p-0659" num="0647">Aspect 64. A method according to any of aspects 61-63, wherein said administering a composition comprising a quantity of genetically modified cytotoxic T cells comprises administering a quantity of genetically modified cytotoxic T cells that is equal to or less than 10<sup>7 </sup>cells/kg body weight.</p><p id="p-0660" num="0648">Aspect 65. A method according to any of aspects 61-64, wherein the individual does not undergo a lymphodepleting regimen prior to the introducing step.</p><p id="p-0661" num="0649">Aspect 66. A method according to any of aspects 62-65, wherein the T-cell modulatory polypeptide is a T cell multimeric polypeptide (TMMP) that comprises at least one heterodimer, said heterodimer comprising:</p><p id="p-0662" num="0650">(i) a first polypeptide comprising a peptide epitope and a first major histocompatibility complex (MHC) polypeptide, wherein the peptide epitope is a peptide having a length of from 4 amino acids to about 25 amino acids, wherein the peptide epitope is an epitope of the preselected antigen;</p><p id="p-0663" num="0651">(ii) a second polypeptide comprising a second MHC polypeptide; and</p><p id="p-0664" num="0652">(iii) at least one immunomodulatory polypeptide,</p><p id="p-0665" num="0653">wherein the first and/or the second polypeptide comprises the immunomodulatory polypeptide, and</p><p id="p-0666" num="0654">optionally, wherein the multimeric polypeptide comprises an immunoglobulin (Ig) Fc polypeptide or a non-Ig scaffold.</p><p id="p-0667" num="0655">Aspect 67. A method according to aspect 66, wherein the TMMP comprises:</p><p id="p-0668" num="0656">a1) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0037" list-style="none">    <li id="ul0037-0001" num="0000">    <ul id="ul0038" list-style="none">        <li id="ul0038-0001" num="0657">i) a peptide epitope; and</li>        <li id="ul0038-0002" num="0658">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0669" num="0659">b1) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0039" list-style="none">    <li id="ul0039-0001" num="0000">    <ul id="ul0040" list-style="none">        <li id="ul0040-0001" num="0660">i) at least one immunomodulatory polypeptide;</li>        <li id="ul0040-0002" num="0661">ii) a second MHC polypeptide; and</li>        <li id="ul0040-0003" num="0662">iii) an immunoglobulin (Ig) Fc polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0670" num="0663">a2) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0041" list-style="none">    <li id="ul0041-0001" num="0000">    <ul id="ul0042" list-style="none">        <li id="ul0042-0001" num="0664">i) a peptide epitope;</li>        <li id="ul0042-0002" num="0665">ii) a first MHC polypeptide; and</li>        <li id="ul0042-0003" num="0666">iii) at least one immunomodulatory polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0671" num="0667">b2) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0043" list-style="none">    <li id="ul0043-0001" num="0000">    <ul id="ul0044" list-style="none">        <li id="ul0044-0001" num="0668">i) a second MHC polypeptide; and</li>        <li id="ul0044-0002" num="0669">ii) an Ig Fc polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0672" num="0670">a3) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0045" list-style="none">    <li id="ul0045-0001" num="0000">    <ul id="ul0046" list-style="none">        <li id="ul0046-0001" num="0671">i) a peptide epitope; and</li>        <li id="ul0046-0002" num="0672">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0673" num="0673">b3) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0047" list-style="none">    <li id="ul0047-0001" num="0000">    <ul id="ul0048" list-style="none">        <li id="ul0048-0001" num="0674">i) a second MHC polypeptide; and</li>        <li id="ul0048-0002" num="0675">ii) an Ig Fc polypeptide; and</li>        <li id="ul0048-0003" num="0676">iii) at least one immunomodulatory polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0674" num="0677">a4) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0049" list-style="none">    <li id="ul0049-0001" num="0000">    <ul id="ul0050" list-style="none">        <li id="ul0050-0001" num="0678">i) a peptide epitope; and</li>        <li id="ul0050-0002" num="0679">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0675" num="0680">b4) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0051" list-style="none">    <li id="ul0051-0001" num="0000">    <ul id="ul0052" list-style="none">        <li id="ul0052-0001" num="0681">i) a second MHC polypeptide; and</li>        <li id="ul0052-0002" num="0682">ii) at least one immunomodulatory polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0676" num="0683">a5) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0053" list-style="none">    <li id="ul0053-0001" num="0000">    <ul id="ul0054" list-style="none">        <li id="ul0054-0001" num="0684">i) a peptide epitope; and</li>        <li id="ul0054-0002" num="0685">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0677" num="0686">b5) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0055" list-style="none">    <li id="ul0055-0001" num="0000">    <ul id="ul0056" list-style="none">        <li id="ul0056-0001" num="0687">i) at least one immunomodulatory polypeptide; and</li>        <li id="ul0056-0002" num="0688">ii) a second MHC polypeptide; or</li>    </ul>    </li></ul></p><p id="p-0678" num="0689">a6) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0057" list-style="none">    <li id="ul0057-0001" num="0000">    <ul id="ul0058" list-style="none">        <li id="ul0058-0001" num="0690">i) a peptide epitope;</li>        <li id="ul0058-0002" num="0691">ii) a first MHC polypeptide; and</li>        <li id="ul0058-0003" num="0692">iii) at least one immunomodulatory polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0679" num="0693">b6) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0059" list-style="none">    <li id="ul0059-0001" num="0000">    <ul id="ul0060" list-style="none">        <li id="ul0060-0001" num="0694">i) a second MHC polypeptide.</li>    </ul>    </li></ul></p><p id="p-0680" num="0695">Aspect 68. A method according to aspect 66 or aspect 67, wherein the at least one immunomodulatory polypeptide is a naturally occurring polypeptide, a variant of a naturally occurring polypeptide, or a fragment of a naturally occurring or variant polypeptide, and wherein the polypeptide is selected from the group consisting of a 4-1BBL polypeptide, a B7-1 polypeptide; a B7-2 polypeptide, an ICOS-L polypeptide, an OX-40L polypeptide, a CD80 polypeptide, a CD86 polypeptide, a PD-L1 polypeptide, a FasL polypeptide, a cytokine, a PD-L2 polypeptide, and combinations thereof.</p><p id="p-0681" num="0696">Aspect 69. A method according to aspect 68, wherein the at least one immunomodulatory polypeptide is a naturally occurring cytokine, a variant of a naturally occurring cytokine, or a fragment of a naturally occurring cytokine.</p><p id="p-0682" num="0697">Aspect 70. A method according to aspect 68, wherein the cytokine is IL-2.</p><p id="p-0683" num="0698">Aspect 71. A method of aspect 66 or aspect 67, wherein the at least one immunomodulatory polypeptide is a naturally occurring polypeptide, a variant of a naturally occurring polypeptide, or a fragment of a naturally occurring or variant polypeptide, optionally wherein the at least one immunomodulatory polypeptide is selected from a 4-1BBL polypeptide and a CD80 polypeptide.</p><p id="p-0684" num="0699">Aspect 72. A method according to any one of aspects 66-71, wherein the TMMP comprises 2 or more immunomodulatory polypeptides.</p><p id="p-0685" num="0700">Aspect 73. A method according to aspect 72, wherein the 2 or more immunomodulatory polypeptides are in tandem.</p><p id="p-0686" num="0701">Aspect 74. A method according to any one of aspects 66-73, wherein the multimeric polypeptide comprises:</p><p id="p-0687" num="0702">a) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0061" list-style="none">    <li id="ul0061-0001" num="0000">    <ul id="ul0062" list-style="none">        <li id="ul0062-0001" num="0703">i) a peptide epitope; and</li>        <li id="ul0062-0002" num="0704">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0688" num="0705">b) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0063" list-style="none">    <li id="ul0063-0001" num="0000">    <ul id="ul0064" list-style="none">        <li id="ul0064-0001" num="0706">i) at least one immunomodulatory polypeptide;</li>        <li id="ul0064-0002" num="0707">ii) a second MHC polypeptide; and</li>        <li id="ul0064-0003" num="0708">iii) an immunoglobulin (Ig) Fc polypeptide.</li>    </ul>    </li></ul></p><p id="p-0689" num="0709">Aspect 75. A method according to any one of aspects 66-73, wherein the multimeric polypeptide comprises:</p><p id="p-0690" num="0710">a) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0065" list-style="none">    <li id="ul0065-0001" num="0000">    <ul id="ul0066" list-style="none">        <li id="ul0066-0001" num="0711">i) a peptide epitope; and</li>        <li id="ul0066-0002" num="0712">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0691" num="0713">b) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0067" list-style="none">    <li id="ul0067-0001" num="0000">    <ul id="ul0068" list-style="none">        <li id="ul0068-0001" num="0714">i) a second MHC polypeptide; and</li>        <li id="ul0068-0002" num="0715">ii) an Ig Fc polypeptide; and</li>        <li id="ul0068-0003" num="0716">iii) at least one immunomodulatory polypeptide.</li>    </ul>    </li></ul></p><p id="p-0692" num="0717">Aspect 76. A method according to any one of aspects 66-73, wherein the multimeric polypeptide comprises:</p><p id="p-0693" num="0718">a) a first polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0069" list-style="none">    <li id="ul0069-0001" num="0000">    <ul id="ul0070" list-style="none">        <li id="ul0070-0001" num="0719">i) a peptide epitope; and</li>        <li id="ul0070-0002" num="0720">ii) a first MHC polypeptide; and</li>    </ul>    </li></ul></p><p id="p-0694" num="0721">b) a second polypeptide comprising, in order from N-terminus to C-terminus:<ul id="ul0071" list-style="none">    <li id="ul0071-0001" num="0000">    <ul id="ul0072" list-style="none">        <li id="ul0072-0001" num="0722">i) a second MHC polypeptide; and</li>        <li id="ul0072-0002" num="0723">ii) at least one immunomodulatory polypeptide.</li>    </ul>    </li></ul></p><p id="p-0695" num="0724">Aspect 77. A method according to any one of aspects 66-76, wherein the first polypeptide and the second polypeptide are linked to one another by a disulfide bond.</p><p id="p-0696" num="0725">Aspect 78. A method according to any of aspects 66-77, wherein the first MHC polypeptide is a &#x3b2;2M polypeptide, and the second MHC polypeptide is a class I MHC heavy chain.</p><p id="p-0697" num="0726">Aspect 79. A method according to aspect 78, wherein the &#x3b2;2M polypeptide and the MHC heavy chain polypeptide are joined by a disulfide bond that joins a Cys residue in the &#x3b2;2M polypeptide and a Cys residue in the MHC heavy chain polypeptide.</p><p id="p-0698" num="0727">Aspect 80. A method according to aspect 79, wherein a Cys at amino acid residue 12 of the &#x3b2;2M polypeptide is disulfide bonded to a Cys at amino acid residue 236 of the MHC heavy chain polypeptide.</p><p id="p-0699" num="0728">Aspect 81. A method according to any of aspects 66-80, wherein the first polypeptide chain comprises a linker between the peptide epitope and the &#x3b2;2M polypeptide.</p><p id="p-0700" num="0729">Aspect 82. A method according to any of aspects 66-81, wherein the first polypeptide chain comprises a linker between the peptide epitope and the &#x3b2;2M polypeptide, and wherein the disulfide bond links a Cys substituted for Gly2 in the linker with a Cys substituted for Tyr84 of the MHC heavy chain polypeptide.</p><p id="p-0701" num="0730">Aspect 83. A method according to any one of aspects 66-82, wherein the immunomodulatory polypeptide is an activating polypeptide.</p><p id="p-0702" num="0731">Aspect 84. A method according to any one of aspects 61-83, wherein said administering is intramuscular, intravenous, peritumoral, or intratumoral.</p><p id="p-0703" num="0732">Aspect 85. A method according to any one of aspects 61-84, further comprising administering one or more checkpoint inhibitors to the individual.</p><p id="p-0704" num="0733">Aspect 86. A method according to aspect 85, wherein the checkpoint inhibitor is an antibody that binds to a polypeptide selected from the group consisting of CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137, ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, CD122, PD-1, PD-L1, and PD-L2.</p><p id="p-0705" num="0734">Aspect 87. A method according to aspect 85, wherein the checkpoint inhibitor is an antibody specific for PD-1, PD-L1, or CTLA4.</p><p id="p-0706" num="0735">Aspect 88. A method according to aspect 85, wherein the one or more checkpoint inhibitors is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, MPDL3280A, MDX-1105, MEDI-4736, arelumab, ipilimumab, tremelimumab, pidilizumab, IMP321, MGA271, BMS-986016, lirilumab, urelumab, PF-05082566, IPH2101, MEDI-6469, CP-870,893, Mogamulizumab, Varlilumab, Avelumab, Galiximab, AMP-514, AUNP 12, Indoximod, NLG-919, INCB024360, KN035, and combinations thereof.</p><p id="p-0707" num="0736">Aspect 89. A composition according to any of Aspects 1-19 or a method according to any of Aspects 20-88, wherein the T cell used to make the mCTL is an allogeneic T cell.</p><p id="p-0708" num="0737">Aspect 90. A composition or method according to Aspect 89, wherein the allogeneic T cell has been modified to present a TCR that is specific for a preselected antigen.</p><p id="p-0709" num="0738">While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000914A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-01-90" num="01-90"><claim-text><b>1</b>.-<b>90</b>. (canceled)</claim-text></claim><claim id="CLM-00091" num="00091"><claim-text><b>91</b>. A method of modulating a modified cytotoxic T cell (&#x201c;mCTL&#x201d;) that comprises a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cancer-associated antigen,<claim-text>wherein the method comprises contacting the mCTL with a dimeric T cell modulatory polypeptide (TMMP),</claim-text><claim-text>wherein the dimeric TMMP comprises two heterodimeric TMMPs, wherein each heterodimer comprises:</claim-text><claim-text>(a) a first polypeptide comprising a &#x3b2;-2 microglobulin (&#x3b2;2M) polypeptide, and a viral antigen peptide epitope; and</claim-text><claim-text>(b) a second polypeptide comprising a class I major histocompatibility complex (MHC) heavy chain polypeptide, one or more variant IL-2 polypeptides, and an immunoglobulin (Ig) Fc polypeptide;</claim-text><claim-text>wherein the &#x3b2;2M polypeptide, the MHC heavy chain polypeptide, and the peptide epitope and together form a peptide-MHC (pMHC) complex that specifically binds to a T cell receptor (TCR) on the mCTL,</claim-text><claim-text>wherein the one or more variant IL-2 polypeptides comprises the amino acid sequence set forth in SEQ ID NO:351, wherein amino acid 16 is Ala, and amino acid 42 is Ala, and</claim-text><claim-text>wherein the heterodimeric TMMPs are covalently linked together by one or more disulfide bonds between the Ig Fc polypeptides of each heterodimer.</claim-text></claim-text></claim><claim id="CLM-00092" num="00092"><claim-text><b>92</b>. The method of <claim-ref idref="CLM-00091">claim 91</claim-ref>, wherein the peptide epitope is a human papilloma virus 16 (HPV16) E7 epitope.</claim-text></claim><claim id="CLM-00093" num="00093"><claim-text><b>93</b>. The method of <claim-ref idref="CLM-00092">claim 92</claim-ref>, wherein each heterodimeric TMMP comprises two variant IL-2 polypeptides in tandem.</claim-text></claim><claim id="CLM-00094" num="00094"><claim-text><b>94</b>. The method of <claim-ref idref="CLM-00093">claim 93</claim-ref>, wherein the class I MHC heavy chain polypeptide of each heterodimeric TMMP comprises an HLA-A heavy chain polypeptide, and the Ig Fc polypeptide comprises an IgG1 Fc polypeptide.</claim-text></claim><claim id="CLM-00095" num="00095"><claim-text><b>95</b>. The method of <claim-ref idref="CLM-00094">claim 94</claim-ref>, wherein:<claim-text>a) the first polypeptide of each heterodimeric TMMP comprises:<claim-text>i) the HPV16 E7 peptide epitope; and</claim-text><claim-text>ii) the &#x3b2;2M polypeptide,</claim-text></claim-text><claim-text>b) the second polypeptide of each heterodimeric TMMP comprises:<claim-text>i) the first variant IL-2 polypeptide;</claim-text><claim-text>ii) the second variant IL-2 variant polypeptide;</claim-text><claim-text>iii) the HLA-A heavy chain polypeptide; and</claim-text><claim-text>vii) the Ig Fc polypeptide, wherein the Ig Fc polypeptide is an IgG1 Fc polypeptide that comprises an amino acid sequence having at least about 95% percent amino acid sequence identity to SEQ ID NO:376,</claim-text></claim-text><claim-text>wherein the &#x3b2;2M polypeptide comprises an amino acid sequence having at least 95% percent amino acid sequence identity to amino acids 21 to 119 of SEQ ID NO:388,</claim-text><claim-text>wherein the HLA-A heavy chain polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:185,</claim-text><claim-text>wherein the TMMP may include one or more independently selected peptide linkers, and</claim-text><claim-text>wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST.</claim-text></claim-text></claim><claim id="CLM-00096" num="00096"><claim-text><b>96</b>. The method of <claim-ref idref="CLM-00095">claim 95</claim-ref>, wherein the &#x3b2;2M polypeptide comprises a Cys at position 12, and the HLA-A heavy chain polypeptide comprises an Ala at position 84 and a Cys at position 236, and<claim-text>wherein the heterodimeric TMMP comprises a disulfide bond joining the Cys at position 12 of the &#x3b2;2M polypeptide, based on the amino acid numbering of SEQ ID NO:202, to the Cys at position 236 of the HLA-A heavy chain polypeptide.</claim-text></claim-text></claim><claim id="CLM-00097" num="00097"><claim-text><b>97</b>. The method of <claim-ref idref="CLM-00096">claim 96</claim-ref>, wherein the IgG1 Fc comprises an L234A substitution and an L235A substitution, which substitutions correspond to positions 14 and 15 of the amino acid sequence set forth in SEQ ID NO:387.</claim-text></claim><claim id="CLM-00098" num="00098"><claim-text><b>98</b>. A composition comprising a quantity of modified cytotoxic T cells (&#x201c;mCTLs&#x201d;), wherein the mCTLs comprise: a) a T-cell receptor (TCR) that is specific for a preselected antigen that is an epitope presented by a peptide-MHC (pMHC) complex, wherein the pMHC complex comprises a &#x3b2;2M polypeptide, an MHC heavy chain polypeptide, and a peptide epitope; and b) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cancer-associated antigen, and wherein the percentage of mCTLs cells in the composition exceeds at least 1% of the total number of T cells in the composition.</claim-text></claim><claim id="CLM-00099" num="00099"><claim-text><b>99</b>. The composition of <claim-ref idref="CLM-00098">claim 98</claim-ref>, wherein the peptide epitope is an epitope of an antigen encoded by a virus or a bacterium.</claim-text></claim><claim id="CLM-00100" num="00100"><claim-text><b>100</b>. The composition of <claim-ref idref="CLM-00099">claim 99</claim-ref>, wherein the peptide epitope is an epitope of an antigen encoded by a virus or bacteria selected from the group consisting of cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus (HPV), adenovirus, influenza virus, and <i>Clostridium tetani. </i></claim-text></claim><claim id="CLM-00101" num="00101"><claim-text><b>101</b>. The composition of <claim-ref idref="CLM-00100">claim 100</claim-ref>, wherein the CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a transmembrane region; and c) a cytoplasmic domain comprising an intracellular signaling domain.</claim-text></claim><claim id="CLM-00102" num="00102"><claim-text><b>102</b>. A method of treating a cancer in an individual, the method comprising the steps of:<claim-text>(i) administering to the individual the composition of <claim-ref idref="CLM-00098">claim 98</claim-ref>, and</claim-text><claim-text>(ii) administering to the individual a composition comprising a dimeric T-cell modulatory polypeptide (TMMP), wherein the TMMP comprises a peptide-major histocompatibility complex (pMHC) complex that presents an epitope of the preselected antigen,</claim-text><claim-text>wherein the dimeric TMMP comprises two heterodimeric TMMPs, wherein each heterodimer comprises:</claim-text><claim-text>(a) a first polypeptide comprising a &#x3b2;-2 microglobulin (&#x3b2;2M) polypeptide, and a viral antigen peptide epitope; and</claim-text><claim-text>(b) a second polypeptide comprising a class I major histocompatibility complex (MHC) heavy chain polypeptide, one or more variant IL-2 polypeptides, and an immunoglobulin (Ig) Fc polypeptide;</claim-text><claim-text>wherein the &#x3b2;2M polypeptide, the MHC heavy chain polypeptide, and the peptide epitope and together form a peptide-MHC (pMHC) complex that specifically binds to a T cell receptor (TCR) on the mCTL,</claim-text><claim-text>wherein the one or more variant IL-2 polypeptides comprises the amino acid sequence set forth in SEQ ID NO:351, wherein amino acid 16 is Ala, and amino acid 42 is Ala, and</claim-text></claim-text><claim-text>wherein the heterodimeric TMMPs are covalently linked together by one or more disulfide bonds between the Ig Fc polypeptides of each heterodimer.</claim-text></claim><claim id="CLM-00103" num="00103"><claim-text><b>103</b>. The method of <claim-ref idref="CLM-00102">claim 102</claim-ref>, wherein the individual does not undergo a lymphodepleting regimen prior to administering step (i).</claim-text></claim><claim id="CLM-00104" num="00104"><claim-text><b>104</b>. The method of <claim-ref idref="CLM-00102">claim 102</claim-ref>, wherein the composition of <claim-ref idref="CLM-00098">claim 98</claim-ref> is administered before the composition comprising the TMMP, after the composition comprising the TMMP, or at the same time as the composition comprising the TMMP.</claim-text></claim><claim id="CLM-00105" num="00105"><claim-text><b>105</b>. The method of <claim-ref idref="CLM-00104">claim 104</claim-ref>, wherein the peptide epitope is an epitope of an antigen encoded by a virus or bacteria selected from the group consisting of cytomegalovirus (CMV), Epstein-Barr virus (EBV), human papilloma virus (HPV), adenovirus, influenza virus, and <i>Clostridium tetani. </i></claim-text></claim><claim id="CLM-00106" num="00106"><claim-text><b>106</b>. A method of making an in vitro composition comprising a quantity of modified cytotoxic T cells, wherein the mCTLs comprise: a) a T-cell receptor (TCR) that is specific for a preselected antigen that is an epitope presented by a peptide-MHC (pMHC) complex, wherein the pMHC complex comprises a &#x3b2;2M polypeptide, an MHC heavy chain polypeptide, and a peptide epitope; and b) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cancer-associated antigen, and wherein the percentage of mCTLs cells in the composition exceeds at least 1% of the total number of T cells in the composition (&#x201c;mCTLs&#x201d;), wherein the method comprises the steps of:<claim-text>(i) providing a composition comprising a quantity of T cells having a T-cell receptor (TCR) specific for the pMHC complex; and</claim-text><claim-text>(ii) modifying the composition in step (i) by introducing into the at least partially separated target T cells one or more nucleic acids comprising nucleotide sequences encoding a chimeric antigen receptor (CAR) that comprises an antigen-binding domain specific for a cancer-associated antigen.</claim-text></claim-text></claim><claim id="CLM-00107" num="00107"><claim-text><b>107</b>. The method of <claim-ref idref="CLM-00106">claim 106</claim-ref>, wherein the CAR comprises: a) an extracellular domain comprising the antigen-binding domain; b) a transmembrane region; and c) a cytoplasmic domain comprising an intracellular signaling domain.</claim-text></claim><claim id="CLM-00108" num="00108"><claim-text><b>108</b>. The method of <claim-ref idref="CLM-00107">claim 107</claim-ref>, wherein the intracellular signaling domain comprises a signaling domain from the zeta chain of human CD3.</claim-text></claim><claim id="CLM-00109" num="00109"><claim-text><b>109</b>. The method of <claim-ref idref="CLM-00108">claim 108</claim-ref>, wherein the cytoplasmic domain comprises one or more costimulatory polypeptides.</claim-text></claim><claim id="CLM-00110" num="00110"><claim-text><b>110</b>. The method of <claim-ref idref="CLM-00109">claim 109</claim-ref>, wherein the costimulatory polypeptide is selected from CD28, 4-1BB, and OX-40.</claim-text></claim></claims></us-patent-application>